---
document_datetime: 2023-09-21 21:02:08
document_pages: 168
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/yervoy-h-c-ws2113-epar-assessment-report-variation_en.pdf
document_name: yervoy-h-c-ws2113-epar-assessment-report-variation_en.pdf
version: success
processing_time: 376.5354861
conversion_datetime: 2025-12-22 10:16:19.115964
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 February 2022 EMA/155438/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

| Yervoy   | ipilimumab   |
|----------|--------------|
| OPDIVO   | nivolumab    |

## Procedure No. EMEA/H/C/xxxx/WS/2113

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................7                                                                        |                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Steps taken for the assessment of the product.........................................................8                                                      |                                                                                                           |
| 2. Scientific discussion                                                                                                                                          | ................................................................................8                         |
| 2.1. Introduction.........................................................................................................8                                       |                                                                                                           |
| 2.1.1. Problem statement                                                                                                                                          | ............................................................................................8             |
| 2.1.2. About the product............................................................................................11                                            |                                                                                                           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                                                         | advice......12                                                                                            |
| 2.2. Non-clinical aspects ............................................................................................12                                          |                                                                                                           |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                                                                  | .........................................................12                                               |
| 2.2.2. Discussion and conclusion on non-clinical aspects................................................12                                                        |                                                                                                           |
| 2.3. Clinical aspects                                                                                                                                             | ..................................................................................................12      |
| 2.3.1. Introduction....................................................................................................12                                         |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................13                                            |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................44                                               |                                                                                                           |
| 2.3.4. PK/PD modelling..............................................................................................44                                            |                                                                                                           |
| 2.3.5. Discussion on clinical pharmacology...................................................................50                                                   |                                                                                                           |
| 2.3.6. Conclusions on clinical pharmacology.................................................................51                                                    |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                                                            | ..................................................................................................51      |
| 2.4.1. Dose response study(ies) 2.4.2. Main                                                                                                                       | .................................................................................51                       |
| study......................................................................................................52                                                     |                                                                                                           |
| 2.4.3. Discussion on clinical efficacy..........................................................................                                                  | 110                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy...................................................................                                                    | 116                                                                                                       |
| 2.5. Clinical safety 2.5.1. Discussion on clinical                                                                                                                | .................................................................................................. 116    |
| safety ............................................................................                                                                               | 153                                                                                                       |
| 2.5.2. Conclusions on clinical safety 2.5.3. PSUR cycle                                                                                                           | .......................................................................... 156 156                        |
| ...................................................................................................                                                               | 156                                                                                                       |
| 2.6. Risk management plan .................................................................................. 2.7. Changes to the Product Information              | ............................................................. 162                                         |
| 2.7.1. User consultation...........................................................................................                                               | 163                                                                                                       |
| 3. Benefit-Risk Balance............................................................................163                                                            |                                                                                                           |
| 3.1. Therapeutic Context .........................................................................................                                                | 163                                                                                                       |
|                                                                                                                                                                   | 163                                                                                                       |
| 3.1.1. Disease or condition.......................................................................................                                                | need..................................................... 163                                             |
| 3.1.2. Available therapies and unmet medical 3.1.3. Main clinical studies ....................................................................................... | 164                                                                                                       |
| 3.2. Favourable effects ............................................................................................                                              | 164                                                                                                       |
| 3.3. Uncertainties and limitations about favourable                                                                                                               | effects...........................................                                                        |
|                                                                                                                                                                   | 165                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................                                                | 165                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable Table....................................................................................................   | effects ....................................... 165                                                       |
| 3.6. Effects                                                                                                                                                      | 165                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                                                              | 166                                                                                                       |
| 3.7.2. Balance of benefits and risks...........................................................................                                                   | 167                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                                                      | ......................................... 167                                                             |
| 3.8. Conclusions                                                                                                                                                  | ..................................................................................................... 167 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ...............................................................................  167 5. EPAR changes  ......................................................................................  168

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

anti-drug antibodies

AE

adverse event

BICR

blinded independent central review

BMS

Bristol-Myers Squibb

Cavg(WX)

average concentration at Week X

CFR

Code of Federal Regulations

chemo

chemotherapy

cHL

classical Hodgkin lymphoma

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

Cmax(WX)

maximum concentration at Week X

CMBP

LabCorp Center for Molecular Biology and Pathology

Cmin(WX)

minimum concentration at Week X

CMH

Cochran-Mantel-Haenszel

CRC

colorectal cancer

CSR

clinical study report

CTC

common terminology criteria

CTLA-4

cytotoxic T-lymphocyte associated protein-4

DMC

data monitoring committee

dMMR

mismatch repair deficient

DOR

duration of response

EAC/OAC

Esophageal/oesophageal adenocarcinoma

EC/OC

esophageal cancer

ECOG

Eastern Cooperative Oncology Group

ECS

esophageal cancer subscale

eCRF

electronic case report form

EMA

European Medicines Agency

E-R

exposure-response

ESMO

European Society for Medical Oncology

FA

final analysis

FACT-E

Functional Assessment of Cancer Therapy-Esophageal

FACT-G7

Functional Assessment of Cancer Therapy - General cancer-related 7-item core mea

FDA

Food and Drug Administration

5-FU

5-fluorouracil

GC

gastric cancer

GEJC

gastroesophageal junction cancer

HCC

hepatocellular carcinoma

HR

hazard ratio

IA

interim analysis

ICH

International Conference on Harmonization

IHC

immunohistochemistry

IMAE

immune-mediated adverse event

IND

Investigational New Drug

ipi

ipilimumab

iPSP

initial pediatric study plan

IRRC

independent radiology review committee;

IRT

interactive response technology

IV

intravenous(ly)

KM

Kaplan-Meier

1L

first-line

2L

second-line

LEG

legally binding procedure

LPLV

last patient's last visit

MedDRA

Medical Dictionary for Regulatory Activities

MPM

malignant pleural mesothelioma

MSI-H

microsatellite instability-high

N

number of subjects

NCCN

National Comprehensive Cancer Network

NCI CTCAE

National Cancer Institute-Common Terminology

nivo

nivolumab

NSCLC

non-small cell lung cancer

OESIs

other events of special interest

ORR

objective response rate

OS

overall survival

OSCC

oesophageal squamous cell carcinoma

PD-(L)1

programmed death-(ligand) 1

PFS

progression-free survival

PFS2/TSST

progression-free survival after next line of treatment/time to second subsequent line

PK

pharmacokinetics

PPK

population pharmacokinetics

PREA

Pediatric Research Equity Act

PRO

patient reported outcome

PS

performance status

QXW

every X weeks

RCC

renal cell carcinoma

RECIST

Response Evaluation Criteria in Solid Tumors

RMST

restricted mean survival time

ROW

rest of the world

SAE

serious adverse event

SAP

statistical analysis plan

(s)BLA

(supplemental) biologics license application

SAWP

Scientific Advice Working Party

SCCHN

squamous cell carcinoma of the head and neck

UC

urothelial carcinoma

US

United States

USPI

United States Prescribing Information

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

VAS visual analog scale WHO World Health Organization

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 28 July 2021 an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) for Opdivo in combination with Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 24.0 of the Opdivo RMP and version 33.0 of the Yervoy RMP have also been submitted.

The requested worksharing procedure proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included EMA Decision(s) P/0432/2020, P/0237/2021 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0237/2021 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the WSA did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The Applicant received Scientific Advice on the development of nivolumab in oesophageal cancer from the CHMP on 28 May 2020 (EMEA/H/SA/2253/12/2020/II). The Scientific Advice pertained to the following clinical aspects:

Regarding amendments to an ongoing randomized Phase 3 study in adult patients with unresectable advanced, recurrent, or metastatic OSCC:

- o Whether OS as a sole primary endpoint would enable a benefit/risk assessment;
- o A change in the primary population from PD-L1 expressors to all randomized, for analysis of overall survival in the nivolumab in combination with ipilimumab arm.

<div style=\"page-break-after: always\"></div>

At that time the MAH was strongly discouraged to amend the analysis plan as proposed/planned, bearing in mind that the trial was at a very late stage (i.e. a few months prior to the planned database lock). The fact that the study is open label and its pivotal nature were also arguments against the proposed late changes that, even if followed from a statistical point of view (e.g. in terms of gain in power for the newly proposed primary comparisons), were anticipated to give raise to major issues in terms of credibility/integrity of the study at the time of assessment of the corresponding type II variation; notwithstanding the Applicant's claims that all changes were proposed based on external data. The MAH followed the scientific advice received and did not implement the changes they proposed during this SA.

## 1.1. Steps taken for the assessment of the product

Appointed Rapporteur for the WS procedure: Blanca Garcia-Ochoa

| Timetable                                                                            | Actual dates     |
|--------------------------------------------------------------------------------------|------------------|
| Submission date                                                                      | 28 July 2021     |
| Start of procedure                                                                   | 14 August 2021   |
| CHMP Rapporteur's preliminary assessment report circulated on                        | 22 October 2021  |
| PRAC Rapporteur's preliminary assessment report circulated on                        | 22 October 2021  |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 28 October 2021  |
| CHMP Rapporteur's updated assessment report circulated on                            | 5 November 2021  |
| Request for supplementary information adopted by the CHMP on                         | 11 November 2021 |
| WSA's responses submitted to the CHMP on                                             | 21 December 2021 |
| CHMP Rapporteur's preliminary assessment report on the WSA's responses circulated on | 1 February 2022  |
| PRAC Rapporteur's preliminary assessment report on the WSA's responses circulated on | 1 February 2022  |
| PRAC RMP advice and assessment overview adopted by PRAC on                           | 10 February 2022 |
| CHMP Rapporteur's updated assessment report on the WSA's responses circulated on     | 18 February 2022 |
| CHMP Opinion adopted on                                                              | 24 February 2022 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Oesophageal cancer (OC) is the eighth-most common cancer and the sixth-most common cause of death worldwide, with an estimated 604,100 new cases (3.1% of all cancers) and 544,076 cancer deaths (5.5% of all cancer deaths) (GLOBOCAN 2020). In the UE, oesophageal cancer is the 19th most common cancer (1.2% of all new cancers), although variability between countries is high and may

<div style=\"page-break-after: always\"></div>

reflect different prevalence of risk factors, use of screening and diagnostic methods. Around 53,000 new cases of OC were registered in Europe in 2020.

## State the claimed therapeutic indication

## Proposed Indication

The MAH initially applied for the following indication:

OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (see section 5.1).

YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (see section 5.1).

During the procedure the indication was amended. The agreed indication is as follows:

OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%

YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.

## Dosage and administration

The recommended dose is either 3 mg/kg nivolumab every 2 weeks or 360 mg nivolumab every 3 weeks administered intravenously over 30 minutes in combination with 1 mg/kg ipilimumab administered intravenously over 30 minutes every 6 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

## Epidemiology and risk factors, screening tools/prevention

The two distinct histologic types of OC are squamous cell carcinoma (SCC) and adenocarcinoma (AC) (Abnet CC 2018). Globally, OSCC remains the predominant histological subtype (approximately 90% of total cases but around 65% in most European countries) (Wong MCS, 2018); however, the incidence of OSCC has been decreasing, while the incidence of OAC has been increasing rapidly, particularly in Western Europe, North America, and Australia.  SCC continues to be the more common OC in Asia. Mortality rates associated with AC are rising and have surpassed those of SCC in several regions in the EU.

Oesophageal carcinoma is rare in young people and increases in incidence with age, peaking in the seventh and eighth decades of life. AC is three to four times as common in men as it is in women, whereas the sex distribution is more equal for SCC.

The main risk factors for OSCC in Western countries are smoking and alcohol consumption, whereas OAC predominantly occurs in patients with chronic gastro-oesophageal reflux disease and their risk is correlated with the patient's body mass index with a higher risk for obese people.

## Aetiology and pathogenesis

Alcohol consumption, smoking and poor socioeconomical status represent major risk factors for OSCC. Differences in exposure to well established common risk factors, such as smoking and alcohol, genetic

<div style=\"page-break-after: always\"></div>

polymorphism in alcohol metabolism genes, and different levels of exposure to suspected risk factors, such as polycyclic aromatic hydrocarbons, may contribute to the observed regional differences in OSCC incidence.

The molecular biology of OSCC is not yet fully understood. Of note, comprehensive molecular analyses of OC by The Cancer Genome Atlas Program (TCGA) have shown that OSCC is molecularly distinct from OAC (Kim J. 2017).  Based on these analyses, OSCC has stronger resemblance to other squamous tumours like SCCHN than to OAC, and consequently, OAC resembles gastric cancer more than OSCC. Squamous cell carcinomas are different from adenocarcinoma in genetic alterations, gene expression and DNA methylation profiles. Frequent alterations in cell cycle regulators, RTK/RAS/PI(3)K pathways and chromatin-modifying enzymes have been observed in OSCC and the patterns were different from those of OAC.

## Clinical presentation, diagnosis and stage/prognosis

All patients with new dysphagia, gastrointestinal bleeding, recurrent aspiration or emesis, weight loss and/or loss of appetite should undergo an upper intestinal endoscopy. Approximately three-quarters of all ACs are found in the distal oesophagus, whereas SCCs occur more frequently in the proximal to middle oesophagus. The differentiation between SCC and AC is of prognostic and clinical relevance. Immunohistochemical stainings are recommended in poorly and undifferentiated cancers (G 3/4) according to WHO to differentiate between SCC and AC.

Approximately 50% of OCs will be locally or locoregionally advanced at diagnosis, and thus amenable to potentially curative loco-regional therapy. Five-year survival rates for all patients with OC have shown modest improvements over the past 35 years, from 5% in 1975 to approximately 20% for patients diagnosed in 2004.  Five-year survival rates for loco-regionally advanced disease treated with surgery alone have been consistently poor, ranging from 6% to 26%.

## Management

The management of OC often requires a multi-disciplinary approach, with treatment decisions involving surgical, radiation, and medical oncology expertise. Recommendations by treatment guidelines for OC are based on histology (i.e., SCC vs. AC). Patients with advanced or metastatic OSCC are generally treated with palliative intent with chemotherapy to extend survival, and with localized treatments, such as radiotherapy (including external radiation or brachytherapy), or endoscopic therapies, such as stents, for the symptomatic treatment of obstruction and dysphagia. Chemotherapy is typically offered to selected patients with good performance status, although its value is less proved than in AC, according to ESMO clinical practice guidelines (2016).

Cytotoxic chemotherapy has remained the mainstay treatment for advanced OSCC for many years. In the first-line (1L) setting, combination chemotherapies are routinely used. Although there are some differences, global guidelines are generally consistent and recommend the combination of a fluoropyrimidine (5-fluorouracil [5-FU] or capecitabine) with a platinum agent (cisplatin or oxaliplatin). The combination of cisplatin and fluorouracil is the only chemotherapy option which is supported by data from a randomized Phase 2 trial in OSCC. In that trial which was conducted in Europe, patients (n=88) with locally advanced or metastatic OSCC were treated with cisplatin 100 mg/m 2 , combined with 5-FU at a dose of 1000 mg/m 2  as a continuous infusion from days 1-5 or with cisplatin alone. Cisplatin in combination with 5-FU (vs cisplatin alone) conferred a response rate of 35% (95% CI: 20, 54%) vs 19% (95% CI: 8, 35%) and median survival of 7.6 vs 6.4 months. Cisplatin may be substituted in clinical practice by oxaliplatin because of a more favourable safety profile and

<div style=\"page-break-after: always\"></div>

fluorouracil may be substituted by alternative fluoropyrimidines, such as capecitabine. This is encouraged by international treatment guidelines such as NCCN.

Recent findings from the KEYNOTE 590 study (median follow-up 10.8 months) showed that immune checkpoint inhibitor pembrolizumab in combination with chemotherapy in the 1L setting was superior to chemotherapy for OS and PFS in patients with locally advanced/unresectable or metastatic EAC, OSCC (73% of the study population), or Siewert type 1 GEJ adenocarcinoma.  In the overall KEYNOTE590 population, median OS was 12.4 months (95% CI: 10.5, 14.0) vs 9.8 months (95% CI: 8.8, 10.8) with pembrolizumab plus chemotherapy vs chemotherapy (HR=0.73 [95% CI: 0.62, 0.86]) and median PFS was 6.3 months (95% CI: 6.2, 6.9) vs 5.8 months (95% CI: 5.0, 6.0), respectively (HR=0.65 [95% CI: 0.55, 0.76]). Based on these study findings, pembrolizumab (in combination with platinum- and fluoropyrimidine-based chemotherapy) received an European Commission decision in June 2021 for the 1L treatment of locally advanced or metastatic oesophageal carcinoma (including OSCC) that is not amenable to surgical resection or definitive chemoradiation in patients whose tumours express PD-L1 with a CPS≥10 (Keytruda II/97).

## Unmet Medical Need

OSCC is an aggressive disease with a poor prognosis; the global 5-year relative survival rate is &lt; 20%. For decades, platinum plus fluoropyrimidine-based chemotherapy was the only recommended 1L treatment for advanced or metastatic OSCC, resulting in poor survival (median OS &lt;1 year). Despite the recent approval of pembrolizumab plus chemotherapy for 1L treatment of OSCC, there are still opportunities to advance new modalities and regimens that improve survival in this setting.

## 2.1.2. About the product

Nivolumab is a human monoclonal antibody that targets the PD-1 receptor and blocks its interaction with its ligands, PD-L1 and PD-L2. Tumours use PD-L1 expression as a defense or escape mechanism against the host's anti-tumour T-cell response; inhibiting PD-(L)1 restores the function of these antitumor T-cells which have become ineffective or suppressed. Therefore, the efficacy of PD-(L)1 inhibition relies on a pre-existing immune response. Nivolumab, as monotherapy, is approved for multiple indications, including for the treatment of patients with advanced or recurrent OSCC who received prior fluoropyrimidine- and platinum-based chemotherapy in the EU.

Ipilimumab is a human monoclonal antibody that targets CTLA-4. CTLA-4 inhibition can induce de novo T-cell responses and recruit novel/additional T cells to the tumour.

In the EU, nivolumab as monotherapy has been approved for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin's lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, oesophageal squamous cell carcinoma and adjuvant treatment of OC or GEJC. The combination of nivolumab with ipilimumab (Yervoy) has been approved for the treatment of melanoma, RCC, malignant pleural mesothelioma and dMMR or MSI-H colorectal cancer, and in combination with platinum-based chemotherapy for the first-line treatment of metastatic NSCLC. The combination of nivolumab with fluoropyrimidine- and platinum-based combination chemotherapy has been approved for the treatment of first-line HER-2 negative gastric, GEJ or oesophageal adenocarcinoma whose tumours express PD-L1 with CPS ≥ 5%, and the combination of nivolumab with cabozantinib has been approved for the first-line treatment of RCC. Ipilimumab, as monotherapy, is approved for the treatment of advanced melanoma.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Study CA209648, a Phase 3, open-label, randomized trial of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in subjects with unresectable advanced, recurrent or metastatic previously untreated oesophageal squamous cell carcinoma is the pivotal study for the current application (see section 4.4.2. Main study).

The MAH did seek Scientific Advice at the CHMP on the design of study CA209648, the pivotal trial for this application (EMEA/H/SA/2253/12/2020/II). Questions referred to the choice of endpoints and primary population (see section 1). The MAH overall followed the recommendations of the CHMP scientific advice.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable.

## 2.2.1. Ecotoxicity/environmental risk assessment

Both nivolumab and ipilimumab are proteins composed of natural amino acids. Proteins are expected to biodegrade in the environment and not be a significant risk. As a protein, nivolumab and ipilimumab are exempt from preparation of an Environmental Risk Assessment under the 1 June 2006 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use'

(EMEA/CHMP/S/4447/00). Nivolumab, ipilimumab and the product excipients do not pose a significant risk to the environment.

## 2.2.2. Discussion and conclusion on non-clinical aspects

Not applicable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the WSA.

The WSA has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study/ Status                                                                                        | Population                                                              | Design                                                                                                                              | Endpoints                                                                                                                                                                                                                                                                                                                   | TestDrugs and Dose                                                                                                                                                                                                                                             | Number of Subjects                                                           |
|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| CA209648 Ongoing Database lock: 01-Mar-2021 for the pre- specified analysis of the primary endpoints | Adults (18 years) with previously untreated advanced or metastatic OSCC | Phase 3, randomized, open-label, 3-arm study of nivo+ipi ornivo+chiemo (fluorouracil+ cisplatin) VS chemo (fluorouracil+ cisplatin) | Primary: OS and PFS (per BICR)in all randomized subjectswith tumor cell PD-L1≥ 1% Secoudary:OSandPFSby BICRinallrandomized subjects, ORR by BICR in all randomizedsubjectswith tumorcellPD-L1≥1%and in allrandomized subjects Key Exploratory:PFS,ORR DOR,andPFS2/TSSTby investigator,DOR byBICR Safety,Immunogenicity, PRO | Nivo+ChemoArm Nivo 240 mg IV Q2W + fluorouracil 800 mg/m2/day IV on Days 1-5 Q4W + cisplatin 80 mg/m²IV on Day 1 Q4W Nivo+Ipi Arm Nivo 3 mg/kg IV Q2W + ipi 1 mg/kg IV Q6W Chemo Arm Fluorouracil 800 mg/m2/day IV on Days 1-5 Q4W+cisplatin80mg/m²IVonDay1Q4W | 970randomized subjects: 325 to nivo+ipi, 321 to nivo+chemo, and 324 to chemo |

Abbreviations: Chemo - chemotherapy, DOR - duration of response, ipi - ipilimumab, IV - intravenous, nivo - nivolumab, ORR - objective response rate, OS overall survival, OSCC - oesophageal squamous cell carcinoma, PFS - progression-free survival, PFS2/TSST - PFS after next line of treatment/time to second subsequent line therapy,PRO-patient-reported outcomes,QXW - everyX weeks

The clinical pharmacology document summarizes the human pharmacokinetics (PK), exposureresponse (E-R), and immunogenicity data of nivolumab (OPDIVO®, BMS-936558, MDX-1106, ONO4538) in support of the efficacious and safe use of nivolumab in combination with ipilimumab for the first-line (1L) treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC).

## 2.3.2. Pharmacokinetics

The purpose of the pharmacometric analyses described in this document is to characterize the pharmacokinetics (PK) of nivolumab (BMS-936558, MDX-1106, ONO-4538) when administered in combination with ipilimumab (BMS-734016) or fluorouracil plus cisplatin and to characterize the PK of ipilimumab when administered in combination with nivolumab as the first-line (1L) treatment in subjects with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC) based on the data from Phase 3 Study CA209648.

Study CA209648 was a randomized, global Phase 3 study of nivolumab plus ipilimumab (nivo+ipi hereafter) or nivolumab in combination with fluorouracil plus cisplatin (nivo+chemo hereafter) versus fluorouracil and cisplatin chemotherapy (chemo hereafter) as 1L-therapy in unresectable advanced, recurrent, or metastatic OSCC. The clinical database lock occurred on 01-Mar-2021 and included data for subjects randomized to the nivo+ipi, nivo+chemo and chemo arms.

The treatment used in this study was nivolumab 3 mg/kg as a 30-minute infusion every 2 weeks (Q2W) plus ipilimumab 1 mg/kg as a 30-minute infusion every 6 weeks (Q6W), or nivolumab 240 mg as a 30-minute infusion Q2W in combination with fluorouracil 800 mg/m2/day as an intravenous (IV) continuous infusion on Day 1 through Day 5 (for 5 days) and cisplatin 80 mg/m2 as a 30- to 120minute infusion on Day 1 of a 4-week cycle (every 4 weeks [Q4W]).

## Pharmacokinetics in the target population

Table 1: Summary of Clinical Studies Included in Population Pharmacometric Analyses

<div style=\"page-break-after: always\"></div>

| Protocol #: Title Study Population                                                                                                                                                                                                                                                                                                                                             | Treatment                                                                                                                                                                                                                                                                                                     |   Planned Sample Sizea,b | Nominal PK/PD Sampling Schedule                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Analysis                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| MDX1106-01(CA209001):Phase 1,open- label,multicenter,dose escalation study to evaluate thesafetyandpharmacokineticsof BMS936588insubjectswithselected refractoryorrelapsedmalignancies Adult subjectswithpathologicallyverified and recunrent or treatment refractory colorectal adenocarcinoma, melanoma, NSCLC, castration-resistantprostateadenocarcinoma, and RCC          | Single-dose Phase (Cycle 1): 0.3,1,3,or10 mg/kgIV infusion administeredover60minutes Re-treatment Phase (Cycle 2): administeredover60minutes on 0.3,1,3,or 10 mg/kg IV infusion Days 1 and 29; eligible subjects were treated with the same dose levelasin theSingle-dosePhase and couldreceive additionalre- |                       39 | Single-dose Phase: Predose,30 minutes into dosing,immediately post-infusion, and30 minutes,and1,2,4,6,8, 24,48, and 72 hours post-infusion end time; on Days 8,15,22, 29, 43, 57, 71, and 85 Re-treatment Phase: Predose and peak on treatment Days 1 and 29; single samples onDays 8,15, 22,36,43,57,85, and 113                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Nivo PPK                                                     |
| MDX1106-03(CA209003):Phase 1,open- label,multicenter,multidose,dose-escalation studytoevaluate thesafetyandtolerabilityof BMS-936588 in subjects with selected advancedorrecurrentmalignancies Adult subjectswith pathologicallyverified and advanced orrecurrent and progressing colorectaladenocarcinoma,melanoma, NSCLC,castration-resistantprostate adenocarcinoma,and RCC | 0.1, 0.3, 1, 3, or 10 mg/kg IV infusion depending upon tumor type, administered over 60 minutes Q2Wfor upto twelve8-week cycles                                                                                                                                                                               |                      306 | Pre-Amendment: Cycle 1: End of Infusion and pre-infusion levels on infusion days: Days 1, 15, 29, and 43 and Cycle 2: Single samples were collected Post-Amendment: Serial PK samples were collectedfrom all subjects enrolled in 0.1, 0.3, and 1 mg/kg melanomacohorts andfirst16subjectseach from 3 and 10 mg/kg NSCLC cohorts. Cycle 1: Day1（after60-minuteinfusion,4,8hr),Days 2 3, 5, 8, and 15; Cycle 2: Day 1 (pre-infusion); Cycle 3: Day 1 (pre-infusion, after 60-minute infusion), and Days 2,3, 5, 8, and 15 Limited PK samples were collected from subjects enrolledin 1 mg/kgRCC cohort, 1 mg/kgNSCLC, andremaining16 subjects each from3 and 10 mg/kg NSCLC. Cycle 1: Day1(after 60-minute infusion) and Days 3, 8, and 15; Cycle 2: Day 1 (pre-infusion); Cycle 3: Day 1 (pre-infusion, after 60-minute infusion), and Days 3, 8, and 15 Each treatment cycle is comprised of4 doses of study drug administered onDays 1,15,29,and 43 of the.cvcle. | Nivo PPK Only include subjects with melanoma, NSCLC, and RCC |
| CA209017:An open-label,randomized Phase 3 trial of BMS-936558(nivolumab) versus docetaxelinpreviously treated advancedor metastatic SQ NSCLC SubjectswithSQNSCLC                                                                                                                                                                                                               | Dose: 3 mg/kg, 1-hr IV infusion Regimen: Q2W                                                                                                                                                                                                                                                                  |                      132 | Day 1 (Cycle 1) and Day 99 (Cycle 8), pre- infusion, after 60-minute infusion and pre- infusionatCycles2and3andeverySthcycle afterCycle8Day1untildiscontinuationof studytreatment Each 14-day dosing period is considered a cycle                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Nivo PPK                                                     |
| CA209057:An open-label,randomized Phase 3 trial ofBMS-936558(nivolumab) versus docetaxel inpreviously treated advanced or metastatic NSQ NSCLC Subjects with NSQ NSCLC                                                                                                                                                                                                         | Dose: 3 mg/kg, 1-hr IV infusion Regimen: Q2W                                                                                                                                                                                                                                                                  |                      287 | Day 1 (Cycle 1) and Day 99 (Cycle 8), pre- infusion,after60-minuteinfusion andpre- infusionat Cycles 2 and3andeverySthcycle afterCycle8Day1 untildiscontinuationof study treatment Each 14-day dosing period is considered a cycle                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Nivo PPK                                                     |
| ONO-4538-07: A Phase 2, multicenter, open- label, uncontrolled study in patients with esophageal cancer Subjects with esophageal cancer                                                                                                                                                                                                                                        | Dose: 3 mg/kg, 1-hr IV infusion Regimen: Every 2 weeks                                                                                                                                                                                                                                                        |                       60 | Cycle 1: Predose and immediately post dose on Day 1, predose on Days 15 and 29 Cycles 2,4,5,7,and 9:Predose on Day1 and immediately post dose on Day 1 (Cycle 4) Follow-up visits Each cycle consists of 6 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Nivo PPK                                                     |
| ONO-4538-24/CA209473:APhase3, multicenter, randomized, open-label study in patients with esophageal cancer refractory or intoleranttocombinationtherapywith fluoropyrimidine and platinum-based drugs Subjects with esophageal cancer                                                                                                                                          | Dose: 240 mg, 30-min IV infusion Regimen: Every 2 weeks                                                                                                                                                                                                                                                       |                      195 | Cycle 1: Predose on Day 1 and Day 29 Cycles 4 and 9:Predose on Day 1 Follow-up visits Each cycle consists of 6 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Nivo PPK                                                     |
| CA209577:A randomized,multicenter,double blindPhaseIstudyof adjuvantnivolumab or placeboin subjects with resected esophageal, or gastroesophagealjunction cancer Subjects withresected esophageal, or gastroesophagealjumction cancer                                                                                                                                          | Dose:240 mg,30-minIV infusion, every 2 weeks for 16 weeks followed by 480 mg Q4W                                                                                                                                                                                                                              |                      506 | Cycles 1, 3, 10, 13, and 17: Predose on Day 1 Cycle 9:Predose on Day 1 and EOI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Nivo PPK                                                     |
| CA184008: A multi-center, single arm Phase 2 study ofMDX-010 (BMS-734016)                                                                                                                                                                                                                                                                                                      | Ipilimumab 10 mg/kgQ3W during induction period (Week 1,4,7,and 10), followed by Q12W during                                                                                                                                                                                                                   |                      144 | Schedule A:On D1 and D43,pre-infusion and 90-min post-infusion.3 additional sampleswere taken between D3-7 after Week 7 dose,D10-15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Ipi PPK                                                      |

<div style=\"page-break-after: always\"></div>

| monotherapy in patients with previously treated unresectable stage IlI orIV melanoma PreviouslytreatedunresectableStageIllorIV melanoma                                                                                                                                                                                                                                                                                                                                                                                                  | maintenance period (starting on Week 24)                                                                                                                                                                                                                                                                         |                                                                       | afterWeek 7 dose and the predose sample on D64 Schedule B: On D1 and D43,predose and 90- min post-infusion, 24, 72 hr post-infusion, D8 (± 27 hrs), D15 (± 48 hrs); 2 additional predose samples Were taken on D22 and D64                                                                                 |                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| CA184022:Arandomized,double-blind,multi- center, Phase 2 fixed dose study of multiple doses of ipilimumab (MDX-010) monotherapy in patientswith previouslytreated unresectable stage III or IV melanoma Advanced Stage IllIorStageIV melanoma, who were previously treated with anyregimen exceptaCD-137agonistoraCTLA4inhibitor or'agonist                                                                                                                                                                                              | Ipi 0.3, 3, or 10 mg/kg Q3W during induction period (Weeks 1, 4, 7, and 10), followed by Q12W during maintenance period (starting on Week 24)                                                                                                                                                                    | 210                                                                   | On D1 and D43 pre-infusion and 90-min post- infusion; 3 additional samples were taken betweenD3-7(post dose) after Week 7dose, D10-15 (post dose)after Week 7 dose and the predose sample on D64                                                                                                           | Ipi PPK                                        |
| CA209227:Anopen-label,randomizedphase3 trial of nivolumab,ornivolumabplus ipilimumab,ornivolumabplusplatinum doublet chemotherapy versus platinum doublet chemotherapy in subjects with chemotherapy- naive stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 227).OnlyPart 1 data willbe used. Chemotherapy-naive stage IV or recurrent NSCLC                                                                                                         | Arm A: nivo 240 mg (30-min infusion) Q2W Arm B/D: nivo 3 mg/kg (30-min infusion) Q2W + ipi 1 mg/kg (60-min infusion) Q6W Arm G: nivo 360 mg (30-min infusion)Q3W in combination with chemotherapy Arm H: nivo 360 mg (30-min infusion)Q3Wincombination with chemotherapy                                         | 1514                                                                  | AmmsB/Dforipi:Bloodsampleswere collected at C1D1 (ipi dose 1), C2D1 (ipi dose 2), C4D1 (ipi dose 2),C10D1 (ipi dose 4),D1 of every 9th cycle after C10D1 until end of study treatment (or ipi doses 7, 10, 13 etc). First 2 follow-up visits(approximatelyup to100 daysfrom discontinuation of study drug) | Nivo and Ipi PPK                               |
| CA209743: A Phase II, randomized, open labeltrialofnivolumabincombinationwith ipilimumab versus pemetrexed with cisplatin of carboplatin as first line therapy in unresectable pleural mesothelioma(CheckMate743: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 743)                                                                                                                                                                                                                                                        | Arm A: nivolumab 3 mg/kg Q2W combinedwithipilimumab1 mg/kg Q6W until progression, unacceptabletoxicity,orother reasons specified in the protocol                                                                                                                                                                 | 300                                                                   | Blood samples were collectedfrom Arm A at predose and EOI time points on C1D1, and at predose only on C1D15, C2D15, and C4D15 and at D15 ofevery 4th cycle (18weeks)thereafter, until discontinuation or up toa maximum of 2 years of treatment (each cycle=6 weeks)                                       | Nivo and Ipi PPK                               |
| Subjectswithhistologicallyprovendiagnosisof advanced, unresectable malignant pleural mesothelioma (MPM) with determination of epithelioid vs non-epithelioid histology                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                  |                                                                       |                                                                                                                                                                                                                                                                                                            |                                                |
| CA209648: A randomized, multicenter, open- label, Phase 3 study of nivolumab plus ipilimumabornivolumabincombinationwith oxaliplatinplusfluoropyrimidine(hereafter referredtoasnivo+chemo)versusoxaliplatin plus fluoropyrimidine (hereafter referred to as chemo) in subjects with previously untreated advanced or metastatic gastroesophageal junction cancer (GEJC), gastric cancer (GC) of esophageal adenocarcinoma cancer(EAC). Subjectswithacvanced ormetastaticgastric or gastroesophageal jumctionor esophageal adenocarcinoma | Dose for Arm A: nivo 3 mg/kg, 30- min infusion, Q2W and ipi 1 mg/kg, 30-min infusion, Q6W Or Dose for Amm B: nivo 240 mg. 30-minute infusion, Q2W, fluorouracil 800 mg/m2/day IV continuous infusion onDay1 through Day 5 (for 5 days), and cisplatin 80 mg/m², 30-to 120-min infusion^ on Day 1 of 4-week cycle | 313 per arm (nivolumab plus chemotherapy, nivolumab plus ipilimumab ) | For Arm A (nivo 3 mg/kg Q2W+ ipi 1 mg/kg Q6W): One Cycle = Every 2 weeks (nivo Q2W, ipi Q6W) Cycles 1,2,4,5,7,9,15,23,35, and 47:Predose on Day 1 ForAmB(nivo240mg,Q2W+fluorouracil 800 mg/m2/day and cisplatin 80 mg/m²): One Cycle = Every 4 weeks (nivo Q2W) Cycles 1,2,3,7,9,17,and25:Predose onDay1   | !dI pue oA!N PPK, E-R efficacy, and E-R safety |

a  As per protocol.

b  Only nivolumab treated subjects are included

c  Subjects are allowed to receive treatment with cisplatin 80 mg/m² as an IV infusion over a period of longer than 120 minutes if it is in accordance with local standard of care/local label.

Abbreviations: C = cycle; D = day; DBL = database lock; EOI = end of infusion; E-R = exposure-response; GC = gastric cancer; hr = hour(s); IV = intravenous; min = minute(s); Ipi = ipilimumab, Nivo = nivolumab; NSCLC = non-small cell lung cancer; NSQ NSCLC = non-squamous cell non-small cell lung cancer; PK = pharmacokinetic(s); PK/PD = pharmacokinetic/pharmacodynamic; PPK = population pharmacokinetics; Q2W = every 2 weeks; Q3W = every 3 weeks; Q6W = every 6 weeks; Q12W = every 12 weeks; RCC = renal cell carcinoma; SCLC = small cell lung cancer; SQ NSCLC = squamous cell non-small cell lung cancer.

## Nivolumab

<div style=\"page-break-after: always\"></div>

Table 3.3.1.1-1: Subjects Included in the Nivolumab PPK Analysis Dataset

|                        | # Subjects        | # Subjects             | # Subjects   | # Subjects                           |
|------------------------|-------------------|------------------------|--------------|--------------------------------------|
| Study                  | Nivolumab Treated | PKDatabase (eToolbor)a | Flagged      | Included (% of Subjects in eIoolbox) |
| MDX1106-01 (CA209001)  | 39                | 39                     | 0            | 39 (100)                             |
| MDX1106-03 (CA209003)  | 306               | 310                    | 6            | 304 (98.1)                           |
| ONO-4538-07            | 65                | 65                     | 0            | 65 (100)                             |
| CA209017               | 125               | 127                    | 2            | 125 (98.4)                           |
| CA209057               | 280               | 282                    | 2            | 280 (99.3)                           |
| CA209227               | 1514              | 1418                   | 112          | 1306 (92.1)                          |
| ONO-4538-24 (CA209473) | 186               | 186                    | 0            | 186 (100)                            |
| CA209577               | 494               | 526                    | 32           | 494 (93.9)                           |
| CA209648               | 632               | 626                    | 51           | 575 (91.9)                           |
| CA209743               | 300               | 300                    | 3            | 297 (99)                             |
| Total                  | 3941              | 3879                   | 208          | 3671 (94.6)                          |

eToolbox or Pharmacokinetic/Pharmacodynamic Analysis and Modeling System (PAMS) included subjects with at least 1 PK sample collected, including pre-first dose samples (before nivolumab treatment) and samples collected after nivolumab treatment.

Abbreviations: PK = pharmacokinetic; PPK = population pharmacokinetic.

Analysis-Directory: /global/pkms/data/CA/209/ec-11/prd/cognigen/sd/final/

Program Source: Analysis-Directory/d1pk-nivo/R/nivo-cv209648-1l-escc-pmr-tfl-section-3.Rmd

Source: Analysis-Directory/d1pk-nivo/tables/rmd-rtf/data-disposition-table-subjects-v01.rtf

Table 3.3.1.2-1: Samples Included in the NivolumabPopulationPharmacokineticAnalysis Dataset

|                        |                                   | Numberof SamplesExcluded   | Numberof SamplesExcluded   | Numberof SamplesExcluded           | Numberof SamplesExcluded   | Numberof SamplesExcluded                       | Numberof SamplesExcluded   |                                   |
|------------------------|-----------------------------------|----------------------------|----------------------------|------------------------------------|----------------------------|------------------------------------------------|----------------------------|-----------------------------------|
| Study                  | Number Samples In PK of Databasea | LLOQb                      | Predose Day 1              | Missing Dose or Sample Information | >2000 μg/mL Conc           | Duplicate Samples atSame Time (Set Up for NCA) | Otherc                     | Analysis (%)d Included in Samples |
| MDX1106-01 (CA209001)  | 915                               | 42                         | 40                         | 33                                 | 0                          | 0                                              | 0                          | 800 (87.4)                        |
| MDX1106-03(CA209003)   | 3733                              | 74                         | 331                        | 32                                 | 2                          | 76                                             | 0                          | 3218 (86.2)                       |
| ONO-4538-07            | 431                               | 3                          | 65                         | 0                                  | 0                          | 1                                              | 0                          | 362 (84.0)                        |
| CA209017               | 585                               | 8                          | 119                        | 4                                  | 0                          | 0                                              | 0                          | 454 (77.6)                        |
| CA209057               | 1355                              | 15                         | 264                        | 16                                 | 0                          | 0                                              | 0                          | 1060 (78.2)                       |
| CA209227               | 4828                              | 30                         | 1170                       | 76                                 | 0                          | 0                                              | 6                          | 3546 (73.4)                       |
| ONO-4538-24 (CA209473) | 618                               | 0                          | 184                        | 0                                  | 0                          | 0                                              | 0                          | 434 (70.2)                        |
| CA209577               | 2503                              | 2                          | 507                        | 8                                  | 1                          | 1                                              | 0                          | 1984 (79.3)                       |
| CA209648               | 2413                              | 2                          | 608                        | 5                                  | 0                          | 0                                              | 0                          | 1798 (74.5)                       |
| CA209743               | 1518                              | 31                         | 286                        | 25                                 | 0                          | 0                                              | 0                          | 1176 (77.5)                       |
| Total                  | 18899                             | 207                        | 3574                       | 199                                | 3                          | 78                                             | 6                          | 14832 (78.5)                      |

d Samples ineToolbox orPharmacokinetic/Pharmacodynamic Analysis and Modeling System PAMS), all of which are included in the analysis dataset with flag as noted.

LLOQ: Post dose nivolumab serum concentration values below the lower limit of quantification.

CPK samples collected using incorect kit and PK samples fom a subject with ndication diferent fom the protocol.

% samples included in analysis =100 * (number of samples in PK database - number of samples excluded)/ number of samples in PK database for each respective study.

Abbreviations: Conc = concentration; LLoQ = lower limit of quantification; NCA = non-compartmental analysis; PK = pharmacokinetic.

Analysis-Directory:/global/pkms/data/CA/209/ec-11/prd/cognigen/sd/final/

Program Source: Analysis-Directory/d1pk-nivo/R/nivo-cv209648-1l-escc-pmr-tl-section-3.Rmd

Source:Analysis-Directory/d1pk-nivo/tables/rmd-rtf/data-disposition-table-samples-v01.rtf

<div style=\"page-break-after: always\"></div>

Table 3.3.1.5-1: SummaryofBaselineCovariatesbySubjectPopulationintheNivolumabPopulationPharmacokinetic AnalysisDataset

| Subject Characteristics              |                  | 2L NSCLC              | 2L+EC           | ADJ EC/GEJC          | IL ESCC              | IL NSCLC                 | IL MESO              | Othersa              | Overall                   |
|--------------------------------------|------------------|-----------------------|-----------------|----------------------|----------------------|--------------------------|----------------------|----------------------|---------------------------|
| Age (years)                          | Mean (SD) Median | 62.2 (9.18) 62 37, 85 | 62.6 (8.23) 63  | 60.5 (9.25) 62 26.82 | 62.5 (9.18) 63 28,90 | 63 (9.79) 64 26.87       | 68.7 (8.53) 69 32.85 | 60.9 (12.2) 61 29,85 | 62.8 (9.68) 64 26.90 3651 |
|                                      | Min, Max         | 539                   | 37, 82 251      | 474                  | 0(0) 58              | 1306 0(0) 69             | 297 0(0)             | 209 0(0)             |                           |
|                                      | n                |                       |                 |                      | 575                  |                          |                      |                      |                           |
|                                      | Missing, n (%)   |                       |                 |                      |                      |                          |                      |                      | 20 (0.545)                |
|                                      |                  | 0(0)                  | 0(0)            | 20 (4.05)            |                      |                          |                      |                      |                           |
| Baseline Body Weight (kg)            | Mean (SD) Median | 73.9 (16.3) 71.6      | 55.2 (10)       | 71.5 (16.2)          | 58.6 (11.9)          | 70.8 (15.8)              | 73.1 (14.9) 71.9     | 85 (20) 82.4         | 69.4 (16.9)               |
|                                      | Min, Max         | 41.6, 158             | 55.1 34.1, 83.1 | 70.8 34.5,119        | 25.7, 125            | 36.8, 131 1304 2 (0.153) | 40, 123 297          | 44.1, 153            | 67.7 25.7, 158            |
|                                      | n                | 538                   | 251             | 494                  | 575                  |                          |                      | 209                  | 3668                      |
|                                      |                  | 1 (0.186)             | 0(0)            | 0(0)                 | 0 (0)                |                          | 0(0)                 | 0 (0)                | 3 (0.0817)                |
|                                      | Missing, n (%)   |                       |                 |                      |                      | 90.8 (16.9)              |                      |                      |                           |
| Baseline GFR (mL/min/1.73 m2)        | Mean (SD)        | 82.7 (19.6)           | 86.8 (17.1)     | 94.7 (14.4)          | 95.8 (12.6)          |                          | 86.5 (15.4)          | 79.4 (20.3)          | 89.6 (17.3)               |
| Baseline GFR (mL/min/1.73 m2)        | Median           | 84.5                  | 91.4            | 95.7                 | 95.9                 | 93.5                     | 88.8                 | 82.6                 | 92.4                      |
| Baseline GFR (mL/min/1.73 m2)        | Min, Max         | 31.2,135              | 31.2,123        | 39.3,136             | 50.1, 145            | 25.1, 158                | 35, 125              | 34.5, 132            | 25.1, 158                 |
| Baseline GFR (mL/min/1.73 m2)        | n                | 537                   | 251             | 471                  | 574                  | 1301                     | 296                  | 206                  | 3636                      |
| Baseline GFR (mL/min/1.73 m2)        | Missing, n (%)   | 2 (0.371)             | 0(0)            | 23 (4.66)            | 1 (0.174)            | 5 (0.383)                | 1 (0.337)            | 3 (1.44)             | 35 (0.953)                |
| Baseline Serum Albumin (g/dL)        | Mean (SD)        | 3.92 (0.487)          | 3.94 (0.429)    | 3.96 (0.388)         | 3.9 (0.519)          | 3.91 (0.496)             | 3.66 (0.612)         | 4.09 (0.507)         | 3.91 (0.5)                |
| Baseline Serum Albumin (g/dL)        | Median           | 4                     | 3.9             | 4                    | 4                    | 4                        | 3.8                  | 4.1                  | 4                         |
| Baseline Serum Albumin (g/dL)        | Min, Max         | 1.9, 5.2              | 2.7, 5.2        | 2.7, 5.1             | 2.2, 5.2             | 1.5, 5.2                 | 1.7, 5               | 2.3, 5.1             | 1.5, 5.2                  |
| Baseline Serum Albumin (g/dL)        | n                | 526                   | 251             | 466                  | 554                  | 1292                     | 293                  | 206                  | 3588                      |
| Baseline Serum Albumin (g/dL)        | Missing, n (%)   | 13 (2.41)             | (0)             | 28 (5.67)            | 21 (3.65)            | 14 (1.07)                | 4 (1.35)             | 3 (1.44)             | 83 (2.26)                 |
| Baseline Lactate Dehydrogenase (U/L) | Mean (SD)        | 330 (264)             | 230 (225)       | 186 (70.7)           | 243 (190)            | 297 (232)                | 221 (97.5)           | 317 (378)            | 269 (224)                 |
| Baseline Lactate Dehydrogenase (U/L) | Median           | 238                   | 192             | 167                  | 195                  | 232                      | 193                  | 199                  | 206                       |
| Baseline Lactate Dehydrogenase (U/L) | Min, Max         | 98,3080               | 101, 3420       | 81,567               | 67,3410              | 74, 3600                 | 99,701               | 91,2980              | 67,3600                   |
| Baseline Lactate Dehydrogenase (U/L) | n                | 534                   | 251             | 484                  | 571                  | 1293                     | 294                  | 204                  | 3631                      |
| Baseline Lactate Dehydrogenase (U/L) | Missing, n (%)   | 5 (0.928)             | 0(0)            | 10 (2.02)            | 4 (0.696)            | 13 (0.995)               | 3 (1.01)             | 5 (2.39)             | 40 (1.09)                 |

| Subject Characteristics            |                       | 2L NSCLC            | 2L+EC          | ADJ EC/GEJC        | IL ESCC                     | IL NSCLC                         | ILMESO             | Othersa             | Overall                            |
|------------------------------------|-----------------------|---------------------|----------------|--------------------|-----------------------------|----------------------------------|--------------------|---------------------|------------------------------------|
| Combination Treatment, n (%)       | Nivo !I+OAIN!         | 539 (100) 0(0) 0(0) | 251 (100) 0(0) | 494 (100) 0(0) (0) | 0 (0) 289 (50.3) 286 (49.7) | 328 (25.1) 484 (37.1) 494 (37.8) | 0(0) 297 (100) (0) | 209 (100) 0(0) 0(0) | 1821 (49.6) 1070 (29.1) 780 (21.2) |
| Combination Treatment, n (%)       | Nivo+Chemo            |                     | (0)            |                    |                             |                                  |                    |                     |                                    |
| Baseline Performance Status, n (%) | 0                     | 136 (25.2)          | 122 (48.6)     | 292 (59.1)         | 278 (48.3)                  | 478 (36.6)                       | 113 (38)           | 113 (54.1)          | 1532 (41.7)                        |
| Baseline Performance Status, n (%) | 1                     | 399 (74)            | 129 (51.4)     | 202 (40.9)         | 297 (51.7)                  | 824 (63.1)                       | 184 (62)           | 92 (44)             | 2127 (57.9)                        |
| Baseline Performance Status, n (%) | 2                     | 4 (0.742)           | (0)            | 0(0)               | 0(0)                        | 3 (0.23)                         | 0(0)               | 4 (1.91)            | 11 (0.3)                           |
| Baseline Performance Status, n (%) | 3                     | 0(0)                | 0(0)           | 0 (0)              | 0 (0)                       | 1 (0.0766)                       | 0(0)               | 0(0)                | 1 (0.0272)                         |
| Race, n (%)                        | White                 | 489 (90.7)          | 5 (1.99)       | 403 (81.6)         | 135 (23.5)                  | 976 (74.7)                       | 260 (87.5)         | 190 (90.9)          | 2458 (67)                          |
| Race, n (%)                        | Black/Afican American | 23 (4.27)           | (0)            | 4 (0.81)           | 3 (0.522)                   | 11 (0.842)                       | 0(0)               | 14 (6.7)            | 55 (1.5)                           |
| Race, n (%)                        | Asian                 | 14 (2.6)            | 246 (98)       | 77 (15.6)          | 421 (73.2)                  | 291 (22.3)                       | 26 (8.75)          | 3 (1.44)            | 1078 (29.4)                        |
| Race, n (%)                        | Others                | 9 (1.67)            | (0)            | 10 (2.02)          | 12 (2.09)                   | 25 (1.91)                        | 5 (1.68)           | 2 (0.957)           | 63 (1.72)                          |
| Race, n (%)                        | Unknown               | 2 (0.371)           | (0)            | 0(0)               | 4 (0.696)                   | 3 (0.23)                         | 6 (2.02)           | 0(0)                | 15 (0.409)                         |
| Race, n (%)                        | Missing               | 2 (0.371)           | 0(0)           | 0(0)               | 0(0)                        | 0(0)                             | 0(0)               | 0(0)                | 2 (0.0545)                         |
| Sex, n (%)                         | Male                  | 326 (60.5)          | 212 (84.5)     | 417 (84.4)         | 471 (81.9)                  | 898 (68.8)                       | 229 (77.1)         | 144 (68.9)          | 2697 (73.5)                        |
| Sex, n (%)                         | Female                | 213 (39.5)          | 39 (15.5)      | 77 (15.6)          | 104 (18.1)                  | 408 (31.2)                       | 68 (22.9)          | 65 (31.1)           | 974 (26.5)                         |
| Immunogenicity                     | Negative              | 1988 (75.7)         | 0(0)           | 1226 (61.8)        | 1651 (91.8)                 | 3110 (87.7)                      | 859 (73)           | 1529 (52.6)         | 10363 (69.9)                       |
| bby Visit Level,                   | Positive              | 166 (6.32)          | 0(0)           | 32 (1.61)          | 130 (7.23)                  | 408 (11.5)                       | 120 (10.2)         | 69 (2.38)           | 925 (6.24)                         |
| N (%)                              | Missing               | 473 (18)            | 796 (100)      | 726 (36.6)         | 17 (0.945)                  | 28 (0.79)                        | 197 (16.8)         | 1307 (45)           | 3544 (23.9)                        |

a Others include subjects with colorectal cancer (CRC), melanoma (MEL), prostate cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC) in StudiesCA209001,CA209003,andCA209227.

Immunogenicity was not a baseline covariate and was summarized by visit level.

Abbreviations: 1L = first-line; 2L = second-line; Adj = adjuvant; Chemo = chemotherapy; EC = esophageal cancer; EC/GEJC = esophageal cancer or gastroesophageal junction cancer;ESCC=esophageal squamous cell carcinoma;Ipi=ipilimumab; GFR=glomerular filtration rate; Max=maximum; MESO=mesothelioma;Min=minimum; N = number of observations; n = number of subjects; Nivo = nivolumab; NSCLC = non-small cell lung cancer; SD = standard deviation.

Analysis-Directory: /global/pkms/data/CA/209/ec-1/prd/cognigen/sd/final/

Program Source: Analysis-Directory/d1pk-nivo/R/nivo-cv209648-1l-escc-pmr-tfl-section-3.Rmd

Source: Analysis-Directory/dlpk-nivo/tables/rmd-rtf/stat-covs-bypop-v01.rtf

<div style=\"page-break-after: always\"></div>

Table 3.3.1.5-2: Summary of Baseline Covariates by Nivolumab Treatment in Study CA209648

| Subject Characteristics              |                | Nivo 240 mg Q2W + Chemo   | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W   | Overall     |
|--------------------------------------|----------------|---------------------------|--------------------------------------|-------------|
| Age [years]                          | Mean (SD)      | 62.6 (9.18)               | 62.4 (9.19)                          | 62.5 (9.18) |
| Age [years]                          | Median         | 63                        | 63                                   | 63          |
|                                      | Min, Max       | 40,90                     | 28,81                                | 28, 90      |
|                                      | 5th, 95th      | 47,76                     | 47,75                                | 47,76       |
|                                      | n              | 286                       | 289                                  | 575         |
|                                      | Missing, n (%) | 0 (0)                     | 0 (0)                                | 0 (0)       |
| Baseline Body Weight [Kg]            | Mean (SD)      | 58.2 (12.5)               | 59 (11.2)                            | 58.6 (11.9) |
| Baseline Body Weight [Kg]            | Median         | 57.4                      | 58.2                                 | 58          |
|                                      | Min, Max       | 29.6, 125                 | 25.7, 104                            | 25.7, 125   |
|                                      | 5th, 95th      | 41.5, 79                  | 43.4, 78.9                           | 42.1, 79    |
|                                      | n              | 286                       | 289                                  | 575         |
|                                      | Missing, n (%) | 0 (0)                     | 0 (0)                                | 0 (0)       |
| Baseline GFR [mL/mim/1.73 m²]        | Mean (SD)      | 96.3 (12.6)               | 95.2 (12.7)                          | 95.8 (12.6) |
| Baseline GFR [mL/mim/1.73 m²]        | Median         | 96.7                      | 94.7                                 | 95.9        |
| Baseline GFR [mL/mim/1.73 m²]        | Min, Max       | 62.6, 145                 | 50.1, 145                            | 50.1, 145   |
| Baseline GFR [mL/mim/1.73 m²]        | 5th, 95th      | 73.6, 116                 | 75.4, 116                            | 73.9, 116   |
| Baseline GFR [mL/mim/1.73 m²]        | n              | 285                       | 289                                  | 574         |
| Baseline GFR [mL/mim/1.73 m²]        | Missing, n (%) | 1 (0.35)                  | 0 (0)                                | 1 (0.174)   |
| Baseline Serum Albumin [g/dL]        | Mean (SD)      | 3.89 (0.515)              | 3.9 (0.524)                          | 3.9 (0.519) |
| Baseline Serum Albumin [g/dL]        | Median         | 3.9                       | 4                                    | 4           |
| Baseline Serum Albumin [g/dL]        | Min, Max       | 2.2, 5.02                 | 2.3,5.2                              | 2.2, 5.2    |
| Baseline Serum Albumin [g/dL]        | 5th, 95th      | 3,4.61                    | 2.9,4.6                              | 2.9, 4.6    |
| Baseline Serum Albumin [g/dL]        | n              | 270                       | 284                                  | 554         |
| Baseline Serum Albumin [g/dL]        | Missing, n (%) | 16 (5.59)                 | 5 (1.73)                             | 21 (3.65)   |
| Baseline Lactate Dehydrogenase [U/L] | Mean (SD)      | 242 (160)                 | 243 (215)                            | 243 (190)   |
| Baseline Lactate Dehydrogenase [U/L] | Median         | 193                       | 198                                  | 195         |
| Baseline Lactate Dehydrogenase [U/L] | Min, Max       | 87,1980                   | 67,3410                              | 67,3410     |
| Baseline Lactate Dehydrogenase [U/L] | 5th, 95th      | 130, 468                  | 128,452                              | 128, 456    |
| Baseline Lactate Dehydrogenase [U/L] | n              | 285                       | 286                                  | 571         |
| Baseline Lactate Dehydrogenase [U/L] | Missing, n (%) | 1 (0.35)                  | 3 (1.04)                             | 4 (0.696)   |
| Age Group, n (%)                     | c 65 years     | 154 (53.8)                | 161 (55.7)                           | 315 (54.8)  |
| Age Group, n (%)                     | 265 years      | 132 (46.2)                | 128 (44.3)                           | 260 (45.2)  |

<div style=\"page-break-after: always\"></div>

Table 3.3.1.5-2: Summary of Baseline Covariates by Nivolumab Treatment in Study CA209648

| Subject Characteristics            |                         | Nivo 240 mg Q2W + Chemo   | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W   | Overall    |
|------------------------------------|-------------------------|---------------------------|--------------------------------------|------------|
| Body Weight Group. (%) u           | ≤50kg                   | 80 (28)                   | 59 (20.4)                            | 139 (24.2) |
| Body Weight Group. (%) u           | > 50-70kg               | 160 (55.9)                | 185 (64)                             | 345 (60)   |
| Body Weight Group. (%) u           | >70kg                   | 46 (16.1)                 | 45 (15.6)                            | 91 (15.8)  |
| Race, n (%)                        | Asian                   | 210 (73.4)                | 211 (73)                             | 421 (73.2) |
| Race, n (%)                        | Others                  | 3 (1.05)                  | 9 (3.11)                             | 12 (2.09)  |
| Race, n (%)                        | Unknowm                 | 3 (1.05)                  | 1 (0.346)                            | 4 (0.696)  |
| Race, n (%)                        | White                   | 70 (24.5)                 | 65 (22.5)                            | 135 (23.5) |
| Race, n (%)                        | Black/Afican American   | 0 (0)                     | 3 (1.04)                             | 3 (0.522)  |
| Primary Chinese Ethmicity, n (%)   | Chinese (Primary)       | 48 (16.8)                 | 43 (14.9)                            | 91 (15.8)  |
| Primary Chinese Ethmicity, n (%)   | Non-Chinese Asian       | 141 (49.3)                | 144 (49.8)                           | 285 (49.6) |
| Primary Chinese Ethmicity, n (%)   | Non-Asian               | 73 (25.5)                 | 77 (26.6)                            | 150 (26.1) |
| Primary Chinese Ethmicity, n (%)   | Chinese (Non-Primary)   | 21 (7.34)                 | 24 (8.3)                             | 45 (7.83)  |
| Primary Chinese Ethmicity, n (%)   | Missing                 | 3 (1.05)                  | 1 (0.346)                            | 4 (0.696)  |
| Secondary Chinese Ethmicity, n (%) | Chinese (Secondury)     | 67 (23.4)                 | 65 (22.5)                            | 132 (23)   |
| Secondary Chinese Ethmicity, n (%) | Non-Chinese Asian       | 141 (49.3)                | 144 (49.8)                           | 285 (49.6) |
| Secondary Chinese Ethmicity, n (%) | Non-Asian               | 73 (25.5)                 | 77 (26.6)                            | 150 (26.1) |
| Secondary Chinese Ethmicity, n (%) | Chinese (Non-Secondary) | 2 (0.699)                 | 2 (0.692)                            | 4 (0.696)  |
| Secondary Chinese Ethmicity, n (%) | Missing                 | 3 (1.05)                  | 1 (0.346)                            | 4 (0.696)  |
| Japanese Ethmicity. (%) u          | Japanese                | 116 (40.6)                | 120 (41.5)                           | 236 (41)   |
| Japanese Ethmicity. (%) u          | Non-Japanese Asian      | 94 (32.9)                 | 91 (31.5)                            | 185 (32.2) |
| Japanese Ethmicity. (%) u          | Non-Asian               | 73 (25.5)                 | 77 (26.6)                            | 150 (26.1) |
| Japanese Ethmicity. (%) u          | Missing                 | 3 (1.05)                  | 1 (0.346)                            | 4 (0.696)  |
| Region, n (%)                      | JapanKorea/Taiwan       | 169 (59.1)                | 169 (58.5)                           | 338 (58.8) |
| Region, n (%)                      | Rest of Asia            | 40 (14)                   | 40 (13.8)                            | 80 (13.9)  |
| Region, n (%)                      | Rest of World           | 77 (26.9)                 | 80 (27.7)                            | 157 (27.3) |
| Sex, n (%)                         | Male                    | 228 (79.7)                | 243 (84.1)                           | 471 (81.9) |
| Sex, n (%)                         | Female                  | 58 (20.3)                 | 46 (15.9)                            | 104 (18.1) |
| Baseline Perfonmance Status, n (%) | 0                       | 139 (48.6)                | 139 (48.1)                           | 278 (48.3) |
| Baseline Perfonmance Status, n (%) | 1                       | 147 (51.4)                | 150 (51.9)                           | 297 (51.7) |

<div style=\"page-break-after: always\"></div>

Table 3.3.1.5-2: Summary of Baseline Covariates by Nivolumab Treatment in Study CA209648

| Subject Characteristics                         |                         | Nivo 240 mg Q2W+Chemo   | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg QoW   | Overall     |
|-------------------------------------------------|-------------------------|-------------------------|--------------------------------------|-------------|
| Disease Status at Curent Diagnosis, n (%)       | Recuurent-Loco-Regional | 18 (6.29)               | 24 (8.3)                             | 42 (7.3)    |
| Disease Status at Curent Diagnosis, n (%)       | Recurent-Distant        | 63 (22)                 | 64 (22.1)                            | 127 (22.1)  |
| Disease Status at Curent Diagnosis, n (%)       | De Novo Metastatic      | 164 (57.3)              | 171 (59.2)                           | 335 (58.3)  |
| Disease Status at Curent Diagnosis, n (%)       | Unresectable Advanced   | 41 (14.3)               | 30 (10.4)                            | 71 (12.3)   |
| Smoking Status, n (%)                           | Never                   | 51 (17.8)               | 43 (14.9)                            | 94 (16.3)   |
| Smoking Status, n (%)                           | Cuurent/Fonmer          | 235 (82.2)              | 246 (85.1)                           | 481 (83.7)  |
| Alcohol Status, n (%)                           | Never                   | 60 (21)                 | 55 (19)                              | 115 (20)    |
| Alcohol Status, n (%)                           | Cuurent/Former          | 226 (79)                | 234 (81)                             | 460 (80)    |
| Number of Organs With Metastases at Base, n (%) | ≤1                      | 143 (50)                | 141 (48.8)                           | 284 (49.4)  |
| Number of Organs With Metastases at Base, n (%) | 22                      | 143 (50)                | 148 (51.2)                           | 291 (50.6)  |
| Prior Surgery, n (%)                            | 91                      | 191 (66.8)              | 197 (68.2)                           | 388 (67.5)  |
| Prior Surgery, n (%)                            | No                      | 95 (33.2)               | 92 (31.8)                            | 187 (32.5)  |
| Prior Radiotherapy. (%) u                       | Ye                      | 45 (15.7)               | 67 (23.2)                            | 112 (19.5)  |
| Prior Radiotherapy. (%) u                       | No                      | 241 (84.3)              | 222 (76.8)                           | 463 (80.5)  |
| PD-L1 Expression (1% Cutoff), n (%)             | Negative                | 145 (50.7)              | 145 (50.2)                           | 290 (50.4)  |
| PD-L1 Expression (1% Cutoff), n (%)             | Positive                | 141 (49.3)              | 141 (48.8)                           | 282 (49)    |
| PD-L1 Expression (1% Cutoff), n (%)             | Missing                 | 0 (0)                   | 3 (1.04)                             | 3 (0.522)   |
| Immmogenicity* by visit level, N (%)            | Negative                | 775 (96.6)              | 876 (88)                             | 1651 (91.8) |
| Immmogenicity* by visit level, N (%)            | Positive                | 19 (2.37)               | 111 (11.1)                           | 130 (7.23)  |
| Immmogenicity* by visit level, N (%)            | Missing                 | 8 (0.998)               | 9 (0.904)                            | 17 (0.945)  |

Immumogenicity was not a baseline covariate and was simmarized by visit level.

Abbreviations: Chemo = chemotherapy: GFR = glomerular filtation rate; Ipi=ipilimumab; Max =maximum; Min = minimum n =mumber of subjects; Nivo = nivolumab; PD-L1 = Programmed death ligand-1; Q2W = every 2 weeks; Q6W = every 6 weeks; SD = stamdard deviation.

Analysis-Directory /global/pkms/data/CA/209/ec-1l/prd/cognigen/sd/final/

Program Source: Amalysis-Directory/dlpk-mivo/R/mivo-cv209648-1l-escc-pmr-tfl-section-3.Rmd

Souuce: Analysis-Directory/dlpk-mivo/tables/rmd-rtf/stat-covs-s648-v01.rtf

<div style=\"page-break-after: always\"></div>

## Figure 5.1.1-1: Schematic Overview of the Population Pharmacokinetic Model Development for Nivolumab

## Base Model

- Re-estimated model parameters from a modified previous PK model using the pooled dataset including data from Study CA209648. The base model included the following covariate-parameter relationships:
- CL: BBWI, baseline PS, BGFR, BALB, sex, Iace (Asian), and BLDH
- VC: BBWT and sex
- Q: BBWT-constrained to same values for Q and CL
- VP: BBWT-constrained to same values for VC and VP

<!-- image -->

## Full Model

- Estimated the effect of co-administration with chemotherapy or ipilimumab and patient population (2L+ EC, 1L ESCC, adjuvant EC/GEJC, 1L NSCLC, 1L MESO, and OTHER) on CL, and pafient population (2L+ EC, 1L ESCC, adjuvant EC/GEJC, 1L NSCLC, 1L MESO, and OTHER) and PS on EMAX in the fill model

<!-- image -->

## Final Model

- Stepwise backward elimination of covariates was perfomed to select a parsimonious model.
- Based on BIC assessment, the following covariates were retained in the final model:
- CL: BBWT, BGFR, baseline PS, sex, race (Asian), BALB, BLDH, adjuvant EC/GEJC popuation, OTHER population, 1L MESO population, ipilimumab co-administration, and chemo co-administration
- VC: BBWT and sex
- Q: BBWT-constrained to same values for Q and CL
- VP: BBWT-constrained to same values for Q and CL
- EMAX: PS, adjuvant EC/GEJC population, and 1L MESO population

## Final model of Nivolumab

The final model for nivolumab was developed from the full model by performing a stepwise backward elimination of the covariate effects of the full model (co-administration with chemotherapy or ipilimumab and subject population on CL, and subject population and PS on Emax) to determine a parsimonious model. Parameter estimates of the final model following backward elimination are presented in Table 5.1.1.3-1. The condition number of the final model was 309, indicating there was no evidence for ill-conditioning.

<div style=\"page-break-after: always\"></div>

Table 5.1.1.3-1: Parameter Estimates of the Nivolumab Final Population Pharmacokinetic Model

| Name [Units]    | Symbol   | Estimateb     | Standard Error (%RSE)c   | 95% Confidence Interval (Bootstrap Derived)d   |
|-----------------|----------|---------------|--------------------------|------------------------------------------------|
|                 |          | Fixed Effects |                          |                                                |
| CLOker [mL/h]e  |          | 12.1          | 0.359 (2.96)             | 11.4-12.8                                      |
| VCker [L]       |          | 4.39          | 0.0457 (1.04)            | 4.3 -4.48                                      |
| QRer [mL/h]e    |          | 39.6          | 4.46 (11.2)              | 31.3 -49.7                                     |
| VPrer [L]       |          | 2.59          | 0.121 (4.66)             | 2.37 -2.83                                     |
| f               |          | 0.489         | 0.0308 (6.31)            | 0.432-0.552                                    |
| f               |          | 0.153         | 0.0274 (17.9)            | 0.0969 - 0.205                                 |
|                 |          | -0.181        | 0.0142 (7.84)            | (-0.207) - (-0.153)                            |
|                 | 010      | 0.126         | 0.0167 (13.2)            | 0.0931-0.163                                   |
| CLRAAS          |          | -0.116        | 0.0143 (12.3)            | (-0.142) - (-0.088)                            |
| f               | B12.     | -0.861        | 0.047 (5.46)             | (-0.951) - (-0.763)                            |
| f               | 013      | 0.287         | 0.0681 (23.7)            | 0.153 - 0.427                                  |
|                 | 014      | 0.0976        | 0.0324 (33.3)            | 0.0296-0.158                                   |
| CLPOPADIECAGEIC | 015      | -0.137        | 0.0232 (16.9)            | (-0.186) - (-0.0888)                           |
| VCeswT' f       | 016      | 0.621         | 0.0293 (4.72)            | 0.562 -0.674                                   |
| VCsEx           | 017      | -0.187        | 0.0222 (11.9)            | (-0.233) -(-0.144)                             |
| EMAXREF         | 018      | -0.387        | 0.0355 (9.16)            | (-0.457) - (-0.317)                            |
| T50 [b]         | 019      | 1400          | 69.1 (4.94)              | 1270 - 1550                                    |
| HILL            | 020      | 2.12          | 0.167 (7.88)             | 1.81 -2.46                                     |
| CLPOPILMESO     | 021      | 0.116         | 0.0289 (25)              | 0.0553 -0.169                                  |
| CLcO-IP         | 022      | 0.0766        | 0.0159 (20.7)            | 0.0471-0.11                                    |

<div style=\"page-break-after: always\"></div>

Table 5.1.1.3-1: Parameter Estimates of the Nivolumab Final Population PharmacokineticModel

| Name [Units]a       | Symbol           | Estimateb        | Standard Error (%RSE)c   | 95% Confidence Interval (Bootstrap Derived)d   |
|---------------------|------------------|------------------|--------------------------|------------------------------------------------|
| CLO-CHEMO           | 023              | -0.123           | 0.0164 (13.3)            | (-0.158)-(-0.0909)                             |
| EMAX.               | 024              | -0.109           | 0.0229 (21)              | (-0.159) -(-0.0644)                            |
| EMAXPOPADIECGEC     | 025              | -0.0956          | 0.0237 (24.8)            | (-0.142)-(-0.0456)                             |
| EMAXPOPILMESO       | 026              | -0.124           | 0.0395 (31.8)            | (-0.201)-(-0.0428)                             |
| Random Effectshi    | Random Effectshi | Random Effectshi | Random Effectshi         | Random Effectshi                               |
| ∞²CL[]              |                  | 0.0728 (0.27)    | 0.00535 (7.35)           | 0.0626 -0.0847                                 |
| ∞²-VC[-]            | 220              | 0.0896 (0.299)   | 0.014 (15.6)             | 0.064-0.119                                    |
| ∞²-VP[-]            | 003,3            | 0.261 (0.511)    | 0.0405 (15.5)            | 0.187-0.343                                    |
| 0²-EMAX[]           | 004,4            | 0.042 (0.205)    | 0.00869 (20.7)           | 0.0246- 0.0596                                 |
| ∞²-CL: ∞²-VC[-]     | 001,2            | 0.0352 (0.188)   | 0.00481 (13.7)           | 0.0272 -0.0469                                 |
| Residual Error      | Residual Error   | Residual Error   | Residual Error           | Residual Error                                 |
| Proportional RV [-] |                  | 0.219            | 0.00617 (2.82)           | 0.208-0.232                                    |

Random effects and residual error parameter names containing a colon () denote corelated parameters.

Random effect and residual error parameter estimates are showm as variance (standard deviation) for diagonal and off-diagonal elements.

- %RSE is the relative standard error (standard error as a percentage of estimate).
- Confidence Interval values are taken from bootstrap calculations (989 successfiul out of a total of 1.000).
- CLRer, VCrer, QRer, VPrer, and EMAXrer are typical values of CL, VC, Q, VP, and EMAX at the reference covariate values. Covariate effects were estimated relative to a reference subject who is a male, with BALB of 4.0 g/dL,BLDHof 200 IU/L, BBWT of80 kg. estimated BGFR of90 mL/min/1.73 m², PS of0, race =non-Asian, defined as White, Black/Afican American, Other, Unknown, or missing.
- The typical values of CL, VC, Q, and Vp corresponding to contimuous valued covariates of subjecti are modeled as:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

- The typical values of CL, VC, and EMAX corresponding to categorical valued covariates of subject i are modeled as:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

- Eta shminkage: ETA\\_CL: 17.7%, ETA\\_VC: 41.3%, ETA\\_VP: 53.0%, ETA\\_EMAX: 52.9%; Epsilon shrimkage: 16.8%.
- iThe calculated correlation coefficient (1) of the off-diagonal omega was 0.436 for cov(V in VC, IIV in CL).

Note: The Others population (POPOTH) was comprised of subjects with colorectal cancer (CRC), melanoma (MEL), prostate cancer, andrenal cell carcinoma (RCC) in Studies CA209001 and CA209003.

Note: The condition mumber was 309 indicating there was no evidence for ill-conditioning.

- Program Source: Analysis-Directory/d1pk-mivo R/nivo-cv209648-1l-escc-pmr-tfl-section-5-modeldevelopment.Rmd

Analysis-Directory. /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

Source: Analysis-Directory/KIWI Rum ID 299402

<!-- formula-not-decoded -->

<div style=\"page-break-after: always\"></div>

The final model was described as 2-compartment model, with zero-order IV infusion and time-varying CL (sigmoidal-Emax function), with a proportional residual error model. Random effects were estimated for CL, VC, and Emax, including the covariance between CL and VC. The covariate effects of BBWT on Q and VP were constrained to be the same as the effects of BBWT on CL and VC, respectively.

The final model estimated (typical value) Emax (-0.387) indicates that nivolumab CL decreases with time, and that the maximal decrease is approximately 32.1% [calculated as: 1 -exp(Emax)]. The typical half-maximal change is estimated to occur at approximately 2 months (T50 = 1,400 hours).

Figure 5.1.1.3-1: Goodness-of-Fit Plots for the Nivolumab Final Population Pharmacokinetic Model, Overall, and by Population Groups

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 5.1.2-1: Prediction-corrected Visual Predictive Check of Trough Concentrations (Log Scale) Versus Actual Time After First Dose for Data from the lL ESCC Population by Treatment Using the Nivolumab Final Population Pharmacokinetic Model

1LESCC NIVO 3mg/kg Q2W + IPI 1 mg/kg Q6W

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 5.1.2-2: Prediction-corrected Visual Predictive Check of All Concentrations (Log Scale) Versus Actual Time After Previous Dose for Data from the IL ESCC Population by Treatment Using the Nivolumab Final Population Pharmacokinetic Model

1LESCC NIVO3mg/kgQ2W+ IPI 1 mg/kg Q6W

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Ipilimumab

Figure 5.2.1-l:

Schematic Overview of the Population Pharmacokinetic Model Development for Ipilimumab

## Base Model

- Re-estimated model parameters from a modified previous PK model using the pooled dataset including data from Study CA209648. The base model included the following covariate-parameter relationships:
- CL: BBWT and baseline LDH
- VC: BBWT
- Q: BBWT-constrained to same values for Q and CL
- VP: BBWT-constrained to same values for VP and VC
- Estimated the effect of patient population (1L ESCC, 1L NSCLC, and 1L MESO) on CL in the fill model.
- Stepwise backward elimination of covariates was perfomed to select a parsimonious model
- Based on BIC assessment, the following covaniates were retained in the final model:
- CL: BBWT, BLDH, 1L MESO population
- VC: BBWT
- Q:BBWT
- VP:BBWT

<!-- image -->

<!-- image -->

## Final Ipilimumab model

The final model for ipilimumab was developed from the full model by performing a stepwise backward elimination of the covariate effects of the full model (subject population on CL) to determine a parsimonious model. The final model estimated (typical value) Emax (-0.238) indicates that ipilimumab CL decreases with time, and that the maximal decrease is approximately 21% [calculated as: 1 -exp(Emax)]. The half -maximal change is estimated to occur at approximately 3.4 months (T50 = 2,480 hours) in all subjects.

Table 5.2.1.3-1: Parameter Estimates of the Ipilimumab Final Population Pharmacokinetic Model

| Name [Units]a   | Symbol        | Estimateb     | Standard Error' (%RSE)c   | 9596 Confidence Interval (Bootstrap Derived)d   |
|-----------------|---------------|---------------|---------------------------|-------------------------------------------------|
| Fixed Effects   | Fixed Effects | Fixed Effects | Fixed Effects             | Fixed Effects                                   |
| CLO [mL/h]e     |               | 15.2          | 0.274 (1.80)              | 14.6 - 15.6                                     |
| VC[L]           |               | 4.3           | 0.0512 (1.19)             | 4.19 -4.40                                      |
| Q[mL/h]e        |               | 25.0          | 2.45 (9.83)               | 19.8 - 29.8                                     |
| VP[L]           |               | 3.65          | 0.114 (3.13)              | 3.45 - 3.90                                     |
|                 | 8             | 0.563         | 0.0462 (8.21)             | 0.474 -0.66                                     |
| VCaawrf,        | 8             | 0.529         | 0.0489 (9.24)             | 0.434-0.623                                     |

<div style=\"page-break-after: always\"></div>

Table 5.2.1.3-1: Parameter Estimates of the Ipilimumab Final Population Pharmacokinetic Model

| Name [Units]a    | Symbol           | Estimate         | Standard Error (%RSE)   | 95%6 Confidence Interval (Bootstrap Derived)d   |
|------------------|------------------|------------------|-------------------------|-------------------------------------------------|
| f                | 6                | 0.779            | 0.0462 (16.0)           | 0.543 - 1.01                                    |
| EMAXe            | 010              | -0.238           | 0.0243(10.2)            | (-0.297) -(-0.19)                               |
| 150 [b]e         | 011              | 2480             | 300 (10.5)              | 2330 - 3670                                     |
| HILL[-]          | 012              | 2.19             | 0.303 (13.9)            | 1.64 - 3.09                                     |
| CLPOPILMEsO\"     | B13              | 0.178            | 0.0237 (13.3)           | 0.132 -0.227                                    |
| Random Effectshi | Random Effectshi | Random Effectshi | Random Effectshi        | Random Effectshi                                |
| ∞² -CL[-]        | 1'io             | 0.106 (0.326)    | 0.00724 (6.81)          | 0.0921 -0.12                                    |
| ∞² -VC[H-]       | 0022             | 0.0651 (0.255)   | 0.0148 (22.8)           | 0.0352 - 0.0945                                 |
| ∞² -EMAX[-]      | 2'60             | 0.0709 (0.266)   | 0.014 (19.7)            | 0.0461 -0.104                                   |
| ∞² CL: ∞² VC []  | z'i0             | 0.0316 (0.178)   | 0.00508 (16.1)          | 0.022 -0.0419                                   |
| Residual Error   | Residual Error   | Residual Error   | Residual Error          | Residual Error                                  |
| Proportional [-] |                  | 0.205            | 0.00751 (3.66)          | 0.189 -0.22                                     |
| Additive []      | 06               | 0.194            | 0.0316 (16.3)           | 0.0764 -0.252                                   |

Random effects and residual error parameter names containing a colon () denote correlated parameters.

Random effect and residual error parameter estimates are showm as variance (standard deviation) for diagonal and off-diagonal elements.

- %RSE is the relative standard error (standard error as a percentage of estimate).
- d Confidence interval values are taken from bootstrap calculations (986 nms successfil out of a total of 1,000).
- e CL0, VC, VP, and Q are typical values of CL, VC, VP, and Q at the reference covariate values. Covariate effects Were estimated relative to a reference subject with baseline LDH of 200 IU/L and body weight of 80 kg.
- The typical values of CL, VC, Q, and VP corresponding to continuous valued covaniates of subject i are modeled as:

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

- The typical values of CL corresponding to categorical valued covariates of subject i are modeled as: CLTV = CLRE X(eCLPOPMESO)POPiLMESO
- h Eta shrinkage: ETA\\_ CL: 11.2%, ETA\\_ VC: 43.6%, ETA \\_EMAX: 56.5%; Epsilon shrinkage: 19.7%.
- The calculated correlation coefficient (t) of the off-diagonal omega was 0.380 for cov(IIV in VC, IIV in CL).

<div style=\"page-break-after: always\"></div>

Figure 5.2.1.3-1: Goodness-of-Fit Plots for the Ipilimumab Final Population Pharmacokinetic Model, Overall, and by Population Groups Overall

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 5.2.2-1: Prediction-corrected Visual Predictive Check of All Concentrations (Log Scale) Versus Actual Time After First Dose for Data from the lL ESCC Subject Population Using the Ipilimumab Final Population Pharmacokinetic Model

<!-- image -->

Abbreviations: 1L = first-line; CI = confidence interval; Conc = concentation; ESCC = esophageal squamous cell carcinoma; Pred Conr = prediction coirected.

Analysis-Directory. /global/pkms/data/CA/209/ec-1l/prd/coguigen/sd/final/ Program Source: Amalysis-Directory/dlpk-ipi/R/ipi-cv209648-1l-escc-pmr-tl-section-5-model-application.Rmd Source: Analvsis-Directorv/dlpk-ipi/graphs/imd-pnghi/voc-ipi-s648only-final-02-atafd-001.png

<div style=\"page-break-after: always\"></div>

Figure 5.2.2-2: Prediction-corrected Visual Predictive Check of All Concentrations (Log Scale) Versus Actual Time After Previous Dose for Data from the lL ESCC Population Using the Ipilimumab Final Population Pharmacokinetic Model

<!-- image -->

Abbreviations: 1L = first-line; CI = confidence interval; Conc = concentration; ESCC = esophageal squamous cell carcinoma; Pred Conr = prediction conrected. Analysis-Directory. /global/pkms/data/CA/209/ec-1l/prd/cognigen/sd/final/

Program Source: Analysis-Directory/dlpk-ipi/R/ipi-cv209648-1l-escc-pmr-tfl-section-5-model-application Rmd Bud-too-pdepe-ro-eug-fogtgs-idi-oda/qaud-puysqdee/d-dipopang-sisfpeuy aomos

## Exposure relevant for safety evaluation

Summary statistics of the individual PK parameter estimates obtained from the final PPK model for subjects with 1L OSCC in Study CA209648 (by treatment group), 2L NSCLC, 2L+ EC, adjuvant EC/GEJC, 1L NSCLC (by treatment group), 1L MESO, and ALL (all subjects in the PPK analysis) populations are provided in Table 5.1.3.1-1 and Figure 5.1.3.1-1.

<div style=\"page-break-after: always\"></div>

Summaiy Statistics (Geometric Mean [%oCVl) of Individual Nivolumab Pharmacokinetic Parameter Estimates by Subject Population and Overall Population in the Population

Table 5.1.3.1-1: Pharmacolinetic Analysis (m = 3671)

| Parameter       | Geometric Mean (9oCV)   | Geometric Mean (9oCV)   | Geometric Mean (9oCV)   | Geometric Mean (9oCV)    | Geometric Mean (9oCV)   | Geometric Mean (9oCV)   | Geometric Mean (9oCV)   | Geometric Mean (9oCV)   | Geometric Mean (9oCV)   | Geometric Mean (9oCV)   |
|-----------------|-------------------------|-------------------------|-------------------------|--------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                 | Nivo Monotherapy        | Nivo Monotherapy        | Nivo Monotherapy        | Nivo+Chemo               | Nivo+Chemo              | Nivo+Chemo              | Nivo+Ipi                | Nivo+Ipi                | Nivo+Ipi                |                         |
|                 | 2L NSCLC (n=539)        | 1L NSCLC (n=328)        | 2L+EC (n=251)           | Adjuvant EC/GEJC (n=494) | 1L ESCC (n=286)         | 1L NSCLC (n=494)        | 1L ESCC (n=289)         | 1L NSCLC (n=484)        | 1L MIESO (n=297)        | ALL (n=3671)            |
| CLO (mL/b)      | 11.6 (34.3)             | 12.1 (32.2)             | 9.21 (27.2)             | 10.2 (24.3)              | 9.03 (29.3)             | 10.4 (31.9)             | 10.8 (29.8)             | 12.7 (33.1)             | 15.5 (29.2)             | 11.3 (34.9)             |
| CLss (mL/b)     | 7.34 (37.4)             | 7.77 (35.1)             | 5.92 (30.6)             | 6.03 (26.8)              | 5.75 (31.5)             | 6.57 (37.0)             | 6.99 (31.6)             | t0'8 (36.7)             | 8.72 (30.9)             | 7.08 (37.6)             |
| Vss (L)         | 6.00 (27.9)             | 6.16 (22.3)             | 5.28 (19.1)             | 6.38 (20.2)              | 5.59 (18.3)             | 6.16 (22.0)             | 5.41 (18.7)             | 6.11 (23.4)             | 6.38 (23.1)             | 6.08 (24.2)             |
| T1/2a,55 (b)    | 24.7 (26.6)             | 26.3 (17.6)             | 25.5 (14.1)             | 27.2 (12.6)              | 26.5 (12.4)             | 26.5 (15.3)             | 25.1 (14.6)             | 26.0 (19.1)             | 26.5 (19.4)             | 26.1 (18.8)             |
| T1/2β,ss (days) | 24.4 (33.6)             | 23.7 (32.1)             | 26.5 (24.2)             | 31.3 (19.0)              | 28.8 (24.7)             | 27.8 (27.6)             | 23.1 (26.5)             | 22.8 (33.5)             | 21.9 (31.7)             | 25.6 (32.3)             |

Note: n= 3671 is the sum of the 2L NSCLC, 2L+ EC, 1L ESCC, adjuvant EC/GEIC, 1L NSCLC, 1L MESO, and Other (not shown) populations comprising the ALL population (overall PPK analysis population).

Abbreviations: 1L = first-line; 2L = second-line; Chemo = chemotherapy; CL0 = clearance at time O; CLss = clearance at steady state; %CV = coefficient of variation expressed as a percentage; EC = esophageal cancer; ESCC = esophageal squamous cell carcinoma; GEIC = gastroesophageal junction cancer, IPI=ipilimuumab; MESO = mesothelioma; n= number of subjects; NSCLC =non-small cell lung cancer; Nivo =mivolumab; T1/2a,ss =alpha half-life at steady state; T1/2β,ss =beta half-life at steady state; Vss = sum of volume of the central compartment and volume of the peripheral compartment.

Analysis-Directory: /globalpkms/data/CA/209/ec-1l/prd/cognigen/sd/final/

Program Source: Analysis-Directory/dlpk-nivo/R/nivo-cv209648-1l-escc-pmr-fl-section-5-model-application.Rmd Source: Analysis-Directory/dlpk-mivo/tables/rmd-rtf/sumstat-pkparams-by-pop-combo-v01.rtf

<div style=\"page-break-after: always\"></div>

Figure 5.1.3.1-1: Distributions of Dose-normalized Nivolumab Cavgl and Cavgss by Subject Populations and by Treatment

<!-- image -->

Treatment

Boxes are 25th, 50th, and 75th percentiles; whiskers are 5th and 95th percentiles. Aslerisks show data. points outside this range. The number of subjects is sbove each box. Tiwo 1L NSCLC subjects with dose-normelized Nirolumab Cavg Steady-stale &gt; 2 in Nivo + Chemo group were excludied from plot for berter visualization.

<!-- image -->

Boxee are 25th, 5oth, and 75th percentiles; whiskers are 5th and 95th percentiles. Asrerisks show data. points outside this range. The number of subjects is above each box.

Abbreviations: 1L = first-line; 2L = second-line; Adj = adjuvant; Cavg = daily average mivolumab concentration; Cavgl = time-averaged serum concentation over the first dosing interval; Cavgss = time-averaged senum concentration at steady state; Chemo = chemotherapy; EC = esophageal camcer; EC/GEIC = esophageal cancer and gastroesophageal  jumction cancer: ESCC= esophageal Tleo smouenbs carcinoma;Ipi = ipilimmab; Meso = mesothelioma; Nivo = mivohmab; NSCLC = non-small cell lumg cancer.

Analysis-Directory: /global/pkms/data/CA/209/ec-1lprd/cognigen/sd/final/

Program Souuce: Amalysis-Directory/dlpk-mivo/R/nivo-cv209648-1l-escc-pm-tfl-section-5-model-applicationRmd Source: Analysis-Directory/dlpk-mivo/graphs/md-pnghi/rpt-b-dncavg-by-popn-combo-v02.png and 1pt-b-dncavgby-popn-combo-v03.png

<div style=\"page-break-after: always\"></div>

Table 5.2.3.1-1:

Summary Statistics (Geometric Mean [%CV]) of Individual Ipilimumab Pharmacokinetic Parameter Estimates by Subject Population and Overall Population in the Population Pharmacokinetic Analysis (n = 1364)

|                 | Geomethic Mean (%oCV)   | Geomethic Mean (%oCV)   | Geomethic Mean (%oCV)   | Geomethic Mean (%oCV)   | Geomethic Mean (%oCV)   |
|-----------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Parameter       | Ipi Monotherapy         | Nivo+Ipi                | Nivo+Ipi                | Nivo+Ipi                | All (n = 1364)          |
|                 | 2L+MEL (n =327)         | IL ESCC (n=278)         | IL NSCLC (n =464)       | IL MESO (n =295)        | All (n = 1364)          |
| CLO (mL/h)      | 15.5 (37.2)             | 12.8 (31.3)             | 14.5 (32.7)             | 17.2 (28)               | 14.9 (34.2)             |
| CLss (mL/h)     | 12.3 (39.7)             | 10.1 (32.5)             | 11.5 (35.1)             | 13.5 (32.3)             | 11.8 (36.6)             |
| Vss (L)         | 7.88 (15.1)             | 6.69 (10.9)             | 7.38 (12.1)             | 7.51 (14.5)             | 7.38 (14.3)             |
| T1/2a,ss (h)    | 48.5 (10.8)             | 49.1 (2.92)             | 48.9 (4.26)             | 47.7 (12.8)             | 48.6 (8.48)             |
| T1/2β,ss (days) | 20.9 (29.5)             | 21.4 (23.8)             | 20.8 (26.8)             | 18.5 (25)               | 20.4 (27.1)             |

Abbreviations: 1L = first-line; 2L=second-line; CL0= clearamce at time 0; CLss = clearance at steady state; %CV= coefficient of variation expressed as a percent; ESCC = esophageal squamous cell carcinomm; Ipi =ipilimmab; MEL=melamoma; MESO=mesothelioma; n =mumber of subjects; NSCLC =non-small cell lumg cancer; Nivo =mivoluab; T1/2a,ss = alpha half-life at steady state; T1/2β,ss = beta half-life at steady state; Vss = sum of volume of the central compartment and vohme of the peripheral compartment.

Analysis-Directory. /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

Program Souuce: Amalysis-Directory/dlpk-ipi/R/ipi-cv209648-1l-escc-pmr-tfl-section-5-model-application.Rmd Source: Analysis-Directory/dlpk-ipitables/imd-rtf/sumstat-pkparams-by-pop-combo-v01.rtf

Figure 5.2.3.1-1: Distributions of Dose-normalized Ipilimumab Cavgl and Cavgss by Subject Populations and by Treatments

<!-- image -->

Boxes are 25th, 50th, and 75th peroentiles; whiskers are 5th and 95th percentiles, Asterisks show data points outside this range. The number of subjects is above each box. One 2L + MEL and one 1L NSCLC subjects with dose-normalized Ipilimumab Cavg Steady-state &gt; 20 were excluded from plot for better visualization.

Abbreviations: 1L = first-line; 2L = second-line; Cavgl = time-averaged senm concentrafion over the first dosing interval; Cavgss = time-averaged senm concentation at steady state: ESCC=esophageal squamous cel carcinoma; Ipi = ipilimumab; MEL=melamoma; MESO = mesothelioma; Nivo = mivolumab; NSCLC = non-smal cell lumg cancer.

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cognigen/sd/final/

<div style=\"page-break-after: always\"></div>

## Special populations

Baseline Body weight on Nivolumab exposure

As presented, nivolumab CL increased approximately 20% with an increase in BBWT from the median to 95th percentile value. The VC was higher with higher BBWT (approximately 28%, between the median and 95th percentile values for BBWT). The impact of this effect on nivolumab exposure was evaluated in subjects with 1L OSCC.

Boxplots of Predicted Nivoluimab Exposures (Cavgl and Cavgss) by Body Weight Quartiles for Nivolumab 240 mg Q2W + Chemotherapy

Figure 5.1.3.2-1: Q4W in Subjects with 1L ESCC

Boxes are 25th, 50th, and 75th percentiles; whiskers are 5th and 95th percentiles. Asterisks show data points outside this range. The number of subjects is above each box.

<!-- image -->

Abbreviations: lL = first-line; Cavgl =time-averaged serum concenhation over the first dosing interval; Cavgss = time-averaged serum concenhation at steady state; Chemo= chemotherapy; Conc = concenhation; ESCC = esophageal squamous cell carcinoma; GM = geomehic mean; NIVO = nivolumab; Q2W = every 2 weeks; Q4W = every 4 weeks.

Analysis-Directory. /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/ Program Source: Analysis-Directory/dlpk-nivo/R/mivo-cv209648-1l-escc-pmur-tfl-section-5-model-application.Rmd Source: Analysis-Directory/dlpk-nivo/graphs/rmd-pnglohpt-b-exp-by-WIQRT-cavg-NIVO240mgQ2WChemov0l.png

<div style=\"page-break-after: always\"></div>

Figure 5.1.3.2-2: Body Weight Quartiles for Nivolumab 3 mg/kg Q2W + Ipilimumab

Boxplots of Predicted Nivolumab Exposures (Cavgl and Cavgss) by 1 mg/kg Q6W in Subjects with 1L ESCC

<!-- image -->

Baseline body weight [kg]

Boxes are 25th, 50th, and 75th percentiles; whiskers are 5th and 95th percentiles. Asterisks show data points outside this range. The number of subjects is above each box.

Abbreviations:1L =first-line;( Cavgl = time-averaged Iserum concentation over the first dosing interval; Cavgss = time-averaged serum concentation at steady state; Conc = concenhation; ESCC = esophageal squamous cell carcinoma; GM= geometic mean; IPI=ipilimumab; NIVO=mivolumab; Q2W = every 2 weeks; Q6W = every 6 weeks.

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/ Program Source: Analysis-Directory/dlpk-nivo/R/nivo-cv209648-1l-escc-pmur-tfl-section-5-model-applieation.Rmd Source:Analysis-Directory/dlpk-nivo/graphs/imd-pnglo/rpt-b-exp-by-WTQRT-cavgNIV03mgkgQ2WIP1lmgkgQ6W-r01.png

<div style=\"page-break-after: always\"></div>

Table 5.1.3.2-1: Predicted Exposures for the 5th/95th Percentiles of Body Weight for a Typical Subject and Percent Differences in Relation to the Median for Nivolumab 240 mg Q2W + Chemotherapy Q4W in Subjects with 1L ESCC

| Exposure   |   P05 (41.5 kg) |   Median (57.4 kg) |   P95 (79.0 kg) |   % Difference (P05-MIedian) |   % Difference (P95-MIedian) |
|------------|-----------------|--------------------|-----------------|------------------------------|------------------------------|
| Cavgl      |            40.1 |               33.2 |            27.6 |                         20.8 |                        -16.9 |
| Cminl      |            27.1 |               22.7 |            19   |                         19.4 |                        -16.3 |
| Cmaxl      |            81.9 |               67   |            55   |                         22.2 |                        -17.9 |
| Cavgss     |           141   |              120   |           103   |                         17.5 |                        -14.2 |
| Cminss     |           115   |               98.5 |            85   |                         16.8 |                        -13.7 |
| Cmaxss     |           196   |              165   |           140   |                         18.8 |                        -15.2 |

Abbreviations: 1L =first-line; Cavgl =time-averaged serum concentation over the first dosing interval; Cavgss =time-averaged serum concentation at steady state; Cmaxl = post dose 1 peak senum concenhation; Cmaxss = peak serum concentration at steady state; Cminl = trough serum concenhation after the first nivolumab dose; Cminss =trough senm concentation at steady state; ESCC =esophageal squamous cell carcinoma; P05 = 5th percentile; P95 = 95th percentile; Q2W = every 2 weeks; Q4W = every 4 weeks

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

Program Source: Analysis-Directory/dlpk-nivo/R/nivo-cv209648-1l-escc-pmur-tfl-section-5-model-application.Rmd Source:Analysis-Directory/dlpk-nivo/tables/rmd-rtf/sumstat-pk-exp-ccov-typical-sub-by-tx-BBWTNIV0240mgQ2WChemo-v0l.rtf

Table 5.1.3.2-2: Predicted Exposures for the 5th/95th Percentiles of Body Weight for a Typical Subject and Percent Differences in Relation to the Median for Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W in Subjects with 1L ESCC

| Exposure   |   P05 (43.4 kg) |   Median (58.2 kg) |   P95 (78.9 kg) |   % Difference (P05-Median) |   % Difference (P95-Median) |
|------------|-----------------|--------------------|-----------------|-----------------------------|-----------------------------|
| Cavgl      |            20.3 |               23   |            26.1 |                       -11.7 |                        13.5 |
| Cminl      |            13.1 |               15   |            17.2 |                       -12.7 |                        14.7 |
| Cmaxl      |            43.2 |               48.3 |            54.2 |                       -10.6 |                        12.2 |
| Cavgss     |            65.1 |               75.7 |            88.4 |                       -14   |                        16.8 |
| Cminss     |            51.2 |               60   |            70.7 |                       -14.7 |                        17.8 |
| Cmaxss     |            94.4 |              108   |           125   |                       -12.6 |                        15.7 |

Abbreviations: 1L =first-line; Cavgl =time-averaged serum concentation over the fiurst dosing interval; Cavgss = time-averaged serum concenhation at steady state; Cmaxl = post dose 1 peak senum concenhation; Cmaxss = peak serum concentration at steady state; Cminl = hrough serum concenhation after the first nivolumab dose; Cminss = trough senum concentation at steady state; ESCC =esophageal squamous cell carcinoma; P05 = 5th percentile; P95 = 95th percentile; Q2W = every 2 weeks; Q6W = every 6 weeks

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

Program Source: Analysis-Directory/dlpk-nivo/R/nivo-cv209648-1l-escc-pmur-tfl-section-5-model-application.Rmd Sowrce: Analysis-Directory/dlpk-nivo/tables/rmd-rtf/sumstat-pk-exp-ccov-typical-sub-by-tx-BBWTNIV03mgkgQ2WIP1lmgkgQ6W-v01.rtf

Baseline Body Weight Impact on Ipilimumab Exposure

<div style=\"page-break-after: always\"></div>

Figure 5.2.3.2-1: Boxplots of Predicted Ipilinumab Exposures (Cavgl and Cavgss) by Body Weight Quartiles for Subjects with lL ESCC

<!-- image -->

Boxes are 25th, 50th, and 75th percentiles; whiskers are 5th and 95th percentiles.

The number of subjects is above each box.

Asterisks show data points outside this range.

Abbreviations:1L=first-line; Cavgl=time-averaged serum concenhation over the first dosing interval; Cavgss = time-averaged serum concentation at steady state; Conc = concentation; ESCC = esophageal squamous cell carcinoma.

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

Program Source: Analysis-Directory/dlpk-ipi/R/ipi-ev209648-1l-escc-pmr-tfl-section-5-model-applieation.Rmd Souce: Analysis-Directory/dlpk-ipi graphs/imd-pnghi/ipt-b-exp-by-WTQRI-cavg-v0l.png

Table 5.2.3.2-1: Predicted Ipilimumab Exposures for the 5th/95th Percentiles of Body Weight for a Typical Subject for the Nivolumab 3 mg/kg Q2W + Ipilimunab 1 mg/kg Q6W

| Exposure       |   P05 (43.7 kg) |   Mfedian (58.4 kg) |   P95 (79.1 kg) |   9% Difference (P05-Median) |   % Difference (P95-MIedian) |
|----------------|-----------------|---------------------|-----------------|------------------------------|------------------------------|
| Cmaxl [ug/mL]  |           13.9  |               16    |           18.4  |                        -13.1 |                         15   |
| Cminl [ug/mL]  |            1.13 |                1.28 |            1.45 |                        -11.7 |                         13.3 |
| Cavgl [ng/mL]  |            3.4  |                3.87 |            4.44 |                        -12.1 |                         14.7 |
| Cmaxss [ug/mL] |           16.1  |               18.4  |           21.2  |                        -12.5 |                         15.2 |
| Cminss [ug/mL] |            5.3  |                6.02 |            6.87 |                        -12   |                         14.1 |
| Cavgss [μg/mL] |            8.28 |                9.42 |           10.8  |                        -12.1 |                         14.6 |

Abbreviations: BBWT = baseline body weight; Cavgl = time-averaged serum concenhation over the first dosing interval; Cavgss = time-averaged senm concenhration at steady state; Cmaxl =post dose 1 peak senm concenhation; Cmaxss = peak senum concentation at steady state; Cminl = trough serum concenhration afer the first mivolumab dose; Cminss = hrough serum concentration at steady state; P05 = 5th percentile; P95= 95th percentile; Q2W = every 2 weeks; Q6W = every 6 weeks.

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

<div style=\"page-break-after: always\"></div>

## Baseline Albumin Impact on Nivolumab Exposure

Table 5.1.3.3-2: Predicted Exposures for the 5th/95th Percentiles of Baseline Serum Albumin for a Typical Subject and Percent Differences in Relation to the Median for Nivolumab 3 mg/kg Q2W + Ipilinumab 1 mg/kg Q6WW in Subjects with IL ESCC

| Exposure   |   P05 (2.9 g/dL) |   Median (4 g/dL) |   (TP/a g't) 96d |   %Difference (P05-MIedian) |   % Difference (P95-MIedian) |
|------------|------------------|-------------------|------------------|-----------------------------|------------------------------|
| Cavgl      |             21.9 |              24.2 |             25.1 |                        -9.5 |                         3.72 |
| Cminl      |             12.8 |              15.8 |             17.1 |                       -19   |                         8.23 |
|            |             50.6 |              50.6 |             50.6 |                         0   |                         0    |
| Cavg5s     |             61.1 |              80.5 |             90.8 |                       -24.1 |                        12.8  |
| Cminss     |             45.1 |              64.1 |             74.2 |                       -29.6 |                        15.8  |
| Cmaxss     |             95.7 |             115   |            125   |                       -16.8 |                         8.7  |

Abbreviations: 1L =first-line; Cavgl =time-averaged senum 1concenhation over the first dosing interval; Cavgss =time-averaged senum concentation at steady state; Cmaxl = post dose l peak senum concenhation;

Cmaxss = peak serum concentration at steady state; Cminl = hrough serum concenhation after the first nivolumab dose; Cminss = trough senum concenhation at steady state; ESCC =esophageal squamous cell carcinoma; P05 = 5th percentile; P95 = 95th percentile; Q2W = every 2 weeks; Q6W = every 6 weeks

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

Program Source: Analysis-Directory/dlpk-nivo/R/nivo-cv209648-1l-escc-pmr-tfl-section-5-model-applicafion.Rmd Source: Analysis-Directory/dlpk-nivo/tables/rmd-rtf/sumstat-pk-exp-ceov-typical-sub-by-tx-BALBNIVO3mgkgQ2WIPIlmgkgQ6W-v01.rtf

## Baseline LDH Impact on Ipilimumab Exposure

Table 5.2.3.3-1: Predicted Exposures for the 5th/95th Percentiles of Baseline LDH for a Typical Subject in the Nivolumab 3 mg/kg Q2W + Ipilinumab 1 mg/kg Q6W Treatment Group

| Exposure   |   P05 (128 U/L) |   Median (197 U/L) |   P95 (454 U/L) |   %6Differelice P05-Mfedian |   % Difference P95-Median |
|------------|-----------------|--------------------|-----------------|-----------------------------|---------------------------|
| Cavgl      |            4.28 |               4.09 |            3.78 |                        4.65 |                     -7.58 |
| Cminl      |            1.51 |               1.35 |            1.1  |                       11.9  |                    -18.5  |
| Cmaxl      |           16.9  |              16.9  |           16.9  |                        0    |                      0    |
| Cavgss     |           10.4  |               9.95 |            9.23 |                        4.52 |                     -7.24 |
| Cminss     |            6.82 |               6.36 |            5.63 |                        7.23 |                    -11.5  |
| Cmaxss     |           19.8  |              19.4  |           18.9  |                        2.06 |                     -2.58 |

Abbreviations: Cavgl = time-averaged serum concenhration over the first dosing interval; Cavgss = time-averaged senum concenhation at steady state; Cmaxl =post dose l peak senm concenhation; Cmaxss=peak senum concenthation at steady state; Cminl = hough serum concentration after the first nivolumab dose; Cminss = trough serum concenhation at steady state; LDH = lactate dehydrogenase; P05 = 5th percentile; P95 = 95th percentile; Q2W = every 2 weeks; Q6W = every 6 weeks.

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cognigen/sd/final/

Program Source: Analysis-Directory/dlpk-ipi/R/ipi-cv209648-1l-escc-pmr-tfl-section-5-model-application.Rmd

Sowrce: Analysis-Directory/ dlpk-ipi/tables/rmd-rtf/sumstat-pk-exp-ccov-typieal-sub-by-tx-BLDH-v0l.rtf

## Dose recommendations

## Nivolumab

Nivolumab Exposures in Subjects with 1L OSCC When Administered as a Flat Dose (240 mg Q2W or 360 mg Q3W) Versus Weight-Based Dosing (3 mg/kg Q2W) In Combination with Ipilimumab

Nivolumab exposures were predicted for subjects with 1L OSCC in Study CA209648 following the nivolumab 3 mg/kg Q2W, 240 mg Q2W, or 360 mg Q3W in combination with ipilimumab treatment

<div style=\"page-break-after: always\"></div>

regimens. The predicted concentration-time profiles were used to calculate key summary measures of exposure.

The geometric mean (with 90% PI) nivolumab concentration-time profiles in subjects with 1L OSCC for the first 28 days and at steady state are presented for the nivolumab 3 mg/kg Q2W and 240 mg Q2W regimens (Figure 5.1.3.8-1).

The geometric mean (with 90% PI) nivolumab concentration-time profiles in subjects with 1L OSCC for the first 42 days and at steady state are presented for the nivolumab 3 mg/kg Q2W and 360 mg Q3W regimens (Figure 5.1.3.8-2).

The steady-state exposure, including Cminss, Cmaxss, and Cavgss of nivolumab 240 mg Q2W was 37.3% to 38% higher compared to nivolumab 3mg/kg Q2W + ipilimumab dosing regimen. The steadystate exposure of nivolumab 360 mg Q3W was 62.7% higher for Cmaxss, 22.3% higher for Cminss, and 38% for Cavgss compared to nivolumab 3 mg/kg Q2W + ipilimumab dosing regimen.

Table 5.1.3.8-1: Summary of Nivolumab Exposures (Geometric Mean) for Nivolumab 3 mg/kg Q2W, Nivolumab 240 mg Q2W,or Nivolumab 360 mg Q3W in Combination With Ipilimumab 1 mg/kg Q6W in Subjects with 1L ESCC in Study CA209648

|          | Summary          | Geometric Mean (9bCV)    | Geometric Mean (9bCV)   | Geometric Mean (9bCV)   | 96 Difference   | q6Difference   |
|----------|------------------|--------------------------|-------------------------|-------------------------|-----------------|----------------|
| Tine     | Erposure (μg/mL) | 3 mg/kg Q2W + Ipi(n=289) | 240 mg Q2W + Ipi(n=289) | 360 mgQ3W + Ipi(n=289)  | (G2-G1)         | (G3-G1) b      |
|          | CmaxW2           | 51.4 (13.7)              | 70.9 (18.9)             | 106 (18.9)              | 37.9            | 106            |
| Week 0-2 | CminW2           | 15.1 (27.3)              | 20.8 (27.2)             | NA                      | 37.7            | NA             |
|          | CavgW2           | 23.7 (17.9)              | 32.7 (19.7)             | NA                      | 38              | NA             |
| Week 0-3 | CmaxW3           | 66.7 (15.4)              | 92.0 (19.3)             | 106 (18.9)              | 37.9            | 58.9           |
| Week 0-3 | CminW3           | NA                       | NA                      | 22.8 (34.3)             | NA              | NA             |

<div style=\"page-break-after: always\"></div>

Iable 5.1.3.8-1: Nivolumab 3 mg/kg Q2W, Nivolumab 240 mg Q2W, or Nivolumab 360 mg Q3W in Combination With Ipilimumab 1 mg/kg Q6W in

Summary of Nivolumab Exposures (Geometric Mean) for Subjects with 1L ESCC in Study CA209648

|              | Summary Erposure   | Geometric Mean (goC W)   | Geometric Mean (goC W)   | Geometric Mean (goC W)     | 96 Difference   | 中Difference   |
|--------------|--------------------|--------------------------|--------------------------|----------------------------|-----------------|---------------|
| Time         | (μg/mL)            | 3mglgQ2W + Ipi (n =289)  | 240mgQ2W + Ipi (n = 289) | 360 mg Q3W + Ipi (n = 289) | (G2-G1)*        | (G3-G1)       |
|              |                    | NA                       | NA                       | 41.7 (21.2)                | NA              | NA            |
|              | CavgW3             |                          |                          |                            |                 |               |
| Week 0-6     | CmaxW6             | 75.5 (17.0)              | 104 (20.1)               | 130 (19.4)                 | 37.7            | 72.2          |
|              | CminW6             | 29.6 (33.4)              | 40.9 (32.8)              | 34.2 (38.0)                | 38.2            | 15.5          |
|              | CavgW6             | 33.9 (21.7)              | 46.8 (22.5)              | 50.1 (23.1)                | 38.1            | 47.8          |
| Steady State | Cmaxss             | 110 (23.0)               | 151 (25.1)               | 179 (23.4)                 | 37.3            | 62.7          |
| Steady State | Cminss             | 56.9 (39.6)              | 78.5 (39.1)              | 69.6 (43.3)                | 38              | 22.3          |
| Steady State | Cavgss             | 73.9 (31.5)              | 102 (31.6)               | 102 (31.6)                 | 38              | 38            |

a Percent difference im geometic mean of 240 mg Q2W (G2) relative to 3 mg/kg mg Q2W (G1)

<!-- image -->

Abbreviations: 1L = first-line; Cavgss = time-averaged serum concenhation at steady state (2 weeks for Q2W and 3 weeks for Q3W); CavgW2 =average mivohumab concentation over the first dosing interval for Q2W (CavgW2 is equivalent to Cavgl for Q2W; CavgW2 is not applicable for Q3W); CavgW3 = average mivolumab concentration over the first dosing interval for over the first 2 dosing interval for Q3W and the first 3 dosing interval for Q2W; Cmaxss =peak senum concentation at steady state; CmaxW2 = maximum mivolhumab senum concentration after the first dose (CmaxW2 is equivalent to Cmaxl for Q2W and Q3W); CmaxW3 =maximum mivolumab concentration after the first dose for Q3W and after the second dose for Q2W (CmaxW3 is equivalent to Cmax1 for Q3W; CmaxW2 and CmaxW3 are equivalent for Q3W); Cmax W6 = maximm nivolumab concentation after the second dose for Q3W and after the third dose for Q2W; CminW2 = minimum nivohumab concentation after the first mivolumab dose for Q2W (CminW2 is equivalent to Cminl for Q2W; Cminss =trough senum concentration at steady state; CminW2 is not applicable for Q3W); CminW3 = minimum mivolumab concentration after the first mivolumab dose for Q3W and not applicable for Q2W (CminW3 is equivalent to Cminl for Q3W); CminW6=minimum mivolumab coucentration after the second nivolumab dose for Q3W and after the third dose for Q2W; %oCV = coefficient of variation expressed as a percent; ESCC = esophageal squamous cell carcinoma; Ipi = ipilimumab; n= number of subjects; NA = not Spam g Aana = Moo sam g Aana = meo isqam g Aana = mto taqegdde

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/

Program Source: Analysis-Directory/dlpk-mivo R/mivo-cv209648-1l-escc-pmur-fl-section-5-model-application.Rmd Source: Analysis-Directory/dlpk-nivo/tables/nmd-rtf/sumstat-pk-exp-by-tx-3-vs-240-vs-360-nivo-ipi-v01.rtf

<div style=\"page-break-after: always\"></div>

Figure 5.1.3.8-1: Predicted GeometricMean(90%oPI)Nivolunab Concentration-Time Profiles by Dosing Regiimens (Nivolunab 3 mg/kg Q2W vs Nivolumab 240 mg Q2W) in Subjects with 1L ESCC

<!-- image -->

Abbreviations: 1L =first-line; Conc = concenhation; ESCC = esophageal squamos cell carcinoma; Ipi = ipilimumab; Nivo = nivolumab; PI = prediction interval; Q2W = every 2 weeks. Analysis-Directory: /global/pkms/data/CA/209/ec-1lprd/cognigen/sd/final/ Program Source: Analysis-Directory/dlpk-nivo/R/mivo-cv209648-1l-escc-pmur-tfl-section-5-model-application.Rmd Source: Analysis-Directory/dlpk-nivo/graphs/rmd-pnghi/l-cp-time-geomean-ci-3nivoipi-240nivoipi-v0l.png

Figure 5.1.3.8-2: Predicted Geometric Mean (9o%o PI) Nivoluinab Concentration-Time Profiles by Dosing Regimens (Nivolumab 3 mg/kg Q2W+Ipilimumab vs Nivolumab 360 mg Q3W+Ipilimumab)in Subjects with 1L ESCC

<!-- image -->

Line represents geometric mean and shaded area represents 90% prediction interval

Abbreviations: 1L = first-line; Conc = concenhation; ESCC = esophageal squamous cell carcinoma; Ipi = ipilimumab; Nivo = nivolumab; PI = prediction interval; Q2W = every 2 weeks; Q3W = every 3 weeks. Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/ Program Source: Analysis-Directory/dlpk-nivo/R/nivo-cv209648-1l-escc-pmr-tfl-section-5-model-application.Rmd Source: Analysis-Directory/dlpk-nivo/graphs/imd-pnghi/l-cp-time-geomean-ci-3nivoipi-240nivoipi-v01.png

<div style=\"page-break-after: always\"></div>

## Ipilimumab

Ipilimumab exposures were predicted for subjects with 1L OSCC in Study CA209648 following the ipilimumab 1 mg/kg Q6W, in combination with nivolumab 3 mg/kg Q2W. The predicted concentrationtime profiles were used to calculate key summary measures of ipilimumab exposure.

The geometric mean (with 90% PI) ipilimumab concentration-time profiles in subjects with 1L OSCC for the first 12 weeks and at steady state are presented (Figure 5.2.3.7-1).

Table 5.2.3.7-1: Summary Statistics (Geoimetric Mean [%CV]) of Ipilimumab Exposure in Subjects with 1L ESCC in Study CA209648 (n = 278)

| Time         | Exposure (μg/mL)   | Geometric Mean (%CV) Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WW   |
|--------------|--------------------|------------------------------------------------------------|
| Week 0-6     | CmaxW6             | 16.2 (11.2)                                                |
| Week 0-6     | CminW6             | 1.18 (52.2)                                                |
| Week 0-6     | CavgW6             | 3.77 (22.4)                                                |
| Steady State | Cmaxss             | 18.8 (14.8)                                                |
| Steady State | Cminss             | 5.92 (33.0)                                                |
| Steady State | Cavgss             | 9.44 (22.4)                                                |

Abbreviations: IL = first-line; Cavgss = time-averaged serum concenhation at steady state; CavgW6 = average concenhation after 2 doses of Q3W regimen or 3 doses of Q2W regimen over the dosing interval of Week 0-6; Cmaxss = steady state maximum nivolumab concentration; Cmax W6 = maximum concenhation after the second dose for Q3W regimen or after the third dose for Q2W regimen at Week 0-6; Cminss = steady state minimum nivolumab concenhation; CminW6=minimum concenhration after the second dose for Q3W regimen or after the third dose for Q2W regimen at Week 6; %CV = coefficient of variation expressed as a percent; ESCC = esophageal squamous cell carcinoma; Ipi = ipilimumab, n = number of subjects; Nivo = nivolumab; Q2W = every 2 weeks; Q6W = every 6 weeks.

Analysis-Directory: /global/pkms/data/CA/209/ec-1l/prd/cogmigen/sd/final/ Program Souwrce: Analysis-Directory/dlpk-ipi R/ipi-cv20964S-1l-esce-pmr-tfl-section-5-model-applieation.Rmd Souce: Analysis-Directory/dlpk-ipi/tables/rmd-rtf/sumstat-pk-exp-lmpk-ipi-v0l.rtf

Figure 5.2.3.7-1: Predicted Geometric Mean (90%6 Pl) Ipilimumab Concentration-Time Profiles in Subjects with 1L ESCC

<!-- image -->

Line represents geometric mean and sheded area represents 90% prediction inlerval

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Mechanism of action

Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) that selectively binds to the programmed death-1 (PD-1) membrane receptor. The PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigenspecific T-cell responses to both foreign antigens and self-antigens.

Ipilimumab is a soluble, fully human monoclonal immunoglobulin (IgG1κ) that selectively binds to the cytotoxic T-cell lymphocyte antigen 4 (CTLA-4; CD152) expressed on a subset of T-cells, thereby blocking the interaction between CTLA-4 and B7 molecules on antigen-presenting cells (APCs) and preventing the inhibitory modulation of T-cell activation promoted by such interaction. Ipilimumab monotherapy is currently approved in the US, EU, and several other countries for the treatment of metastatic melanoma and the adjuvant treatment of melanoma and is being investigated across tumor types in combination with other modalities such as chemotherapy, radiation therapy, and other immunotherapies.

## 2.3.4. PK/PD modelling

## Exposure-efficacy

E-R Analysis of Efficacy for OS - Nivo+Ipi - Overall Study Population: For the E-R OS model of nivo+ipi vs chemo, both linear and log-linear functional forms of nivolumab and ipilimumab CavgW6 were assessed in the full model for the overall study population. Due to a high correlation (r &gt; 0.97) between nivolumab and ipilimumab exposures, ipilimumab CavgW6 was removed from the full model. Ipilimumab treatment was tested and still resulted in a high correlation with nivolumab exposure and was removed from the model. Among the evaluated functional forms of exposure effect, the linear function of nivolumab CavgW6 had the lowest BIC value but did not meet the criteria of a reduction in BIC of at least 2. Therefore, log-linear nivolumab CavgW6 was selected for the full model development.

The interaction between nivolumab CavgW6 and sex and nivolumab CavgW6 and age reduced BIC by 5 and 0.4, respectively. However, the interaction between nivolumab CavgW6 and age was not included in the model due to high correlations. No other significant covariates resulted in an interaction effect with nivolumab CavgW6 that decreased the BIC. Thus, the full model included only the interaction between nivolumab CavgW6 and sex. Figure 3 is a graphical presentation of the estimated effects in the full OS model for nivo+ipi in the overall study population, showing the HRs of OS across the predictor ranges and the associated 95% CIs, relative to the median value (for continuous covariates except CavgW6) or reference group (for categorical covariates). The effect of nivolumab CavgW6 on HR of OS was calculated relative to the chemo-only arm.

In the full model assessment, the relationship between nivolumab CavgW6 with OS was dependent on whether subjects with 1L OSCC were male or female. Males had a slightly lower OS HR than females at the same nivolumab CavgW6. In male subjects, nivolumab CavgW6 exposures were associated with significantly (95% CI interval excluded 1) lower risk of death than the chemo alone (HR of 0.62 [95% CI: 0.5, 0.76] over chemo [CavgW6 = 0] at the 5th percentile of CavgW6 [CavgW6 = 24 μg/mL], and HR of 0.6 [95% CI: 0.47, 0.75] over chemo at the 95th percentile of CavgW6 [CavgW6 = 48 μg/mL]). In female subjects, nivolumab CavgW6 exposures were associated with lower risk of death than the chemo alone (HR of 0.828 [95% CI: 0.665, 1.03] over chemo [CavgW6 = 0] at the 5th percentile of

<div style=\"page-break-after: always\"></div>

CavgW6 [CavgW6 = 24 μg/mL], and HR of 0.854 [95% CI: 0.668, 1.09] over chemo at the 95th percentile of CavgW6 [CavgW 6 = 48 μg/mL]). The E -R relationship was relatively flat across the range of nivolumab CavgW6 in this study as evidenced by the limited range of HRs associated with the 5th and 95th percentiles of nivolumab CavgW6.

The categorical variables that were identified as significant predictors (95% CI of effect did not include 1) on OS in the full model were race and PS. The risk of death increased with PS (= 1) and decreased with Asian race.

The continuous variables identified as significant predictors (95% CI of effect did not include 1) on OS in the full model were nivolumab CavgW6, age, baseline weight, baseline tumour size, and baseline ALB. The risk of death increased with higher baseline tumour size (HR of 1.38 [95% CI: 1.09, 1.74] for 95th percentile of baseline tumour size relative to the median), lower baseline weight (HR of 1.34 [95% CI: 1.13, 1.58] for 5th percentile of weight relative to the median weight), younger age (HR of 1.35 [95% CI: 1.12, 1.62] for 5th percentile of age relative to the median age), and lower baseline ALB (HR of 1.85 [95% CI: 1.49, 2.3] for 5th percentile of ALB relative to the median baseline ALB).

The 95% CI of the HRs for all the other predictor variables evaluated (eg, sex, tumor PD-L1 1% status, number of organs with metastases at baseline, disease status, smoking status, and alcohol use) included 1, indicating that these factors did not have statistically significant effects on OS. The VPC plots indicate the model-predicted median (90% PI) was in good agreement with the observed KM of OS, indicating adequate model performance. Model-predicted cumulative probabilities of OS using predicted CavgW6 for the nivo 3 mg/kg Q2W+ipi and nivo 360 mg every 3 weeks (Q3W)+ipi as well as the chemo-only arm in Study CA209648 are presented in Figure 4. Both nivolumab-treated regimens showed improved OS compared to the chemo-only group.

<div style=\"page-break-after: always\"></div>

Figure 3:

## Estimated Covariate Effects of the Exposure-Response of OS (Full Model) in Study CA209648 (Nivo+Ipi) - Overall Study Population

Covariate

<!-- image -->

Note: The effect of nivolumab Cavg Week 6 in males was based on the nivolumab Cavg effect alone. The effect of nivolumab Cavg Week 6 in females was based on the nivolumab Cavg effect plus the interaction between nivolumab Cavg and females.

Abbreviations: ALB = albumin; Cavg = average concentration; C/F = current/former; CI = confidence interval; CI = confidence interval; Cont. Var = continuous variable; Ipi = ipilimumab; LOCO = loco fegional; N = number of subjects or never; Nivo = nivolumab; OS = overall survival; PDL1 = programmed death-ligand 1.

Analysis-Directory: /global/pkms/data/CA/209/ec-11/prd/cognigen/sd/final/

Program Source: Analysis-Directory/010063/d1pkpd-eff/R/os/er-0s-alltreat-model-dev-code.Rmd

<div style=\"page-break-after: always\"></div>

Figure 4: CavgW6 from 2 Proposed Dosing Regimens (Nivo 3 mg/kg Q2W ol

Nivo 360 mg Q3IW+Ipi) in Subjects with 1L ESCC in Study CA209648 - Overall Study Population

<!-- image -->

Abbreviations: 1L = first-line; CavgW6 = average serum concentration at Week 6: Chemo = chemotherapy: ESCC = esophageal squamous cell carcinoma; Ipi= ipilimumab; Nivo =nivolumab; OS = overall survival; PI = prediction interval; Q2W = every 2 weeks; Q3W = every 3 weeks; Q6W = every 6 weeks.

Analysis-Directory:/global/pkms/data/CA/209/ec-11/prd/cognigen/sd/final/

Program Source: Analysis-Directory/010063/d1pkpd-eff/R/os/er-os-alltreat-model-dev-code.Rmd

Source: Analysis-Directory/010063/d1pkpd-eff/graphs/R/os-alltreat/os-alltreat-model-app-km-ni-360vs3mgkgpi.png

## E-R Analysis of Efficacy for OS - Nivo+Ipi - Tumor Cell PD-L1 Expression ≥ 1% Population:

For the E-R OS model of nivo+ipi vs chemo, both linear and log-linear functional forms of nivolumab and ipilimumab CavgW6 were assessed in the full model for the tumor cell PD-L1 expression ≥ 1% population. Due to a high correlation (r &gt; 0.97) between nivolumab and ipilimumab exposures, ipilimumab CavgW6 was removed from the full model. Ipilimumab treatment was tested and still resulted in a high correlation with nivolumab exposure and was removed from the model. Among the evaluated functional forms of exposure effect, the linear function of nivolumab CavgW6 had the lowest BIC value but did not meet the criteria of a reduction in BIC of at least 2. Therefore, the log-linear effect of nivolumab CavgW6 was selected for inclusion in the full model. No significant covariates resulted in an interaction effect with nivolumab CavgW6 that decreased the BIC.

The categorical variables that were identified as significant predictors (95% CI of effect did not include 1) on OS in the full model were race and sex. The risk of death decreased with female sex and with Asian race.

<div style=\"page-break-after: always\"></div>

The continuous variables that were identified as significant predictors (95% CI of effect did not include 1) on OS in the full model were nivolumab CavgW6, baseline weight, and baseline ALB. Higher nivolumab CavgW6 exposures were associated with significantly (95% CI interval excluded 1) lower risk of death than the chemo alone (HR of 0.56 [95% CI: 0.42, 0.74] over chemo [CavgW6 = 0] at the 5th percentile of CavgW6 [CavgW6 = 24 μg/mL], and HR of 0.54 [95% CI: 0.4, 0.73] over chemo at the 95th percentile of CavgW6 [ CavgW6 = 48 μg/mL]). The risk of death increased with lower baseline weight (HR of 1.34 [95% CI: 1.05, 1.71] for 5th percentile of weight relative to the median weight) and lower baseline ALB (HR of 1.82 [95% CI: 1.39, 2.39] for 5th percentile of ALB relative to the median baseline ALB).

The 95% CI of the HRs for all the other predictor variables evaluated (eg, age, baseline tumor size, PS, number of organs with metastases at baseline, disease status, smoking status, and alcohol use) included 1, indicating that these factors did not have statistically significant effects on OS. The VPC plots indicate the model-predicted median (90% PI) was in good agreement with the observed KM of OS, indicating adequate model performance.

## Exposure-safety

E-R Analysis of Safety for Gr2+ IMAEs: For the E-R safety model, both linear and log-linear functional forms of daily exposure of nivolumab and ipilimumab were assessed for their effect on the risk of Gr2+ IMAEs in the full model. Among the evaluated functional forms of exposure effect, the loglinear function of nivolumab daily Cavg and ipilimumab daily Cavg had the lowest BIC value and was selected as the full model. An ipilimumab treatment effect was tested instead of the log-linear ipilimumab daily Cavg, but it did not lower the BIC by 2 points and therefore was not included in the Gr2+ IMAE full model. No interactions between nivolumab or ipilimumab daily Cavg and covariates were significant predictors of Gr2+ IMAEs that reduced the BIC, and therefore none were included in the full model.

<div style=\"page-break-after: always\"></div>

Figure 5: Estimated Covariate Effects of the Exposure-Response of Gr2+ IMIAEs (Full MIodel) in Study CA209648 - All Treated Subjects

Covariate

<!-- image -->

Note: Time-varying daily Cavg was used in E-R Gr2+ IMAEs model development. The effects of exposure were calculated using the average concentration of the daily Cavg values from Day 1 to the day of event/censor. The hazard ratio of the effect of nivolumab plus ipilimumab Cavg was calculated as exp(O. 257·(LCAVGDN-reference median) + 0.167-(LCAVGDI-reference median)) where LCAVGDN/LCAVGDI are the 5th and 95th percentiles and references are the median of log nivolumab/ipilimumab daily Cavg based on the sum of nivolumab and ipilimumab effects.

Abbreviations: ALB = albumin; Cavg = averaged nivolumab daily Cavg from beginning of treatment to the day of event/censor; C/F = current/former; CI = confidence interval; Chemo = chemotherapy: Cont. Var = continuous variable; E-R = exposure-response; Gr2+ IMAEs = Grade ≥ 2 immune-mediated adverse events; LCAVGDN = log nivolumab daily Cavg: LCAVGI = log ipilimumab daily Cavg: LOCO = loco regional; N = number of subjects of never; PDL1 = programmed death-ligand 1.

Analysis-Directory: /global/pkms/data/CA/209/ec-11/prd/cognigen/sd/final/

Program Source: Analysis-Directory/010063/d1pkpd-safR/er-saf-model-dev.Rmd

Source: Analysis-Directory/010063/dlpkpd-saf/graphs/R/rpt-saf-coveff-full-model.png

<div style=\"page-break-after: always\"></div>

Figure 7: Predicted Median [90% P1] Probability of Gr2+ IMAEs Using Simulated Nivolumab and Ipilimnumab Cavg from 2 Proposed Dosing Regimens (Nivo 3 mg/kg Q2V or Nivo 360 mg Q3WW+Ipi) in Subjects with 1L ESCC for Study CA209648 - Overall Study Population

## Treatment

<!-- image -->

Abbreviations:1L =first-line;Cavg = average concentration;Chemo = chemotherapy: ESCC= esophageal squamous cell carcinoma; Gr2+ IMAEs = Grade≥2 immune-mediated adverse events; Ipi = ipilimumab; Nivo = nivolumab; PI= prediction interval; Q2W = every 2 weeks; Q3W = every 3 weeks.

Analysis-Directory: /global/pkms/data/CA/209/ec-11/prd/cognigen/sd/final/

Program Source: Analysis-Directory/010063/d1pkpd-saf/R/er-saf-model-dev.Rmd

Source: Analysis-Directory/010063/d1pkpd-saf/graphs/R/saf-model-app-km-pi-ni.png

## 2.3.5. Discussion on clinical pharmacology

## Population PK model

The Applicant has conducted a model-based approach by implementing the previously developed population PK models of nivolumab and ipilimumab in patients with oesophageal squamous cell carcinoma (OSCC). The modelling strategy is endorsed and the data analysis, exploratory assessment and data handling seems appropriate.

The population PK model of nivolumab is able to characterize the time-course profile based on the pcVPC and GOF plots of nivolumab in OSCC patients. The statistically significant covariate relationships were included and allowed to partially reduce the inter-individual variability.

The clinical impact of significant covariates on nivolumab exposure has been conducted, suggesting no clinically relevant changes in nivolumab exposure due to body weight, and clinically relevant differences on Cmin,ss and Cavg,ss in patients with very low (5 th  percentile) baseline albumin levels, which could partially explain the differences in the exposure-efficacy relationship.

<div style=\"page-break-after: always\"></div>

The population PK model of ipilimumab is able to characterize the time-course profile based on the pcVPC and GOF plots of ipilimumab in OSCC patients. The statistically significant covariate relationships were included and allowed to partially reduce the inter-individual variability.

No clinically relevant changes in ipilimumab exposure were predicted among the covariates tested in OSCC patients, suggesting that there is no need for ipilimumab dose adjustment in special sub-groups of populations.

## Dosing regimens

The evaluation of alternative dosing schedules of nivolumab (3 mg/kg Q2W vs. 240 mg Q2W and 3 mg/kg Q2W vs. 360 mg Q3W) in combination with ipilimumab through a model-based approach is appreciated, but should be considered based on the impact in terms of efficacy or safety endpoints, which is unclear especially in patients with extreme baseline body-weight and baseline albumin levels. A clinically relevant increase in exposure at steady-state conditions has been predicted when 240 mg Q2W (37.3% on Cmax,ss, 38% on Cmin,ss, and 38% Cave,ss) and 360 mg Q3W (62.7% on Cmax,ss, 22.3% on Cmin,ss, and 38% Cave,ss).

## Exposure-efficacy analysis

The evaluation of the exposure-efficacy on OS and PFS endpoints using the overall study population and the stratified group of tumour cell PD-L1 expression population revealed the improved efficacy when nivolumab+ipilimumab vs. chemo alone arms are selected. The recommendation of nivolumab in combination with ipilimumab seems to be justified in the overall population and tumour cell PD-L1 expression ≥ 1% population based on the OS and PFS in adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, although the predicted probability for OS is only slightly improved in the nivo+ipi arm vs. chemotherapy.

## Exposure-safety

The exposure-safety evaluation revealed a higher probability of Grade2+ IMAE (50-60%) when nivolumab is co-administered with ipilimumab vs. the chemo group, suggesting a clear higher incidence when ipilimumab is selected vs. chemotherapy. A similar benefit/risk assessment was predicted when a flat dosing regimen (360 mg Q3W) of nivolumab was compared with a body weight regimen of 3 mg/kg Q2W of nivolumab.

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology properties of nivolumab+ipilimumab groups were evaluated through the implementation of a previously developed population PK model of nivolumab and ipilimumab, which has been adapted to patients with oesophageal squamous cell carcinoma. The pharmacokinetic characterization seems appropriate based on the evidence provided. The exposure-efficacy and exposure-safety analyses demonstrated the adequacy of the exposure metrics selected to predict the OS/PFS and the incidence of Grade2+ IMAE across the different sub-groups of patients.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No dose-response studies were submitted as part of this application.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

Study CA209648 : A randomized Phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in subjects with unresectable advanced, recurrent or metastatic previously untreated oesophageal squamous cell carcinoma.

## Methods

Figure 1. CA209648 Study Design Schematic

<!-- image -->

This study will consist of 3 phases: screening, treatment, and follow-up. Subjects will be evaluated for disease progression every 6 weeks from the date of first dose (± 7 days) up to and including Week 48, and then every 12 weeks (± 7 days) thereafter, regardless of treatment schedule, until disease progression or the subject discontinues the study, whichever comes first.

## Study participants

## Key inclusion criteria

Subjects were required to be ≥ 18 years of age and have histologically confirmed squamous cell carcinoma or adenosquamous cell carcinoma (predominant squamous differentiation) of the oesophagus that was classified as unresectable advanced, recurrent or metastatic ( per AJCC 7th edition). Disease must not have been amenable to curative approaches such as definitive chemoradiation and/or surgery, and no prior systemic anticancer therapy was allowed as primary therapy for advanced or metastatic disease. Prior adjuvant, neoadjuvant, or definitive, chemotherapy/ radiotherapy/ chemoradiotherapy for OSCC was permitted if given as part of curative intent regimen and completed before enrolment. A minimum 24-week recurrence-free period was required after completion of neoadjuvant or adjuvant chemotherapies or after completion of multimodal therapies for locally advanced disease.

In addition, all subjects were required to have:

- -Baseline ECOG PS of ≤ 1.

<div style=\"page-break-after: always\"></div>

- -A least one measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria performed within 28 days prior to randomization.
- -PD-L1 immunohistochemistry (IHC) testing, with evaluable results, performed by the central lab during the Screening period. Either 1 formalin-fixed paraffin-embedded (FFPE) tumour tissue block or 15 unstained tumour tissue slides, with an associated pathology report if available, were to be submitted for biomarker evaluation prior to study drug administration.
- -In order to be randomized, subjects were required to have an evaluable tumour cell PD-L1 expression classification (≥ 1%, &lt; 1%, or indeterminate) as determined by the central lab. Subjects with non-evaluable results will not be allowed to be randomized.

## Key exclusion criteria

- -Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before randomization.
- -Prior malignancy requiring active treatment within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- -Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment. Patients may be randomized if the metastasis is asymptomatic and requires no treatment.
- -Patients at high risks of bleeding or fistula due to apparent invasion of tumour to organs (the aorta or the trachea) adjacent to oesophageal lesions.
- -Subjects with active, known, or suspected autoimmune disease. Subjects with Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll.
- -Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- -Subjects with a condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses &gt; 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- -Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

## Treatments

Eligible subjects were randomized to one of the following open label treatments (Arms A, B, and C):

- Arm A (nivo + ipi): nivolumab 3 mg/kg every 2 weeks (Q2W) intravenously (IV) + ipilimumab 1 mg/kg every 6 weeks (Q6W) IV.
- Arm B (nivo + chemo): nivolumab 240 mg Q2W IV + fluorouracil 800 mg/m2/day IV on Day 1 through Day 5 + cisplatin 80 mg/m2 IV on Day 1 of a 4-week cycle.
- Arm C (chemo): fluorouracil 800 mg/m2/day IV Day 1 through Day 5 + cisplatin 80 mg/m2 IV on Day 1 of a 4-week cycle.

<div style=\"page-break-after: always\"></div>

Treatment with nivolumab or nivolumab with ipilimumab was to be given for up to 24 months in the absence of disease progression (unless treatment beyond progression was permitted) or unacceptable toxicity. No dose escalations or reductions of nivolumab and ipilimumab were allowed. Doses of nivolumab and/or ipilimumab could be interrupted, delayed, or discontinued depending on how well the subject tolerated the treatment. If a subject met the criteria for discontinuation of nivolumab but not for ipilimumab, both nivolumab and ipilimumab were to be discontinued. If discontinuation criteria were met for ipilimumab but not for nivolumab, treatment with nivolumab might be continued if ipilimumab was discontinued.

Treatment beyond initial, investigator-assessed RECIST 1.1-defined progression was permitted in the nivo + ipi or nivo + chemo arms if the subject had investigator-assessed clinical benefit and was tolerating treatment.

Fluorouracil + cisplatin chemotherapy was given as per the study dosing schedule until disease progression or unacceptable toxicity. Doses of fluorouracil and/or cisplatin could be interrupted, delayed, reduced, or discontinued depending on how well the subject tolerated the treatment.

Note that country-specific CA209648 Protocol Amendment 10 (27-Sep-2018) allowed for a 4-day continuous infusion of 1000 mg/m 2  fluorouracil as an alternative to a 5-day continuous infusion for subjects in Korea and Taiwan in the nivo +chemo arm or chemo arm. The total dose of fluorouracil per cycle remained 4000 mg/m 2 .

## Objectives

Primary objectives

- ­ To compare the OS of nivolumab plus ipilimumab (Arm A) to fluorouracil plus cisplatin chemotherapy (Arm C) in subjects with PD-L1 expression ≥ 1%.
- ­ To compare the OS of nivolumab combined with fluorouracil plus cisplatin (Arm B) to fluorouracil plus cisplatin chemotherapy (Arm C) in subjects with PD-L1 expression ≥ 1%.
- ­ To compare the PFS of nivolumab plus ipilimumab (Arm A) to fluorouracil and cisplatin combination (Arm C) as assessed by BICR in subjects with PD-L1 expression ≥ 1%.
- ­ To compare the PFS of nivolumab combined with fluorouracil plus cisplatin (Arm B) to fluorouracil and cisplatin combination (Arm C) as assessed by BICR in subjects with PD-L1 expression ≥ 1%.

## Secondary objectives

- ­ To compare the OS of nivolumab plus ipilimumab (Arm A) and nivolumab combined with fluorouracil plus cisplatin (Arm B) to fluorouracil and cisplatin combination (Arm C) in all randomized subjects.
- ­ To compare the PFS of nivolumab plus ipilimumab (Arm A) and nivolumab combined with fluorouracil plus cisplatin (Arm B) to fluorouracil and cisplatin combination (Arm C) as assessed by BICR in all randomized subjects.
- ­ To compare the objective response rate (ORR) of nivolumab plus ipilimumab (Arm A) and nivolumab combined with fluorouracil plus cisplatin (Arm B) to fluorouracil and cisplatin combination (Arm C) as assessed by BICR in subjects with PD-L1 expression ≥ 1%.
- ­ To compare the ORR of nivolumab plus ipilimumab (Arm A) and nivolumab combined with fluorouracil plus cisplatin (Arm B) to fluorouracil and cisplatin combination (Arm C) as assessed by BICR in all randomized subjects.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

## Primary endpoint

Primary endpoints are overall survival (OS) and progression free survival (PFS) in subjects with PD-L1 expressing tumours.

OS is defined as the time between the date of randomization and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive.

PFS is defined as the time from randomization to the date of the first documented PD per BICR or death due to any cause. Subjects who die without a reported prior PD per BICR (and die without start of subsequent therapy) will be considered to have progressed on the date of death. Subjects who did not have documented PD per BICR per RECIST1.1 criteria and who did not die, will be censored at the date of the last evaluable tumour assessment on or prior to initiation of the subsequent anti-cancer therapy. Subjects who did not have any on-study tumour assessments and did not die (or died after initiation of the subsequent anti-cancer therapy) will be censored at the randomization date. Subjects who started any subsequent anti-cancer therapy without a prior reported PD per BICR will be censored at the last tumour assessment on or prior to initiation of the subsequent anti-cancer therapy.

## Secondary endpoints

- ­ OS in All Randomized subjects.
- ­ PFS (as assessed by BICR) in All Randomized subjects.
- ­ Objective Response Rate (ORR) (as assessed by BICR) in subjects with PD-L1 expressing tumours and All Randomized subjects.

It is defined as the number of subjects with a best overall response (BOR) of CR or PR divided by the number of randomized subjects in the population for each treatment group. BOR is defined as the best response designation as determined by BICR, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1 as determined by BICR) or the date of subsequent anti-cancer therapy (including tumour-directed radiotherapy and tumourdirected surgery), whichever occurs first. For subjects without documented progression or subsequent anti-cancer therapy, all available response designations will contribute to the BOR determination.

## Exploratory endpoints

- ­ PFS (as assessed by investigator) in subjects with PD-L1 expressing tumours and All Randomized subjects.
- ­ ORR (as assessed by investigator) in subjects with PD-L1 expressing tumours and All Randomized subjects.
- ­ Duration of Response (DOR) (as assessed by BICR and as assessed by investigator) is defined as the time between the date of first documented response (CR or PR) to the date of the first disease progression, per RECIST 1.1 or death due to any cause, whichever occurs first.
- ­ PFS2/TSST in subjects with PD-L1 expressing tumours and all randomized subjects. PFS2/TSST is defined as the time from randomization to the date of investigator-defined documented second objective disease progression or start of second subsequent therapy or death due to any cause, whichever comes first.
- ­ Patient-reported Outcomes (PRO).

<div style=\"page-break-after: always\"></div>

## Sample size

Sample size calculations assumed that the prevalence of subjects with tumour cell PD-L1 expression ≥ 1% was approximately 50%, and the proportion of subjects with (≥ 1%) or without (&lt; 1% or indeterminate) PD-L1 tumour expression was monitored during enrolment.

The study sample size was based on the primary objectives, i.e., on the comparisons of the PFS/OS distributions of subjects with tumour cell PDL1 expression ≥ 1% between those who were randomized to receive nivolumab plus ipilimumab and those randomized to receive chemotherapy, and between those who were randomized to receive nivolumab plus chemotherapy and those randomized to receive chemotherapy. For both experimental arms, the same OS distributions and the same PFS distributions were assumed. A piecewise mixture cure rate model was used for the design setup, with cure rates in the experimental arms of 15% for OS in tumour cell PDL1 ≥ 1%, 10% for OS in tumour cell PD -L1 &lt; 1%, and 0% for PFS per BICR. As a result, for each of the nivo + ipi (Arm A) vs. chemo (Arm C) and nivo + chemo (Arm B) vs. chemo (Arm C) comparisons:

- 250 PFS events in approximately 313 subjects with tumour cell PDL1 expression ≥ 1% would provide approximately 90% power to detect an average hazard ratio (HR) of 0.62 with a Type I error of 1.5% (two-sided);
- 250 OS events in approximately 313 subjects with tumour cell PDL1 expression ≥ 1% would provide approximately 90% power to detect an average HR of 0.6 with a Type I error of 1% (two-sided).

In case the significance level from the corresponding primary endpoint in subjects with tumour cell PDL1 ex pression ≥ 1% was passed to the secondary endpoint in all randomized subjects:

- 512 PFS events in approximately 626 subjects (all comers) would provide approximately 90% power to detect an average HR of 0.72 with a Type I error of 1.5% (two-sided);
- 514 OS events in approximately 626 subjects (all comers) would provide approximately 94% power to detect an average HR of 0.68 with a Type I error of 1% (two-sided).

To have approximately 313 randomized subjects with tumour cell PDL1 expression ≥ 1% for each comparison, approximately 470 subjects with tumour cell PDL1 expression ≥ 1% needed to be randomized in a 1:1:1 ratio in the 3 arms. This translated to a total of approximately 939 subjects (with any PD-L1 result) to be randomized in a 1:1:1 ratio to the nivo + ipi (Arm A) or nivo + chemo (Arm B) or chemo (Arm C) arms. Assuming a piecewise constant accrual rate, it was estimated that these 939 subjects would be accrued within 29 months.

## Randomisation

Eligible subjects were randomized in a 1:1:1 ratio to one of the treatments. At randomization, patients were stratified according to the following stratification factors:

- ­ Tumour cell PDL1 status: ≥ 1% vs . &lt; 1% (including indeterminate)*
- ­ Region: East Asia (Japan, Korea, Taiwan) vs. Rest of Asia (China, Hong Kong, Singapore) vs. Rest of World (RoW)
- ­ Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0 vs. 1)
- ­ Number of organs with metastases (≤ 1 vs . ≥ 2)

<div style=\"page-break-after: always\"></div>

*The proportions of subjects with or without tumour cell PD-L1 expression were monitored and reassessed as needed to ensure that the sample size of randomized subjects with tumour cell PD-L1 expression ≥ 1% was adequate for analysis (i .e. approximately 50% of all randomized).

## Blinding (masking)

Not applicable as the trial was open-label.

## Statistical methods

## Populations for analyses

The following definitions of populations will be applicable for subjects whose tumours express PD-L1 and also for subjects regardless of PD-L1 expression.

- -All Enrolled Subjects: All subjects who signed an informed consent form and were registered into the IRT
- -All Randomized Subjects: All enrolled subjects who were randomized to any treatment arm in the study
- -All Treated Subjects: All randomized subjects who received at least one dose of study drug during the study
- -PK Subjects: All randomized subjects with available serum time-concentration data.
- -Outcome Research subjects: All randomized subjects who have an assessment at screening/baseline and at least 1 follow-up assessment
- -Immunogenicity subjects: All randomized subjects who have an assessment at screening/baseline and at least 1 follow-up assessment
- -Biomarker subjects: All randomized subjects with available biomarker data.

## Protection of Type I error

Family-wise Type I error will be protected in the strong sense across all primary and secondary endpoints. The p-values from sensitivity analyses for efficacy endpoints are for descriptive purpose only and not adjusted for multiplicity.

The primary and secondary endpoints were tested using the Bonferroni-based graphical approach by Maurer and Bretz (2013). Figure below presents a graphical display of the multiple testing procedure.

<div style=\"page-break-after: always\"></div>

Figure 2. Graphical Representation of the Testing Strategy for the Primary and Secondary Endpoints

<!-- image -->

The planned test procedure was identical for the nivo + ipi (Arm A) vs. chemo (Arm C) and for the nivo + chemo (Arm B) vs. chemo (Arm C) comparisons and was conducted as follows.

At the time of the PFS final analysis, all 4 primary endpoints were tested, with the following initially allocated (endpoint-specific) 2-sided alpha levels:

- ­ PFS in subjects with tumour cell PDL1 expression ≥ 1%: 0.015 (2 -sided)
- ­ OS in subjects with tumour cell PDL1 expression ≥ 1%: the overall initially allocated (endpoint-specific) alpha of 0.01 (2 sided) would be distributed over the IA and FA based on the actual number of deaths for each comparison at OS IA, using Lan-DeMets alpha spending function with O'Brien-Fleming boundaries.

Alpha levels in this study are 2-sided. Upon availability of study data after database lock, the statistical testing procedure proceeded as follows.

Nivo + ipi vs. chemo:

- ­ For PFS: since the primary endpoint of PFS in all randomized subjects with tumor cell PD-L1 expression ≥ 1% was not significant at the 2-sided alpha level 0.015 (p-value: 0.8958), then the PFS and ORR secondary endpoints were not formally tested and no alpha was passed to the PFS/ORR secondary endpoints and OS primary endpoint from the secondary endpoint of PFS in all randomized subjects.
- ­ For OS: the observed number of OS events in all randomized subjects with tumor cell PD-L1 expression ≥ 1% at IA was 227 [90.8% of the target final number of 250 OS events]. With the total overall alpha of 0.02 (initial allocated overall alpha of 0.01 plus 0.01 alpha passed from the secondary OS endpoint in all randomized subjects for nivo + chemo vs. chemo), the

<div style=\"page-break-after: always\"></div>

significance level was 0.014 for OS IA in all randomized subjects with tumor cell PD-L1 expression ≥ 1%. Since the primary endpoint of OS was significant at the IA 2-sided alpha level 0.014 (p-value: 0.0010), then the secondary endpoint of OS in all randomized subjects was tested with the overall 2-sided alpha level 0.02. The observed number of OS events in all randomized subjects at IA was 448 [87.2% of the target final number of 514 OS events]. With the overall alpha of 0.02, the significance level was 0.018 for OS IA in all randomized subjects. The secondary endpoint of OS was significant at the IA 2-sided alpha level of 0.018 (p-value: 0.0110). Per testing procedure, the alpha can only be passed in one direction between 2 comparisons, therefore the alpha of 0.02 for OS in nivo + ipi vs. chemo cannot be passed back to OS in nivo + chemo vs chemo.

## Analysis of primary endpoints

OS and PFS as assessed by BICR in all subjects with tumour cell PDL1 expression ≥ 1% were planned to be compared between nivo + ipi (Arm A) and chemo (Arm C), and between nivo + chemo (Arm B) and chemo (Arm C) using a two-sided log-rank test, stratified by the following stratification factors: ECOG performance s tatus (0 vs. 1) and number of organs with metastases (≤ 1 vs. ≥ 2). Though the study randomization was stratified by region (East Asia vs. Rest of Asia vs. RoW), region was excluded from all stratified analyses due to small sample size in Rest of Asia.

For each comparison, the HR of PFS and OS with its associated two-sided 100(1α)% confidence intervals (CIs) were estimated via a stratified Cox model with treatment arm as the only covariate in the model.

Median OS and PFS for each treatment arm were estimated and plotted using the Kaplan-Meier (KM) product-limit method. Median OS and PFS along with 95% CIs were constructed based on a log-log transformed CI for the survival function.

Per Revised Protocol 05, final PFS analysis could have had either an event-based trigger (ie, conducted when 136 events were observed among the subjects with tumour cellPDL1 expression ≥ 1% in the chemo arm) or a time-based trigger (i.e., conducted when at least 12 months of minimum follow-up was reached). The trigger for the final PFS analysis based on the 01-Mar-2021 database lock was the time-based trigger of achieving a minimum follow-up of at least 12 months.

At the time of the final PFS analysis, a formal interim analysis for OS was planned to be conducted. Analyses of OS and PFS in all randomized subjects were planned to be carried out at the time of the primary analysis in all randomized subjects with tumour cell PDL1 expression ≥ 1%. OS and PFS in all randomized subjects were to be tested only if significance level was passed on them. As the OS comparisons were statistically significant at the interim analysis, OS analyses (database lock: 01-Mar2021) are considered final.

## Sensitivity analyses for OS and PFS

Sensitivity analyses for both OS and PFS included the following:

- 2-sided, unstratified log-rank test using an unstratified Cox proportional hazards model with treatment as the single covariate.
- A multivariate adjusted, stratified Cox model was fitted to assess the treatment effect when adjusted for potential prognosti c factors, including: age (&lt; 65 vs ≥ 65), sex (male vs female), race (Asian vs. nonAsian), weight (&lt; 60 kg vs ≥ 60 kg), disease status at current diagnosis (recurrent vs metastatic vs unresectable advanced), smoking status (current/former vs never/unknown), and alcohol use (current/former vs never/unknown).

<div style=\"page-break-after: always\"></div>

- Max-combo analysis of OS and PFS per BICR when the KM curves indicated the HR was not constant over time, such as with a clear delayed separation.
- PFS analysis accounting for assessment on/after subsequent therapy. PFS will be defined similarly to the primary definition except that events (progression or death) and disease assessments that occurred on or after subsequent anti-cancer therapy will be considered (no time point truncation).

Two sensitivity analyses were not performed due to not meeting sample-size thresholds for analysis: analyses using stratification factors as obtained from the baseline CRF pages (instead of IRT) if &gt; 10% of subjects with discordance, and analyses of subjects with no relevant deviation if &gt; 10% of subjects with relevant protocol deviations.

## Analysis of secondary endpoints

If any of the primary endpoints was significantly superior, the corresponding secondary endpoint of OS and PFS per BICR in all randomized subjects was compared using a two-sided log-rank test at the allocated significance level, stratified by: ECOG PS, number of organs with metastases, and tumour cell PDL1 expression (≥ 1% vs &lt; 1% or indeterminate)

For each comparison, the HR with its associated two-sided 95% CI (in case the given endpoint is formally tested, also with the 100[1α]% CI) was estimated via a stratified Cox model with treatment arm as the only covariate in the model. OS and PFS for each treatment arm were estimated and plotted using the KM product-limit method. Median OS and PFS with associated two-sided 95% CI were constructed based on a log-log transformed CI for the survival function.

The same additional analyses were carried out for OS and PFS in all randomized subjects as for OS and PFS in all randomized subjects with tumour cell PDL1 ≥ 1%.

ORR (as assessed by BICR) in subjects with PD-L1 expressing tumours and in all randomized subjects was to be tested only if significance level is passed on them.

ORR was computed in each treatment group along with the exact 95% CI using Clopper-Pearson method. An estimate of the difference in ORRs and corresponding 95% CI (in case the given endpoint is formally tested, also with the 100[1α]% CI) were calculated using Cochran -Mantel-Haenszel (CMH) methodology  and adjusted by the stratification factors. The stratified (source: IRT) odds ratios (Mantel-Haenszel estimator) between the treatments were provided along with the 95% CI (in case the given endpoint is formally tested, also with the 100[1α]% CI).

## Analysis of PRO

Analysis of EQ-5D-3L and FACT-E (including FACT-G7 and ECS) data was performed in all randomized subjects with tumour cell PDL1 ≥ 1% and all randomized subjects who had a PRO assessment at baseline (assessment on or prior to first dose on Day 1) and at least 1 subsequent assessment while on treatment. EQ-5D-3L and FACT-E data were summarized of each dimension/category by assessment time point and changes from baseline.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 3. Participant Flow Chart - All Randomized Subjects in the Nivo + Chemo, Nivo + Ipi, and Chemo Arms in CA209648 (01-Mar-2021 Database Lock)

<!-- image -->

- (a) Enrolled patients included all concurrently randomized subjects to nivo + chemo, nivo + ipi, or chemo.
- (b) Included death (n = 11), adverse events (n = 6), lost to follow-up (n = 1), poor/noncompliance (n = 1), and additional (other) reasons (n = 5: each 1 subject: subject no longer fit for trial/screen fail, Investigator's opinion, 'decided  to  participate  in  JCOG',  acute  lacunar  cerebral  infarction  needed  treatment,  subject  voluntarily discontinued).
- (c) Relevant protocol deviations were noted in 5 (0.5%) subjects. This included 2 subjects in the nivo + chemo arm (1 subject at study entry without squamous cell carcinoma or adenosquamous cell carcinoma of the oesophagus [subject had sarcomatoid carcinoma of the oesophagus and was randomized but never treated], and 1 subject reported by the investigator to have received concurrent anti-cancer therapies, specifically botanical formulations and  traditional  medicines  used  for  cancer  treatment: Glycyrrhiza spp.  root, Panax  ginseng root,  and  taxus wallichiana . Its use by this subject was considered as a prohibited concomitant medication. However, this particular therapy  is  not  considered  as  anti-cancer  therapy  by  the  Sponsor,  and  is,  thus,  not  a  prohibited  concomitant medication for this study.) and 3 subjects in the chemo arm (1 subject without measurable disease at baseline, and 2 subjects who received concurrent anti-cancer therapies, specifically 1 subject received botanical formulations and traditional medicines used for cancer treatment: Astragalus spp. root, cantharidin, Eleutherococcus senticosus root with rhizome, and Pa nax ginseng root, and 1 subject received 'unspecified' herbal/traditional medicine).
- (d) additional (other) reasons (n = 2: each 1 subject: worsening of PS, did not meet selection criteria)
- (e) additional (other) reasons (n = 1: miscommunication over eligibility)
- (f) additional (other) reasons (n = 1: renal function before administration)
- (g) Included death (n = 3), maximum clinical benefit (n = 3), completion of treatment as per protocol (n = 8), and additional (other) reasons (n = 7: each 1 subject: 'visiting is difficult', only agreed to survey by phone or letter, 'patient unconscious, wife refuses follow-up', subject withdrew for safety, alternative therapy, 'subject dropped out due to violation', new treatment by radio-chemotherapy)
- (h) Included death (n = 5), pregnancy (n = 1), maximum clinical benefit (n = 1), completion of treatment as per protocol (n = 13), not reported (n = 1), and additional (other) reasons (n = 12: Investigator's decision [n=4], and each  1  subject:  loss  of  clinical  performance,  tubulointerstitial  nephritis,  hyperthyroidism  and  eating  disorder,

<div style=\"page-break-after: always\"></div>

'double cancer', delay more than 12 weeks due to subject refusal, internal bleeding, 'patient returned to Taitung for treatment', attend another trial')

(i) Included death (n = 4), maximum clinical benefit (n = 4), and additional (other) reasons (n = 15: Investigator's decision [n=3], Investigator's decision due to perception of no additional benefit to subject [n=3], Investigator's concern of clinical risk or toxicity to subject [n=2], worsened status of subject [n=2], and each 1 subject: 'CCR data met discontinuation', withdrawal of consent about visiting for exam, for the treatment of membranous nephropathy, 'independent central review judged PD', 'good response to chemotherapy'.

In CA209648, 1358 subjects were enrolled, and 970 subjects were randomized; this includes 325 subjects in the nivo + ipi arm, 321 subjects in the nivo + chemo arm and 324 subjects in the chemo arm. A total of 936 subjects were treated; this includes 322 subjects in the nivo +ipi arm, 310 subjects in the nivo + chemo arm and 304 subjects in the chemo arm.

Table 1. End of Treatment Period Status Summary - All Enrolled, Randomized, and Treated Subjects

|                                                          | Nivo+Ipi   | Nivo+Chemo   | Chemo      |
|----------------------------------------------------------|------------|--------------|------------|
| Enrolled=1358(all enrolled)                              |            |              |            |
| Randomizeda                                              | 325        | 321          | 324        |
| Treatedb                                                 | 322 (99.1) | 310 (96.6)   | 304 (93.8) |
| Not Treated                                              | 3          | 11           | 20         |
| Reason for Not Being Treated, n (%)                      |            |              |            |
| Disease progression                                      | 1 (0.3)    | 1 (0.3)      | 2 (0.6)    |
| Adverse event unrelated to study drug                    | 1 (0.3)    | 3 (0.9)      | 1 (0.3)    |
| Subject request to discontinue study treatment           | 0          | 0            | 2 (0.6)    |
| Subject withdrew consent                                 | 0          | 1 (0.3)      | 12 (3.7)   |
| Subject no longer meets study criteria                   | 0          | 4 (1.2)      | 2 (0.6)    |
| Other                                                    | 1 (0.3)    | 2 (0.6)      | 1 (0.3)    |
| Continuing in the Treatment Period, n (%)C               | 21 (6.5)   | 25 (8.1)     | 4 (1.3)    |
| Not Continuing in the Treatment Period, n (%)C           | 301 (93.5) | 285 (91.9)   | 300 (98.7) |
| Reason for Not Continuing in the Treatment Period, n (%) |            |              |            |
| Disease progression                                      | 174 (54.0) | 184 (59.4)   | 193 (63.5) |
| Study drug toxicity                                      | 59 (18.3)  | 33 (10.6)    | 40 (13.2)  |
| Death                                                    | 5 (1.6)    | 3 (1.0)      | 4 (1.3)    |
| Adverse event unrelated to study drug                    | 19 (5.9)   | 28 (9.0)     | 12 (3.9)   |
| Subject request to discontinue study treatment           | 13 (4.0)   | 15 (4.8)     | 20 (6.6)   |
| Subject withdrew consent                                 | 3 (0.9)    | 4 (1.3)      | 12 (3.9)   |
| Pregnancy                                                | 1 (0.3)    | 0            | 0          |
| Maximum clinical benefit                                 | 1 (0.3)    | 3 (1.0)      | 4 (1.3)    |
| Completed therapy as per protocol                        | 13 (4.0)   | 8 (2.6)      | 0          |
| Other                                                    | 12 (3.7)   | 7 (2.3)      | 15 (4.9)   |
| Not reported                                             | 1 (0.3)    | 0            | 0          |
| Continuing in the Study, n (%)                           | 93 (28.9)  | 91 (29.4)    | 61 (20.1)  |
| Not Continuing in the Study, n (%)                       | 229 (71.1) | 219 (70.6)   | 243 (79.9) |

Reason for Not Continuing in the Study, n (%)

<div style=\"page-break-after: always\"></div>

| Death                    | 206 (64.0)   | 196 (63.2)   | 216 (71.1)   |
|--------------------------|--------------|--------------|--------------|
| Subject withdrew consent | 16 (5.0)     | 19 (6.1)     | 27 (8.9)     |
| Lost to follow-up        | 2 (0.6)      | 1 (0.3)      | 0            |
| Other                    | 5 (1.6)      | 3 (1.0)      | 0            |

a Percentages based on subjects entering period.

h Percentages based on number of randomized subjects

Percentages based on number of treated subjects

Abbreviations: Chemo - chemotherapy; CSR - clinical study report; Ipi - ipilimumab; Nivo - nivolumab; PD-L1 programmed cell death protein ligand 1, ROW - rest of world

## Recruitment

Enrolment in CA209648 study started on 29-June-2017 and was closed on 22-Nov-2019. The clinical cut-off occurred on 18-Jan-2021 (LPLV), clinical DBL occurred on 01-Mar-2021. The study is ongoing.

This study was conducted at 187 sites in 26 countries (Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, France, Hong Kong, Italy, Japan, Mexico, Peru, Poland, Republic of Korea, Romania, Russian Federation, Singapore, Spain, Taiwan, Turkey, United Kingdom [UK], and United States [US]). A total of 182 sites enrolled subjects (subjects were randomized at 175 sites).

## Conduct of the study

## Protocol amendments

The original protocol for this study was dated 01-Jun-2016. As of the 01-Mar-2021 DBL, there were a total of 5 global protocol revisions, with 1 global amendment; 12 country-specific revised protocols (5 in the UK, 7 in France) and 12 country-specific amendments to address local requirements; 2 global administrative letters, and 1 country-specific administrative letter.

Key global changes to the CA209648 protocol are explained as follows:

- Revised Protocol 01 incorporating Protocol Amendment 02 (dated 21-Dec-2016) changed CA209648 (originally planned as a Phase 2, 2-arm study of nivolumab plus ipilimumab vs. chemotherapy in oesophageal and gastric cancer) into a randomized global, Phase 3, 3-arm study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin compared with cisplatin and fluorouracil in subjects with inoperable advanced, recurrent or metastatic, previously untreated OSCC. The expansion of the oesophageal cohort into a 3-arm randomized Phase 3 study addressed a high unmet medical need in 1L OSCC. The gastric cohort was removed. This amendment applied to all sites. Note that enrolment to CA209648 was initiated after the approval and implementation of Amendment 02 (i.e., no subjects were enrolled prior to Amendment 02).
- Revised Protocol 05 (dated 29-Oct-2020) added another trigger for the interim analysis (Final PFS/Interim OS).

Per Revised Protocol 01, the planned interim analysis (PFS final analysis and OS interim analysis) was to be triggered when 136 PFS events per BICR were observed among subjects expressing at least 1% tumour cell PD-L1 in the chemotherapy arm (Arm C). PFS event tracking was conducted by an independent external statistical group (AXIO), which supported statistical analyses and generated reports for review by an independent DMC. BMS remained blinded to the number of PFS events in Arm A and Arm B. Event tracking commenced in Jul-

<div style=\"page-break-after: always\"></div>

2020. PFS events were observed to be tracking at a much slower rate than projected per protocol. This was largely due to censoring due to the start of subsequent therapy or withdrawal of consent prior to progression, the extent of which was unforeseen when the Revised Protocol 01 was developed.

The revised protocol allowed for the final PFS analysis to be triggered when 136 PFS events per BICR were observed among the subjects with tumour cell PDL1 ≥ 1% in the chemotherapy arm, or when at least 12 months minimum follow-up (defined as the time from the date the last patient was randomized to the clinical cut-off date) was reached. In the eventuality that the target number of PFS events was not reached, the 12 months minimum follow-up ensured adequate follow-up for PFS in this patient population. As per original design, OS IA was to be conducted at the same time as PFS FA, and the alpha allocation was to be calculated per the specified method.

Table 2. Summary of key global changes to Protocol CA209648

| Document (Amendment) / Date                      | Summary of Key Global Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                          |   Planned Sample Size |   Total No. of Subjects Randomized Prior to Protocol Revision or Amendment |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------------|
| Revised Protocol 01 (Amendment 02) / 21-Dec-2016 | • CA209648 (originally planned as a Phase 2 study in oesophageal and gastric cancer) was amended into a randomized global Phase 3 study of nivo + ipi or nivo + chemo compared with chemo (cisplatin and fluorouracil) in subjects with inoperable advanced, recurrent or metastatic, previously untreated OSCC. The expansion of the oesophageal cohort into a 3-arm randomized Phase 3 study addresses a high unmet medical need in first line OSCC. The gastric cohort was removed. |                   939 |                                                                          0 |
| Revised Protocol 02 / 25-Oct-2017                | • Clarified terminology in description of study subjects, replacing 'inoperable' with 'unresectable' advanced, recurrent or metastatic oesophageal squamous cell carcinoma to ensure consistency of terminology used across the study protocol. • Rationale for Arm B nivolumab dose updated to reflect current approval by FDA of nivolumab 240 mg Q2W for a variety of tumour types, and under review by other health authorities.                                                   |                   939 |                                                                         17 |
| Revised Protocol 03 / 02-Feb-2018                | • Removed the procedures for the reinitiation of nivo ± ipi treatment after disease progression for up to 1 additional year. In addition, it added clarification to the treatment beyond progression procedures to limit treatment to a maximum duration of 24 months. There is minimal, if any, benefit derived from continuing IO treatment beyond 2 years in advanced tumours. Treatment beyond 2 years is no longer allowed in studies with nivolumab.                             |                   939 |                                                                         70 |
| Revised Protocol 04 / 12-Sep-2018                | • Restricted study entry to participants of previous nivolumab clinical studies where OS was listed as a primary or co-primary endpoint since participation in CA209648 could confound the interpretation of efficacy results in these studies. • Live /attenuated vaccines were prohibited to address any potential safety risks.                                                                                                                                                     |                   939 |                                                                        316 |

<div style=\"page-break-after: always\"></div>

| Document (Amendment) / Date       | Summary of Key Global Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Planned Sample Size   | Total No. of Subjects Randomized Prior to Protocol Revision or Amendment   |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------------|
|                                   | • Inclusion criterion related to renal function assessment was expanded to allow consideration of measured creatinine clearance instead of calculated creatinine clearance per Cockcroft-Gault formula on the basis that measured creatinine clearance represents an accurate estimation of glomerular filtration rate. • Cisplatin infusion times longer than 120 minutes were allowed if deemed necessary by investigator per local standard of care/local label. • PFS2/TSST was added as an exploratory endpoint to help understand the relevance of meaningful improvements in PFS. • Biomarker assessments section was revised to reflect current prioritizations in the biomarker analyses plan. • Program updates were added and internal inconsistencies were corrected. |                       |                                                                            |
| Revised Protocol 05 / 29-Oct-2020 | • Added provision for triggering the planned IA when at least 12 months minimum follow-up is reached, in the eventuality that the planned 136 PFS events per BICR among subjects with tumour cell PD-L1 ≥1% in the chemotherapy arm was unlikely to be reached. If the target number of PFS events was not reached, the 12 months minimum follow-up ensured adequate follow-up for PFS in this patient population.                                                                                                                                                                                                                                                                                                                                                                | 939                   | 970                                                                        |

## Protocol deviations

Important Protocol Deviations ( IPDs ), previously known as Significant Protocol Deviations (SPDs), are a subset of protocol deviations that may significantly impact the completeness, accuracy, and/or reliability of the study data or that may significantly affect a subject's rights, safety, or well-being.

A total of 404 IPDs/SPDs were reported among all enrolled subjects.

Table 3. Summary of Important/Significant Protocol Deviations - All Enrolled Subjects

| Protocol Deviation Category                                                                                   | Protocol Deviation                                                                                            |   Not random ized |   Randomiz ed to Nivo + Chemo |   Randomi zed to Nivo + Ipi |   Randomi zed to Chemo Total No. of IPDs |     |
|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-------------------|-------------------------------|-----------------------------|------------------------------------------|-----|
| Overall Total of IPDs/SPDs                                                                                    | Overall Total of IPDs/SPDs                                                                                    |                 6 |                           151 |                         115 |                                      132 | 404 |
| Discontinuation                                                                                               | Discontinuation                                                                                               |                 0 |                             4 |                           0 |                                        1 |   5 |
| Dosing continued after discontinuation criteria met a                                                         | Dosing continued after discontinuation criteria met a                                                         |                 0 |                             4 |                           0 |                                        1 |   5 |
| Inclusion/Exclusion Criteria                                                                                  | Inclusion/Exclusion Criteria                                                                                  |                 0 |                             1 |                           2 |                                        4 |   7 |
| Failure to meet inclusion                                                                                     | criteria                                                                                                      |                 0 |                             1 |                           2 |                                        3 |   6 |
| Subject met exclusion                                                                                         | criteria                                                                                                      |                 0 |                             0 |                           0 |                                        1 |   1 |
| Informed Consent / Ethics (IEC/IRB)                                                                           | Informed Consent / Ethics (IEC/IRB)                                                                           |                 2 |                            14 |                          10 |                                       17 |  43 |
| Implementation of protocol changes prior to IRB/IEC review or failure to implement IRB/IEC approved amendment | Implementation of protocol changes prior to IRB/IEC review or failure to implement IRB/IEC approved amendment |                 1 |                             4 |                           7 |                                        7 |  19 |

<div style=\"page-break-after: always\"></div>

| Protocol Deviation Category          | Protocol Deviation                                                                 |   Not random ized |   Randomiz ed to Nivo + Chemo |   Randomi zed to Nivo + Ipi | Randomi zed to Chemo   |   Total No. of IPDs |
|--------------------------------------|------------------------------------------------------------------------------------|-------------------|-------------------------------|-----------------------------|------------------------|---------------------|
|                                      | Subject not re-consented in a timely manner                                        |                 1 |                             4 |                           1 | 9                      |                  15 |
|                                      | Consent for treatment beyond progression not signed                                |                 0 |                             4 |                           1 | 1 b                    |                   6 |
|                                      | Deficiency in consent process                                                      |                 0 |                             2 |                           1 | 0                      |                   3 |
| Prohibited Concomitant Medication    | Prohibited Concomitant Medication                                                  |                 0 |                             3 |                           3 | 5                      |                  11 |
|                                      | Prohibited concomitant medication or concurrent therapy                            |                 0 |                             3 |                           3 | 5                      |                  11 |
| Safety Reporting                     | Safety Reporting                                                                   |                 4 |                            33 |                          23 | 31                     |                  91 |
|                                      | Failure to report SAE within the required window per protocol                      |                 4 |                            33 |                          23 | 31                     |                  91 |
| Study Intervention (Study Treatment) | Study Intervention (Study Treatment)                                               |                 0 |                            26 |                          11 | 19                     |                  56 |
|                                      | Dose administration error                                                          |                 0 |                            15 |                           6 | 10                     |                  31 |
|                                      | Dose not delayed or reduced per protocol                                           |                 0 |                             9 |                           0 | 4                      |                  13 |
|                                      | IRT stratification error                                                           |                 0 |                             2 |                           5 | 5                      |                  12 |
| Trial Procedures                     | Trial Procedures                                                                   |                 0 |                            70 |                          66 | 55                     |                 191 |
|                                      | Baseline procedures not performed per protocol                                     |                 0 |                             6 |                           7 | 11                     |                  24 |
|                                      | Dosing visit schedule not maintained                                               |                 0 |                            22 |                          18 | 4                      |                  44 |
|                                      | First dose of study treatment greater than 5 days after randomization              |                 0 |                             6 |                           2 | 1                      |                   9 |
|                                      | Tumor tissue used for eligibility greater than maximum time prior to randomization |                 0 |                             4 |                           2 | 2                      |                   8 |
|                                      | Pregnancy testing not performed per protocol                                       |                 0 |                             0 |                           2 | 3                      |                   5 |
|                                      | Required labs not performed prior to dosing                                        |                 0 |                             0 |                           2 | 1                      |                   3 |
|                                      | Tumor assessment missed or performed out of window per protocol                    |                 0 |                            32 |                          33 | 33                     |                  98 |

Note that the grand total is the sum of all IPDs/SPDs, but not the total of all subjects with IPDs/SPDs, as one subject may have more than one deviation.

The window for tumor assessments were every 6 weeks (±7 days) from first dose up to and including Week 48, then every 12 weeks (±7 days) regardless of treatment schedule until disease progression (unless treatment beyond progression was permitted). The SAE reporting window was 24 hours.

a  Treatment discontinuation criteria are listed in Section 4.5.5 of the CA209648 protocol.

b  For Subject CA209648-xx-xxxx (chemo arm), as part of continued periodic, administrative review of PDs, it was discovered after the Erratum to the CA209648 Primary CSR was prepared that this occurrence did  not  meet  criteria  for  an  IPD.  The  subject  was  recorded  as  having  progressed,  and  discontinued treatment 9 days later.

Relevant protocol deviations ( RPDs ) are IPDs that could affect the interpretability of key study results, are programmable deviations from clinical database, and are protocol-specific.

A total of 5 (0.5%) subjects reported with at least 1 RPD among all randomized subjects; the proportions of subjects with at least 1 RPD and the individual RPDs were as follows:

<div style=\"page-break-after: always\"></div>

Nivo + chemo (2 subjects [0.6%]):

- ­ 1 subject (0.3%) at study entry without squamous cell carcinoma or adenosquamous cell carcinoma of the oesophagus. This subject had sarcomatoid carcinoma of the oesophagus and was randomized but never treated.
- ­ 1 subject (0.3%) was reported by the investigator to have received concurrent anti-cancer therapies, specifically botanical formulations and traditional medicines used for cancer treatment: Glycyrrhiza spp. root, Panax ginseng root, and taxus wallichiana. Its use by this subject was considered as a prohibited concomitant medication. However, this particular therapy is not considered as anti-cancer therapy by the Sponsor, and is, thus, not a prohibited concomitant medication for this study.

Nivo + ipi: 0 subjects

Chemo (3 subjects [0.9%]):

- ­ 1 subject (0.3%) without measurable disease at baseline.
- ­ 2 subjects (0.6%) who received concurrent anti-cancer therapies, specifically botanical formulations and traditional medicines used for cancer treatment: Astragalus spp. root, cantharidin, Eleutherococcus senticosus root with rhizome, and Panax ginseng root.

Table 4. Relevant Protocol Deviations Summary - All Randomized Subjects

|                                                                                                        | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|--------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                                                                        | Nivo + Ipi N= 325        | Nivo+ Chemo N = 321      | Chemotherapy N = 324     | Total N = 970            | Total N = 970            |
| SUBJECTSWITHATLEASTONEDEVIATION ATENIRANCE                                                             | 0                        | 2（ 0.6)                  | 3 (0.9)                  | 5( 0.5)                  |                          |
| SUBJECTSWITHOUTSQUAMOUSCELLCARCINOMAOR                                                                 | 0                        | 1 0.3)                   | 0                        | 1 0.1)                   |                          |
| ADENOSQUAMOUSCELLCARCINOMAOFESOPHAGUS SUBJECTS WITHNOUNRESECTABLE ADVANCED，RECURRENT OR METASTATICESCC | 0                        | 1 0.3)                   | 0                        | 1 0.1)                   |                          |
| SUBJECTSWHOHAVERECEIVEDPRIORSYSTEMICTHERAPYFOR ADVANCEDORMETASTATICDISEASE                             | 0                        | 0                        | 0                        | 0                        |                          |
| SUBJECTWITHBASELINEECOGPERFORMANCESTATUS>1                                                             | 0                        | 000                      | 0                        | 0 0.1)                   |                          |
| SUBJECTSWITHOUTANYMEASURABLEDISEASEATBASELINE                                                          |                          |                          | 1 0.3)                   | 1                        |                          |
| SUBJECTSWITHOUTANYTUMORCELLPD-L1RESULT                                                                 | 00                       |                          | 0                        | 0                        |                          |
| ON-TREATMENT                                                                                           |                          |                          |                          | 0.3)                     |                          |
| SUBJECTSRECEIVINGCONCURRENTANTI-CANCERTHERAPY                                                          | 0                        | 1 (0.3)                  | 2 (0.6)                  |                          |                          |
| SUBJECTTREATEDDIFFERENTLYASRANDOMIZED                                                                  | 0                        | 0                        | 0                        | 0                        |                          |

## Baseline data

Table 5 . Key Demographic and Baseline Characteristics - All Randomized Subjects

|                           | Nivo+Ipi N=325   | Nivo+Chemo N=321   | Chemo N=324   | Total N=970   |
|---------------------------|------------------|--------------------|---------------|---------------|
| Age                       |                  |                    |               |               |
| Mean (SD) (y)             | 62.2 (9.1)       | 63.1 (9.2)         | 63.3 (8.7)    | 62.9 (9.0)    |
| Median (min, max) (y)     | 63.0 (28, 81)    | 64.0 (40, 90)      | 64.0 (26, 81) | 64.0 (26, 90) |
| <65                       | 185 (56.9)       | 167 (52.0)         | 166 (51.2)    | 518 (53.4)    |
| ≥65                       | 140 (43.1)       | 154 (48.0)         | 158 (48.8)    | 452 (46.6)    |
| ≥65 - <75                 | 116 (35.7)       | 123 (38.3)         | 129 (39.8)    | 368 (37.9)    |
| ≥75                       | 24 (7.4)         | 31 (9.7)           | 29 (9.0)      | 84 (8.7)      |
| Sex                       |                  |                    |               |               |
| Male                      | 269 (82.8)       | 253 (78.8)         | 275 (84.9)    | 797 (82.2)    |
| Female                    | 56 (17.2)        | 68 (21.2)          | 49 (15.1)     | 173 (17.8)    |
| Race                      |                  |                    |               |               |
| White                     | 79 (24.3)        | 85 (26.5)          | 84 (25.9)     | 248 (25.6)    |
| Black or African American | 4 (1.2)          | 1 (0.3)            | 6 (1.9)       | 11 (1.1)      |

<div style=\"page-break-after: always\"></div>

|                                                    | Nivo+Ipi N=325         | Nivo+Chemo N=321       | Chemo N=324            | Total N=970            |
|----------------------------------------------------|------------------------|------------------------|------------------------|------------------------|
| American Indian or Alaska Native                   | 1 (0.3)                | 2 (0.6)                | 1 (0.3)                | 4 (0.4)                |
| Asian Indian                                       | 1 (0.3)                | 4 (1.2)                | 3 (0.9)                | 8 (0.8)                |
| Chinese                                            | 71 (21.8)              | 74 (23.1)              | 70 (21.6)              | 215 (22.2)             |
| Japanese                                           | 131 (40.3)             | 126 (39.3)             | 137 (42.3)             | 394 (40.6)             |
| Asian Other                                        | 28 (8.6)               | 23 (7.2)               | 17 (5.2)               | 68 (7.0)               |
| Other                                              | 10 (3.1)               | 6 (1.9)                | 6 (1.9)                | 22 (2.3)               |
| IRT Stratification Factors:                        |                        |                        |                        |                        |
| Tumour Cell PD-L1 Expression ≥1%                   | 158 (48.6)             | 158 (49.2)             | 157 (48.5)             | 473 (48.8)             |
| <1% or indeterminate                               | 167 (51.4)             | 163 (50.8)             | 167 (51.5)             | 497 (51.2)             |
| Region                                             |                        |                        |                        |                        |
| East Asia (Japan, Korea,                           | 185 (56.9)             | 183 (57.0)             | 184 (56.8)             | 552 (56.9)             |
| Taiwan) Rest of Asia (China, Hong Kong, Singapore) | 44 (13.5)              | 42 (13.1)              | 42 (13.0)              | 128 (13.2)             |
| Rest of World PS                                   | 96 (29.5)              | 96 (29.9)              | 98 (30.2)              | 290 (29.9)             |
| ECOG 0                                             | 151 (46.5)             | 150 (46.7)             | 154 (47.5)             | 455 (46.9)             |
| 1                                                  | 174 (53.5)             | 171 (53.3)             | 170 (52.5)             | 515 (53.1)             |
| Number of organs with metastases (BICR)            |                        |                        |                        |                        |
| ≤1                                                 | 160 (49.2)             | 158 (49.2)             | 158 (48.8)             | 476 (49.1)             |
| ≥2                                                 | 165 (50.8)             | 163 (50.8)             | 166 (51.2)             | 494 (50.9)             |
| Country by Geographic Region (per CRF)             |                        |                        |                        |                        |
| Asia                                               | 229 (70.5)             | 225 (70.1)             | 226 (69.8)             | 680 (70.1)             |
| Non-Asia                                           | 96 (29.5)              | 96 (29.9)              | 98 (30.2)              | 290 (29.9)             |
| Tumour Cell PD-L1 Expression (CRF), n/N (%)        |                        |                        |                        |                        |
| Tumour cell PD-L1 quantifiable at                  | 322/325 (99.1)         | 321/321                | 322/324 (99.4)         | 965/970 (99.5)         |
| baseline ≥1%                                       | 158/322 (49.1)         | (100.0) 158/321 (49.2) | 156/322 (48.4)         | 472/965 (48.9)         |
| <1%                                                | 164/322 (50.9)         | 163/321 (50.8)         | 166/322 (51.6)         | 493/965 (51.1)         |
| ≥5%                                                | 120/322 (37.3)         | 120/321 (37.4)         | 115/322 (35.7)         | 355/965 (36.8)         |
| <5%                                                | 202/322 (62.7)         | 201/321 (62.6)         | 207/322 (64.3)         | 610/965 (63.2)         |
| ≥10%                                               | 103/322 (32.0)         | 102/321 (31.8)         | 97/322 (30.1)          | 302/965 (31.3)         |
| <10%                                               | 219/322 (68.0)         | 219/321 (68.2)         | 225/322 (69.9)         | 663/965 (68.7)         |
| Indeterminate                                      | 3/325 (0.9)            | 0                      | 2/324 (0.6)            | 5/970 (0.5)            |
| Weight (kg)                                        |                        |                        |                        |                        |
| Mean (SD)                                          | 58.819 (11.218)        | 58.014 (12.509)        | 60.140 (11.141)        | 58.994 (11.657)        |
| Median (Min, Max)                                  | 58.000 (25.70, 103.80) | 57.000 (29.60, 125.20) | 58.900 (33.90, 105.20) | 58.050 (25.70, 125.20) |
| Adenosquamous                                      |                        |                        |                        | 1 (0.1)                |
| Other                                              | 3 (0.9)                | 9 (2.8)                | 0                      |                        |
| Squamous cell carcinoma cell carcinoma             | 322 (99.1)             | 311 (96.9)             | 318 (98.1) 6 (1.9)     | 951 (98.0) 18 (1.9)    |
|                                                    | 0                      | 1 (0.3)                |                        |                        |
| Disease status at current diagnosis                |                        |                        |                        |                        |
| De novo metastatic                                 | 196 (60.3)             | 184 (57.3)             | 187 (57.7)             | 567 (58.5)             |
| Recurrent - distant                                | 73 (22.5)              | 72 (22.4)              | 60 (18.5)              | 205 (21.1)             |
| Recurrent - loco-regional                          | 25 (7.7)               | 21 (6.5)               | 25 (7.7)               | 71 (7.3)               |
| Unresectable advanced                              | 31 (9.5)               | 44 (13.7)              | 52 (16.0)              | 127 (13.1)             |
| Disease stage at initial diagnosis                 |                        |                        |                        |                        |
| Stage I-III                                        | 115 (35.4)             | 114 (35.5)             | 117 (36.1)             | 346 (35.7)             |
| Stage IV                                           | 208 (64.0)             | 206 (64.2)             | 206 (63.6)             | 620 (63.9)             |
| Not reported                                       | 2 (0.6)                | 1 (0.3)                | 1 (0.3)                | 4 (0.4)                |
| Location at initial diagnosis                      |                        |                        |                        |                        |
| Upper thoracic                                     | 64 (19.7)              | 60 (18.7)              | 51 (15.7)              | 175 (18.0)             |
| Middle thoracic                                    | 131 (40.3)             | 121 (37.7)             | 134 (41.4)             | 386 (39.8)             |

<div style=\"page-break-after: always\"></div>

|                                                      | Nivo+Ipi N=325   | Nivo+Chemo N=321   | Chemo N=324   | Total N=970   |
|------------------------------------------------------|------------------|--------------------|---------------|---------------|
| Lower thoracic                                       | 103 (31.7)       | 112 (34.9)         | 119 (36.7)    | 334 (34.4)    |
| Gastroesophageal junction                            | 25 (7.7)         | 28 (8.7)           | 18 (5.6)      | 71 (7.3)      |
| Not reported                                         | 2 (0.6)          | 0                  | 2 (0.6)       | 4 (0.4)       |
| Smoking status                                       |                  |                    |               |               |
| Current/former                                       | 268 (82.5)       | 254 (79.1)         | 256 (79.0)    | 778 (80.2)    |
| Never smoker                                         | 57 (17.5)        | 67 (20.9)          | 68 (21.0)     | 192 (19.8)    |
| Alcohol use                                          |                  |                    |               |               |
| Current/former                                       | 260 (80.0)       | 246 (76.6)         | 250 (77.2)    | 756 (77.9)    |
| Never                                                | 65 (20.0)        | 75 (23.4)          | 74 (22.8)     | 214 (22.1)    |
| Time from Initial Disease Diagnosis to Randomization |                  |                    |               |               |
| < 6 months                                           | 224 (68.9)       | 227 (70.7)         | 240 (74.1)    | 691 (71.2)    |
| 6 months - < 1 year                                  | 19 (5.8)         | 25 (7.8)           | 18 (5.6)      | 62 (6.4)      |
| 1 - < 2 years                                        | 51 (15.7)        | 38 (11.8)          | 34 (10.5)     | 123 (12.7)    |
| 2 - < 3 years                                        | 15 (4.6)         | 14 (4.4)           | 15 (4.6)      | 44 (4.5)      |
| 3 - < 4 years                                        | 8 (2.5)          | 8 (2.5)            | 4 (1.2)       | 20 (2.1)      |
| 4 - < 5 years                                        | 4 (1.2)          | 6 (1.9)            | 6 (1.9)       | 16 (1.6)      |
| ≥ 5 years                                            | 3 (0.9)          | 3 (0.9)            | 7 (2.2)       | 13 (1.3)      |
| Not reported                                         | 1 (0.3)          | 0                  | 0             | 1 (0.1)       |

## Tumour Cell PD-L1

Among all randomized subjects, 321 (100%), 322 (99.1%), and 322 (99.4%) of subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively, had quantifiable tumour cell PD-L1 expression at baseline. Among all randomized subjects with quantifiable tumour cell PD-L1 expression at baseline, tumour cell PD-L1 levels were well balanced across the nivo + chemo, nivo + ipi, and chemo arms.

The 5 (0.5%) subjects with indeterminate tumour cell PD-L1 expression among all randomized subjects were considered as having tumour cell PD-L1 &lt; 1% for IRT-based stratification but were considered separately in subgroup analyses of efficacy and were not included in the safety subgroups analyses.

Table 6. Frequency of PD-L1 Tumour Cell Expression Status - All Randomized Subjects

| Population                                                                                                                                        | Nivo + Ipi N = 325            | Nivo + Chemo N = 321                      | Chemotherapy N= 324                        | Total N = 970                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------------------|--------------------------------------------|--------------------------------------------|
| PD-L1Expression Category                                                                                                                          |                               |                                           |                                            |                                            |
| SUBJECTSWITHPD-L1EXPRESSION                                                                                                                       | 0                             | 0                                         | 0                                          | 0                                          |
| MISSING AT BASELINE (N(&)) SUBJECTSWITHPD-L1QUANTIFIABLE AT BASELINE (N(%))                                                                       | 322 ( 99.1)                   | 321 (100.0)                               | 322 (99.4)                                 | 965 ( 99.5)                                |
| PD-L1 EXPRESSION (%) MEAN MEDIAN MIN ， MAX Q、Q STANDARDDEVIATION SUBJECTS WITHBASELINEPD-L1EXPRESSION< 58 SUBJECTSWITHBASELINEPD-L1EXPRESSION<10% | 14.9 0.0 0，100 0.0, 20.0 26.1 | 13.9 0.0 0，100 0.6, 20.0 24.5             | 13.7 0.0 0，100 0.6, 10.0 25.1              | 14.2 0.0 0，100 0.6 , 15.0 25.2             |
| SUBJECTSWITHBASELINEPD-L1EXPRESSION<18 SUBJECTSWITHBASELINE PD-L1EXPRESSION>=5%                                                                   | 158/322 (49.1) 164/322 50.9)  | 158/321 49.2) 163/321 50.8) 120/321 37.4) | 156/322 (48.4) 166/322 51.6) 115/322 35.7) | 472/965 (48.9) 493/965 51.1) 355/965 36.8) |
| SUBJECTSWITH INDETERMINATE PD-L1EXPRESSION                                                                                                        | 120/322 37.3) 202/322 62.7)   | 201/321 62.6) 102/321 31.8)               | 207/322 64.3) 97/322 30.1)                 | 610/965 63.2)                              |
|                                                                                                                                                   | 103/322 32.0) 219/322 ( 68.0) | 219/321 (68.2) 0                          | 225/322 (69.9)                             | 302/965 31.3) 663/965 (68.7)               |
| ATBASELINE(N(%))                                                                                                                                  | 3 (0.9)                       |                                           | 2 (0.6)                                    | 5 (0.5)                                    |
| SUBJECTSWITHPD-L1EXPRESSION                                                                                                                       | 0                             |                                           |                                            |                                            |
| AT BASELINE NOT EVALUABLE(N(%))                                                                                                                   |                               | 0                                         |                                            | 0                                          |
|                                                                                                                                                   |                               |                                           | 0                                          |                                            |

## Previous treatments

Among all randomized subjects, 23.3% received prior systemic anticancer therapy in the adjuvant, neo-adjuvant, or definitive chemotherapy/radiotherapy/chemoradiotherapy (CRT) treatment setting, with similar proportions of subjects observed across treatment arms. Prior surgery related to cancer or

<div style=\"page-break-after: always\"></div>

radiotherapy was reported in 29.7% and 19.9% of subjects, respectively, and similar proportions of subjects were observed across treatment arms.

Note that, due to a data entry error, 1 (0.4%) subject in the chemo arm was reported to have received prior treatment in the metastatic setting with vinorelbine; however, this subject received vinorelbine as subsequent therapy.

In subjects with prior systemic therapy, the time from prior systemic treatment in the adjuvant, neoadjuvant, or definitive CRT treatment setting to randomization was similar across treatment arms, with study treatment for most subjects starting 6 to &lt; 12 months (39.6%) or ≥ 12 months (53.8%) after prior treatment.

Table 7. Prior Cancer Therapy Summary - All Randomized Subjects

|                                                           | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   | Number of Subjects (%)   |
|-----------------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                           | Nivo + Ipi N= 325        | Nivo + Chemo N= 321      | Chemotherapy N = 324     | Total N = 970            |
| TYPE OF PRIOR SYSTEMIC THERAPY RECEIVED(A)                |                          |                          |                          |                          |
| ANYPRIOR SYSTEMIC THERAPY NOPRIORSYSTEMICTHERAPY          | 81 (24.9) 244 ( 75.1)    | 72 (22.4) 249 ( 77.6)    | 23 (23:3                 | 226 ( 23.3) 744 ( 76.7)  |
|                                                           |                          |                          |                          | 39                       |
| SETTING OF PRIOR SYSTEMIC THERAPY REGIMEN RECEIVED(A)(F)  |                          |                          |                          |                          |
| ADJUVANT THERAPY                                          | 17 (21.0)                | 10 (13.9)                | 12 (16.4)                | (17.3)                   |
| METASTATICTHERAPY                                         | 0                        | 0                        | 1 1.4)                   | 1 _0.4)                  |
| NEO-ADJUVANT THERAPY                                      | 42 (51.9)                | 45 (62.5)                | 38 (52.1)                | 125 (55.3)               |
| DEFINITIVE CRT THERAPY                                    | 24 (29.6)                | 18 (25.0)                | 26 (35.6)                | 68 ( 30.1)               |
| TIMEFROMCOMPLETIONOFPRIORADJUVANT/NEO-ADJUVANT/DEFINITIVE |                          |                          |                          |                          |
| THERAPY TO TREAIMENT (B)                                  |                          |                          |                          |                          |
| <6MONTHS                                                  | 2 2.5)                   | 1 1.4)                   | 3 4.2)                   | 6 2.7)                   |
| 6-<12MONTHS                                               | 31 38.3)                 | 41.7)                    | 38.9)                    | 89 (39.6)                |
| >= 12 MONIHS                                              | 47 58.0)                 | 365 50.0)                | 28.83 52.8)              | 121 (53.8)               |
| NOT REPORTED                                              | 1 1.2)                   | 6.9)                     | 4.2)                     | 9 4.0)                   |
| PRIOR SURGERYRELATEDTOCANCER                              |                          |                          |                          |                          |
| YES NO                                                    | 215 ( 66.2) 110 ( 33.8)  | 217 ( 67.6) 104( 32.4)   | 207 ( 63.9) 117( 36.1)   | 639 ( 65.9) 331 ( 34.1)  |
| TIME FROM PRIOR SURGERY (C)                               |                          |                          |                          |                          |
| <3MONTHS                                                  | 166 ( 77.2)              | 153 (70.5)               | 156 ( 75.4)              | 475 ( 74.3)              |
| 3 - <= 6 MONTHS                                           | 8 3.7)                   | 16 7.4)                  | 10 4.8)                  | 34 .5.3) 110             |
| > 6 MONTHS NOT REPORTED                                   | 39 18.1)                 | 39 18.0)                 | 32 (15.5) 9 4.3)         | 17.2)                    |
|                                                           | 2 0.9)                   | 9 4.1)                   |                          | 20 3.1)                  |
| TYPE OF SURGERY (C)                                       |                          |                          |                          |                          |
| BIOPSY OTHER                                              | 167 (77.7) 100 (46.5)    | 165 (76.0) 102 （ 47.0)   | 168 (81.2) 86 (41.5)     | 500 (78.2) 288 ( 45.1)   |
| PRIOR SURGERY RELATED TO CANCER (EXCLUDING BIOPSY) YES NO | 100 ( 30.8) 225 ( 69.2)  | 102 (31.8) 219 (68.2)    | 86 ( 26.5) 238 ( 73.5)   | 288 ( 29.7) 682 ( 70.3)  |
| TIME FROM PRIOR SURGERY (EXCLUDING BIOPSY）(D)             |                          |                          |                          |                          |
| <3MONTHS                                                  | 27 (27.0)                | 20 (19.6)                | 17 (19.8)                | 64 (22.2)                |
| 3-<=6MONTHS                                               | 7 7.0)                   | 15 (14.7)                | 9 (10.5)                 | 31 10.8)                 |
| > 6 MONTHS                                                | 64 (64.0)                | 61 (59.8)                | 55 (64.0)                | 180 62.5)                |
| NOT REPORTED                                              | 2 2.0)                   | 6 5.9)                   | 5 5.8)                   | 13 4.5)                  |
| TYPE OF SURGERY (EXCLUDING BIOPSY)(D)                     |                          |                          |                          |                          |
| TOTAL                                                     | 100                      | 102                      | 86                       | 288                      |
| TRANSTHORACICESOPHAGECTOMY                                | 21 (21.0)                | 31 30.4)                 | 22 (25.6)                | 74 25.7)                 |
| TRANSHIATALESOPHAGECTOMY                                  | 2 2.0)                   | 2 2.0)                   | 1 1.2)                   | 5 1.7)                   |
| THORACOABDOMINALESOPHAGECTOMY                             | 26 26.0)                 | 18 17.6) 11 10.8)        | 14 16.3) 8 9.3)          | 58 20.1) 28 9.7)         |
| OTHER                                                     |                          |                          |                          | 39 13.5)                 |
| YES                                                       | 9 9.0)                   |                          | 2号  8:3                  | 19 (8:1)                 |
|                                                           | 11 (14.9)                | 11 (18.3)                | 10 (16.9)                | 32 (16.6)                |
| MINIMALLYINVASIVEESOPHAGECIOMY LYMPHADENECTOMY            | 16 16.0)                 | 11 10.8)                 | 12 14.0)                 |                          |
| ENDOSCOPICMUCOSALRESECTION                                | 2 2.0)                   | 1 1.0)                   | 3 3.5)                   | 6 2.1)                   |
|                                                           | 5 5.0)                   | 7 6.9)                   | 3 3.5)                   | 15 5.2)                  |
| ENDOSCOPICSUBMUCOSALDISSECTION                            | 46( 46.0)                | 41 (40.2)                | 40 (46.5)                | 127 44.1)                |
| PRIOR RADIOTHERAPY                                        |                          |                          |                          |                          |
| NO                                                        | 254 ( 2%:23]             | 60 (18.7) 261 (81.3)     |                          |                          |
| TIME FROM PRIOR RADIOTHERAPY (E)                          |                          |                          |                          |                          |
| <3MONTHS                                                  |                          |                          |                          |                          |
| 3 - <= 6 MONTHS > 6 MONTHS                                | 1 _1.4)                  | 0                        | .0                       | 1 0.5) 141 73.1)         |
| NOT REPORTED                                              | 59 (79.7)                | 40 66.7)                 | 42 71.2)                 | 19 9.8)                  |
|                                                           | 3 4.1)                   | 9 15.0)                  | 7 11.9)                  |                          |

(A) s

(C) Percentages are based on 1 subjects with prior surgery related to cancer.

(B) Percentages are based on subjects with prior adjuvant/neo-adjuvant/definitive therapy.

(D) Percentages are based on subjects with prior surgery related to cancer (excluding biopsy) .

Percentages are based on subjects with any prior systemic therapy.

() Percentages are based on 1 subjects with prior radiotherapy.

<div style=\"page-break-after: always\"></div>

Among all randomized subjects (N = 970), 226 (23.3%) subjects received anti-neoplastic agents, which were primarily cisplatin (16.2%) and/or fluorouracil (15.6%). These drugs were used at similar proportions across the treatment arms:

- ­ Nivo + chemo arm: 15.3% received prior cisplatin and 16.8% received prior fluorouracil
- ­ Nivo + ipi arm: 17.8% received prior cisplatin and 14.5% received prior fluorouracil
- ­ Chemo arm: 15.4% received prior cisplatin and 15.4% received prior fluorouracil

No subject received immunotherapy prior to randomization.

## Subsequent anti-cancer therapy

More subjects in the chemo arm (62.7%) compared with the nivo + chemo (50.8%) and nivo + ipi (51.7%) arms initiated any subsequent therapy. Proportions of all randomized subjects who received subsequent cancer therapy in the nivo + chemo, nivo + ipi, and chemo arms were as follows, respectively:

- ­ Subsequent systemic therapy: 46.4%, 46.5%, and 55.9%.
- ­ Subsequent anti-PD-(L)1 immunotherapy: 5.0%, 4.3%, and 15.7%

One subject in the nivo + ipi arm received ipilimumab in combination with nivolumab as subsequent therapy.

Table 8. Subsequent Cancer Therapy Summary - All Randomized Subjects

|                                                                                           | Number of Subjects (%)         | Number of Subjects (%)   | Number of Subjects (%)         |
|-------------------------------------------------------------------------------------------|--------------------------------|--------------------------|--------------------------------|
|                                                                                           | Nivo + Ipi N = 325             | Nivo + Chemo N=321       | Chemotherapy N = 324           |
| SUBJECTS WITH ANY SUBSEQUENT THERAPY (%)(1)                                               | 168 (51.7)                     | 163 (50.8)               | 203 ( 62.7)                    |
| SUBJECTS WHO RECEIVED SUBSEQUENT RADIOTHERAPY (%) RADIOTHERAPY FOR TREAIMENT OF TUMORS(*) | 75 ( 23.1)                     | 70 (21.8)                | 91 (28.1)                      |
| CURATIVE PALLIATIVE                                                                       | 1.5) 70 ( 21.5)                | 9 (2.8) 62 ( 19.3)       | 8 3(2.5) 83 ( 25.6)            |
| SUBJECTS WHO RECEIVED SUBSEQUENT SURGERY(*) SURGERY FOR TREATMENT OF TUMORS(%)            | 1.2)                           | 9 (2.8)                  | 9( 2.8)                        |
| TUMOR RESECTION CURATIVE TUMOR RESECTION PALLIATIVE                                       | 1 0.3) 3 0.9) 0                | 1 0.3) 8 2.5) 0          | 4 1.2) 4 1.2) 1 0.3)           |
| OTHER                                                                                     |                                |                          |                                |
| SUBJECIS WHORECEIVEDSUBSEQUENTSYSTEMIC THERAPY()                                          |                                |                          |                                |
|                                                                                           | 151 (46.5)                     | 149 (46.4)               | 181 (55.9)                     |
| ANTI-PD1 NIVOLUMAB                                                                        | 14 4.3) 12 3.7) 1              | 16 5.0) 13 4.0) 0.6)     | 51 15.7) 38 11.7) 2 0.6)       |
| CAMRELIZUMAB BI 754091 SINTILIMAB                                                         | 0.3) 1 0.3)                    | 020100                   | 6 1.9)                         |
| PEMBROLIZUMAB                                                                             |                                |                          | 1 0.3)                         |
|                                                                                           | 0:0                            | 0.3)                     | 2 0.6)                         |
| SUGEMALIMAB                                                                               | 0 0                            |                          | 1 0.3)                         |
| TISLELIZUMAB                                                                              |                                |                          | 1 0.3)                         |
| TORIPALIMAB                                                                               |                                |                          | 1 0.3)                         |
|                                                                                           | 0                              | 0                        |                                |
| ANTI-CTLA4 IPILIMUMAB                                                                     | 1  8:3                         | 00 148 46.1)             | 00 167 51.5) 64 19.8) 45 13.9) |
| OTHERSYSTEMICANTICANCERTHERAPY FLUOROURACIL CISPLATIN                                     | 149 (45.8) 108 33.2) 102 31.4) | 43 13.4) 33 10.3)        |                                |
| DOCETAXEL                                                                                 | 30 9.2)                        | 44 13.7)                 | 41 12.7)                       |
| PACLITAXEL                                                                                | 51 15.7)                       | 75 23.4)                 | 85 26.2)                       |
| OXALIPLATIN                                                                               | 4.9)                           | 12 3.7)                  | 12 3.7)                        |
| CARBOPLATIN NEDAPLATIN                                                                    | 16 11                          | 12 3.7 18 5.6)           | 13 4.0) 16 4.9)                |
|                                                                                           | 3.4)                           |                          |                                |
| GIMERACIL;OIERACIL POTASSIUM;TEGAFUR                                                      | 11 3.4) 10 3.1)                | 5.0)                     | 15 4.6)                        |
| IRINOTECAN CAPECITABINE                                                                   |                                | 16                       |                                |
|                                                                                           | 9 2.8) 8                       | 320 0.9) 0.6)            | 10 3.1)                        |
| ASTRAGALUS PROPINQUUS                                                                     | 2.5) 2 0.6)                    |                          | 01 0.3)                        |
| ROOT;OXYMATRINE;PANAX GINSENG DRY EXTRACT                                                 | 2 0.6)                         | 0                        | 1 0.3)                         |
| BEVACIZUMAB                                                                               |                                | 4                        | 0.3)                           |
| GEMCITABINEHYDROCHLORIDE                                                                  | 2 0.6)                         | 1.2)                     |                                |

(1) Subject may have received more than one type of subsequent therapy. Subsequent therapy was defined as therapy started on or after first dosing date (randomization date if subject never treated).

Note: The complete table has not been included in the AR and only a summary of most frequent 'other systemic anticancer therapy' has been kept.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 9. Analysis populations presented in CA209648

| Population                 | Nivo+Ipi   | Nivo+Chemo   | Chemo   |   Total |
|----------------------------|------------|--------------|---------|---------|
| Enrolled Subjects          |            |              |         |    1358 |
| AllRandomizedSubjects      | 325        | 321          | 324     |     970 |
| Tumor Cell PD-L1 ≥1%       | 158        | 158          | 157     |     473 |
| QuantifiableTumorCellPD-L1 | 322        | 321          | 322     |     965 |
| Quantifiable PD-L1 by CPS  | 297        | 305          | 304     |     906 |
| All Treated Subjects       | 322        | 310          | 304     |     936 |

Abbreviations: Chemo - chemotherapy; CPS - combined positive score; CSR - clinical study report; Ipi - ipilimumab; Nivo - nivolumab; PD-L1 - programmed cell death protein ligand 1

## Outcomes and estimation

The current initial analyses of efficacy data were based on a clinical data cut-off of 18-Jan-2021 (LPLV) and a clinical database lock (DBL) of 01 Mar-2021. Minimum follow-up (date the last patient was randomized to the clinical cut-off date) for OS was 12.9 months for the comparison of nivo + chemo vs. chemo and 13.1 months for the comparison of nivo + ipi vs. chemo. Across arms, the median follow-up was 23.7 months (range: 12.9, 40.7 months).

During the procedure, updated efficacy data with a minimum follow-up of 20 months based on a DBL of 04-Oct-2021 were provided.

Data presented below are based on the initial DBL (01 Mar 2021) unless otherwise specified.

Table 10. Results of the statistical testing hierarchy for Study CA209648

|                      |                                                                | Nivo+Chemo vs Chemo                                   | Nivo+Chemo vs Chemo   | Nivo+Chemo vs Chemo   | Nivo+Ipi vs Chemo                                    | Nivo+Ipi vs Chemo    | Nivo+Ipi vs Chemo    |
|----------------------|----------------------------------------------------------------|-------------------------------------------------------|-----------------------|-----------------------|------------------------------------------------------|----------------------|----------------------|
| Hierarchy            | Study Population                                               | Significan ce Level Threshol d (overall alpha for OS) | p- value              | Met the Threshol d?   | Significan ce Level Threshold (overall alpha for OS) | p- valu e            | Met the Threshol d?  |
| Primary Endpoints:   | Primary Endpoints:                                             | Primary Endpoints:                                    | Primary Endpoints:    | Primary Endpoints:    | Primary Endpoints:                                   | Primary Endpoints:   | Primary Endpoints:   |
| OS                   | All Randomized Subjects with Tumour Cell PD- L1 Expression ≥1% | 0.005 a (0.01)                                        | <0.00 01              | Yes                   | 0.014 c (0.02 d )                                    | 0.001 0              | Yes                  |
| PFS per BICR         | All Randomized Subjects with Tumour Cell PD- L1 Expression ≥1% | 0.015                                                 | 0.002 3               | Yes                   | 0.015                                                | 0.895 8              | No                   |
| Secondary Endpoints: | Secondary Endpoints:                                           | Secondary Endpoints:                                  | Secondary Endpoints:  | Secondary Endpoints:  | Secondary Endpoints:                                 | Secondary Endpoints: | Secondary Endpoints: |
| OS                   | All Randomized Subjects                                        | 0.009 b (0.01)                                        | 0.002 1               | Yes                   | 0.018 e (0.02)                                       | 0.011 0              | Yes                  |
| PFS per BICR         | All Randomized Subjects                                        | 0.015                                                 | 0.035 5               | No                    | N.A.                                                 | N.A.                 | Not formally tested  |
| ORR per BIC R        | All Randomized Subjects with Tumour Cell PD- L1 Expression ≥1% | N.A.                                                  | N.A.                  | Not formally tested   | N.A.                                                 | N.A.                 | Not formally tested  |

<div style=\"page-break-after: always\"></div>

|               |                         | Nivo+Chemo vs Chemo                                   | Nivo+Chemo vs Chemo   | Nivo+Chemo vs Chemo   | Nivo+Ipi vs Chemo                                    | Nivo+Ipi vs Chemo   | Nivo+Ipi vs Chemo   |
|---------------|-------------------------|-------------------------------------------------------|-----------------------|-----------------------|------------------------------------------------------|---------------------|---------------------|
| Hierarchy     | Study Population        | Significan ce Level Threshol d (overall alpha for OS) | p- value              | Met the Threshol d?   | Significan ce Level Threshold (overall alpha for OS) | p- valu e           | Met the Threshol d? |
| ORR per BIC R | All Randomized Subjects | N.A.                                                  | N.A.                  | Not formally tested   | N.A.                                                 | N.A.                | Not formally tested |

a  Based on O'Brien-Fleming alpha spending function with 87.6% (219/250) observed information fraction at interim.

b  Based on Pocock alpha spending function with 85.8% (441/514) observed information fraction at interim.

c  Based on O'Brien-Fleming alpha spending function with 90.8% (227/250) observed information fraction at interim.

d  The overall alpha of 0.02 for OS is the sum of 1) an initial allocated overall alpha of 0.01 for OS in all randomized subjects with tumour cell PD-L1 expression ≥ 1% for nivo + ipi vs chemo and 2) 0.01 alpha passed from the secondary OS endpoint in all randomized subjects for nivo + chemo vs chemo.

e  Based on Pocock alpha spending function with 87.2% (448/514) observed information fraction at interim.

Table 11. Summary of Key Efficacy Results - Nivolumab +Ipilimumab vs. Chemotherapy - All Randomized Subjects with Tumour Cell PD-L1 ≥ 1% and All Randomized Subjects

|                                                      | All Randomized Subjects with Tumor Cell PD- L1 ≥1%   | All Randomized Subjects with Tumor Cell PD- L1 ≥1%   | All Randomized Subjects                   | All Randomized Subjects                   | All Randomized Subjects                   |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Efficacy Parameter                                   | Nivo+Ipi N = 158                                     | Chemo N = 157                                        | Nivo+Ipi N = 325                          | Chemo N = 324                             | Chemo N = 324                             |
| OS                                                   | Primary Endpoint                                     | Primary Endpoint                                     | Secondary Endpoint                        | Secondary Endpoint                        | Secondary Endpoint                        |
| Events, n (%) HR (alpha-adjusted CI) a HR (95% CI) a | 106 (67.1) 0.64 (98.6% CI: 0.64 (0.49, 0.84)         | 121 (77.1) 0.46, 0.90)                               | 216 (66.5) 0.78 (98.2% CI: 0.78 (0.65,    | 232 (71.6) 0.62, 0.98)                    | 232 (71.6) 0.62, 0.98)                    |
| Stratified 2-sided log- rank                         | 0.0010                                               | 0.0010                                               |                                           |                                           |                                           |
| test p-value b Median OS, mo                         |                                                      |                                                      | 0.0110                                    | 0.0110                                    | 0.0110                                    |
| (95% CI) c                                           | 13.70 (11.24, 17.02)                                 | 9.07 (7.69, 9.95)                                    | 12.75 (11.27, 15.47)                      | 10.71 (9.40, 11.93)                       | 10.71 (9.40, 11.93)                       |
| OS Rate (95% CI), c % At 6 mo. At 12 mo.             | 74.44 (66.84, 80.55) 57.11                           | 72.80 (64.83, 79.26) 37.07 (29.22, 44.91)            | 74.03 (68.85, 78.49) 53.50 (47.83, 58.83) | 75.85 (70.65, 80.26) 44.32 (38.63, 49.85) | 75.85 (70.65, 80.26) 44.32 (38.63, 49.85) |
|                                                      | (48.97, 64.44) Primary Endpoint                      | (48.97, 64.44) Primary Endpoint                      |                                           |                                           |                                           |
|                                                      | (77.8)                                               | 100 (63.7)                                           |                                           | 210 (64.8)                                | 210 (64.8)                                |
| PFS per BICR                                         |                                                      |                                                      | Secondary Endpoint                        | Secondary Endpoint                        | Secondary Endpoint                        |
| Events, n (%)                                        | 123                                                  |                                                      | 258 (79.4)                                |                                           |                                           |
| HR (98.5% CI) a HR (95% CI) a                        | 1.02 (0.73, 1.43) 1.02 (0.78, 1.34)                  | 1.02 (0.73, 1.43) 1.02 (0.78, 1.34)                  | 1.26 (NA, NA) 1.26 (1.04, 1.52)           | 1.26 (NA, NA) 1.26 (1.04, 1.52)           | 1.26 (NA, NA) 1.26 (1.04, 1.52)           |
| Stratified 2-sided log- rank test p-value b          | 0.8958                                               |                                                      | 2.92 (2.66,                               | 5.59 (4.27, 5.88)                         | 5.59 (4.27, 5.88)                         |
| CI) c PFS Rate (95% CI) c ,%                         |                                                      |                                                      | NA                                        | NA                                        | NA                                        |
| Median PFS, mo. (95%                                 | 4.04 (2.40, 4.93)                                    | 4.44 (2.89, 5.82)                                    | 4.17)                                     |                                           |                                           |
| At 6-mo. At 12-mo.                                   | 34.83 (27.26, 42.48) 26.40                           | 39.04 (30.07, 47.90) 10.45                           | 31.69 (26.50, 37.00) (36.96, 22.70        |                                           |                                           |
|                                                      | (19.45, 33.85)                                       |                                                      | (11.02,                                   | (17.99,                                   | (17.99,                                   |
|                                                      |                                                      | (4.71,                                               |                                           |                                           |                                           |
| ORR per BICR                                         | Secondary                                            | 18.84)                                               | 27.75) Secondary                          |                                           |                                           |
|                                                      |                                                      |                                                      | Endpoint                                  | Endpoint                                  | Endpoint                                  |
| N Responders (%) d                                   | 56 (35.4)                                            | 31 (19.7)                                            | 90 (27.7)                                 |                                           |                                           |
| 95% CI                                               |                                                      |                                                      |                                           |                                           |                                           |
|                                                      |                                                      |                                                      |                                           | 87 (26.9)                                 | 87 (26.9)                                 |
|                                                      | (28.0, 43.4)                                         | (13.8, 26.8)                                         | (22.9,                                    | (22.1,                                    | (22.1,                                    |
|                                                      |                                                      |                                                      | 32.9) 32.0)                               | 32.9) 32.0)                               | 32.9) 32.0)                               |
|                                                      |                                                      |                                                      |                                           |                                           | Endpoint                                  |

<div style=\"page-break-after: always\"></div>

|                                    | All Randomized Subjects with Tumor Cell PD- L1 ≥1%   | All Randomized Subjects with Tumor Cell PD- L1 ≥1%   | All Randomized Subjects   | All Randomized Subjects   |
|------------------------------------|------------------------------------------------------|------------------------------------------------------|---------------------------|---------------------------|
| Efficacy Parameter                 | Nivo+Ipi N = 158                                     | Chemo N = 157                                        | Nivo+Ipi N = 325          | Chemo N = 324             |
| ORR Difference (95% CI) e          | 15.7 (5.9, 25.4)                                     |                                                      | 0.9 (-5.9, 7.6)           | 0.9 (-5.9, 7.6)           |
| Complete Response, n (%)           | 28 (17.7)                                            | 8 (5.1)                                              | 36 (11.1)                 | 20 (6.2)                  |
| DOR per BICR                       | Exploratory                                          | Endpoint                                             | Exploratory Endpoint      | Exploratory Endpoint      |
| n events/N responders (%)          | 31/56 (55.4)                                         | 17/31 (54.8)                                         | 53/90 (58.9)              | 51/87 (58.6)              |
| Median, mo. (95% CI)               | 11.83 (7.10, 27.43)                                  | 5.68 (4.40, 8.67)                                    | 11.07 (8.31, 14.00)       | 7.13 (5.65, 8.21)         |
| Min, Max, mo.                      | 1.4+, 34.5+                                          | 1.4+, 31.8+                                          | 1.4+, 34.5+               | 1.4+, 31.8+               |
| Proportion (95% CI) c with DOR of: |                                                      |                                                      |                           |                           |
| ≥6 mo.                             | 0.67 (0.52, 0.77)                                    | 0.39 (0.19, 0.59)                                    | 0.66 (0.55, 0.75)         | 0.54 (0.41, 0.65)         |
| ≥12 mo.                            | 0.49 (0.35, 0.62)                                    | 0.13 (0.02, 0.33)                                    | 0.48 (0.36, 0.58)         | 0.23 (0.13, 0.34)         |
| PFS per Investigator               | Exploratory Endpoint                                 |                                                      | Exploratory Endpoint      | Exploratory Endpoint      |
| Events, n (%)                      | 127 (80.4)                                           | 122 (77.7)                                           | 268 (82.5)                | 249 (76.9)                |
| HR (95.0% CI) a                    | 0.83 (0.64,                                          | 1.07)                                                | 1.01 (0.85, 1.21)         | 1.01 (0.85, 1.21)         |
| Median PFS, mo. (95% CI) c         | 4.01 (2.66, 5.42)                                    | 4.21 (3.06, 5.39)                                    | 3.52 (2.76, 4.24)         | 5.39 (4.21, 5.68)         |
| PFS Rate (95% CI) c ,%             |                                                      |                                                      |                           |                           |
| At 6 mo.                           | 36.16 (28.64, 43.71)                                 | 32.94 (24.95, 41.14)                                 | 33.19 (28.03, 38.44)      | 39.36 (33.52, 45.13)      |
| At 12 mo.                          | 26.25 (19.48, 33.50)                                 | 6.24 (2.65, 11.98)                                   | 21.94 (17.44, 26.78)      | 9.52 (6.14, 13.78)        |
| PFS2/TSST per Investigator         | Exploratory Endpoint                                 |                                                      | Exploratory Endpoint      |                           |
| Events, n (%) HR (95.0% CI) a      | 115 (72.8) 0.59 (0.45,                               | 131 (83.4) 0.76)                                     | 239 (73.5) 0.74           | 260 (80.2) (0.62, 0.88)   |
| Median PFS, mo. (95% CI) c         | 9.86 (8.48, 12.16)                                   | 7.06 (6.54, 7.82)                                    | 9.72 (8.48, 11.24)        | 7.89 (7.13, 8.44)         |

Stratified Cox proportional hazards model. HR is Nivo + Ipi over Chemo.

b Logrank test stratified by ECOG PS (0 vs 1) and number of organs with metastases (≤ 1 vs ≥ 2) as recorded in IRT for All Randomized Subjects with Tumor Cell PDL1 ≥1%, and stratified by ECOG PS, number of organs with metastases, and tumor cell PD-L1 expre ssion (≥1% or &lt;1% and indeterminate) as recorded in IRT for All Randomized Subjects.

c Based on Kaplan-Meier estimates.

- d CR or PR per RECIST 1.1. CI based on the Clopper and Pearson method.

e Strata adjusted difference in objective response rate (nivo+ipi - chemo) based on CMH method of weighting. Stratified by ECOG PS (0 vs 1) and number of organs with metastases (≤1 vs ≥2) per IRT for all randomized subjects with tumor cell PDL1 ≥1%, and stratified by ECOG PS, number of organs with metastases, and tum or cell PDL1 expression (≥1% or &lt;1% and indeterminate) per IRT for all randomized subjects.

Symbol + indicates a censored value

Database lock: 01-Mar-2021. Minimum follow-up for OS was 13.1 months.

## Primary endpoints

## o Overall Survival - All Randomized Subjects with Tumour Cell PDL1 ≥ 1%

At DBL (01-Mar-2021), minimum follow-up for OS among all randomized subjects with tumor cell PDL1 expression ≥ 1% was 13.1 months.

<div style=\"page-break-after: always\"></div>

In all randomized subjects with tumor cell PDL1 expression ≥ 1%, a s tatistically significant and clinically relevant improvement in OS was observed with nivo + ipi vs. chemo. The OS HR was 0.64 (98.6% CI: 0.46, 0.90) with a stratified 2-sided log-rank test p-value = 0.0010. Median OS (95% CI) was longer in the nivo + ipi arm compared with the chemo arm: 13.70 (11.24, 17.02) vs. 9.07 (7.69, 9.95) months, with non-overlapping CIs. OS rates (95% CI) in the nivo + ipi vs. chemo arms were as follows:

- -At 6 months: 74.44% (66.84, 80.55) vs. 72.80% (64.83, 79.26)
- -At 12 months: 57.11% (48.97, 64.44) vs. 37.07% (29.22, 44.91)

The KM curves crossed at approximately 6 months favoring nivo + ipi over chemo, with an increased separation over time.

52 (32.9%) subjects in the nivo + ipi arm and 36 (22.9%) subjects in the chemo arm were censored for OS at DBL. Of the censored subjects, 11/52 (21.2%) and 0 subjects in the nivo + ipi and chemo arms, respectively, were continuing on-treatment and 37/52 (71.2%) and 19/36 (52.8%) subjects in the nivo + ipi and chemo arms, respectively, were in follow-up. Of the subjects off study in the nivo + ipi (n = 4) and chemo (n = 17) arms, all 4 of the subjects in the nivo + chemo arm and 15/17 subjects in the chemo arm withdrew consent.

Follow-up for OS was current for the majority of subjects: 98.1% of subjects in the nivo + ipi arm and 89.8% of subjects in the chemo arm either died or had a last known alive date on or after the clinical cutoff date (18-Jan-2021).

Results for the following sensitivity analyses were consistent with the primary OS analysis:

- -Unstratified analysis with treatment as the single covariate: HR = 0.62 (98.6% CI: 0.45, 0.87); 2-sided unstratified log-rank test descriptive p-value = 0.0005.
- -Max-combo analysis of OS data: HR = 0.52 (adjusted 95% CI: 0.39, 0.69), descriptive p-value &lt; 0.0001.
- -In the post-hoc analysis of piecewise HRs for the nivo + ipi vs. chemo comparison, HRs were &gt; 1.00 from study start to 4 months and &lt; 1.00 thereafter. HRs (95% CI) by interval: 1.45 (0.59, 3.54) for 0 to ≤ 2 months, 1.57 (0.51, 4.82) for &gt; 2 to ≤ 3 months, 3.15 (1.02, 9.78) for &gt; 3 to ≤ 4 months, 0.64 (0.21, 1.96) for &gt; 4 to ≤ 5 months, 0.21 (0.06, 0.71) for &gt; 5 to ≤ 6 months, and 0.50 (0.35, 0.69) for &gt; 6 months.
- -In a multivariate analysis of OS, the treatment effect of nivo + ipi vs chemo was consistent with the primary OS analysis: HR = 0.62, 95.0% CI: 0.47, 0.82; multivariate Cox model descriptive p-value = 0.0007.

<div style=\"page-break-after: always\"></div>

Figure 4 : Kaplan-Meier Plot of Overall Survival - Nivolumab + Ipilimumab vs. Chemotherapy - All Randomized Subjects with Tumor Cell PD-L1 ≥1%

<!-- image -->

Statistical model for hazard ratio and p-value: stratified Cox proportional hazard model and stratified log-rank test. Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (≤ 1 vs. ≥ 2) as recorded in IR T.

## o Progression-free Survival per BICR - All Randomized Subjects with Tumour Cell PDL1 ≥ 1%

In all randomized subjects with tumor cell PDL1 expression ≥ 1%, the PFS per BICR (primary definition) results for nivo + ipi vs. chemo did not meet the criteria for statistical significance: HR =  1.02 (98.5% CI: 0.73, 1.43; p = 0.8958). Median PFS per BICR (95% CI) was 4.04 (2.40, 4.93) and 4.44 (2.89, 5.82) months in the nivo + ipi vs. chemo arms, respectively. PFS rates (95% CI) in the nivo + ipi and chemo arms were as follows:

- -At 6 months: 34.83% (27.26, 42.48) vs. 39.04% (30.07, 47.90)
- -At 12 months: 26.40% (19.45, 33.85) vs. 10.45% (4.71, 18.84)

Results for PFS per BICR accounting for assessment on/after subsequent therapy (ie, including events and disease assessments that occurred on or after subsequent anti-cancer therapy) were as follows: HR = 0.85 (98.5% CI: 0.63, 1.15).

<div style=\"page-break-after: always\"></div>

Figure 5: Kaplan-Meier Plot of Progression-Free Survival per BICR  - Nivolumab + Ipilimumab vs. Chemotherapy - All Randomized Subjects with Tumor Cell PDL1 ≥1%

<!-- image -->

Nivo + Ipi vs Chemotherapy - hazard ratio (98.5% Cl): 1.02 (0.73, 1.43)

- -+- - Chemotherapy (events : 100/157), median and 95% Cl : 4.44 (2.89, 5.82)

Nivo + Ipi vs Chemotherapy - hazard ratio (95% Cl): 1.02 (0.78, 1.34)

Stratifiedlog-rank test p-value: 0.8958

Statistical model for hazard ratio and p-value: stratified Cox proportional hazard model and stratified log-rank test.

Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (≤ 1 vs ≥ 2) as recorded in IRT .

<div style=\"page-break-after: always\"></div>

Figure 6: Kaplan-Meier Plot of Progression Free Survival per BICR - Nivolumab + Ipilimumab over Chemotherapy - Analysis Accounting for Assessment on/after Subsequent Therapy - All Randomized Subjects with Tumor Cell PDL1 ≥1%

<!-- image -->

Statistical model for hazard ratio and p-value: stratified Cox proportional hazard model and stratified log-rank test.

Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (≤ 1 vs ≥ 2) as recorded in IRT .

## Updated data (DBL 04 Oct 2021) - All randomised subjects with tumour cell PD-L1 ≥ 1%

Table 12. Efficacy of Nivo + Ipi vs Chemo - All Randomized Subjects with Tumour Cell PD-L1 ≥ 1% in CA209648 (01-Mar-2021 and 04-Oct-2021 Database Locks)

|                           | 01-Mar-2021 DBL      | 01-Mar-2021 DBL   | 04-Oct-2021 DBL a       | 04-Oct-2021 DBL a     |
|---------------------------|----------------------|-------------------|-------------------------|-----------------------|
|                           | Nivo + Ipi N = 158   | Chemo b N = 157   | Nivo + Ipi N = 158      | Chemo b N = 157       |
| Overall survival          |                      |                   |                         |                       |
| Events, n (%)             | 106 (67.1)           | 121 (77.1)        | 119 (75.3)              | 130 (82.8)            |
| Hazard ratio (95% CI) c   | 0.64 (0.49, 0.84)    | 0.64 (0.49, 0.84) | 0.63 (0.49, 0.82)       | 0.63 (0.49, 0.82)     |
| Median (95% CI), d months | 13.70 (11.24, 17.02) | 9.07 (7.69, 9.95) | 13.700 (11.236, 17.413) | 9.068 (7.688, 10.021) |

<div style=\"page-break-after: always\"></div>

|                                           | 01-Mar-2021 DBL      | 01-Mar-2021 DBL      | 04-Oct-2021 DBL a      | 04-Oct-2021 DBL a    |
|-------------------------------------------|----------------------|----------------------|------------------------|----------------------|
|                                           | Nivo + Ipi N = 158   | Chemo b N = 157      | Nivo + Ipi N = 158     | Chemo b N = 157      |
| OS Rate (95% CI), d %                     |                      |                      |                        |                      |
| At 6 months                               | 74.44 (66.84, 80.55) | 72.80 (64.83, 79.26) | 74.44 (66.84, 80.55)   | 73.17 (65.27, 79.55) |
| At 12 months                              | 57.11 (48.97, 64.44) | 37.07 (29.22, 44.91) | 57.11 (48.97, 64.44)   | 37.26 (29.45, 45.06) |
| At 18 months                              | -                    | -                    | 40.92 (33.15, 48.52)   | 21.09 (14.85, 28.08) |
| Progression-free survival per BICR        |                      |                      |                        |                      |
| Events, n (%)                             | 123 (77.8)           | 100 (63.7)           | 128 (81.0)             | 101 (64.3)           |
| Hazard ratio (95% CI) c                   | 1.02 (0.78, 1.34)    | 1.02 (0.78, 1.34)    | 1.02 (0.77, 1.34)      | 1.02 (0.77, 1.34)    |
| Median (95% CI), d months                 | 4.04 (2.40, 4.93)    | 4.44 (2.89, 5.82)    | 4.041 (2.398, 4.928)   | 4.435 (2.891, 5.815) |
| PFS Rate (95% CI), d %                    |                      |                      |                        |                      |
| At 6 months                               | 34.83 (27.26, 42.48) | 39.04 (30.07, 47.90) | 34.83 (27.26, 42.48)   | 39.58 (30.62, 48.39) |
| At 12 months                              | 26.40 (19.45, 33.85) | 10.45 (4.71, 18.84)  | 26.45 (19.50, 33.88)   | 10.30 (4.64, 18.59)  |
| At 18 months                              | -                    | -                    | 17.56 (11.67, 24.45)   | 2.75 (0.27, 11.28)   |
| Objective response rate per BICR, e n (%) | 56 (35.4)            | 31 (19.7)            | 56 (35.4)              | 31 (19.7)            |
| (95% CI) e                                | (28.0, 43.4)         | (13.8, 26.8)         | (28.0, 43.4)           | (13.8, 26.8)         |
| Complete response                         | 28 (17.7)            | 8 (5.1)              | 27 (17.1)              | 8 (5.1)              |
| Partial response                          | 28 (17.7)            | 23 (14.6)            | 29 (18.4)              | 23 (14.6)            |
| Difference (95% CI), f %                  | 15.7 (5.9, 25.4)     | 15.7 (5.9, 25.4)     | 15.7 (5.9, 25.4)       | 15.7 (5.9, 25.4)     |
| Duration of response per BICR             |                      |                      |                        |                      |
| Median (95% CI), d months                 | 11.83 (7.10, 27.43)  | 5.68 (4.40, 8.6 7)   | 12.649 (7.097, 18.628) | 5.684 (4.402, 8.674) |
| Min, Max, g months                        | 1.4+, 34.5+          | 1.4+, 31.8+          | 1.4+, 35.8+            | 1.4+, 40.1+          |
| Proportion (95% CI) d with DOR of:        |                      |                      |                        |                      |
| ≥ 6 months                                | 0.67 (0.52, 0.77)    | 0.39 (0.19, 0.59)    | 0.67 (0.52, 0.77)      | 0.39 (0.19, 0.59)    |
| ≥ 12 months                               | 0.49 (0.35, 0.62)    | 0.13 (0.02, 0.33)    | 0.50 (0.36, 0.63)      | 0.13 (0.02, 0.33)    |

Minimum follow-up for 01-Mar-2021 DBL: 13.1 months. Minimum follow-up for 04-Oct-2021 DBL: 20 months.

a Descriptive analysis based on database lock of 04-Oct-2021.

b Fluorouracil and cisplatin.

c Stratified Cox Proportional hazards model. Hazard Ratio is Nivo + Ipi vs Chemo. Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2) as recorded in IRT. Region is excluded from the stratified analysis due to small size in Rest of Asia.

d Based on Kaplan-Meier estimates.

e CR+PR, confidence interval based on the Clopper and Pearson method.

f Strata adjusted difference in objective response rate (Nivo + Ipi - Chemo) based on Cochran-Mantel-Haenszel (CMH) method of weighting. Stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2) as recorded in IRT. Region is excluded from the stratified analysis due to small size in Rest of Asia.

<div style=\"page-break-after: always\"></div>

Figure 7. Kaplan-Meier Plot of Overall Survival for Nivo + Ipi vs Chemo - All Randomized Subjects with Tumor Cell PD L1 ≥ 1% in CA209648 (04 Oct -2021 Database Lock)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 8. Kaplan-Meier Plot of Progression-free Survival per BICR for Nivo + Ipi vs Chemo - All Randomized Subjects with Tumour Cell PD L1 ≥ 1% in CA209648 (04 -Oct-2021 Database Lock)

<!-- image -->

Nivo + Ipi vs Chemotherapy - hazard ratio (95% Cl): 1.02 (0.77, 1.34)

Statistical model for hazard ratio: Stratified Cox proportional hazard model. Symbols represent censored observations. Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2) as recorded in IRT. Region is excluded from the stratified analysis due to small size in rest of Asia.

## Secondary endpoints

## o Overall survival - All Randomized Subjects

A statistically significant improvement in OS was observed for all randomized subjects with nivo + ipi vs. chemo. Minimum follow-up for OS in the nivo + ipi and chemo arms was 13.1 months. The OS HR was 0.78 (98.2% CI: 0.62, 0.98); stratified 2-sided log-rank test p-value = 0.0110. Median OS (95% CI) was approximately 2 months longer in the nivo + ipi arm compared to the chemo arm: 12.75 (11.27, 15.47) vs. 10.71 (9.40, 11.93) months. Landmark OS rates (95% CI) for nivo + ipi vs. chemo were as follows:

- -At 6 months: 74.03% (68.85, 78.49) vs. 75.85% (70.65, 80.26)
- -At 12 months: 53.50% (47.83, 58.83) vs. 44.32% (38.63, 49.85)

The KM curves for nivo + ipi over chemo crossed at approximately 6.5 months, with an increased separation over time favoring nivo + ipi over chemo.

<div style=\"page-break-after: always\"></div>

109 (33.5%) subjects in the nivo + ipi arm and 92 (28.4%) subjects in the chemo arm were censored for OS at DBL. Of the censored subjects, 21/109 (19.3%) and 4/92 (4.3%) subjects in the nivo + ipi and chemo arms, respectively, were continuing on-treatment and 72/109 (66.1%) and 57/92 (62.0%) subjects in the nivo + ipi and chemo arms, respectively, were in follow-up. The majority of subjects who were off study in the nivo + ipi (N = 16) and chemo (N = 31) arms, withdrew consent: 10/16 (62.5%) and 27/31 (87.1%), respectively.

Follow-up for OS was current for the majority of subjects: 95.4% of subjects in the nivo + ipi arm and 91.0% of subjects in the chemo arm either died or had a last known alive date on or after the clinical cutoff date (18-Jan-2021).

Results for the following sensitivity analyses were consistent with the primary OS analysis:

- -Unstratified analysis with treatment as the single covariate: HR = 0.78 (98.2% CI: 0.62, 0.98); 2-sided unstratified log-rank descriptive p-value = 0.0088.
- -Max-combo analysis of OS data: HR = 0.67 (adjusted 95% CI: 0.55, 0.81), descriptive p-value &lt; 0.0001.
- -In the post-hoc analysis of piecewise HRs for the nivo + ipi vs chemo comparison, HRs were &gt; 1.00 from study start to 4 months and &lt; 1.00 thereafter. HRs (95% CI) by interval: 2.02 (1.07, 3.82) for 0 to ≤ 2 months, 1.36 (0.64, 2.88) for &gt; 2 to ≤ 3 months , 1.96 (0.94, 4.09) for &gt; 3 to ≤ 4 months, 0.79 (0.33, 1.87) for &gt; 4 to ≤ 5 months, 0.39 (0.18, 0.83) for &gt; 5 to ≤ 6 months, and 0.63 (0.49, 0.79) for &gt; 6 months.
- -In a multivariate analysis of OS, the treatment effect of nivo + ipi vs chemo was consistent with the primary OS analysis: HR = 0.77, 95.0% CI: 0.63, 0.93; multivariate Cox model descriptive p value = 0.0064.

<div style=\"page-break-after: always\"></div>

Figure 9: Kaplan-Meier Plot of Overall Survival - Nivolumab + Ipilimumab vs Chemotherapy - All Randomized Subjects

<!-- image -->

Statistical model for hazard ratio and p-value: stratified Cox proportional hazard model and stratified log-rank test.

Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs. 1), number of organs with metastases (≤ 1 vs. ≥ 2), and tumor cell PD -L1 expression (≥1% vs . &lt;1% or indeterminate) as recorded in IRT.

## o Progression-free Survival - All Randomized Subjects

In all randomized subjects, the HR for PFS per BICR for nivo + ipi vs. chemo was 1.26 (95% CI: 1.04, 1.52). Median PFS per BICR (95% CI) was 2.92 (2.66, 4.17) and 5.59 (4.27, 5.88) months in the nivo + ipi and chemo arms, respectively. PFS rates (95% CI) in the nivo + ipi and chemo arms were as follows, respectively:

- -At 6 months: 31.69% (26.50, 37.00) vs. 43.15% (36.96, 49.19)
- -At 12 months: 22.70% (17.99, 27.75) vs. 16.02% (11.02, 21.86)

Results for the sensitivity analyses were as follows:

- ­ Max-combo analysis when the proportionality assumption did not hold: HR = 0.81 (adjusted 95% CI: 0.65, 1.01).
- ­ The post-hoc analysis comparing the RMST of PFS per BICR between nivo + ipi and chemo was performed when the proportionality assumption did not hold. Long-term PFS benefit was demonstrated with nivo + ipi vs chemo, with a difference over time favoring nivo + ipi over

<div style=\"page-break-after: always\"></div>

chemo: -0.83 (-1.15, -0.51) at 6 months, 0.90 ( 1.58, -0.22) at 12 months, -0.11 ( 1.34, 1.11) at 24 months, and 0.35 ( 1.27, 1.98) at 33.3 months

Results for the PFS analysis accounting for assessment on/after subsequent therapy (ie, including events and disease assessments that occurred on or after subsequent anti-cancer therapy) were as follows: HR =1.09 (95% CI: 0.92, 1.29).

Figure 10: Kaplan-Meier Plot of Progression-Free Survival per BICR - Nivolumab + Ipilimumab vs. Chemotherapy - All Randomized Subjects

<!-- image -->

Nivo + Ipi vs Chemotherapy - hazard ratio (98.5% Cl): N.A.

Nivo + Ipi vs Chemotherapy - hazard ratio (95% Cl): 1.26 (1.04, 1.52)

Stratified log-rank test p-value : N.A.

Statistical model for hazard ratio and p-value: stratified Cox proportional hazard model and stratified log-rank test. Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (≤ 1 vs ≥ 2) as recorded in IRT.

<div style=\"page-break-after: always\"></div>

Figure 11: Kaplan-Meier Plot of Progression Free Survival per BICR - Nivolumab + Ipilimumab over Chemotherapy - Analysis Accounting for Assessment on/after Subsequent Therapy - All Randomized Subjects

<!-- image -->

Nivo + Ipi vs Chemotherapy - hazard ratio (98.5% Cl): N.A.

Stratified log-rank test p-value : N.A.

Statistical model for hazard ratio and p-value: stratified Cox proportional hazard model and stratified log-rank test. Symbols represent censored observations.

Stratification f actors are ECOG Performance Status (0 vs 1), number of organs with metastases (≤ 1 vs ≥ 2) as recorded in IRT.

## o Objective Response Rate - All Randomized Subjects with Tumour Cell PDL1 ≥ 1%

In all randomized subjects with tumor cell PD-L1 expression ≥ 1%, an improvement in BICR -assessed ORR (95% CI) was observed with nivo + ipi vs. chemo, with non-overlapping CIs: 35.4% (28.0, 43.4) vs 19.7% (13.8, 26.8), respectively. CRs per BICR were observed in 28 (17.7%) subjects in the nivo + ipi arm vs. 8 (5.1%) subjects in the chemo arm.

ORR (95% CI) per investigator for nivo + ipi and chemo were comparable to those per BICR 39.9% (32.2, 48.0) and 22.9% (16.6, 30.3).

Table 13: Best Overall Response per BICR - Nivolumab + Ipilimumab over Chemotherapy - All Randomized Subjects with Tumor PDL1 ≥ 1%

<!-- image -->

BEST OVERALL RESPONSE

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

<div style=\"page-break-after: always\"></div>

| COMPLETE RESPONSE (CR) PARTIAL RESPONSE (PR) STABLE DISEASE (SD) PROGRESSIVE DISEASE (PD) UNABLE TO DETERMINE (UTD)   | 28 ( 17.7) 8 ( 5.1) 28 ( 17.7) 23 ( 14.6) 43 ( 27.2) 72 ( 45.9) 48 ( 30.4) 24 ( 15.3) 11 ( 7.0) 30 ( 19.1)   |
|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| OBJECTIVE RESPONSE RATE (1) (95% CI)                                                                                  | 56/158 ( 35.4%) 31/157 ( 19.7%) (28.0, 43.4) (13.8, 26.8)                                                    |
| DIFFERENCE OF OBJECTIVE RESPONSE RATES (2, (95% CI) (99.25% CI)                                                       | 15.7% (5.9, 25.4) N.A.                                                                                       |
| ESTIMATE OF ODDS RATIO (3, 4) (95% CI) (99.25% CI)                                                                    | 2.26 (1.35, 3.78) N.A.                                                                                       |
| P­VALUE (5)                                                                                                           | N.A.                                                                                                         |

(3) Stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2) as recorded in IRT.

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ Per RECIST 1.1. (1) CR+PR, confidence interval based on the Clopper and Pearson method. (2) Strata adjusted difference in objective response rate (Nivo + Ipi ­ Chemo) based on Cochran­Mantel­Haenszel (CMH) method of weighting.

(4) Strata adjusted odds ratio (Nivo + Ipi over Chemo) using Mantel­Haenszel method.

(5) Two­sided p­value from stratified CMH Test.

## o Objective response rate - All Randomized Subjects

In all randomized subjects, BICR-assessed ORR (95% CI) was similar in the nivo + ipi and chemo arms: 27.7% (22.9, 32.9) vs. 26.9% (22.1, 32.0). CRs by BICR were observed in 36 (11.1%) subjects treated with nivo + ipi and 20 (6.2%) subjects treated with chemo.

ORRs (95% CI) per investigator for nivo + ipi (31.1%; 26.1, 36.4) and chemo (28.7%; 23.8, 34.0) were comparable to those per BICR.

Table 14: Best Overall Response per BICR - Nivolumab + Ipilimumab over Chemotherapy - All Randomized Subjects

| ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­   | Number of Subjects (%)                                                                                             | Number of Subjects (%)                                                 |
|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
|                                                                                                   | Nivo + Ipi N = 325 ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ | ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ Chemotherapy N = 324 |
| BEST OVERALL RESPONSE                                                                             |                                                                                                                    |                                                                        |
| COMPLETE RESPONSE (CR) PARTIAL RESPONSE (PR) STABLE DISEASE (SD) PROGRESSIVE DISEASE (PD)         | 36 ( 11.1) 54 ( 16.6) 103 ( 31.7) 103 ( 31.7) 29 ( 8.9) 90/325 (                                                   | 20 ( 6.2) 67 ( 20.7) 148 ( 45.7) 38 ( 11.7)                            |
| OBJECTIVE RESPONSE RATE (1) (95% CI)                                                              | (22.9,                                                                                                             | 87/324 ( 26.9%) (22.1, 32.0)                                           |
| ESTIMATE OF ODDS RATIO (3, 4) (95% CI) (99.25% CI) P­VALUE (5)                                    | N.A.                                                                                                               |                                                                        |
| UNABLE TO DETERMINE (UTD)                                                                         |                                                                                                                    | 51 ( 15.7)                                                             |
| DIFFERENCE OF OBJECTIVE RESPONSE RATES (2, (95% CI) (99.25% CI)                                   | 27.7%) 32.9) 0.9% (­5.9, 7.6) N.A. 1.04                                                                            |                                                                        |
|                                                                                                   | (0.74, 1.47) N.A.                                                                                                  |                                                                        |

(3) Stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2), PD­L1 status (&gt;= 1% vs. &lt; 1% or indeterminate) as recorded in IRT.

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ Per RECIST 1.1. (1) CR+PR, confidence interval based on the Clopper and Pearson method. (2) Strata adjusted difference in objective response rate (Nivo + Ipi ­ Chemo) based on Cochran­Mantel­Haenszel (CMH) method of weighting.

(4) Strata adjusted odds ratio (Nivo + Ipi over Chemo) using Mantel­Haenszel method.

(5) Two­sided p­value from stratified CMH Test.

<div style=\"page-break-after: always\"></div>

## Updated data (DBL 04 Oct 2021) All Randomized Subjects

Table 15. Efficacy of Nivo + Ipi vs Chemo - All Randomized Subjects in CA209648 (01-Mar-2021 and 04 Oct 2021 Database Locks)

|                                           | 01-Mar-2021 DBL      | 01-Mar-2021 DBL      | 04-Oct-2021 DBL a       | 04-Oct-2021 DBL a      |
|-------------------------------------------|----------------------|----------------------|-------------------------|------------------------|
|                                           | Nivo + Ipi N = 325   | Chemo b N = 324      | Nivo + Ipi N = 325      | Chemo b N = 324        |
| Overall survival                          |                      |                      |                         |                        |
| Events, n (%)                             | 216 (66.5)           | 232 (71.6)           | 236 (72.6)              | 250 (77.2)             |
| Hazard ratio (95% CI) c                   | 0.78 (0.62, 0.98)    | 0.78 (0.62, 0.98)    | 0.77 (0.65, 0.93)       | 0.77 (0.65, 0.93)      |
| Median (95% CI), d months                 | 12.75 (11.27, 15.47) | 10.71 (9.40, 11.93)  | 12.813 (11.269, 15.507) | 10.710 (9.363, 11.926) |
| OS Rate (95% CI), d %                     |                      |                      |                         |                        |
| At 6 months                               | 74.03 (68.85, 78.49) | 75.85 (70.65, 80.26) | 74.06 (68.89, 78.51)    | 76.01 (70.83, 80.39)   |
| At 12 months                              | 53.50 (47.83, 58.83) | 44.32 (38.63, 49.85) | 53.66 (48.00, 58.98)    | 44.36 (38.69, 49.87)   |
| At 18 months                              | -                    | -                    | 39.96 (34.51, 45.34)    | 27.54 (22.61, 32.69)   |
| Progression-free survival per BICR        |                      |                      |                         |                        |
| Events, n (%)                             | 258 (79.4)           | 210 (64.8)           | 266 (81.8)              | 214 (66.0)             |
| Hazard ratio (95% CI) c                   | 1.26 (1.04, 1.52)    | 1.26 (1.04, 1.52)    | 1.24 (1.03, 1.50)       | 1.24 (1.03, 1.50)      |
| Median (95% CI), d months                 | 2.92 (2.66, 4.17)    | 5.59 (4.27, 5.88)    | 2.924 (2.661, 4.172)    | 5.618 (4.271, 5.914)   |
| PFS Rate (95% CI), d %                    |                      |                      |                         |                        |
| At 6 months                               | 31.69 (26.50, 37.00) | 43.15 (36.96, 49.19) | 31.69 (26.50, 37.00)    | 43.61 (37.43, 49.61)   |
| At 12 months                              | 22.70 (17.99, 27.75) | 16.02 (11.02, 21.86) | 22.73 (18.03, 27.78)    | 16.41 (11.39, 22.23)   |
| At 18 months                              | -                    | -                    | 14.25 (10.32, 18.79)    | 7.99 (4.18, 13.38)     |
| Objective response rate per BICR, e n (%) | 90 (27.7)            | 87 (26.9)            | 90 (27.7)               | 86 (26.5)              |
| (95% CI) e                                | (22.9, 32.9)         | (22.1, 32.0)         | (22.9, 32.9)            | (21.8, 31.7)           |
| Complete response                         | 36 (11.1)            | 20 (6.2)             | 36 (11.1)               | 20 (6.2)               |
| Partial response                          | 54 (16.6)            | 67 (20.7)            | 54 (16.6)               | 66 (20.4)              |
| Difference (95% CI), f %                  | 0.9 (-5.9, 7.6)      | 0.9 (-5.9, 7.6)      | 1.2 (-5.6, 7.9)         | 1.2 (-5.6, 7.9)        |
| Duration of response per BICR             |                      |                      |                         |                        |
| Median (95% CI), d months                 | 11.07 (8.31, 14.00)  | 7.13 (5.65, 8. 21)   | 11.072 (8.312, 14.259)  | 7.129 (5.651, 8.214)   |
| Min, Max, g months                        | 1.4+, 34.5+          | 1.4+, 31.8+          | 1.4+, 35.8+             | 1.4+, 40.1+            |
| Proportion (95% CI) d with DOR of:        |                      |                      |                         |                        |
| ≥ 6 months                                | 0.66 (0.55, 0.75)    | 0.54 (0.41, 0.65)    | 0.67 (0.56, 0.76)       | 0.54 (0.41, 0.65)      |

<div style=\"page-break-after: always\"></div>

|             | 01-Mar-2021 DBL    | 01-Mar-2021 DBL   | 04-Oct-2021 DBL a   | 04-Oct-2021 DBL a   |
|-------------|--------------------|-------------------|---------------------|---------------------|
|             | Nivo + Ipi N = 325 | Chemo b N = 324   | Nivo + Ipi N = 325  | Chemo b N = 324     |
| ≥ 12 months | 0.48 (0.36, 0.58)  | 0.23 (0.13, 0.34) | 0.49 (0.37, 0.59)   | 0.23 (0.13, 0.34)   |

Minimum follow-up for 01-Mar-2021 DBL: 13.1 months. Minimum follow-up for 04-Oct-2021 DBL: 20 months.

a Descriptive analysis based on database lock of 04-Oct-2021.

b Fluorouracil and cisplatin.

- c Stratified Cox Proportional hazards model. Hazard Ratio is Nivo + Ipi vs Chemo. Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2), PD-L1 statu s (≥ 1% vs &lt; 1% or indeterminate) as recorded in IRT. Region is excluded from the stratified analysis due to small size in Rest of Asia.
- d Based on Kaplan-Meier estimates.
- e CR+PR, confidence interval based on the Clopper and Pearson method.
- f Strata adjusted difference in objective response rate (Nivo + Ipi - Chemo) based on Cochran-Mantel-Haenszel (CMH) method of weighting. Stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2) , PDL1 status (≥ 1% vs &lt; 1% or indeterminate) as recorded in IRT. Region is excluded from the stratified analysis due to small size in Rest of Asia.

g Symbol + indicates a censored value

Figure 12. Kaplan-Meier Plot of Overall Survival for Nivo + Ipi vs Chemo - All Randomized Subjects in CA209648 (04-Oct-2021 Database Lock)

<!-- image -->

Number of Subjects at Risk

Nivo + Ipi

32527423319316614212210482

Chemotherapy

324283

Overall Survival (Months)

60

323117213210381

64

45

35

43

21

33

13

21

6

15

3

6

1

Nivo + Ipi (events : 236/325), median and 95% Cl : 12.813 (11.269, 15.507)

-+--

- Chemotherapy (events : 250/324), median and 95% Cl : 10.710 (9.363, 11.926)

Nivo + Ipi vs Chemotherapy - hazard ratio (95% Cl): 0.77 (0.65, 0.93)

Statistical model for hazard ratio: Stratified Cox proportional hazard model.

Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases

(&lt;= 1 vs. &gt;= 2), PD-L1 status (&gt;= 1% vs. &lt; 1% or indeterminate) as recorded in IRT.

Region is excluded from the stratified analysis due to small size in rest of Asia.

3

0

0

0

<div style=\"page-break-after: always\"></div>

Figure 13. Kaplan-Meier Plot of Progression-free Survival per BICR for Nivo + Ipi vs Chemo All Randomized Subjects in CA209648 (04-Oct-2021 Database Lock)

<!-- image -->

Statistical model for hazard ratio: Stratified Cox proportional hazard model.

Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2), PD-L1 status (&gt;= 1% vs. &lt; 1% or indeterminate) as recorded in IRT. Region is excluded from the stratified analysis due to small size in rest of Asia.

## Exploratory endpoints

## o PFS by Investigator in All Randomized Subjects with Tumour Cell PDL1 ≥ 1%

In all randomized subjects with tumor cell PDL1 ≥ 1%, analysis of PFS assessed by investigator showed an improved HR compared with the BICR-based primary analysis, favoring nivo + ipi over chemo: HR = 0.83 (95% CI: 0.64, 1.07). Median PFS (95% CI) in the nivo + ipi and chemo arms was 4.01 (2.66, 5.42) vs. 4.21 (3.06, 5.39) months. Landmark rates of PFS by investigator in the nivo + ipi vs. chemo arms were 36.16% (95% CI: 28.64, 43.71) vs 32.94% (95% CI: 24.95, 41.14) at 6 months and 26.25% (95% CI: 19.48, 33.50) vs. 6.24% (95% CI: 2.65, 11.98) at 12 months, respectively.

<div style=\"page-break-after: always\"></div>

Figure  14:  Kaplan-Meier  Plot  of  Progression  Free  Survival  per  Investigator :  Nivolumab  + Ipilimumab over Chemotherapy - All Randomized Subjects with Tumour Cell PDL1 ≥ 1%

<!-- image -->

Nivo + Ipi vs Chemotherapy - hazard ratio (95% Cl): 0.83 (0.64, 1.07)

Statistical model for hazard ratio: Stratified Cox proportional hazard model Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2) as recorded in IRT.

## o PFS by Investigator in All Randomized Subjects

In all randomized subjects, analysis of PFS assessed by investigator for nivo + ipi vs chemo compared resulted in a HR = 1.01 (95% CI: 0.85, 1.21). Median PFS (95% CI) in the nivo + ipi and chemo arms was 3.52 (2.76, 4.24) vs. 5.39 (4.21, 5.68) months. Landmark rates of PFS by investigator in the nivo + ipi vs. chemo arms were 33.19% (95% CI: 28.03, 38.44) vs 39.36% (95% CI: 33.52, 45.13) at 6 months and 21.94% (95% CI: 17.44, 26.78) vs. 9.52% (95% CI: 6.14, 13.78) at 12 months, respectively.

<div style=\"page-break-after: always\"></div>

Figure 15: Kaplan-Meier Plot of Progression Free Survival per Investigator - Nivolumab + Ipilimumab over Chemotherapy - All Randomized Subjects

<!-- image -->

Statistical model for hazard ratio: Stratified Cox proportional hazard model Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs. 1), number of organs with metastases

(&lt;= 1 vs. &gt;= 2), PD -L1 status (&gt;= 1% vs. &lt; 1% or indeterminate) as recorded in IRT.

## o Time to response and duration of Response - All Responders

Among responders per BICR in the nivo + ipi (N = 90) vs. chemo (N = 87) arms:

Median TTR (min, max) per BICR was similar in the nivo + ipi (1.51 [1.2, 8.4] months) and chemo (1.51 [1.1, 9.7] months) arms.

Median DOR (95% CI) was numerically longer with nivo + ipi vs. chemo: 11.07 (8.31, 14.00) vs. 7.13 (5.65,  8.21)  months  and  separation  of  the  KM  curves  favoring  nivo  +  ipi  over  chemo  began  at approximately 6 months. In the nivo + ipi vs. chemo arms, 66% (55%, 75%) vs. 54% (41%, 65%) of subjects had a DOR (95% CI) of at least 6 months, and 48% (36%, 58%) vs. 23% (13%, 34%) of subjects had a DOR (95% CI) of at least 12 months.

## o PFS2/TSST All Randomized Subjects with Tumor Cell PDL1 ≥ 1%

A numerical improvement in PFS2/TSST per investigator was observed with nivo + ipi compared to chemo in all randomized subjects with tumor cell PDL1 ≥ 1%:

Median PFS2/TSST (95% CI) per investigator was numerically longer with nivo + ipi vs. chemo: 9.86 (8.48, 12.16) vs. 7.06 (6.54, 7.82) months. The HR favored nivo + ipi over chemo, with the upper bound

<div style=\"page-break-after: always\"></div>

of the 95% CI below 1: 0.59 (95% CI: 0.45, 0.76). The 12-month PFS2/TSST rates (95% CI) were 44.92% (37.00, 52.52) vs. 23.77% (17.19, 30.97), respectively.

Figure  16:  Kaplan-Meier  Plot  of  PFS  on  Next-line  Therapy/Time  to  Second  Subsequent Therapy per Investigator - Nivolumab + Ipilimumab over Chemotherapy - All Randomized Subjects with Tumour Cell PD-L1 ≥1%

<!-- image -->

Statistical model for hazard ratio and p-value: stratified Cox proportional hazard model and stratified log-rank test. Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs. 1), number of organs with metastases (≤ 1 vs . ≥ 2) as recorded in IRT.

## o PFS2/TSST - All Randomized Subjects

A numerical improvement in PFS2/TSST per investigator was observed with nivo + ipi compared to chemo in all randomized subjects:

Median PFS2/TSST (95% CI) per investigator was numerically longer with nivo + ipi vs. chemo: 9.72 (8.48, 11.24) vs. 7.89 (7.13, 8.44) months. The HR favoured nivo + ipi over chemo, with the upper bound of the 95% CI below 1: 0.74 (95% CI: 0.62, 0.88).

51.7% vs. 62.7% of subjects, respectively, received subsequent cancer therapy. Among subjects who did not receive any subsequent cancer therapy, 68 (20.9%) vs. 42 (13.0%) were censored, respectively (Table S.5.114.3). Among subjects who received at least 1 subsequent cancer therapy, 18 (5.5%) vs. 22 (6.8%) were censored, respectively.

## Biomarker analysis

Efficacy by tumour cell PD-L1 expression

<div style=\"page-break-after: always\"></div>

Table 16. Efficacy of Nivolumab + Ipilimumab vs. Chemotherapy by Baseline Tumour Cell PD-L1 Levels - All Randomized Subjects

|                             | PD-L1 <1%              | PD-L1 <1%              | PD-L1 ≥ 1%           | PD-L1 ≥ 1%         | PD-L1 < 5%           | PD-L1 < 5%          | PD-L1≥ 5%            | PD-L1≥ 5%          | PD-L1 < 10%          | PD-L1 < 10%         | PD-L1≥ 10%          | PD-L1≥ 10%         |
|-----------------------------|------------------------|------------------------|----------------------|--------------------|----------------------|---------------------|----------------------|--------------------|----------------------|---------------------|---------------------|--------------------|
|                             | Nivo+ Ipi N=164        | Chemo N=166            | Nivo+ Ipi N=158      | Chemo N=156        | Nivo+ Ipi N=202      | Chemo N=207         | Nivo+ Ipi N=120      | Chemo N=115        | Nivo+ Ipi N=219      | Chemo N=225         | Nivo+ Ipi N=103     | Chemo N=97         |
| OS                          |                        |                        |                      |                    |                      |                     |                      |                    |                      |                     |                     |                    |
| HR (95% CI)a                | 0.96 (0.74, 1.25)      | 0.96 (0.74, 1.25)      | 0.63 (0.48, 0.82)    | 0.63 (0.48, 0.82)  | 0.86 (0.68, 1.09)    | 0.86 (0.68, 1.09)   | 0.66 (0.48, 0.90)    | 0.66 (0.48, 0.90)  | 0.82 (0.65, 1.02)    | 0.82 (0.65, 1.02)   | 0.71 (0.51,1.00)    | 0.71 (0.51,1.00)   |
| Events, n                   | 108                    | 111                    | 106                  | 120                | 134                  | 146                 | 80                   | 85                 | 145                  | 161                 | 69                  | 70                 |
| Median OS, mo (95% CI)b     | 11.96 (10.09, 16.03)   | 12.16 (10.71, 14.00)   | 13.70 (11.24, 17.02) | 9.20 (7.72, 10.02) | 12.42 (10.74, 16.20) | 11.14 (9.59, 12.88) | 13.04 (11.17, 17.02) | 9.49 (7.82, 11.37) | 12.52 (10.91, 15.74) | 10.84 (9.40, 12.35) | 13.04 (9.49, 19.98) | 9.49 (8.51, 12.19) |
| PFS per BICR                |                        |                        |                      |                    |                      |                     |                      |                    |                      |                     |                     |                    |
| HR (95% CIa                 | 1.45 (1.13, 1.88)      | 1.45 (1.13, 1.88)      | 0.98 (0.75, 1.29)    | 0.98 (0.75, 1.29)  | 1.35 (1.07, 1.70)    | 1.35 (1.07, 1.70)   | 0.95 (0.70, 1.30)    | 0.95 (0.70, 1.30)  | 1.30 (1.04, 1.62)    | 1.30 (1.04, 1.62)   | 0.98 (0.70, 1.39)   | 0.98 (0.70, 1.39)  |
| Events, n                   | 132                    | 108                    | 123                  | 100                | 161                  | 134                 | 94                   | 74                 | 175                  | 147                 | 80                  | 61                 |
| Median PFS, mo. (95% CI)  b | 2.83 (1.68, 4.17)      | 5.75 (5.39, 6.97)      | 4.04 (2.40, 4.93)    | 4.44 (2.89, 5.82)  | 2.79 (1.91, 4.04)    | 5.68 (4.44, 6.90)   | 4.24 (2.66. 5.55)    | 4.40 (2.83. 5.91)  | 2.83 (2.14, 4.04)    | 5.65 (4.27, 6.37)   | 4.24 (2.63, 5.55)   | 4.50 (2.86, 6.93)  |
| ORR per BICR (CR + PR)      | ORR per BICR (CR + PR) | ORR per BICR (CR + PR) |                      |                    |                      |                     |                      |                    |                      |                     |                     |                    |
| ORR (95% CI)                | 20.1 (14.3, 27.1)      | 33.7 (26.6, 41.5)      | 35.4 (28.0, 43.4)    | 19.9 (13.9. 27.0)  | 22.3 (16.7, 28.6)    | 30.9 (24.7, 37.7)   | 36.7 (28.1, 45.9)    | 20.0 (13.1, 28.5)  | 23.3 (17.9, 29.5)    | 29.3 (23.5, 35.8)   | 36.9 (27.6, 47.0)   | 21.6 (13.9, 31.2)  |
| CR, n (%)                   | 8 (4.9)                | 12 (7.2)               | 28 (17.7)            | 8 (5.1)            | 16 (7.9)             | 14 (6.8)            | 20 (16.7)            | 6 (5.2)            | 18 (8.2)             | 15 (6.7)            | 18 (17.5)           | 5 (5.2)            |
| Partial Response, n (%)     | 25 (15.2)              | 44 (26.5)              | 28 (17.7%)           | 23 (14.7)          | 29 (14.4)            | 50 (24.2)           | 24 (20.0)            | 17 (14.8)          | 33 (15.1)            | 51 (22.7)           | 20 (19.4)           | 16 (16.5)          |
| Stable Disease, n (%)       | 60 (36.6)              | 74 (44.6)              | 43 (27.2)            | 72 (46.2)          | 68 (33.7)            | 92 (44.4)           | 35 (29.2)            | 54 (47.0)          | 74 (33.8)            | 102 (45.3)          | 29 (28.2)           | 44 (45.4)          |
| Progressive Disease, n (%)  | 53 (32.3)              | 14 (8.4)               | 48 (30.4)            | 24 (15.4)          | 71 (35.1)            | 22 (10.6)           | 30 (25.0)            | 16 (13.9)          | 76 (34.7)            | 24 (10.7)           | 25 (24.3)           | 14 (14.4)          |
| Unable to Determine, n (%)  | 18 (11.0)              | 22 (13.3)              | 11 (7.0)             | 29 (18.6)          | 18 (8.9)             | 29 (14.0)           | 11 (9.2)             | 22 (19.1)          | 18 (8.2)             | 33 (14.7)           | 11 (10.7)           | 18 (18.6)          |

Tumor cell PD-L1 expression subgroups are based on CRF.

Unstratified Cox proportional hazards model.

Based on Kaplan-Meier estimates.

In subjects with measurable disease. Confidence interval based on the Clopper and Pearson method.

Abbreviations: BICR -Blinded Independent Central Review; Chemo - chemotherapy; CI -confidence interval; CR - complete response; CRF -case report form; CSR - clinical study report; HR -hazard ratio; Ipi -ipilimumab; Nivo - nivolumab; ORR - objective response rate; OS - overall survival, PD-L1- programmed death ligand 1; PFS - progression-free survival; PR -partial response

Figure 17: Nivo+Ipi vs. Chemo: OS KM by Tumour Cell PD-L1 (All Randomised Patients)

<!-- image -->

<div style=\"page-break-after: always\"></div>

```
DBL: 01-Mar-2021 Nivo + Ipi --+--Chemo
```

The MAH fitted a Cox proportional hazards regression model with treatment, PD-L1 status, and treatment by PD-L1 status interaction for both OS and PFS. See results in the table below.

Table 17. Predictive Relationship of PD-L1 status for efficacy endpoints: Nivo+Ipi over Chemo - All PD-L1 evaluable subjects

<!-- image -->

Although not powered to determine statistical significance, the descriptive p-values for the interactions between tumour cell PD-L1 status ( ≥ 1% and &lt; 1%) and treatment were p=0.0241 for PFS per BICR and p=0.0278 for OS from the Cox proportional hazard model, indicating that there was as signal of interaction between treatment and baseline tumour cell PD-L1 status at the 1% cut-off for PFS per BICR and OS at a prespecified significance level of 0.2.

Updated efficacy data by tumour cell PD-L1 expression (DBL 04 Oct 2021)

Table 18. Overall Survival of Nivo + Ipi vs Chemotherapy by Baseline Tumour Cell PD-L1 Levels - All Randomized Subjects (01-Mar-2021 and 04-Oct-2021 Database Locks) - Exploratory Analysis

|                         | PD-L1 < 1%           | PD-L1 < 1%           | PD-L1 ≥ 1%           | PD-L1 ≥ 1%         | PD-L1 < 5%           | PD-L1 < 5%          | PD-L1 ≥ 5%           | PD-L1 ≥ 5%         | PD-L1 < 10%          | PD-L1 < 10%         | PD-L1 ≥ 10%         | PD-L1 ≥ 10%        |
|-------------------------|----------------------|----------------------|----------------------|--------------------|----------------------|---------------------|----------------------|--------------------|----------------------|---------------------|---------------------|--------------------|
|                         | Nivo+ Ipi N=164      | Chemo N=166          | Nivo+ Ipi N=158      | Chemo N=156        | Nivo+ Ipi N=202      | Chemo N=207         | Nivo+ Ipi N=120      | Chemo N=115        | Nivo+ Ipi N=219      | Chemo N=225         | Nivo+ Ipi N=103     | Chemo N=97         |
| 01-MIar-2021DBL         |                      |                      |                      |                    |                      |                     |                      |                    |                      |                     |                     |                    |
| HR (95% C1)a            | 0.96 (0.74, 1.25)    | 0.96 (0.74, 1.25)    | 0.63 (0.48, 0.82)    | 0.63 (0.48, 0.82)  | 0.86 (0.68, 1.09)    | 0.86 (0.68, 1.09)   | 0.66 (0.48, 0.90)    | 0.66 (0.48, 0.90)  | 0.82 (0.65,1.02)     | 0.82 (0.65,1.02)    | 0.71 (0.51, 1.00)   | 0.71 (0.51, 1.00)  |
| Events, n               | 108                  | 111                  | 106                  | 120                | 134                  | 146                 | 80                   | 85                 | 145                  | 161                 | 69                  | 70                 |
| Median OS, mo (95% CI)b | 11.96 (10.09, 16.03) | 12.16 (10.71, 14.00) | 13.70 (11.24, 17.02) | 9.20 (7.72, 10.02) | 12.42 (10.74, 16.20) | 11.14 (9.59, 12.88) | 13.04 (11.17, 17.02) | 9.49 (7.82, 11.37) | 12.52 (10.91, 15.74) | 10.84 (9.40, 12.35) | 13.04 (9.49, 19.98) | 9.49 (8.51, 12.19) |
| 04-0ct-2021 DBL         |                      |                      |                      |                    |                      |                     |                      |                    |                      |                     |                     |                    |
| HR (95% CI)a            | 0.96 (0.74, 1.24)    | 0.96 (0.74, 1.24)    | 0.64 (0.50, 0.83)    | 0.64 (0.50, 0.83)  | 0.86 (0.69, 1.08)    | 0.86 (0.69, 1.08)   | 0.68 (0.51, 0.92)    | 0.68 (0.51, 0.92)  | 0.82 (0.66, 1.02)    | 0.82 (0.66, 1.02)   | 0.75 (0.54,1.03)    | 0.75 (0.54,1.03)   |
| Events, n               | 115                  | 120                  | 119                  | 129                | 144                  | 158                 | 90                   | 91                 | 156                  | 174                 | 78                  | 75                 |
| Median OS, mo (95% CI)b | 11.959 (10.086,      | 12.156 (10.710,      | 13.700 (11.236,      | 9.199 (7.721,      | 12.682 (10.743,      | 11.039 (9.495,      | 13.043 (11.170,      | 9.495 (8.115,      | 12.682 (10.908,      | 10.842 (9.363,      | 13.043 (9.495,      | 9.626 (8.509,      |
|                         | 16.197)              | 13.996)              | 17.413)              | 10.021)            | 16.427)              | 12.879)             | 18.300)              | 11.368)            | 16.033)              | 12.353)             | 19.778)             | 12.189)            |

Minimumfollow-upfor01-Mar-2021DBL:13.1months.Minimumfollow-upfor04-Oct-2021DBL:20months.

Unstratified Cox proportional hazards model.

b Based on Kaplan-Meier estimates.

Minimum follow-up for 01-Mar-2021 DBL: 13.1 months. Minimum follow-up for 04-Oct-2021 DBL: 20 months.

a Unstratified Cox proportional hazards model.

b Based on Kaplan-Meier estimates.

HR is not computed for subset category with less than 10 subjects per treatment group. Biomarker result as recorded in CRF.

<div style=\"page-break-after: always\"></div>

Figure 18. Kaplan-Meier Plot of Overall Survival for Nivo + Ipi vs Chemo - All Randomized Subjects (by Tumor Cell PD-L1 Expression) in CA209648 (04-Oct-2021 Database Lock) - Exploratory Analysis

<!-- image -->

Table 19. Progression-free Survival (per BICR) of Nivo + Ipi vs Chemotherapy by Baseline Tumor Cell PD-L1 Levels - All Randomized Subjects (01-Mar-2021 and 04-Oct-2021 Database Locks) - Exploratory Analysis

|                              | PD-L1 < 1%           | PD-L1 < 1%           | PD-L1 ≥ 1%           | PD-L1 ≥ 1%           | PD-L1 < 5%           | PD-L1 < 5%           | PD-L1≥ 5%            | PD-L1≥ 5%            | PD-L1 < 10%          | PD-L1 < 10%          | PD-L1 ≥ 10%          | PD-L1 ≥ 10%          |
|------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                              | Nivo+ Ipi N=164      | Chemo N=166          | Nivo+ Ipi N=158      | Chemo N=156          | Nivo+ Ipi N=202      | Chemo N=207          | Nivo+ Ipi N=120      | Chemo N=115          | Nivo+ Ipi N=219      | Chemo N=225          | Nivo+ Ipi N=103      | Chemo N=97           |
| 01-MIar-2021DBL HR (95% CI)a | 1.45 (1.13, 1.88)    | 1.45 (1.13, 1.88)    | 0.98 (0.75, 1.29)    | 0.98 (0.75, 1.29)    | 1.35 (1.07, 1.70)    | 1.35 (1.07, 1.70)    | 0.95 (0.70,1.30)     | 0.95 (0.70,1.30)     | 1.30 (1.04, 1.62)    | 1.30 (1.04, 1.62)    | 0.98 (0.70,1.39)     | 0.98 (0.70,1.39)     |
| Events, n                    | 132                  | 108                  | 123                  | 100                  | 161                  | 134                  | 94                   | 74                   | 175                  | 147                  | 80                   | 61                   |
| Median PFS, mo. (95% CI) b   | 2.83 (1.68, 4.17)    | 5.75 (5.39, 6.97)    | 4.04 (2.40, 4.93)    | 4.44 (2.89, 5.82)    | 2.79 (1.91, 4.04)    | 5.68 (4.44, 6.90)    | 4.24 (2.66, 5.55)    | 4.40 (2.38, 5.91)    | 2.83 (2.14, 4.04)    | 5.65 (4.27, 6.37)    | 4.24 (2.63, 5.55)    | 4.50 (2.86, 6.93)    |
| 04-0ct-2021DBL HR (95% C1)a  | 1.44 (1.12, 1.85)    | 1.44 (1.12, 1.85)    | 0.98 (0.75, 1.29)    | 0.98 (0.75, 1.29)    | 1.34 (1.06, 1.68)    | 1.34 (1.06, 1.68)    | 0.95 (0.70, 1.31)    | 0.95 (0.70, 1.31)    | 1.29 (1.04, 1.61)    | 1.29 (1.04, 1.61)    | 0.98 (0.69, 1.38)    | 0.98 (0.69, 1.38)    |
| Events, n                    | 135                  | 111                  | 128                  | 101                  | 168                  | 138                  | 95                   | 74                   | 183                  | 151                  | 80                   | 61                   |
| Median PFS, mo. (95% CI) b b | 2.825 (1.676, 4.172) | 5.749 (5.487, 6.998) | 4.041 (2.398, 4.928) | 4.435 (2.891, 5.815) | 2.793 (1.906, 4.041) | 5.717 (4.435, 6.899) | 4.238 (2.661, 5.552) | 4.402 (2.825, 5.914) | 2.825 (2.136, 4.041) | 5.684 (4.304, 6.374) | 4.238 (2.628, 5.552) | 4.501 (2.858, 6.932) |

Minimumfollow-upfor 01-Mar-2021DBL:13.1months.Minimumfollow-upfor04-Oct-2021DBL:20months.

Unstratified Cox proportional hazards model.

Based onKaplan-Meier estimates.

HR is not computed for subset category with less than 10 subjects per treatment group. Biomarker result as recorded in CRF.

<div style=\"page-break-after: always\"></div>

Figure 19. Kaplan-Meier Plot of Progression-free Survival (per BICR) for Nivo + Ipi vs Chemo - All Randomized Subjects (by Tumour Cell PD-L1 Expression) in CA209648 (04-Oct-2021 Database Lock) Exploratory Analysis

<!-- image -->

Table 20. Objective Response Rate (per BICR) and Duration of Response (per BICR) of Nivo + Ipi vs Chemotherapy by Baseline Tumour Cell PD-L1 Levels - All Randomized Subjects (01-Mar-2021 and 04Oct-2021 Database Locks) - Exploratory Analysis

|                              | PD-L1 < 1%          | PD-L1 < 1%        | PD-L1 ≥ 1%          | PD-L1 ≥ 1%        | PD-L1 < 5%           | PD-L1 < 5%        | PD-L1 ≥ 5%          | PD-L1 ≥ 5%        | PD-L1 < 10%         | PD-L1 < 10%       | PD-L1 ≥ 10%         | PD-L1 ≥ 10%       |
|------------------------------|---------------------|-------------------|---------------------|-------------------|----------------------|-------------------|---------------------|-------------------|---------------------|-------------------|---------------------|-------------------|
|                              | Nivo+ Ipi N=164     | Chemb N=166       | Nivo+ Ipi N=158     | Chemo N=156       | Nivo+ Ipi N=202      | Chemo N=207       | Nivo+ Ipi N=120     | Chemo N=115       | Nivo+ Ipi N=219     | Chemo N=225       | Nivo+ Ipi N=103     | Chemo N=97        |
| 01-MIar-2021 DBL             |                     |                   |                     |                   |                      |                   |                     |                   |                     |                   |                     |                   |
| ORR (CR+PR)a, % (95% CI)     | 20.1 (14.3, 27.1)   | 33.7 (26.6, 41.5) | 35.4 (28.0, 43.4)   | 19.9 (13.9, 27.0) | 22.3 (16.7, 28.6)    | 30.9 (24.7, 37.7) | 36.7 (28.1, 45.9)   | 20.0 (13.1, 28.5) | 23.3 (17.9, 29.5)   | 29.3 (23.5, 35.8) | 36.9 (27.6, 47.0)   | 21.6 (13.9, 31.2) |
| CR, n (%)                    | 8 (4.9%)            | 12 (7.2%)         | 28 (17.7%)          | 8 (5.1%)          | 16 (7.9%)            | 14 (6.8%)         | 20 (16.7%)          | 6 (5.2%)          | 18 (8.2%)           | 15 (6.7%)         | 18 (17.5%)          | 5 (5.2%)          |
| Median DoR (95% CI),° months | 11.07 (5.68, 14.26) | 7.16 (5.68, 9.72) | 11.83 (7.10, 27.43) | 5.68 (4.40, 8.67) | NA                   | NA                | NA                  | NA                | NA                  | NA                | NA                  | NA                |
| 04-Oct-2021DBL               |                     |                   |                     |                   |                      |                   |                     |                   |                     |                   |                     |                   |
| ORR (CR+PR)a, % (95% CI)     | 20.1 (14.3, 27.1)   | 33.1 (26.0, 40.8) | 35.4 (28.0, 43.4)   | 19.9 (13.9, 27.0) | 22.3 (16.7, 28.6)    | 30.4 (24.2, 37.2) | 36.7 (28.1, 45.9)   | 20.0 (13.1, 28.5) | 23.3 (17.9, 29.5)   | 28.9 (23.1, 35.3) | 36.9 (27.6, 47.0)   | 21.6 (13.9, 31.2) |
| CR, n (%)                    | 9 (5.5%)            | 12 (7.2%)         | 27 (17.1%)          | 8 (5.1%)          | 17 (8.4%)            | 14 (6.8%)         | 19 (15.8%)          | 6 (5.2%)          | 19 (8.7%)           | 15 (6.7%)         | 17 (16.5%)          | 5 (5.2%)          |
| Median DoR (95% CI),b months | 11.07 (6.70, 14.26) | 7.16 (5.68, 9.72) | 12.65 (7.10, 18.63) | 5.68 (4.40, 8.67) | 12.62, (8.31, 17.97) | 7.16 (5.59, 9.72) | 10.25 (5.91, 15.34) | 5.68 (4.30, 8.71) | 12.25 (6.70, 17.97) | 7.13 (5.68, 8.67) | 10.84 (6.83, 15.34) | 5.68 (4.27, 8.71) |

Minimumfollow-upfor 01-Mar-2021 DBL: 13.1 months.Minimum follow-up for04-Oct-2021 DBL: 20 months.

In subjects with measurable disease. Confidence interval based on the Clopper and Pearson method.

Based on Kaplan-Meier estimates.

NA = not available.

Biomarker result as recorded in CRF.

<div style=\"page-break-after: always\"></div>

## Efficacy in PD-L1 by CPS subgroups

Table 21. Efficacy of Nivolumab + Ipilimumab vs. Chemotherapy by Baseline PD-L1 CPS - All Randomized Subjects

|                               | CPS<1                         | CPS<1                         | CPS ≥1               | CPS ≥1             | CPS<5               | CPS<5              | CPS ≥5               | CPS ≥5              | CPS<10              | CPS<10             | CPS ≥ 10             | CPS ≥ 10            |
|-------------------------------|-------------------------------|-------------------------------|----------------------|--------------------|---------------------|--------------------|----------------------|---------------------|---------------------|--------------------|----------------------|---------------------|
|                               | +0AIN Ipi N=31                | Chemo N=24                    | +OAIN Ipi N=266      | Chemo N=280        | Nivo+ Ipi N=106     | Chemo N=91         | Nivo+ Ipi N=191      | Chemo N=213         | +0AIN Ipi N=171     | Chemo N=159        | +OAIN Ipi N=126      | Chemo N=145         |
| OS                            |                               |                               |                      |                    |                     |                    |                      |                     |                     |                    |                      |                     |
| HR (95% CIa                   | 1.00 (0.52, 1.94)             | 1.00 (0.52, 1.94)             | 0.76 (0.62, 0.93)    | 0.76 (0.62, 0.93)  | 0.87 (0.62, 1.21)   | 0.87 (0.62, 1.21)  | 0.72 (0.57, 0.91)    | 0.72 (0.57, 0.91)   | 0.89 (0.69, 1.14)   | 0.89 (0.69, 1.14)  | 0.64 (0.47, 0.86)    | 0.64 (0.47, 0.86)   |
| Events, n                     | 21                            | 16                            | 179                  | 205                | 73                  | 66                 | 127                  | 155                 | 121                 | 118                | 79                   | 103                 |
| Median OS, mo (95% CI)b       | 11.47 (5.88, 20.96)           | 12.09 (9.33, 17.12)           | 12.75 (10.91, 15.47) | 9.76 (8.84, 11.63) | 11.43 (8.48, 13.08) | 9.40 (8.44, 10.84) | 14.52 (11.24, 17.02) | 11.14 (9.20, 12.55) | 11.24 (8.67, 12.81) | 9.69 (8.61, 10.97) | 16.69 (12.12, 21.19) | 11.63 (8.84, 13.54) |
| PFSperBICR(primarydefinition) | PFSperBICR(primarydefinition) | PFSperBICR(primarydefinition) |                      |                    |                     |                    |                      |                     |                     |                    |                      |                     |
| HR (95% CIa                   | 1.49 (0.78, 2.85)             | 1.49 (0.78, 2.85)             | 1.18 (0.97, 1.45)    | 1.18 (0.97, 1.45)  | 1.41 (1.00, 1.97)   | 1.41 (1.00, 1.97)  | 1.11 (0.88, 1.40)    | 1.11 (0.88, 1.40)   | 1.45 (1.11, 1.88)   | 1.45 (1.11, 1.88)  | 0.98 (0.73, 1.30)    | 0.98 (0.73, 1.30)   |
| Events, n                     | 29                            | 14                            | 206                  | 184                | 88                  | 56                 | 147                  | 142                 | 138                 | 99                 | 97                   | 66                  |
| Median PFS, mo. (95% CI)  b   | 3.22 (1.54, 4.80)             | 5.68 (2.86, 11.24)            | 2.83 (2.60, 4.17)    | 5.55 (4.24, 5.91)  | 2.79 (1.51, 4.14)   | 4.27 (3.22. 5.88)  | 3.65 (2.63, 4.44)    | 5.62 (4.27, 6.90)   | 2.60 (1.51, 2.89)   | 4.76 (4.17, 5.75)  | 4.44 (2.79, 5.82)    | 5.78 (4.24, 7.06)   |

a Unstratified Cox proportional hazards model.

Based on Kaplan-Meier estimates.

Abbreviations: BICR - Blinded Independent Central Review; Chemo - chemotherapy; CI - confidence interval; CPS - combined positive score; CSR - clinical study report; HR -hazard ratio; Ipi -ipilimumab; Nivo -nivolumab; OS -overall survival, PD-L1- programmed death ligand 1; PFS -progression-free survival

Figure 20. Nivo+Ipi vs. Chemo: Subgroup Analyses of OS by PD-L1 CPS Cut-offs

<!-- image -->

## Ancillary analyses

## Subgroup analyses

In a subgroup analysis of all randomized subjects with tumour cell PDL1 expression ≥ 1 %, OS HRs (95% CIs) for all but one subgroup favoured nivo + ipi over chemo (point estimate of HR &lt; 1). The point estimate of HR for the Rest of Asia region subgroup was 1.00. However, the number of subjects in this subgroup was small (n = 48), and the 95% CI of the HR was wide (0.53, 1.88); thus, interpretation of this result is limited.

Chemo

<div style=\"page-break-after: always\"></div>

Figure 21. Forest Plot of Treatment Effect on Overall Survival in Predefined Subsets - Nivolumab + Ipilimumab vs. Chemotherapy - All Randomized Subjects with Tumor Cell PDL1 ≥1%

<!-- image -->

|                                                                                                                 |                          | Nivo + Ilpi NofEvents                |                                                                                                                            | Chemotherapy NofEvents                             |                                                                                                | Unstratified HazardRatio(95%C)                                                        |                                                           |
|-----------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------------------------------------|
|                                                                                                                 | N                        | (Nof Subjects) (95% CI)              |                                                                                                                            |                                                    |                                                                                                | Nivo+Ipivs.Chemotherapy                                                               |                                                           |
| Overall                                                                                                         | 315                      | 106 (158)                            | 13.70 (11.24, 17.02)                                                                                                       | 121 (157)                                          | 9.07 (7.69,9.95)                                                                               | 0.62 (0.48,0.81)                                                                      |                                                           |
| Age Categorization <65                                                                                          | 177                      | 68（9 95)                             | 12.88 (8.67,15.51) 14.62 (10.87,25.30)                                                                                     | 61 (82) 49 60)                                     | 9.49 (7.43,12.22)                                                                              | 0.81 (0.57, 1.14)                                                                     |                                                           |
| >= 65 and < 75 >=75                                                                                             | 115 23 138               | 35 55) 3 8 38 (63)                   | N.A.(2.00,N.A.) 17.02 (11.24, 27.10)                                                                                       | 11 15 60 (75)                                      | 8.57 (7.36,11.37) 9.76 (5.75,14.00) 8.84 (7.46, 11.14)                                         | 0.49 (0.31, 0.77) 0.44 (0.29,0.68)                                                    |                                                           |
| >= 65 Sex Male                                                                                                  | 262                      | 87 (131) 19 (27)                     | 13.86 (11.24, 17.41) 12.12 (8.71,19.98)                                                                                    | 103 (131) 18 (26)                                  | 8.80 (7.52, 9.76) 13.11 (7.13, 18.86)                                                          | 0.60 (0.45,0.81)                                                                      |                                                           |
| Female                                                                                                          | 53 230                   | 76 (117) 85 30 (41)                  | 15.11 (11.27,18.30)                                                                                                        |                                                    | 9.92 (8.11,12.19)                                                                              | 0.77 (0.40, 1.49)                                                                     |                                                           |
| Race Asian Non-Asian                                                                                            | 181 48 86 229 86 142 172 | 54(91) 21 25) 31(42) 75 (116)        | 12.06 (6.57,19.98) 17.61 (12.29,25.95) 8.67 (7.26,13.70) 12.09(6.80,19.98) 14.62 (11.27,18.30)                             | 82 (113) 39 (44) 63 (90) 19(23) 39 (44)            | 7.61 (6.80, 9.49) 9.92 (8.57,12.81) 8.77 (3.88,13.83) 7.61 (6.80, 9.49)                        | 0.65 (0.47,0.89) 0.55 (0.33, 0.90) 0.59 (0.41,0.85) 1.00 (0.53,1.88) 0.52 (0.32,0.86) | Region_(per CRF) J/K/T RestofAsia RestofWorld Region Asia |
| 0 Not Reported 1 Weight 60kg >=60 kg DiseaseStage at Initial Diagnosis Stage !                                  | 1 179 136                | 31 ( 42) 45 (72) 61 o（ (86)          | 12.09 (6.80,19.98) 17.61 (13.08,24.08) 11.17 (7.29,13.70) N.A. 12.62 (8.74,17.02) 14.42 (12.06, 25.30) 29.27 (12.12, N.A.) | 82 (113) 39 (44) 50 (70)                           | 9.92 (8.11,12.19) 7.61 (6.80, 9.49) 10.09 (7.82,13.40) 14.75 (N.A., N.A.) 7.89 (6.80,9.49)     | 0.66 (0.48,0.90) 0.52 (0.32,0.86) 0.59 (0.39,0.88) 0.66 (0.47, 0.94)                  | Non-Asia ECOG PS (per CRF)                                |
| Stage lIl Stage Ill! StageIV NotReported HistologicGrade at Initial Diagnosis                                   | 82 211 1 25 16 114       | 68 (96) 38 (62) 5) 4 25 33)          |                                                                                                                            | 70 1 86) 1) 62（8 83) 59 (74) 3 5) 4 6 39 49 75 97) | 9.07 (7.49,10.09) 8.97 (7.46, 12.19) 17.77 (9.49, N.A.) 5.29 (0.72, N.A.) 9.40 (7.06,13.11)    | 0.70(0.49,0.99) 0.53 (0.35,0.80) 0.72 (0.43, 1.20) 0.59(0.43,0.82)                    |                                                           |
| Gx G1 G2 G3                                                                                                     | 10 11                    | 73 (114) 1)                          | 9.72 (5.26, N.A.) 11.27(7.98,15.51) 14.42 (11.24,19.98) 6.57 (N.A.,N.A.)                                                   | 0 11 (14) 7 8 44 28                                | 8.80(7.52,9.92) N.A. 7.62 (5.62, 17.25) 9.12(4.76,10.09) 8.57 (6.51,12.81)                     | 0.90 (0.34,2.33)                                                                      |                                                           |
| G4 Histological Classification atInitialDiagnosis NotOtherwiseSpecified                                         | 68 .2 90                 | 7 (11) 5 8 39 58) 22 28) 1 2) 32 51) | 11.24 (2.00, N.A.) 12.57(2.46,N.A.) 12.52(8.71,25.95) 14.42 (5.88,24.08) N.A. (20.24, N.A.) 14.62 (10.28,19.29)            | 56) （40) 。 31(39)                                  | 10.02 (8.61,14.78) N.A. 7.82 (6.28,12.09) 9.20 (7.72,10.02)                                    | 0.54 (0.35,0.85) 0.83 (0.47, 1.48) 0.54 (0.33,0.90)                                   |                                                           |
| SquamousCellCarcinoma AdenosquamousCarcinoma Other                                                              | 312 3 0                  | (157) 0 1) 0 0                       | 13.08 (11.24, 17.02) N.A. N.A.                                                                                             | 2 2) 0                                             | 4.73 (3.94, 5.52) N.A.                                                                         | 0.64 (0.49, 0.83)                                                                     |                                                           |
| Location at Initial Diagnosis UpperThoracic MiddleThoracic LowerThoracic Gastroesophageal Junction              | 66 108 120 20 1          | 24 （ 37) 34 50) 37 59) 10 11) 1)     | 17.02 (7.59, 21.03) 12.29 (8.74,17.61) 14.00 (9.20,26.78) 8.80(3.02,21.19) 12.52 (N.A., N.A.)                              | 22 29) 46 58) 46( 61) 6                            | 9.12 (7.06, 15.31) 8.57 (6.80,9.95) 9.63 (7.43,11.73) 9.63 (5.68,12.81) N.A.                   | 0.74 (0.41,1.33) 0.59 (0.37,0.92) 0.62 (0.40, 0.96)                                   |                                                           |
| Not Reported <=1                                                                                                | 159 156 254 47           | 57(.78) 82 (128) 20 25) 4 4)         | 14.42 (11.27,20.24) 9.72 (5.26,15.11) 13.77 (2.04,25.95)                                                                   | 63 (78) 100 (126) 16 22) 2 3 4) 5                  | 8.61 (7.52, 9.92) 8.80 (7.49,9.92) 9.02 (5.29,14.75) 15.38 (8.11,N.A.) 16.07 (5.39, N.A.) N.A. | 0.56 (0.38,0.82) 0.73 (0.50,1.05)                                                     |                                                           |
| Numberof Organs with Metastases at Baseline (perIRT) >=2 TimefromInitial DiseaseDiagnosistoRandomization <1Year | 51 8                     | 0 0（ 1)                              | N.A. N.A.                                                                                                                  |                                                    |                                                                                                | 0.96 (0.50,1.85)                                                                      |                                                           |
| 1-<3Years 3-<5Years >=5 Years Not Reported Prior Surgery (Excluding Biopsy)                                     | 85 230                   | 29 (.41) 77(117)                     | 12.88 (7.26,17.41) 13.70 (11.27,19.29)                                                                                     | 32 (.44) 89 (113)                                  | 9.49 (7.36,12.81) 8.80 (7.49,9.95)                                                             | 0.75 (0.45, 1.25) 0.58 (0.43,0.80)                                                    |                                                           |
| Yes No_                                                                                                         | 54 261                   | 20 (.26) 86 (132)                    | 12.11 (4.34,16.43)                                                                                                         | 22 (.28)                                           | 7.52 (5.95,11.14)                                                                              |                                                                                       |                                                           |
| Yes                                                                                                             |                          |                                      | 13.86 (11.24,19.29)                                                                                                        | 99 (129)                                           | 9.43 (7.82, 11.37)                                                                             | 0.76 (0.41,1.40)                                                                      |                                                           |
| Prior Radiotherapy                                                                                              |                          |                                      |                                                                                                                            |                                                    |                                                                                                |                                                                                       |                                                           |
| No                                                                                                              |                          |                                      |                                                                                                                            |                                                    |                                                                                                |                                                                                       |                                                           |
|                                                                                                                 |                          |                                      |                                                                                                                            |                                                    |                                                                                                | 0.60 (0.45, 0.81)                                                                     |                                                           |
|                                                                                                                 |                          |                                      |                                                                                                                            |                                                    |                                                                                                | 0.54 (0.40,0.73)                                                                      |                                                           |
|                                                                                                                 |                          | 49 （80）                              |                                                                                                                            |                                                    |                                                                                                |                                                                                       |                                                           |
|                                                                                                                 |                          | 106                                  | 17.61 (12.88,25.30) 9.49 (7.59,13.08)                                                                                      |                                                    |                                                                                                |                                                                                       |                                                           |
|                                                                                                                 |                          |                                      |                                                                                                                            |                                                    | 9.49 (7.13,12.22)                                                                              |                                                                                       |                                                           |
|                                                                                                                 |                          |                                      |                                                                                                                            | 58 (79)                                            |                                                                                                |                                                                                       |                                                           |
|                                                                                                                 |                          |                                      |                                                                                                                            | 119 (155)                                          |                                                                                                |                                                                                       |                                                           |

In a subgroup analysis of all randomized subjects , OS HRs (95% CIs) for most subgroups favored nivo + ipi over chemo (point estimate of HR &lt; 1).

Figure 22. Forest Plot of Treatment Effect on Overall Survival in Pre-Defined Subsets - Nivolumab + Ipilimumab over Chemotherapy - All Randomized Subjects

<!-- image -->

|                   | N   | Nivo + Ipi N.ofEvents (NofSubjects) mos (95%CI)   | Nivo + Ipi N.ofEvents (NofSubjects) mos (95%CI)   | Chemotherapy NofEvents (NofSubjects) mos 95%CI)   | Chemotherapy NofEvents (NofSubjects) mos 95%CI)   | Unstratified HazardRatio(95%CJ) Nivo+lpivs.Chemotherapy   | Unstratified HazardRatio(95%CJ) Nivo+lpivs.Chemotherapy   |
|-------------------|-----|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Overall           | 649 | 216 (325)                                         | 12.75 (11.27, 15.47)                              | 232 (324)                                         | 10.71 (9.40, 11.93)                               | 0.78 (0.65,0.94)                                          |                                                           |
| AgeCategorization |     |                                                   |                                                   |                                                   |                                                   |                                                           |                                                           |
| <65               | 351 | 130 (185)                                         | 12.09 (8.71,13.86)                                | 118 (166)                                         | 10.18 (8.77,12.25)                                | 0.92 (0.72,1.18)                                          |                                                           |
| >=65and<75        | 245 | 73 (116)                                          | 15.47 (11.43, 21.26)                              | 96 （129）                                          | 10.84(8.80,12.55）                                 | 0.65 （0.48,0.89）                                          |                                                           |
| >=75              | 53  | 13 24)                                            | 24.61 (10.74, N.A.)                               | 18 29                                             | 11.14 (7.06,14.62                                 | 0.55 (0.26,1.15）                                          |                                                           |
| >=65              | 298 | 86 (140)                                          | 16.03 (11.93,22.83)                               | 114 （158)                                         | 10.97 (8.97,12.55)                                | 0.63 (0.47,0.84)                                          |                                                           |
| Sex               |     |                                                   |                                                   |                                                   |                                                   |                                                           |                                                           |
| Male              | 544 | 174 (269)                                         | 13.70 (11.27, 16.43)                              | 203 (275)                                         | 9.95 (8.97, 11.37)                                | 0.70 (0.57,0.86)                                          |                                                           |
| Female            | 105 | 42 (56)                                           | 11.73 (8.02, 15.05)                               | 29 （49）                                           | 14.75 (9.26, 20.90)                               | 1.36 (0.85,2.20)                                          |                                                           |
| Race              |     |                                                   |                                                   |                                                   |                                                   |                                                           |                                                           |
| Asian             | 458 | 150 (231)                                         | 14.00 (11.53,17.08)                               | 153 (227)                                         | 11.66 (9.92,13.54)                                | 0.81 (0.64,1.01)                                          |                                                           |
| Non-Asian         | 191 | 66 (94)                                           | 11.43 (6.80,15.05)                                | 79 (97)                                           | 8.61 (7.43,10.18)                                 | 0.73 (0.52, 1.02)                                         |                                                           |
| Region (perCRF)   |     |                                                   |                                                   |                                                   |                                                   |                                                           |                                                           |
| J/K/T             | 369 | 114 (185)                                         | 16.43 (12.12, 18.99)                              | 119 (184)                                         | 12.09 (9.92,14.78)                                | 0.79 (0.61,1.03)                                          |                                                           |
| RestofAsia        | 86  | 35 44)                                            | 10.97 (7.59, 13.70)                               | 32 42)                                            | 11.06 (6.37,13.73)                                | 0.94 4(0.58,1.53）                                         |                                                           |
| RestofWorld       | 194 | 67 96)                                            | 11.43 (7.23, 15.05)                               | 81 98)                                            | 8.51 (7.20, 9.69)                                 | 0.69 (0.50,0.96)                                          |                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Additional analyses

Table 22. Restricted Mean Survival Time, Overall Survival: Nivo + Ipi over Chemo All Randomized Subjects

|                                                        | Nivo + Ipi N = 325                                                                             | Chemotherapy N= 324 Difference (95& CI)                                                                                                                                                 |
|--------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                        | RMST(95CI)                                                                                     | RMST(95 CI)                                                                                                                                                                             |
| 6 MONTHS 12 MONTHS 24 MONTHS 36 MONTHS 36.2 MONTHS (A) | 5.15 (4.97,5.33) 8.95（8.50, 9.39) 13.80 (12.83,14.77) 16.78 3(15.31,18.24) 16.82 (15.35,18.30) | 5.45 (5.30,5.59) -0.30(-0.53，-0.06) 8.95 （8.56， 9.35) 0.00 (-0.60, 0.59) 12.43 (11.56,13.29) 1.37 (0.07, 2.67) 14.23 (12.90,15.57) 2.54 0.56, 4.52) 14.26 (12.92,15.60) 2.56 0.57, 4.55 |

RMST=RestrictedMean SurvivalTime

Basedontrapezoidalintegration of thearea under theKaplan-Meier estimatedcurveumtilrestrictedtimepoint.

(A) The minimm of the longest survival time in each treatment arm, regardlless of censoring.

The clifference of RMST is Nivo + Ipi over Chemo.

Table 23. Restricted Mean Survival Time, Progression Free Survival per BICR: Nivo + Ipi over Chemo All Randomized Subjects

|                | Nivo + Ipi N=325   | Nivo + Ipi N=325   | Nivo + Ipi N=325   | Chemotherapy N=324   | Chemotherapy N=324   | Chemotherapy N=324   |            |               |
|----------------|--------------------|--------------------|--------------------|----------------------|----------------------|----------------------|------------|---------------|
|                | RMST               | (95%CI)            |                    | RMST                 | (95CI)               |                      | Difference | (95 CI)       |
| 6MONTHS        | 3.49               | （3.26，             | 3.73)              |                      | 4.32(4.10,           | 4.54)                | -0.83      | (-1.15,-0.51) |
| 12 MONTHS      | 5.08               | 4.59,              | 5.56)              | 5.98                 | 5.51,                | 6.45)                | -0.90      | (-1.58,-0.22） |
| 24 MONTHS      | 6.85               | 5.95,              | 7.74)              | 6.96                 | 6.13,                | 7.79)                | -0.11      | (-1.34,1.11)  |
| 33.3MONTHS (A) | 7.72               | 6.54,8.91)         |                    | 7.37                 | 6.26,                | 8.48)                | 0.35       | (-1.27,1.98)  |
| 36MONTHS       | N.A.               |                    |                    | N.A.                 |                      |                      | N.A.       |               |

<div style=\"page-break-after: always\"></div>

RMST=RestrictedlMeanSurvivalTime Basedon trapezoidalintegrationof thearea under theKaplan-Meier estimatedcurveuntilrestrictedtimepoint. The clifference of RMST is Nivo + Ipi over Chemo. (A) The minimm of the longest survival .time in each .treatment arm, regardlless of \\_censoring.

## Early deaths

Based on visual evaluation of the OS Kaplan-Meier (K-M) curves, an early crossing in the OS K-M curves between nivo +ipi and chemo arms occurred at approximately 6.5 months, suggesting an initial higher survival rate with the chemo arm compared with the nivo + ipi arm. Thus, exploratory post-hoc analyses were conducted in CA209648, to identify the first timepoint when the smoothed hazards were equal thus define the timing cut-off of early death, to assess the potential risks of early death for nivo + ipi vs. chemo, and to investigate baseline demographic and disease characteristics of patients for whom nivo + ipi may not provide a treatment benefit due to the initial increase in the risk of early death. The analyses conducted are based on data from CA209648 with the DBL of 01-Mar-2021. The population for analyses was limited to all randomized subjects in the nivo + ipi and chemo arms for the study.

A stratified piecewise Cox-regression model with treatment arm as covariate was produced for all randomized subjects of the nivo + ipi and chemo arms. Piecewise time intervals were defined as 0-2, &gt; 2-3, &gt; 3-4, &gt; 4-5, &gt; 5-6, and &gt; 6 months. The point estimate of the piecewise HR of death between the 2 arms was evaluated for each of these time intervals. Based on the stratified piecewise Coxregression model, a higher piecewise HR was noted for nivo + ipi arm vs. chemo arm up to 4 months (HR between 0-2 months: 2.02, 95% CI: 1.07 - 3.82; HR between 2-3 months: 1.36, 95% CI: 0.64 2.88; and HR between 3-4 months: 1.96, 95% CI: 0.94 - 4.09). The piecewise HRs became &lt; 1 in favour of nivo + ipi starting from Month 4, and remained &lt; 1 between 5-6 months, and &gt; 6 months.

Table 24. Piecewise Hazard Ratios of Overall Survival - All Randomized Subjects in the Nivolumab + Ipilimumab and Chemotherapy Arms

| Overall Survival   | Nivo + Ipi N= 325   | Nivo + Ipi N= 325   |                     |              |       |
|--------------------|---------------------|---------------------|---------------------|--------------|-------|
| Overall Survival   |                     | #EVENIS/# SUBJECTS  | #EVENIS/ # SUBJECIS | HR (95 CI)   |       |
| 0 to <= 2          | 29/325(             | 8.9)                | 14/324( 4.3)        | 2.02 (1.07,  | 3.82) |
| >2to<=3            | 16/325 (            | 4.9)                | 12/324（ 3.7)        | 1.36 (0.64,  | 2.88) |
| >3 to<=4           | 20/325（             | 6.2)                | 11/324 3.4)         | 1.96 ( 0.94, | 4.09) |
| >4to<=5            | 9/325 (2.8)         |                     | 12/324 (3.7)        | 0.79(0.33,   | 1.87) |
| >5 to=6            | 9/325 (2.8)         |                     | 25/324 (7.7)        | 0.39(0.18,   | 0.83) |
| >6                 | 133/325 ( 40.9)     |                     | 158/324 ( 48.8)     | 0.63(0.49,   | 0.79) |

Stratified Cox proportional hazard model. Hazard Ratio is over Chemotherapy.

Stratification factors are ECOG performance status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2), tumor cell PD-L1 status (= 1% vs. &lt; 1% or indeterminate) as recorded in IRT.

Region is excluded from the stratified analysis due to small size in Rest of Asia.

A plot of smoothed instantaneous hazard of death for each treatment arm was produced in all randomized subjects of the nivo + ipi and chemo arms. The first time point when the smoothed curves of instantaneous hazard of death for two treatment arms crossed (i.e., hazards of death were equal) was at 4.05 months. An early death was defined as a death of a subject with a death date prior to or on 4.05 months (subjects censored prior to or on 4.05 months were considered as having non-early deaths), after which any potential risk of death was no longer higher in the nivo + ipi arm. The instantaneous hazard rates were equal at 19.5, 21 and 25 months, which reflected fluctuations in the hazard of death driven by the small numbers of events.

<div style=\"page-break-after: always\"></div>

Figure 23. Plot of Smoothed Instantaneous Hazard of Death over Time - All Randomized Subjects in the Nivolumab + Ipilimumab and Chemotherapy Arms

<!-- image -->

Kermel-smoothedestimates usingEpanechnikovkernelwith abandwidthof 2months. Program Source:/opt/zfs001/prd/bms239897/stats/ebr2675/prog/figures Program Name: rg-ef-ossmooth648rand.sas 10MA021:00:06:19

The piecewise HRs and instantaneous hazards in the subgroups of subjects with tumour cell PD-L1 ≥1% or &lt;1% were consistent with the results in all randomized subjects.

Early deaths (i.e. a death prior to or on 4.05 months after randomization) were reported for 66/325 (20.3%) and 38/324 (11.7%) randomized subjects, in the nivo + ipi and chemo arms, respectively.

The cause of death in the early-death population was summarized by treatment arm in the table below.

<div style=\"page-break-after: always\"></div>

Table 25. Early Deaths - All Randomized Subjects in the Nivolumab + Ipilimumab and Chemotherapy Arms

|                                        | Nivo + Ipi N = 66   | Chemotherapy N = 38   |
|----------------------------------------|---------------------|-----------------------|
| NUMBER OF SUBJECTS WITH EARLY DEATH () | 66 (100.0)          | 38 (100.0)            |
| FRIMARY REASON FOR IEATH (%)           |                     |                       |
| DISEASE                                | 45 ( 68.2)          | 30 ( 78.9)            |
| STUDY IRUG TOXICITY                    | 4321 6.1)           | 410m 10.5)            |
| FRIOR FD                               | 4.51                | 2.6)                  |
| RADIOGRAFHIC FD                        | 3.01                |                       |
| NO FRIOR. PD                           | 1.5)                | 7.9)                  |
| OTHER.                                 | 19.7)               | NOON 5.3)             |
| FRIOR FD                               | 9.11                |                       |
| RADIOGRAFHIC FD                        | 7.6                 |                       |
| NO FRIOR PD                            | 10.6)               | 5.3)                  |
| UNKNOIN                                | 6.1)                | 5.31                  |
| FRIOR FD                               | 3.01                | 2.6)                  |
| RADIOGRAFHIC PD                        |                     |                       |
| NO FRIOR. PD                           | 3.8                 | 1 2.61                |

Early Death is defined as a subject who died prior to or on 4.05 months after randomization. Cutoff defined based om smoothed hazard curves figume. or radiographic) as assessed per investigator) had oocurred before or on the death date. Otherwise No FRIoR FD.

Table 26. Early Deaths with Reasons of ' Other ' / ' Unknown ' in the Nivolumab + Ipilimumab and Chemotherapy Arms

| Early Death    | Cause of Death   | SAE with Fatal Outcome            | Causality of SAE if Applicable   | DiseaseProgression                |
|----------------|------------------|-----------------------------------|----------------------------------|-----------------------------------|
| Nivo + Ipi Arm |                  |                                   |                                  |                                   |
| 1              | Other            | Bacteriemia                       | not related                      | Yes                               |
| 2              | Other            | Worsening of pneumonia aspiration | not related                      | Yes*                              |
| 3              | Other            | Pneumonia                         | not related                      | Yes                               |
| 4              | Other            | Acuterespiratory failure          | not related                      | Yes                               |
| 5              | Other            | High digestive bleeding           | not related                      | Yes                               |
| 6              | Other            | Esophageal hemorrhage             | not related                      | Yes (clinical)                    |
| 7              | Other            | Lung infection                    | not related                      | Yes                               |
| 8              | Other            | Pneumonia                         | not related                      | Death prior to disease assessment |
| 9              | Other            | Respiratory insufficiency         | not related                      | Death prior to disease assessment |
| 10             | Other            | Death not otherwise specified     | not related                      | Death prior to disease assessment |
| 11             | Other            | Dyspnea                           | not related                      | Death prior to disease assessment |
| 12             | Other            | Sepsis                            | not related                      | Death prior to disease assessment |
| 13             | Other            | Internal bleeding                 | related                          | Death prior to disease assessment |
| 14             | Unknown          | Lung infection                    | not related                      | Yes                               |
| 15             | Unknown          | Death due to unknown cause        | not related                      | Death prior to disease assessment |
| 16             | Unknown          | Death duetounknown cause          | not related                      | Yes (clinical)                    |
| 17             | Unknown          | Deathduetounknowncause            | not related                      | Death prior to disease assessment |
| Chemo Arm      |                  |                                   |                                  |                                   |
| 1              | Other            | acute hypoxic respiratory failure | not related                      | Death prior to disease assessment |
| 2              | Other            | sudden death                      | not related                      | Death prior to disease assessment |
| 3              | Unknown          | death duetounknown cause          | related                          | Death prior to disease assessment |
| 4              | Unknown          | no AE/SAE leading to death        | n/a                              | Yes (clinical)                    |

* Progressive disease per Blinded Independent Central Review (BICR). This case was categorized as a case without prior progression per investigator in Table 3.2-1. Deaths may be captured on death, adverse event, ECOG performance status, status and follow-up CRF pages. The primary source of Death date is the death CRF. Early Death is defined as a subject who died prior to or on 4.05 months after randomization. Cutoff is defined based on smoothed hazard curves in all randomized subjects.

There were 7 baseline demographic and disease variables identified with imbalance ≥ 10% in earlydeath rate between the nivo + ipi and chemo arms.

<div style=\"page-break-after: always\"></div>

Table 27. Incidence of Early Death with ≥ 10% Difference in Pre-defined Subsets - All Randomized Subjects in the Nivolumab + Ipilimumab and Chemotherapy Arms

|                                      |                                     | Nivo + Ipi Arm N=325   | Nivo + Ipi Arm N=325   | Chemo Arm N=324   | Chemo Arm N=324       |
|--------------------------------------|-------------------------------------|------------------------|------------------------|-------------------|-----------------------|
| Parameter                            | Subgroup Category                   | Early Death n=66       | Non-Early Death n=259  | Early Death n=38  | Non-Early Death n=286 |
| Overall                              |                                     | 66/325 (20.3)          | 259/325 (79.7)         | 38/324 (11.7)     | 286/324 (88.3)        |
| Liver Metastases per Investigator    | Yes                                 | 33/66 (50.0)           | 57/259 (22.0)          | 8/38 (21.1)       | 83/286 (29.0)         |
| Liver Metastases per Investigator    | No                                  | 33/66 (50.0)           | 202/259 (78.0)         | 30/38 (78.9)      | 203/286 (71.0)        |
| Weight                               | <60 KG                              | 44/66 (66.7)           | 147/259 (56.8)         | 18/38 (47.4)      | 154/286 (53.8)        |
| Weight                               | ≥ 60 KG                             | 22/66 (33.3)           | 112/259 (43.2)         | 20/38 (52.6)      | 132/286 (46.2)        |
| Alcohol Use                          | Current/former                      | 48/66 (72.7)           | 212/259 (81.9)         | 33/38 (86.8)      | 217/286 (75.9)        |
| Alcohol Use                          | Never/unknown                       | 18/66 (27.3)           | 47/259 (18.1)          | 5/38 (13.2)       | 69/286 (24.1)         |
| Disease Stage at Initial Diagnosis   | Stage I                             | 0/66                   | 13/259 (5.0)           | 0/38              | 11/286 (3.8)          |
| Disease Stage at Initial Diagnosis   | Stage II                            | 4/66 (6.1)             | 22/259 (8.5)           | 3/38 (7.9)        | 11/286 (3.8)          |
| Disease Stage at Initial Diagnosis   | Stage III                           | 15/66 (22.7)           | 61/259 (23.6)          | 12/38 (31.6)      | 80/286 (28.0)         |
| Disease Stage at Initial Diagnosis   | Stage IV                            | 47/66 (71.2)           | 161/259 (62.2)         | 23/38 (60.5)      | 183/286 (64.0)        |
| Disease Stage at Initial Diagnosis   | Not reported                        | 0/66                   | 2/259 (0.8)            | 0/38              | 1/286 (0.3)           |
| Tumor Cell PD-L1 Expression from Lab | ≥5%                                 | 27/66 (40.9)           | 93/259 (35.9)          | 11/38 (28.9)      | 104/286 (36.4)        |
| Tumor Cell PD-L1 Expression from Lab | <5%                                 | 38/66 (57.6)           | 164/259 (63.3)         | 27/38 (71.1)      | 180/286 (62.9)        |
| Tumor Cell PD-L1 Expression from Lab | ≥10%                                | 23/66 (34.8)           | 80/259 (30.9)          | 8/38 (21.1)       | 89/286 (31.1)         |
| Tumor Cell PD-L1 Expression from Lab | <10%                                | 42/66 (63.6)           | 177/259 (68.3)         | 30/38 (78.9)      | 195/286 (68.2)        |
| Tumor Cell PD-L1 Expression from Lab | Indeterminate/not evaluable/missing | 1/66 (1.5)             | 2/259 (0.8)            | 0/38              | 2/286 (0.7)           |
| PD-L1 by CPS from CRF                | ≥5                                  | 39/66 (59.1)           | 152/259 (58.7)         | 26/38 (68.4)      | 187/286 (65.4)        |
| PD-L1 by CPS from CRF                | <5                                  | 26/66 (39.4)           | 80/259 (30.9)          | 9/38 (23.7)       | 82/286 (28.7)         |
| PD-L1 by CPS from CRF                | Indeterminate/not evaluable/missing | 1/66 (1.5)             | 27/259 (10.4)          | 3/38 (7.9)        | 17/286 (5.9)          |
| Region (per CRF)                     | JKT                                 | 28/66 (42.4)           | 157/259 (60.6)         | 12/38 (31.6)      | 172/286 (60.1)        |
| Region (per CRF)                     | Rest of Asia                        | 7/66 (10.6)            | 37/259 (14.3)          | 8/38 (21.1)       | 34/286 (11.9)         |
| Region (per CRF)                     | ROW                                 | 31/66 (47.0)           | 65/259 (25.1)          | 18/38 (47.4)      | 80/286 (28.0)         |

Percentages for OVERALL are based on N. Percentages for subsets are based on n. Early Death is defined as a subject who died prior to or on 4.05 months after randomization. Cutoff defined based on smoothed hazard curves figure.

The identified treatment-specific risk factors were included in the multivariate logistic model along with their interaction with treatment in all randomized subjects pooling the nivo + ipi and the chemo arms together. The final multivariate logistic regression model included risk factors identified within each treatment arm and their interaction terms with treatment if the p-value was less than 0.15.

The final model identified the following poor prognostic factors: non-Asia region (p &lt; 0.001), baseline neutrophil/lymphocyte ratio ≥ 4 (p = 0.001), baseline tumo ur burden (≥ Q3, p = 0.003), ECOG PS of 1 (p = 0.006), and male (p = 0.088). The final model included the interactions of treatment arm with liver metastases (p &lt; 0.001), never/unknown alcohol use (p = 0.078), and weight (p = 0.123), which had p-values less than 0.15. Neither tumour cell PD-L1 nor PD-L1 by CPS was identified as a risk factor for early death, in either univariate or multivariate logistic model.

<div style=\"page-break-after: always\"></div>

Table 28. Final Multivariate Logistic Regression Death Occurring in ≤4.05 Months from Randomization - Risk Factors in All Randomized Subjects in the Nivolumab + Ipilimumab and Chemotherapy Arms

|                                                                                                                                                  |                                                                              |                                                                              | No. of Early Death/ No. Randlcmizedl Subjects                                | No. of Early Death/ No. Randlcmizedl Subjects                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|                                                                                                                                                  | OdllsRatio(95Wald CI)                                                        |                                                                              |                                                                              | P-value  Nivo + Ipi  Chemotherapy                                            |
| TREATMENT (NIVOLUMAB 3 MG/KG + IPILIMUMAB 1 MG/KG,REFERENCE = CHEMOTHERAPY)                                                                      |                                                                              | <0.001                                                                       |                                                                              |                                                                              |
| REGION (FER CRF)(J/K/T&REST OF ASIA,REFERENCE =ROW)                                                                                              |                                                                              | <0.001                                                                       |                                                                              |                                                                              |
| BASELINE NEUIROFHIL/LMMPHOCYTE RATIO (< 4, REFERENCE = >= 4 & NR)                                                                                |                                                                              | 0.001                                                                        |                                                                              |                                                                              |
| BASELINETUMORBURIENFERBICR(>=Q3，REFERENCE=<Q3&NR)                                                                                                |                                                                              | 0.003                                                                        |                                                                              |                                                                              |
| ECOG PS (FER CRF)(O, REFERENCE = 1 & NR)                                                                                                         |                                                                              | 0.006                                                                        |                                                                              |                                                                              |
| SEX(MAIE，REFFRENCE=FEVAIE)                                                                                                                       |                                                                              | 0.088                                                                        |                                                                              |                                                                              |
| FRESENCE OF LIVER METASTASES FER INV (YES,REFERENCE =NO)                                                                                         |                                                                              | 0.932                                                                        |                                                                              |                                                                              |
| TREATMENT*FRESENCEOFLIVERMETASTASESPERINV                                                                                                        |                                                                              | <0.001                                                                       |                                                                              |                                                                              |
| FRESENCE OF LIVER METASTASES FER INV (YES, REFERENCE = NO) AT TREAIMENT VAIUE NIVOLUMAB 3 MG/KG + IPILIMMAB 1 MG/KG ATTREATMENTVAIUECHEMOTHERAPY | 2.64 0.40                                                                    |                                                                              |                                                                              |                                                                              |
| ALCOHOL USE (CURRENT/FORMER, REFERENCE = NEVER/UNKNOAN)                                                                                          |                                                                              | 0.126                                                                        |                                                                              |                                                                              |
| TREATMENT*AICOHOLUSE                                                                                                                             |                                                                              | 0.078                                                                        |                                                                              |                                                                              |
| ALOOHOLUSE(CURRENT/FORMER,REFERENCE=NEVER/UNKNONN) AT TREAIMENT VAIUE NIVOLUMAB3MG/KG+IPILIMMAB1 MG/KG AT TREAIMENTVALUE CHEMOTHERAPY            | 96'0 (0.45, 2.06) 2.95 '1} (98'8                                             |                                                                              |                                                                              |                                                                              |
| WEIGHT (>= 60 KG, REFERENCE =< 60 KG)                                                                                                            |                                                                              | 0.214                                                                        |                                                                              |                                                                              |
| TREAIMENT*WEIGHT                                                                                                                                 |                                                                              | 0.123                                                                        |                                                                              |                                                                              |
| WEIGHT（>=60KG，REFERENCE=<60KG) AT TREAIMENT VAIUE NIVOLIMAB 3 MG/KG + IPILIMMAB 1 MG/KG ATTREATMENTVALUECHEMOTHERAPY                             | 1: 1 8:强; 2:23)                                                              |                                                                              |                                                                              |                                                                              |
| TREAIMENT (NIVOLUMAB 3 MG/KG + IPILIMIMAB 1 MG/KG, REFERENCE = CHEMOTHERAPY)                                                                     | TREAIMENT (NIVOLUMAB 3 MG/KG + IPILIMIMAB 1 MG/KG, REFERENCE = CHEMOTHERAPY) | TREAIMENT (NIVOLUMAB 3 MG/KG + IPILIMIMAB 1 MG/KG, REFERENCE = CHEMOTHERAPY) | TREAIMENT (NIVOLUMAB 3 MG/KG + IPILIMIMAB 1 MG/KG, REFERENCE = CHEMOTHERAPY) | TREAIMENT (NIVOLUMAB 3 MG/KG + IPILIMIMAB 1 MG/KG, REFERENCE = CHEMOTHERAPY) |
| AT WEIGHT VALUE > 6O KG, AT AICOHOL USE VAIUE CURRENI/FORMER, AT FRESENCEOFLIVERMETASTASESFERINWVAIUEYES                                         | 4.04 (1.42, 11.52)                                                           |                                                                              | 11/ 32                                                                       | 3/ 29                                                                        |
| ATWEIGHTVALUE>6OKG，ATAIOOHOLUSEVALUECURRENT/FORMER,AT ERESENCEOFLIVERMETASTASESPERINVVALUENO                                                     | 0.61 ( 0.27,1.36)                                                            |                                                                              | 6/ 81                                                                        | 14/ 87                                                                       |
| ATWEIGHTVALUE>6OKG，ATAIOOHOLUSEVALUENEVER/UNKNONN，AT                                                                                             | 12.36 ( 2.97, 51.53)                                                         |                                                                              | 2/9                                                                          | 1/ 14                                                                        |
| ATWEIGHTVALUE>6OKG，ATAIOOHOLUSEVALUENEVER/UNKNONN,AT ERESENCEOFLIVERMETASTASESPERINVVAIUENO                                                      | 1.86 (0.49,7.10)                                                             |                                                                              | 3/ 12                                                                        | 2/22                                                                         |
| AT WEIGHT VAIUE < 6O KG, AT AIOOHOL USE VAIUE CURRENT/FORMER, AT FRESENCE OFLIVERMETASTASESFERINVVAIUEYES                                        | 8.59 (2.94, 25.08)                                                           |                                                                              | 13/ 34                                                                       | 3/ 36                                                                        |
| AT WEIGHT VALUE< 6OKG，AT ALOOHOLUSE VALUE CURRENT/FORMER,AT ERESENCEOFLIVER METASTASESPERINVVAIUENO                                              | 1.29 (0.62,2.71)                                                             |                                                                              | 18/113                                                                       | 13/ 98                                                                       |
| AT WEIGHT VALUE< 6OKG， AT ALOOHOLUSE VALUE NEVER/UNKNONN, AT FRESENCEOFLIVERMETASTASESPERINVVAIUEYES                                             | 26.30 (6.48, >99.99)                                                         |                                                                              | 7/ 15                                                                        | 1/ 12                                                                        |
| ATWEIGHTVALUE<6OKG，ATAICOHOLUSEVALUENEVER/UNKNONN，AT ERESENCE OF LIVER METASTASES FERINV VAIUE NO                                                | 3.96 (1.13, 13.84)                                                           |                                                                              | 6/ 29                                                                        | 1/ 26                                                                        |

Progmostic oovariates identified within each anm using backward selecticn method (SLsTAY=0.25).Covariates with p-value&lt; 0.15 and treatment anm by covariate interacticn effects with a p-value &lt;0.15 incluckd. P-values andl oddls ratios frcm mltivariate logistic regressicn modll. )  ( x        ( Aloohol Use (ref=Never/Unkmown) ; Presence of Liver Metastases per INV (ref=No) ; Baseline Neutrophil/Lymqhocyte Ratio (ref=&gt;=4 &amp; NR) ; Baseline Tumor Burden per BICR (ref=&lt;Q3 &amp; NR) .

<div style=\"page-break-after: always\"></div>

Table 29. Univariate Logistic Regression - Death Occurring ≤ 4.05 Months from Randomization Including Treatment, One Risk Factor and its Interaction with Treatment - All Randomized Subjects in the Nivolumab + Ipilimumab and Chemotherapy Arms

|                                          |         | Nivo + Ipi Total Subjects   | Chemotherapy                             | Nivo+Ipivs Chemotherapy   | Nivo+Ipivs Chemotherapy       | Nivo+Ipivs Chemotherapy   | Nivo+Ipivs Chemotherapy      | Nivo+Ipivs Chemotherapy   |
|------------------------------------------|---------|-----------------------------|------------------------------------------|---------------------------|-------------------------------|---------------------------|------------------------------|---------------------------|
| Subgroup                                 | N       | WithanEvent (N Subjects)    | Total Subjects With anEvent (N Subjects) |                           | Odlcls Ratio(95&Wald CI)      | P-value                   | Test for Interaction P-value |                           |
| PRESENCEOFLIVERMETASTASESPERINV YES NO   | 181 468 | 33 (06 33 (235)             | 8 ( 91) 30 233)                          | 1.11                      | 6.01 (2.59,13.95) (0.65,1.88) | 660'0                     | <0.001                       |                           |
| AICOHOL USE CURRENT/FORMER NEVER/UNKNOWN | 510 139 |                             |                                          |                           | 营:8 :B影; 13:±3                | 0.717                     | 0.033                        |                           |
| WEIGHT <60KG > 60 KG                     | 363 286 | 44 (191) 22(134)            | 18 (172) 20 (152)                        | 2.56 (1.42, 1.30 (0.67,   | 4.63) 2.50)                   | 0.720                     | 0.131                        |                           |

Odlls Ratios andl p-values basedl on univariatelogistic model

Referencelevelfor covariates areRegion frcm CRF RoW;BaselineECoG1&amp;NRfrcm CRF;Number of Organs withMetastases at Baseline fromIRT&lt;=1;TumorPD-LlExpressionLevelfrcm labwithcutoffs&gt;=1&amp;，5and10;PD-L1byCPSfrcm CRFwith cutoffs &gt;= 1, 5 and 10; Age Categorization I &lt; 65; Sex Female; RACE Non-Asian; Region Non-Asia; Weight &lt; 60 KG; Disease Stage at Initial Diagmosis StageIV;Histologic Gradeat InitialDiagmosis NoS &amp;Non-G3/G4;Location at InitialDiagmosis Gastroesophageal Junction&amp;NR;DiseaseStatus at CurrentDiagmosisNon-DeNovoMetastatic;SmokingStatusandAlcoholUseNever/Unkmowm; Time from Initial Disease Diagmosis to Randcmization &gt; 1 Year &amp; NR; Prior Surgery (Exclucling Biopsy) No; Prior Racliotherapy No; Presence of Liver Metastases per INV No; Presence of Bone Metastases per INV No; Baseline Neutrophil/Lymphocyte Ratio &gt; 4&amp; NR; Baseline Tumor Burden per BICR &lt; Q3 &amp; NR; Baseline Lung Immune Progmostic Index 1 &amp; 2 &amp; NR.

## Analyses to support contribution of components

In order to evaluate the contribution of the ipilimumab component in the nivo + ipi regimen in CA209648, analyses were pre-specified in the CSR SAP version 4.0 Section 8.0 to compare the efficacy data descriptively between the nivo + ipi and nivo + chemo arms.

Table 30. Summary of Key Efficacy Results Including Descriptive Comparison of Nivo + Ipi and Nivo + Chemo Arms - All Randomized Subjects

| Efficacy Parameter                   | Nivo+Ipi N=325            | Nivo+Chemo N=321          | Chemo N=324         |
|--------------------------------------|---------------------------|---------------------------|---------------------|
| OS                                   |                           |                           |                     |
| Events, n (%)                        | 216 (66.5)                | 209 (65.1)                | 232 (71.6)          |
| HR vs Chemo a                        | 0.78                      | 0.74 CI:                  | --                  |
|                                      | (98.2% CI: 0.62, 0.98)    | (99.1% 0.58, 0.96)        | --                  |
| Stratified log-rank p-value vs Chemo | 0.0110 b                  | 0.0021 b                  | --                  |
| HR (CI) Nivo+Ipi vs Nivo+Chemo       | 1.04 (95% CI: 0.86, 1.26) | 1.04 (95% CI: 0.86, 1.26) | --                  |
| 0 to ≤ 2 months                      | 2.43 (95% CI: 1.24, 4.77) | 2.43 (95% CI: 1.24, 4.77) | --                  |
| > 2 to ≤ 3 months                    | 1.45 (95% CI: 0.69, 3.08) | 1.45 (95% CI: 0.69, 3.08) | --                  |
| > 3 to ≤ 4 months                    | 1.70 (95% CI: 0.85, 3.42) | 1.70 (95% CI: 0.85, 3.42) | --                  |
| > 4 to ≤ 5 months                    | 0.76 (95% CI: 0.32, 1.78) | 0.76 (95% CI: 0.32, 1.78) | --                  |
| > 5 to ≤ 6 months                    | 0.85 (95% CI: 0.36, 2.01) | 0.85 (95% CI: 0.36, 2.01) | --                  |
| > 6 months                           | 0.88 (95% CI: 0.69, 1.12) | 0.88 (95% CI: 0.69, 1.12) | --                  |
| Median OS, mo. c (95% CI)            | 12.75 (11.27, 15.47)      | 13.21 (11.14, 15.70)      | 10.71 (9.40, 11.93) |
| Restricted mean OS time (95% CI) d   |                           |                           |                     |
| 12 mo.                               | 8.95 (8.50, 9.39)         | 9.50 (9.12, 9.88)         | --                  |

<div style=\"page-break-after: always\"></div>

| Efficacy Parameter                   | Nivo+Ipi N=325       | Nivo+Chemo N=321     | Chemo N=324       |
|--------------------------------------|----------------------|----------------------|-------------------|
| Difference (95% CI) e                | -0.56 (-1.14, 0.03)  | -0.56 (-1.14, 0.03)  | --                |
| 24 mo.                               | 13.80 (12.83, 14.77) | 14.36 (13.46, 15.27) | --                |
| Difference (95% CI) e                | -0.56 (-1.89, 0.76)  | -0.56 (-1.89, 0.76)  | --                |
| 36 mo.                               | 16.78 (15.31, 18.24) | 17.25 (15.81, 18.70) | --                |
| Difference (95% CI) e                | -0.48 (-2.53, 1.58)  | -0.48 (-2.53, 1.58)  | --                |
| 38.7 mo. f                           | 17.39 (15.79, 18.98) | 17.52 (15.96, 19.09) | --                |
| Difference (95% CI) e                | -0.14 (-2.37, 2.10)  | -0.14 (-2.37, 2.10)  | --                |
| ORR per BICR g                       |                      |                      |                   |
| N Responders (%)                     | 90 (27.7)            | 152 (47.4)           | 87 (26.9)         |
| 95% CI h                             | (22.9, 32.9)         | (41.8, 53.0)         | (22.1, 32.0)      |
| Complete Response, n (%)             | 36 (11.1)            | 43 (13.4)            | 20 (6.2)          |
| Partial Response, n (%)              | 54 (16.6)            | 109 (34.0)           | 67 (20.7)         |
| Stable disease, n (%)                | 103 (31.7)           | 103 (32.1)           | 148 (45.7)        |
| Progressive disease, n (%)           | 103 (31.7)           | 42 (13.1)            | 38 (11.7)         |
| Unable to determine, n (%)           | 29 (8.9)             | 24 (7.5)             | 51 (15.7)         |
| ORR Difference (95% CI) vs Chemo i   | 0.9 (-5.9, 7.6) j    | 20.6 (13.4, 27.7) j  | --                |
| Odds Ratio (95% CI) vs Chemo k       | 1.04 (0.74, 1.47) j  | 2.48 (1.78, 3.45) j  | --                |
| DOR per BICR                         |                      |                      |                   |
| N Events/N Responders (%)            | 53 (58.9)            | 96 (63.2)            | 51 (58.6)         |
| Median, mo. c (95% CI)               | 11.07 (8.31, 14.00)  | 8.18 (6.90, 9.69)    | 7.13 (5.65, 8.21) |
| Min, Max, mo. l                      | 1.4+, 34.5+          | 1.4+, 35.9+          | 1.4+, 31.8+       |
| Proportion (95% CI) with DOR ≥ 12 mo | 0.48 (0.36, 0.58)    | 0.39 (0.30, 0.47)    | 0.23 (0.13, 0.34) |

Stratified Cox proportional hazard model. Hazard ratio is Nivo+ipi over Chemo b 2-sided logrank test stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (≤ 1 vs ≥ 2), PDL1 status (≥ 1% vs &lt; 1% or indeterminate) as recorded in IRT.

c Based on Kaplan-Meier estimates d Restricted mean survival time (RMST) is based on trapezoidal integration of the area under the Kaplan-Meier estimated curve until restricted time point.

e The difference of RMST is nivo + ipi over nivo + chemo.

f The minimum of the longest survival time in each treatment arm, regardless of censoring g Per RECIST 1.1; ORR = CR+PR.

h Confidence interval based on the Clopper and Pearson method.

i Strata adjusted difference in ORR (Nivo+ipi - chemo or Nivo+chemo - chemo) based on Cochran-Mantel-Haenszel (CMH) method of weighting j Stratified by ECOG Performance Status (0 vs 1), number of organs with metastases (≤ 1 vs ≥ 2), PD -L1 status (≥ 1% vs &lt; 1% or indeterminate) as recorded in IRT.

- k Strata adjusted odds ratio (Nivo+ipi over chemo or Nivo+chemo over chemo) using Mantel-Haenszel method

l Symbol + indicates a censored value.

Abbreviations: BICR - blinded independent central review, Chemo - chemotherapy, CI - confidence interval, CR complete response, CSR - clinical study report, DOR - duration of response, ECOG - Eastern Cooperative Oncology Group, HR - hazard ratio, Ipi - ipilimumab, IRT - interactive response technology, Nivo - nivolumab, ORR - objective response rate, OS - overall survival, PS - performance status, RECIST - Response Evaluation Criteria in Solid Tumors, PFS - progression-free survival, PR - partial response

<div style=\"page-break-after: always\"></div>

Figure 24. Kaplan-Meier Plot of Overall Survival - Nivo + Ipi, Nivo + Chemo, and Chemo - All Randomized Subjects

<!-- image -->

Statistical model for hazard ratio and p-value: Stratified Cox proportional hazard model and stratified log-rank test. Symbols represent censored observations.

Stratification factors are ECOG Performance Status (0 vs 1), number of organs with metastases (&lt;= 1 vs. &gt;= 2), and tumour cell PDL1 expression (≥ 1% or &lt; 1% and indeterminate) as recorded in IRT.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 31. Summary of Efficacy for trial CA209648

| Title: A Randomized Phase 3 Study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in subjects with unresectable advanced, recurrent or metastatic previously untreated oesophageal squamous cell carcinoma   | Title: A Randomized Phase 3 Study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in subjects with unresectable advanced, recurrent or metastatic previously untreated oesophageal squamous cell carcinoma                               | Title: A Randomized Phase 3 Study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in subjects with unresectable advanced, recurrent or metastatic previously untreated oesophageal squamous cell carcinoma                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                    | CA209648                                                                                                                                                                                                                                                                                                        | CA209648                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                                              | Phase 3, randomized, study of nivolumab plus ipilimumab (nivo + ipi) or nivolumab in combination with fluorouracil plus cisplatin (nivo + chemo) versus fluorouracil plus cisplatin (chemo) as first line-therapy in unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). | Phase 3, randomized, study of nivolumab plus ipilimumab (nivo + ipi) or nivolumab in combination with fluorouracil plus cisplatin (nivo + chemo) versus fluorouracil plus cisplatin (chemo) as first line-therapy in unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). |
|                                                                                                                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                  | From 29 Jun 2017 (FPFV) to 18 Jan 2021 (LPLV) not applicable not applicable                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Hypothesis                                      | Superiority                    | Superiority                                                                            | Superiority                                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                              |
|-------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups                               | Arm A (nivo+ipi)               | Arm A (nivo+ipi)                                                                       | Nivolumab 3 mg/kg IV Q2W Ipilimumab 1 mg/kg IV Q6W Until progression, unacceptable toxicity, withdrawal of consent, or completion of 24 months of treatment, whichever occurred first. N=325                                                                                             | Nivolumab 3 mg/kg IV Q2W Ipilimumab 1 mg/kg IV Q6W Until progression, unacceptable toxicity, withdrawal of consent, or completion of 24 months of treatment, whichever occurred first. N=325                                                                                             |
| Treatments groups                               | Arm B (nivo+chemo)             | Arm B (nivo+chemo)                                                                     | Nivolumab 240 mg IV Q2W Fluorouracil 800 mg/m2/day IV Days 1-5 Cisplatin 80 mg/m2 IV Day 1, of a 4-week cycle Treatment continued until progression, unacceptable toxicity, or withdrawal of consent, whichever occurred first. Nivolumab treatment was given for up to 24 months. N=321 | Nivolumab 240 mg IV Q2W Fluorouracil 800 mg/m2/day IV Days 1-5 Cisplatin 80 mg/m2 IV Day 1, of a 4-week cycle Treatment continued until progression, unacceptable toxicity, or withdrawal of consent, whichever occurred first. Nivolumab treatment was given for up to 24 months. N=321 |
| Treatments groups                               | Arm C (chemo)                  | Arm C (chemo)                                                                          | Fluorouracil 800 mg/m2/day IV Days 1-5 Cisplatin 80 mg/m2 IV Day 1, of a 4-week cycle Chemotherapy will be given until disease progression, unacceptable toxicity or other reasons specified in the protocol. N= 324                                                                     | Fluorouracil 800 mg/m2/day IV Days 1-5 Cisplatin 80 mg/m2 IV Day 1, of a 4-week cycle Chemotherapy will be given until disease progression, unacceptable toxicity or other reasons specified in the protocol. N= 324                                                                     |
| Endpoints and definitions                       | Primary endpoint               | Overall survival (OS), in subjects with PD- L1≥1 %                                     | Time from randomisation until death from any cause.                                                                                                                                                                                                                                      | Time from randomisation until death from any cause.                                                                                                                                                                                                                                      |
| Endpoints and definitions                       | Primary endpoint               | Progression free survival (PFS), in subjects with PD- L1≥1 %                           | Time from randomization to the date of the first documented PD per BICR or death due to any cause, whichever was earlier.                                                                                                                                                                | Time from randomization to the date of the first documented PD per BICR or death due to any cause, whichever was earlier.                                                                                                                                                                |
| Endpoints and definitions                       | Secondary endpoint             | OS in all randomised subjects                                                          | See definition above                                                                                                                                                                                                                                                                     | See definition above                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                       | Secondary endpoint             | PFS in all randomised subjects                                                         | See definition above                                                                                                                                                                                                                                                                     | See definition above                                                                                                                                                                                                                                                                     |
| Endpoints and definitions                       | Secondary endpoint             | Objective response rates (ORR) in subjects with PD- L1≥1 % and all randomised subjects | Percentage of patients whose best overall response is either confirmed complete or partial response as assessed by BICR per RECIST 1.1                                                                                                                                                   | Percentage of patients whose best overall response is either confirmed complete or partial response as assessed by BICR per RECIST 1.1                                                                                                                                                   |
| Database lock                                   | 01 Mar 2021                    | 01 Mar 2021                                                                            | 01 Mar 2021                                                                                                                                                                                                                                                                              | 01 Mar 2021                                                                                                                                                                                                                                                                              |
| Results and Analysis                            | Results and Analysis           | Results and Analysis                                                                   | Results and Analysis                                                                                                                                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                                                                     |
| Analysis description                            | Primary Analysis               | Primary Analysis                                                                       | Primary Analysis                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                         |
| Analysis population and time point description  | Intent to treat                | Intent to treat                                                                        | Intent to treat                                                                                                                                                                                                                                                                          | Intent to treat                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Treatment group                | Treatment group                                                                        | Nivo+Ipi                                                                                                                                                                                                                                                                                 | Chemo                                                                                                                                                                                                                                                                                    |
| Descriptive statistics and estimate variability | Number of subjects 325 All 158 | Number of subjects 325 All 158                                                         | randomised PD-L1 ≥1 %                                                                                                                                                                                                                                                                    | 324 All randomised 157 PD- L1≥1 %                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                | OS ( PD-L1 ≥ 1% ) (median, months)      | 13.70                         | 9.07               |
|--------------------------------|-----------------------------------------|-------------------------------|--------------------|
|                                | 95% CI                                  | 11.24, 17.02                  | 7.69, 9.95         |
|                                | PFS ( PD- L1≥1 % ) (median, months)     | 4.04                          | 4.44               |
|                                | 95% CI                                  | 2.40, 4.93                    | 2.89, 5.82         |
|                                | OS ( all randomised ) (median, months)  | 12.75                         | 10.71              |
|                                | 95% CI                                  | 11.27, 15.47                  | 9.40, 11.93        |
|                                | PFS ( all randomised ) (median, months) | 2.92                          | 5.59               |
|                                | 95% CI                                  | 2.66, 4.17                    | 4.27, 5.88         |
|                                | ORR (PD- L1≥1 %) (%)                    | 35.4                          | 19.7               |
|                                | 95% CI                                  | 28.0, 43.4                    | 13.8, 26.8         |
|                                | ORR (All randomised) (%)                | 27.7                          | 26.9               |
|                                | 95% CI                                  | 22.9, 32.9                    | 22.1, 32.0         |
| Effect estimate per comparison | Primary endpoint OS (PD- L1≥1 %)        | Comparison groups             | Nivo+Ipi vs. Chemo |
|                                | Primary endpoint OS (PD- L1≥1 %)        | Hazard ratio (HR)             | 0.64               |
|                                | Primary endpoint OS (PD- L1≥1 %)        | 98.6% CI                      | 0.46, 0.90         |
|                                | Primary endpoint OS (PD- L1≥1 %)        | p value (stratified 2- sided) | 0.0010             |
|                                | Primary endpoint PFS (PD- L1≥1 %)       | Comparison groups             | Nivo+Ipi vs. Chemo |
|                                | Primary endpoint PFS (PD- L1≥1 %)       | Hazard ratio (HR)             | 1.02               |
|                                | Primary endpoint PFS (PD- L1≥1 %)       | 98.5% CI                      | 0.73, 1.43         |
|                                | Primary endpoint PFS (PD- L1≥1 %)       | p value (stratified 2- sided) | 0.8958             |
|                                | Secondary endpoint OS (all randomised)  | Comparison groups             | Nivo+Ipi vs. Chemo |
|                                | Secondary endpoint OS (all randomised)  | Hazard ratio (HR)             | 0.78               |
|                                | Secondary endpoint OS (all randomised)  | 98.2% CI                      | 0.62, 0.98         |
|                                | Secondary endpoint OS (all randomised)  | p value (stratified 2- sided) | 0.0110             |
|                                | Secondary endpoint PFS (all randomised) | Comparison groups             | Nivo+Ipi vs. Chemo |
|                                | Secondary endpoint PFS (all randomised) | Hazard ratio (HR)             | 1.26               |
|                                | Secondary endpoint PFS (all randomised) | 98.5% CI                      | NA, NA             |
|                                | Secondary endpoint PFS (all randomised) | p value (stratified 2- sided) | NA                 |
|                                | Secondary endpoint ORR (PD- L1≥1 %)     | Comparison groups             | Nivo+Ipi vs. Chemo |
|                                | Secondary endpoint ORR (PD- L1≥1 %)     | Difference                    | 15.7               |
|                                | Secondary endpoint ORR (PD- L1≥1 %)     | 95% CI                        | 5.9, 25.4          |
|                                | Secondary endpoint ORR (PD- L1≥1 %)     | P-value                       | Not applicable     |
|                                | Secondary endpoint ORR (all randomised) | Comparison groups             | Nivo+Ipi vs. Chemo |
|                                | Secondary endpoint ORR (all randomised) | Difference                    | 0.9                |
|                                | Secondary endpoint ORR (all randomised) | 95% CI                        | -5.9, 7.6          |
|                                | Secondary endpoint ORR (all randomised) | P-value                       | Not applicable     |
| Notes                          |                                         |                               |                    |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable

<div style=\"page-break-after: always\"></div>

## Clinical studies in special populations

Table 32: Summary of Subject Disposition by Age Category - All Randomized Subjects - By Treatment Arm and Total for Study CA209648

<!-- image -->

|                     | Age65-74 (Oldersubjectsmumber/totalmumber)   | Age65-74 (Oldersubjectsmumber/totalmumber)   | Age65-74 (Oldersubjectsmumber/totalmumber)   | Age65-74 (Oldersubjectsmumber/totalmumber)   | Age75-84 (Oldersubjectsmumber/totalmumber)   | Age75-84 (Oldersubjectsmumber/totalmumber)   | Age75-84 (Oldersubjectsmumber/totalmumber)   | Age75-84 (Oldersubjectsmumber/totalmumber)   | Age85+ (Oldersubjectsmumber/totalmumber)   | Age85+ (Oldersubjectsmumber/totalmumber)   | Age85+ (Oldersubjectsmumber/totalmumber)   | Age85+ (Oldersubjectsmumber/totalmumber)   |
|---------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                     | Nivo + ipi                                   | Nivo + Chemo                                 | Chemo                                        | Total                                        | Nivo + Ipi                                   | Nivo + Chemo                                 | Chemo                                        | Total                                        | Nivo + Ipi                                 | Nivo + Chemo                               | Chemo                                      | Total                                      |
| ControlledTrials    | 116/325 (35.7)                               | 123/321 (38.3)                               | 129/324 (39.8)                               | 368/970 (37.9)                               | 24/325 (7.4)                                 | 28/321 (8.7)                                 | 29/324 (9.0)                                 | 81/970 (8.4)                                 | 0/325                                      | 3/321 (0.9)                                | 0/324                                      | 3/970 (0.3)                                |
| NonControlledtrials | Not applicable                               | Not applicable                               | Not applicable                               | Not applicable                               | Not applicable                               | Not applicable                               | Not applicable                               | Not applicable                               | Not applicable                             | Not applicable                             | Not applicable                             | Not applicable                             |

Source: Table S.3.2.1.2 (all randomized subjects) in the CA209648 Primary CSR

## Supportive study(ies)

Not applicable

## 2.4.3. Discussion on clinical efficacy

This is an application for an extension of the indication for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC).

An application has been submitted in parallel for a new indication for nivolumab in combination with chemotherapy for the same target population (EMEA/H/C/3985/II/107).

## Design and conduct of clinical studies

This application is based on the results of study CA209648 , a randomised, open-label, phase 3 study of nivolumab+ipilimumab or nivolumab in combination with chemotherapy (fluorouracil plus cisplatin) versus chemotherapy (fluorouracil plus cisplatin) in patients with recurrent or metastatic previously untreated OSCC. Overall, the study design can be considered adequate to support a marketing authorisation in the claimed indication.

The study was open-label. However, considering the primary endpoints were overall survival (OS) and progression free survival (PFS) as assessed by blinded independent central review (BICR), this is considered acceptable.

## Patient population

Overall, inclusion and exclusion criteria are considered acceptable. Patients with an advanced disease of squamous cell histology, who were treatment-naïve and had a good performance status (ECOG 0 or 1), were enrolled in the study. Patients with brain or meninx metastasis were only allowed to enter the study if asymptomatic and not requiring treatment. This population can be considered representative of a patient population for which chemotherapy is considered the standard of care.

Patients were included in the study regardless of tumour cell PD-L1 expression. However, tumour tissue was required for PD-L1 expression determination by a central lab. Patients with non-evaluable results were not allowed to enter the study.

## Treatments

Nivolumab was used at a dose of 3 mg/kg Q2W in combination with ipilimumab 1 mg/kg Q6W. This regimen has been used in previous clinical trials (e.g. study CA209743 in patients with malignant pleural mesothelioma) and therefore is considered acceptable.

<div style=\"page-break-after: always\"></div>

With regards to the comparator (5-FU+cisplatin), it is considered adequate since this is one of the regimens recommended in the current guidelines for the treatment of advanced oesophageal cancer. In the NCCN guideline a combination of fluoropyrimidine (either 5-FU or capecitabine) and cisplatin or oxaliplatin are the preferred recommended regimens 1 . Use of oxaliplatin is also preferred over cisplatin due to lower toxicity. According to the ESMO guideline the value of palliative chemotherapy is less clear for OSCC than for oesophageal adenocarcinoma, although reference to cisplatin combinations is made 2 .

The recommended regimen in the CA209648 study was 5-FU 800 mg/m 2  IV for 5 days (days 1 to 5) plus cisplatin 80 mg/m 2  IV on day 1, cycled every 4 weeks. As stated by the MAH, the 5-FU+cisplatin regimen varies among countries. Current NCCN guidelines recommend 5-FU (750 - 1000 mg/m² on Days 1 - 4) plus cisplatin (75 - 100 mg/m² on Day 1) every 4 weeks. The proposed regimen is considered acceptable.

Further, the proposed posology in the PI is 3 mg/kg nivolumab Q2W or 360 mg Q3W in combination with 1 mg/kg ipilimumab Q6W. The justification for the additional posology for nivolumab (i.e. 360 mg Q3W) is mainly based on pharmacology data (see PK/PD section).

According to the protocol, treatment beyond radiological confirmed progression was allowed if the subject had investigator-assessed clinical benefit and was tolerating treatment. There were 81 patients (42 patients with tumour cell PDL1 expression ≥1%) in the nivo+ipi arm who were treated beyond progression, with a median treatment duration of 1.12 months (range: 0.1, 22.6). According to the MAH among patients treated beyond progression there were patients with confirmed disease progression and patients for whom disease progression was doubtful and that required further confirmation. The MAH stated that treatment beyond progression was not allowed in the chemo arm, however, investigator could continue study therapy while awaiting the RECIST 1.1 assessment. There were 23 patients in the chemo arm that received treatment beyond progression. In response to the follow-up request received the MAH provided the total duration of treatment and duration of postprogression treatment in patients with tumor cell PDL1 expression ≥ 1% and in patients with tumor cell PD-L1 &lt; 1%. The data presented for both tumor cell PD-L1 ≥ 1% and tumor cell PD -L1 &lt; 1% show that some patients treated with nivo + ipi or nivo + chemo received therapy up to several months after investigator-assessed progression. The continuation of therapy beyond progression in this subset of patients indicates the investigator's assessment of continued benefit, as treatment was to be discontinued at the time of progression in the absence of ongoing clinical benefit.

According to the protocol, treatment beyond radiological confirmed progression was allowed if the subject had investigator-assessed clinical benefit and was tolerating treatment. Considering the population of patients with tumour cell PD-L1 ≥ 1%, there were 42 patients in the nivo+ipi arm who were treated beyond progression, with a median treatment duration of 1.10 months (range: 0.1, 16.8). According to the MAH among patients treated beyond progression there were patients with confirmed disease progression and patients for whom disease progression was doubtful and that required further confirmation. The MAH was requested to provide separate numbers of the patients that received treatment beyond unequivocal progression and those who received treatment while awaiting confirmation/rejection of progression, but these data were not available. Treatment beyond progression was not allowed in the chemo arm, however, investigator could continue study therapy while awaiting the RECIST 1.1 assessment. There were 13 patients with PD-L1 ≥ 1% in the chemo arm that received treatment beyond progression with a median treatment duration of 0.23 months (range: 0.1,  4.3). Bearing in mind that the number of patients with a long duration of treatment was low (only 5 patients in the nivo+ipi arm received treatment for more than 4 months, which was the maximum

1 NCCN Clinical Practice Guidelines in Oncology. Esophageal and Esophagogastric junction cancers. Version 4.2021. 2  Lordick F, Mariette C, Haustermans K et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 27 (Supplement 5): v50-v57, 2016

<div style=\"page-break-after: always\"></div>

reported in the chemo arm where treatment beyond progression was not allowed), it is considered unlikely that this may have impacted the (OS) results. No further actions are considered necessary.

## Endpoints

The dual primary endpoints of the study were OS and PFS (as assessed by BICR per RECIST 1.1 criteria) in patients with PDL1≥1 %. Secondary endpoints included OS and PFS in all randomised subjects and ORR (both in PDL1≥1% and the overall population, by BI CR). Duration of response, PFS and ORR according to investigator assessment, PFS2/TSST and PRO were exploratory endpoints. The choice of the primary and secondary endpoints is considered appropriate.

## Sample size

The operating characteristics concerning the sample size calculation are clearly described. The MAH has assumed the same distributions for OS and PFS and a piecewise mixture cure rate model was applied for the current design. Overall, the proposal for the sample size is acceptable and meets regulatory requirements.

## Statistical analysis

The MAH has designed a graphical testing strategy to control the Type I Error through different endpoints and in particular, the primary endpoints and a number of secondary endpoints were tested using the Bonferroni-based graphical approach by Maurer and Bretz (2013). Overall, the strategy is considered acceptable.

Regarding the analysis of OS, the MAH planned to perform an interim analysis (IA) for OS at the time the PFS final analysis was triggered. The decision was foreseen when 136 PFS events were observed among the population selected for the primary analysis in the chemo arm. The tracking was conducted by an independent external statistical group (AXIO). In the revised protocol v05, the MAH decided to add  an  additional  criterion  to  trigger  the  PFS  final  analysis  (and  OS  interim  analysis),  a  12-month minimum follow-up since the collection of PFS events were slow.

Concerning the primary analyses, the MAH has considered the hypothetical strategy; in particular the MAH has censored the intercurrent events which deals with the administration of subsequent therapy and  withdrawal  of  consent.  Sensitivity  analyses  considering  intercurrent  events  as  events  were consistent with the primary analyses.

## Study conduct

The study was originally designed as a Phase 2 study of nivolumab monotherapy (Arm A) and in combination with ipilimumab (Arm B) in subjects with advanced or metastatic previously treated gastric, GEJ or previously untreated oesophageal cancer. With amendment 2, the study was modified into a randomized Phase 3 study with three treatment arms including only patients with squamous oesophageal cancer. At the time of this amendment no patients had been randomised.

Afterwards several further changes were performed although it is not considered that these changes could have impacted the results. Of importance, with revision 5 (dated 29 Oct 2020) a time-based trigger for the IA (final PFS/IA OS) was added.

Five patients had relevant protocol deviations (2 subjects in the nivo+chemo arm and 3 subjects in the chemo arm). One subject in the nivo+chemo arm had sarcomatoid carcinoma of the oesophagus, although this patient was not treated; a second patient in the chemo arm, entered the study without measurable disease at baseline; and there were 3 patients that received concurrent traditional medicines used for cancer treatment (botanical formulations). No relevant protocol deviations were reported in the nivo+ipi arm. Taking into account the low number of patients with protocol deviations no impact on the results is expected.

<div style=\"page-break-after: always\"></div>

The MAH has provided information on important protocol deviations (IPDs), which according to the MAH reflect protocol deviations that may significantly impact completeness, accuracy and/or reliability of the study data. A total of 404 IPDs were reported among all enrolled subjects (151 in the nivo+chemo arm, 115 in the nivo+ipi arm, 132 in the chemo arm and 6 in patients who were not randomised). After a review of the reported IPDs, it is not considered that this could have impacted the results.

## Efficacy data and additional analyses

## Baseline characteristics

The median age of patients included in the study was 64 (range: 26, 90) years. There were 84 (8.7%) patients who were 75 years or older. Demographics and other baseline characteristics were overall well balanced between treatment arms.

With regards to prior treatment, 23% of patients had received prior systemic therapy in the neoadjuvant (55%) or adjuvant (17%) setting, or definitive CRT therapy (30%). Prior radiotherapy was received by around 20% of patients.

The proportion of patients that received subsequent systemic therapy was comparable between treatment arms (51.7% nivo+ipi and 55.9% chemo). In the chemo group, a higher number of patients received anti-PD-(L)1 therapy (15.7% vs. 4.3%), mainly nivolumab. In contrast, 5-FU and cisplatin were among the most frequent subsequent therapies received in the nivo+ipi arm.

## Efficacy outcomes

The efficacy data provided are based on a clinical data cut-off of 18 Jan 2021 and a clinical DBL of 1 Mar 2021, with a median follow-up of 23.7 months (range: 12.9, 40.7). The submission is based on results of the final analysis of PFS and an IA of OS, which is now considered the final analysis.

The study met its primary objective since the combination of nivo+ipi demonstrated a statistically significant improvement in OS compared with chemo (HR 0.64; 98.6% CI: 0.46, 0.90) in the primary efficacy population (i.e. PDL1≥1% ). The median OS was of 13.7 (95% CI: 11.24, 17.02) months in the nivo+ipi arm vs. 9.07 (95% CI: 7.69, 9.95) months in the chemo arm. However, no statistically significant differences were observed in PFS, as assessed by BICR (HR 1.02; 98.5% CI: 0.73, 1.43). PFS analysis according to the investigator was consistent with the primary analysis (HR 0.83; 95% CI: 0.64, 1.07). Sensitivity analyses, including PFS per BICR accounting for assessment on/after subsequent therapy (HR 0.85; 98.5% CI: 0.63, 1.15), were overall in line with the primary analysis.

Since PFS did not meet the criteria for statistical significance in the PDL1≥1% population, as per the hierarchical testing strategy, PFS in the all-randomised patients was not formally tested (HR 1.26; 95% CI: 1.04, 1.52); neither was ORR.

In the all-randomised patients, with 216 (66.5%) events in the nivo+ipi arm and 232 (71.6%) in the chemo arms (87.2% of the target final number of OS events), a statistically significant improvement in OS was observed with nivo+ipi over chemo (HR 0.78; 98.2% CI: 0.62, 0.98). Median OS was of 12.75 months vs. 10.71 months, respectively. Sensitivity analyses were consistent with the primary analysis.

Notwithstanding the above, there was a higher rate of early deaths in the nivo+ipi arm, with crossing of the KM curves at approximately 6.5 months. Exploratory post-hoc analyses were carried out. Early deaths were defined as deaths that occurred during the first 4 months (4.05 moths). During this period, 66 patients died in the nivo+ipi arm compared with 38 patients in the chemo arm. The main cause of death was disease progression (45 [68.2%] vs. 30 [78.9%], respectively), followed by a cause named as 'other' (13 [19.7% nivo+ipi vs. 2 [5.3%] chemo).  According to these analyses, the

<div style=\"page-break-after: always\"></div>

presence of liver metastasis was identified as a risk factor for early death in the nivo+ipi arm vs. chemo arm. Further, body weight (low) and alcohol use (never/unknown) were also associated with early death among patients treated with nivo+ipi in the exploratory multivariate logistic analyses, although results may be influenced by some imbalances in baseline characteristics and the small patients with liver metastases, low body weight (&lt;60 kg) and alcohol use value never/unknown. Tumour cell PD-L1 was not identified as a predictive risk factor for early death. A warning has been that physicians should consider the delayed onset of effect of nivolumab in combination with ipilimumab before initiating treatment in patients with poorer prognostic features and/or aggressive disease.

With regards to the subgroup analysis by PD-L1 expression, which was in fact one of the stratification factors, there is an apparent lack of benefit in the subgroup of patients with PD-L1 &lt;1% in OS (HR; 0.96; 95% CI: 0.74, 1.25) and PFS (HR 1.45; 95% CI: 1.13, 1.88). Moreover ORR was lower in the KM curves in favour of the experimental arm is observed. Besides, as for the overall population, crossing of the KM curves is observed at approximately 9 months. When considering a cut-off of 5%, while statistical significance was not reached in OS (HR 0.82; 95% CI: 0.65, 1.04) a slight separation in KM curves is observed after approximately 9 months (with crossing of KM curves at 6.5 months). Bearing in mind the above results, only an indication restricted to patients with tumour cell PD-L1 expression ≥ 1% could be envisaged. The MAH was requested to further discuss the benefit in the PDL1&lt;1% population to justify an 'all comers' indication. The MAH argues that the proposed combination is a non-chemotherapy containing regimen which may be an option for patients unwilling to receive convincing argumentation. Even if it is agreed that this combination may be an alternative regimen to chemotherapy, with a different safety profile which can be considered reasonably manageable, the reported efficacy results do not support a positive benefit/risk in the proposed broad indication with updated efficacy data confirming the results initially observed in the PD-L1&lt;1% population, see below. Further, the increased rate of early deaths in patients treated with nivo+ipi is also of concern, particularly in the subgroup of patients with PD-L1&lt;1% in whom the initial lack of control of the sample size of some subgroups (i.e. never/unknown alcohol use). The highest risk is observed among included in section 4.4 of the SmPC regarding the higher number of early deaths within 4 months and The OS subgroup analysis was overall consistent with the primary analysis (all-randomised population) for most of the subgroups analysed, except for the subgroup of female patients, where no apparent benefit was observed with the combination of nivo+ipi over chemo (HR 1.36; 95% CI: 0.85, 2.20). It is acknowledged this is a relatively small subgroup (n=105) and as stated by the MAH, the control arm performed better in female patients compared with the overall population (median OS 14.75 months vs. 10.71 in the overall population). Nevertheless, CIs barely overlap, suggesting differences observed by gender might not be a chance finding. The MAH argued there were some imbalances in prognostic factors between both treatment arms, although it is not clear how these imbalances may have impacted the results. In the subgroup of female patients with PDL1≥1%, a more favourable effect was observed (HR 0.77; 95%CI: 0.40, 1.49) while clearly not in patients with PD-L1&lt;1% (HR 2.44; 95% CI: 1.18, 5.04), although these subgroups are even smaller, thus results should be interpreted with caution. A similar pattern was observed with pembrolizumab in study KEYNOTE-590, in patients with oesophageal cancer 3 . The KM curves for the subgroup of female patients suggest a lower OS with nivo+ipi during all study period. However, taking into account this is a subgroup analysis, with important inherent limitations, the relatively small sample size of this subgroup and the fact that a biological rationale cannot be confirmed, no conclusions can be drawn. nivo+ipi arm compared with the chemo arm (20.1% vs. 33.7%). Further, no clear separation of the OS chemo and that the use of nivo + ipi 'will be best tailored at the patient level'. This is not considered a

3  European Public Assessment Report Keytruda (pembrolizumab). Available in: https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0097-epar-assessment-report-variation\\_en.pdf

<div style=\"page-break-after: always\"></div>

disease together with the reported lower effect do not allow to conclude that this combination is able to provide benefit. As a result the indication has been restricted to patients with tumour cell PD-L1 expression ≥1% (see below).

Regarding ORR (by BICR), in patients with PDL1≥1% a higher ORR was reported in the nivo+ipi arm vs. chemo (35.4% vs. 19.7%). However, ORR was comparable between treatment arms in the allrandomised patient population (27.7% nivo+ipi vs. 26.9% chemo). The MAH argues that median DoR was slightly longer in the nivo+ipi arm (11.07 months vs. 7.13 months), with a DoR rate at 12 months of 48% in the nivo+ipi arm vs. 23% in the chemo arm. It should however be noted that comparing median DoR lacks value as this is a non-randomised comparison (i.e. deriving from objective responses which are a post-baseline event), while OS and PFS data are available in the context of a randomized clinical trial.

Other exploratory endpoints, such as PFS2/TTST favoured the nivo+ipi arm (HR 0.74; 95% CI: 0.62, 0.88).

PROs were assessed using the EQ-5D-3L VAS and Utility Index and FACT-E. According to the information provided, survey completion was of more than 90% at baseline and more than 80% at most subsequent treatment assessments. However, taking into account the open-label design of the study and the exploratory nature of this endpoint, no firm conclusions can be drawn in this regard.

During the procedure updated efficacy data (DBL 04 Oct 2021) with a minimum follow-up of 20 months were provided. Overall, results were consistent with the primary analysis. An improvement was observed with nivo+chemo over chemo in OS (HR 0.63; 95% CI: 0.49, 0.82) and ORR (35.4% vs. 19.7%) in patients with tumour cell PD-L1 ≥ 1% (i.e. the primary efficacy population). However, no benefit was observed in PFS (HR 1.02; 95% CI: 0.77, 1.34). In the all randomised patients (the intended target population) the combination of nivo+ipi resulted in improved OS (HR 0.77; 95% CI: 0.65, 0.93), but no benefit was observed in PFS, with even a detrimental effect (HR 1.24; 95% CI: 1.03, 1.50), and ORR was similar between arms (27.7% vs. 26.5%). In patients with PD-L1&lt;1% results were also consistent with prior data. Even if the exploratory nature of data reported in this subgroup analysis is acknowledged, no apparent benefit was observed with nivo+ipi over chemo in OS (HR 0.96; 95% CI: 0.74, 1.24), a detrimental effect in PFS with the combination was observed (HR 1.44; 95% CI: 1.12, 1.85) and the ORR was also lower in the nivo+ipi arm (20.1% nivo+ipi vs. 33.1% chemo).

## Biomarker analysis

Additional exploratory biomarker analyses are planned for study CA209648, such as MSI, TMB, genetic alterations of select genes an inflammatory gene signature. The MAH is requested to provide results of these analyses once available.

## Contribution of the monocomponents

A justification on the combination of nivolumab plus ipilimumab has been provided. The rationale for the dual checkpoint inhibition is acknowledged and the combination is currently approved in a variety of tumour types (i.e. NSCLC, melanoma, RCC, MSI-H/dMMR CRC). The MAH argues that neither nivolumab nor ipilimumab alone are expected to improve the efficacy of chemotherapy. However, this statement is based on efficacy data from studies carried out in a different setting (i.e. later lines of OSCC or gastric cancer and even squamous NSCLC) and therefore it is not known whether different (better) results may have been reached with nivolumab as monotherapy in treatment naïve patients with oesophageal cancer. Nivolumab, as monotherapy, is currently approved in patients with OSCC after prior fluoropyrimidine- and platinum-based chemotherapy. In order to further support the contribution of ipilimumab to the combination, comparative efficacy data (descriptive) of the nivo+chemo arm (which has demonstrated superiority over chemo alone) versus nivo+ipi arm have

<div style=\"page-break-after: always\"></div>

been provided. This descriptive analysis was pre-specified in the SAP. Efficacy data shows no differences between nivo+ipi vs. nivo+chemo in OS (HR 1.04; 95%CI: 0.86, 1.26). According to an exploratory analysis of piecewise OS HRs, a higher benefit may be expected with nivo+ipi after the first 4 months. However, the ORR was higher in the nivo+chemo arm compared with the nivo+ipi (47.4% vs. 27.7%), although DoR appears longer with nivo+ipi (8.18 months chemo vs. 11.07 months nivo+ipi). Having all considered, the contribution of nivolumab can be considered demonstrated based on the results of the nivo+chemo arm over chemo alone. Further, and as mentioned above, OS results are consistent between both combinations (i.e. nivo+ipi and nivo+chemo) also supporting that the contribution of ipilimumab can be considered established.

The finally agreed indication is:

OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.

YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.

As discussed above, based on the available data, a broad indication regardless of PD-L1 expression was not considered acceptable and therefore the indication was restricted to patients with tumour cell PDL1 expression ≥1%.

## Additional expert consultation

Not applicable

## Assessment of paediatric data on clinical efficacy

Not applicable

## 2.4.4. Conclusions on the clinical efficacy

In study CA209648, in adult patients with advanced or metastatic OSCC, treatment with nivolumab in combination with ipilimumab showed a statistically significant clinically relevant OS improvement compared with chemotherapy alone in patients with tumour cell PD-L1 expression ≥ 1%. No statistically significant differences were observed in PFS, although lack of correlation between PFS and OS has been previously observed with immunotherapy. These results can be considered of clinical relevance.

A higher rate of early deaths in the nivo+ipi arm was observed during the first months of treatment. These early deaths were observed regardless of tumour cell PD-L1 expression and are compatible with lack of control of the disease during the first months. This issue has been observed in other clinical trials with immunotherapy. A warning has been included in section 4.4 of the SmPC.

## 2.5. Clinical safety

## Introduction

Safety assessment for this application is based on All Treated Population (N=936) in study CA209648. In particular, safety data from 322 subjects treated with 1L nivo + ipi (nivo 3 mg/kg IV Q2W + ipi 1 mg/kg IV Q6W) from treatment arm A and 304 subjects treated with chemo from arm C were used to

<div style=\"page-break-after: always\"></div>

characterize the safety profile of this combination regimen application in subjects with advanced or metastatic OSCC.

This is a phase 3, global, randomised, open-label study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin vs. fluorouracil plus cisplatin in patients with unresectable advanced, recurrent or metastatic previously untreated oesophageal squamous cell carcinoma. Randomization was stratified by tumour cell PD-L1 expression, region, ECOG PS and number of organs with metastases.

Patients in the Nivo + Ipi arm were to receive nivolumab 3 mg/kg as a 30-minute IV infusion Q2W and ipilimumab 1 mg/kg as an IV infusion Q6W. Patients in the Chemo arm were to receive fluorouracil 800 mg/m 2 /day as a continuous IV infusion on Days 1-5 Q4W and  cisplatin 80 mg/m 2  as a 30-120-minute IV infusion (or longer if in accordance with local standard of care/local label) on Day 1 Q4W.

CA209648 study was conducted at 175 sites in 26 countries. The clinical cutoff occurred on 18-Jan2021 and DBL occurred on 01-Mar-2021 for the CA209648 Primary CSR. Updated safety data were later provided based on a 04-Oct-2021 DBL and a summary of these results are included after the initial assessment.

## Patient exposure

With the DBL of 01-Mar-2021, 936 subjects were treated: 310 with nivo + chemo, 322 with nivo + ipi and 304 with chemo. At the time of DBL, study treatment was discontinued in 91.9%, 93.5%, and 98.7% of the subjects treated with nivo + chemo, nivo + ipi and chemo, respectively. The reasons for not continuing on study treatment are displayed in Table 33.

Table 33. End of Treatment Period Status Summary - All Enrolled, Randomized, and Treated Subjects from CA209648

| Status (%)                                                         | Nivo + Ipi            | Nivo + Chemo                   | Chemotherapy                                                                                                                    | Total                          |
|--------------------------------------------------------------------|-----------------------|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| ­­­­­                                                              |                       |                                | ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ |                                |
| ENROLLED                                                           |                       |                                |                                                                                                                                 | 1358 (100.0)                   |
| RANDOMIZED (a)                                                     | 325                   | 321                            | 324                                                                                                                             | 970 ( 71.4)                    |
| NOT RANDOMIZED (a)                                                 |                       |                                |                                                                                                                                 | 388 ( 28.6)                    |
| REASON FOR NOT RANDOMIZED                                          |                       |                                |                                                                                                                                 |                                |
| DEATH                                                              |                       |                                |                                                                                                                                 | 11 ( 0.8)                      |
| ADVERSE EVENT                                                      |                       |                                |                                                                                                                                 | 6 ( 0.4)                       |
| SUBJECT WITHDREW CONSENT                                           |                       |                                |                                                                                                                                 | 34 ( 2.5)                      |
| LOST TO FOLLOW­UP                                                  |                       |                                |                                                                                                                                 | 1 ( 0.1)                       |
| POOR/NON­COMPLIANCE                                                |                       |                                |                                                                                                                                 | 1 ( 0.1)                       |
| SUBJECT NO LONGER MEETS STUDY CRITERIA                             |                       |                                |                                                                                                                                 | 330 ( 24.3)                    |
| OTHER                                                              |                       |                                |                                                                                                                                 | 5 ( 0.4)                       |
| TREATED (b)                                                        | 322 ( 99.1)           | 310 ( 96.6)                    | 304 ( 93.8)                                                                                                                     | 936 ( 96.5)                    |
| NOT TREATED                                                        | 3 ( 0.9)              | 11 ( 3.4)                      | 20 ( 6.2)                                                                                                                       | 34 ( 3.5)                      |
| REASON FOR NOT TREATED                                             |                       |                                |                                                                                                                                 |                                |
| DISEASE PROGRESSION                                                | 1 ( 0.3)              | 1 ( 0.3)                       | 2 ( 0.6)                                                                                                                        | 4 ( 0.4)                       |
| ADVERSE EVENT UNRELATED TO STUDY DRUG                              | 1 ( 0.3)              | 3 ( 0.9)                       | 1 ( 0.3)                                                                                                                        | 5 ( 0.5)                       |
| SUBJECT REQUEST TO DISCONTINUE STUDY TREATMENT                     | 0                     | 0                              | 2 ( 0.6)                                                                                                                        | 2 ( 0.2)                       |
| SUBJECT WITHDREW CONSENT                                           | 0                     | ( 0.3)                         | ( 3.7)                                                                                                                          | 13 ( 1.3)                      |
| SUBJECT NO LONGER MEETS STUDY CRITERIA                             | 0                     | 1 4 ( 1.2)                     | 12 2 ( 0.6)                                                                                                                     | 6 ( 0.6)                       |
| OTHER                                                              | 1 ( 0.3)              | 2 ( 0.6)                       | 1 ( 0.3)                                                                                                                        | 4 ( 0.4)                       |
| CONTINUING IN THE TREATMENT PERIOD (c)                             | 21 ( 6.5)             | 25 ( 8.1)                      | 4 ( 1.3)                                                                                                                        | 50 ( 5.3)                      |
| NOT CONTINUING IN THE TREATMENT PERIOD                             | 301 ( 93.5)           | 285 ( 91.9)                    | 300 ( 98.7)                                                                                                                     | 886 ( 94.7)                    |
| REASON FOR NOT CONTINUING IN THE TREATMENT PERIOD                  |                       |                                |                                                                                                                                 |                                |
| DISEASE PROGRESSION                                                | 174 ( 54.0)           | 184 ( 59.4)                    | 193 ( 63.5)                                                                                                                     | 551 ( 58.9)                    |
| STUDY DRUG TOXICITY                                                | 59 ( 18.3)            | 33 ( 10.6)                     | 40 ( 13.2)                                                                                                                      | 132 ( 14.1)                    |
| DEATH                                                              | 5 ( 1.6)              | 3 ( 1.0)                       | 4 ( 1.3)                                                                                                                        | 12 ( 1.3)                      |
| ADVERSE EVENT UNRELATED TO STUDY DRUG                              | 19 ( 5.9)             | ( 9.0)                         | 12 ( 3.9)                                                                                                                       | 59 ( 6.3)                      |
| SUBJECT REQUEST TO DISCONTINUE STUDY TREATMENT                     | 13 ( 4.0)             | 28 15 ( 4.8)                   | 20 ( 6.6)                                                                                                                       | 48 ( 5.1)                      |
| SUBJECT WITHDREW CONSENT                                           | 3 ( 0.9)              | 4 ( 1.3)                       | 12 ( 3.9)                                                                                                                       | 19 ( 2.0)                      |
| PREGNANCY                                                          | 1 ( 0.3)              | 0                              | 0                                                                                                                               | 1 ( 0.1)                       |
| MAXIMUM CLINICAL BENEFIT                                           | 1 ( 0.3)              | ( 1.0)                         | 4 ( 1.3)                                                                                                                        | 8 ( 0.9)                       |
| COMPLETED TREATMENT AS PER PROTOCOL                                | 13 ( 4.0)             | 3 8 ( 2.6)                     | 0                                                                                                                               | 21 ( 2.2)                      |
| OTHER                                                              | 12 ( 3.7)             | 7 ( 2.3)                       | 15 ( 4.9)                                                                                                                       | 34 ( 3.6)                      |
| NOT REPORTED                                                       | 1 ( 0.3)              | 0                              | 0                                                                                                                               | 1 ( 0.1)                       |
| CONTINUING IN THE STUDY (c)                                        | 93 ( 28.9)            | 91 ( 29.4)                     | 61 ( 20.1)                                                                                                                      | 245 ( 26.2)                    |
| NOT CONTINUING IN THE STUDY REASON FOR NOT CONTINUING IN THE STUDY | 229 ( 71.1)           | 219 ( 70.6)                    | 243 ( 79.9)                                                                                                                     | 691 ( 73.8)                    |
| DEATH SUBJECT WITHDREW CONSENT TO FOLLOW­UP                        | 206 ( 64.0) 16 ( 5.0) | 196 ( 63.2) 19 ( 6.1) 1 ( 0.3) | 216 ( 71.1) 27 ( 8.9) 0                                                                                                         | 618 ( 66.0) 62 ( 6.6) 3 ( 0.3) |
| LOST OTHER                                                         | 2 ( 0.6) 5 ( 1.6)     | 3 ( 1.0)                       | 0                                                                                                                               | 8 ( 0.9)                       |

<div style=\"page-break-after: always\"></div>

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

```
­­­­­ (a) Percentages based on subjects entering period. (b) Percentages based on number of randomized subjects (c) Percentages based on number of treated subjects
```

The primary reason for not continuing in the treatment period was disease progression: 59.4% subjects in the nivo + chemo arm, 54% in the nivo + ipi arm and 63.5% in the chemo arm. Study drug toxicity was reported as the reason for not continuing in the treatment period for the 10.6% of subjects in the nivo + chemo arm, 18.3% in the nivo + ipi arm and 13.2% in the chemo arm.

Among all treated subjects, the median durations of study therapy were 5.68 (0.1-30.6) months in the nivo + chemo arm, 2.79 (0-24.0) months in the nivo + ipi arm, and 3.35 (0-19.0) months in the chemo arm. The proportion of subjects with treatment durations &gt;3 months was higher in the chemo arm (54.3%) compared with the nivo + ipi arm (47.8%) while this trend is reversed when we look at long-term data. The proportions of subjects with durations of therapy of &gt;9 months were numerically higher in the nivo + chemo (28.4%) and nivo + ipi (20.5%) arms vs. the chemo arm (9.2%).

The median (min - max) number of doses of each therapy per arm were:

- Nivo + chemo arm (N = 310):
- o 12.0 (1 - 54) doses of nivolumab
- o 5.0 (1 - 24) doses of cisplatin
- o 6.0 (1 - 31) doses of fluorouracil
- Nivo + ipi arm (N = 322):
- o 6.0 (1 - 52) doses of nivolumab
- o 3.0 (1 - 18) doses of ipilimumab
- Chemo arm:
- o 4.0 (1 - 17) doses of cisplatin (N = 304)
- o 4.0 (1 - 21) doses of fluorouracil (N = 302)

The proportions of subjects who received ≥ 90% of the planned relative dose intensity of each therapy were as follows by arm:

- Nivo + chemo arm (N = 310):
- o 67.4% for nivolumab
- o 55.5% for cisplatin
- o 58.4% for fluorouracil
- Nivo + ipi arm (N = 322):
- o 76.1% for nivolumab
- o 87.0% for ipilimumab
- Chemo arm:
- o 68.1% for cisplatin (N = 304)
- o 76.2% for fluorouracil (N = 302)

<div style=\"page-break-after: always\"></div>

The numbers of doses and cumulative dose per therapy are summarized in Table 2.

Table 34 Summary of Study Treatment Duration, Cumulative Dose, and Relative Dose Intensity - All Treated Subjects

<!-- image -->

|                            | Nivo + Ipi N = 322   | Nivo + Ipi N = 322   | Nivo + Ipi N = 322   | CUEU + O4TN N = 310   | CUEU + O4TN N = 310   | Chamotherapy N = 304   | Chamotherapy N = 304   |
|----------------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------|------------------------|------------------------|
| DURATION OETHERADY(MONTHS) |                      |                      |                      |                       |                       |                        |                        |
| MEAN (MIN, MAX) MEDIAN     | 5.47 (0.0,24.0) 2.79 | 5.47 (0.0,24.0) 2.79 | 5.47 (0.0,24.0) 2.79 | 7.43 (0.1,30.6) 5.68  | 7.43 (0.1,30.6) 5.68  | 4.11(0.0, 19.5) 3.35   | 4.11(0.0, 19.5) 3.35   |
| >3 MONTHS (%)              | 154 (47.8)           | 154 (47.8)           | 154 (47.8)           | 224 72.3)             | 224 72.3)             | 165 54.3)              | 165 54.3)              |
| > 6 MONTHS [3)             | 90 28.0)             | 90 28.0)             | 90 28.0)             | 148 47.7)             | 148 47.7)             | 65 21.4)               | 65 21.4)               |
| > 9 MONTHS (%)             | 66 20.5)             | 66 20.5)             | 66 20.5)             | 88 28.4)              | 88 28.4)              | 28 9.2)                | 28 9.2)                |
| >12 MONIHS()               | 49 9( 15.2)          | 49 9( 15.2)          | 49 9( 15.2)          | 62 （20.0)             | 62 （20.0)             | 3.3)                   | 3.3)                   |
|                            |                      |                      |                      |                       |                       | 10                     | 10                     |
|                            | Nivolumab N = 322    | Ipilimmab N=322      | Nivolumab N = 310    | Cisplatin N= 310      | Fluorouracil N = 310  | Cisplatin N=304        | Fluorouracil N = 302   |
| DURATION OETHERAPY(MONTHS) |                      |                      |                      |                       |                       |                        |                        |
| MEAN                       | 5.47                 | 4.88                 | 7.31                 | 4.24                  | 68*9                  | 3.52                   | 4.13                   |
| (SD)                       | [6.41)               | (6.41)               | (6.11)               | (3.06)                | (5.16)                | (2.98)                 | (3.49)                 |
| MEDIAN                     | 2.79                 | 2.76                 | 5.62                 | 4.04                  | 4.80                  | 2.91                   | 3.35                   |
| (MIN - MAX)                | (0.0 - 24.0)         | (0.0 - 24.0)         | (0.0 - 24.7)         | (0.0 - 21.3)          | (0.1 - 30.6)          | (0.0 - 16.9)           | (0.1 - 19.5)           |
| NUMBEROEDOSESRECEIVED      |                      |                      |                      |                       |                       |                        |                        |
| NHEN                       | 11.8                 | 4.3                  | 15.4                 | 5.1                   | 6.6                   | 4.5                    | 5.0                    |
| (SD)                       | (12.9)               | (4.3)                | (12.5)               | (3.1)                 | (5.2)                 | (2.9)                  | (3.5)                  |
| MEDIAN                     | 6.0                  | 3.0                  | 12.0                 | 5.0                   | 6.0                   | 4.0                    | 4.0                    |
| (XHK- ND0                  | (1 - 52)             | (1 - 18)             | (1 - 54)             | (1 - 24)              | (1 - 31)              | (1 - 17)               | (1 - 21)               |
| CUMULATIVEDOSE(I)          |                      |                      |                      |                       |                       |                        |                        |
| MEAN                       | 35.40                | 4.26                 | 3685.59              | 370.36                | 24929.68              | 339.41                 | 19391.17               |
| (SD)                       | (38.16)              | [4.28]               | (2989.49)            | (213.53)              | (20012.03)            | (216.59)               | (13750.25)             |
| MEDIAN                     | 18.86                | 2.88                 | 2880.00              | 322.39                | 20203.17              | 317.74                 | 16123.79               |
| (MIN 一                     | (2.9 -               | [0.9 -               | (240.0 -             | (23.7 -               | (828.4-               | (73.3 -                | (1206.7 -              |
| MAX)                       | 155.0)               | 18.1)                | 12960.01             | 1093.1)               | 120876.0)             | 1348.7)                | 84236.6)               |
| RELATIVEDOSEINIENSITY()    |                      |                      |                      |                       |                       |                        |                        |
| >= 1104                    | 0.6)                 | 3 0.9)               | 0                    | 1 0.3)                | 0                     | 1 [ 0.3)               | 0                      |
| 90%10 <110%                | 243 75.5)            | 277 86.0)            | 209 67.4)            | 171 55. 2)            | 181 58.4)             | 206 67.8)              | 230 76.2)              |
| 70%10< 90%                 | 64 19.9)             | 38 11.8)             | 87 28.1)             | 79 25.5 5)            | 93 30.01              | 71 23.4)               | 62 20.5)               |
| 50%10 < 70%                | 10 3.1)              | 4 1.2)               | 13 4.2)              | 51 16.5)              | 32 (10.3)             | 24 [ 7.9)              | 7 2.3)                 |
| 50%                        | 3 0.9)               | 0                    | 1 0.3)               | 8 2.6)                | 4 1.3)                | 2 0.7)                 | 3 1.0)                 |

(1) Dose wnits: Niwo+Ipi aim: Nivo and Ipi in mg/kg; NiwotChemo and Chemo arms: Nivo in mg, Fluorouracil and Cisplatin in mg/m2. Source: Table S.4.1.2 (Cumulative Dose and Relative Dose Intensity Summary), Table S.4.61.2 (Duration of Study Therapy Summary)

## Adverse events

The overall safety summary focuses on the comparison of the nivo + chemo and nivo + ipi arms with the chemo arm, which is the most relevant comparison in assessing benefit and risk of nivo + chemo and nivo + ipi combination therapies.

Table 35. Summary of Safety - All Treated Subjects

|                                 | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|---------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Safety Parameter                | Nivo+Ipi (N=322)      | Nivo+Ipi (N=322)      | Nivo+Chemo (N=310)    | Nivo+Chemo (N=310)    | Chemo (N=304)         | Chemo (N=304)         |
| Deaths                          | 215 (66.8)            | 215 (66.8)            | 200 (64.5)            | 200 (64.5)            | 224 (73.7)            | 224 (73.7)            |
| Primary Reason for Death        |                       |                       |                       |                       |                       |                       |
| Disease                         | 176 (54.7)            | 176 (54.7)            | 168 (54.2)            | 168 (54.2)            | 204 (67.1)            | 204 (67.1)            |
| Study Drug Toxicity             | 5 (1.6)               | 5 (1.6)               | 5 (1.6)               | 5 (1.6)               | 4 (1.3)               | 4 (1.3)               |
| Unknown                         | 12 (3.7)              | 12 (3.7)              | 10 (3.2)              | 10 (3.2)              | 8 (2.6)               | 8 (2.6)               |
| Other                           | 22 (6.8)              | 22 (6.8)              | 17 (5.5)              | 17 (5.5)              | 8 (2.6)               | 8 (2.6)               |
|                                 | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             |
| All-causality SAEs              | 214 (66.5)            | 146 (45.3)            | 180 (58.1)            | 132 (42.6)            | 128 (42.1)            | 96 (31.6)             |
| Drug-related SAEs               | 103 (32.0)            | 73 (22.7)             | 74 (23.9)             | 57 (18.4)             | 49 (16.1)             | 38 (12.5)             |
| All-causality AEs leading to DC | 81 (25.2)             | 54 (16.8)             | 126 (40.6)            | 51 (16.5)             | 77 (25.3)             | 28 (9.2)              |

<div style=\"page-break-after: always\"></div>

|                                         | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|-----------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Safety Parameter                        | Nivo+Ipi (N=322)      | Nivo+Ipi (N=322)      | Nivo+Chemo (N=310)    | Nivo+Chemo (N=310)    | Chemo (N=304)         | Chemo (N=304)         |
| Drug-Related AEs leading to DC          | 57 (17.7)             | 41 (12.7)             | 106 (34.2)            | 29 (9.4)              | 59 (19.4)             | 14 (4.6)              |
| All-causality AE                        | 316 (98.1)            | 192 (59.6)            | 308 (99.4)            | 216 (69.7)            | 301 (99.0)            | 165 (54.3)            |
| Drug-related AEs                        | 256 (79.5)            | 102 (31.7)            | 297 (95.8)            | 147 (47.4)            | 275 (90.5)            | 108 (35.5)            |
| ≥ 15% Drug-related AEs in Any Treatment |                       |                       |                       |                       |                       |                       |
| Rash                                    | 55 (17.1)             | 7 (2.2)               | 24 (7.7)              | 1 (0.3)               | 5 (1.6)               | 0                     |
| Diarrhoea                               | 32 (9.9)              | 2 (0.6)               | 60 (19.4)             | 3 (1.0)               | 46 (15.1)             | 6 (2.0)               |
| Fatigue                                 | 29 (9.0)              | 4 (1.2)               | 61 (19.7)             | 7 (2.3)               | 50 (16.4)             | 11 (3.6)              |
| Nausea                                  | 26 (8.1)              | 1 (0.3)               | 182 (58.7)            | 11 (3.5)              | 158 (52.0)            | 8 (2.6)               |
| Decreased appetite                      | 19 (5.9)              | 5 (1.6)               | 132 (42.6)            | 13 (4.2)              | 130 (42.8)            | 9 (3.0)               |
| Vomiting                                | 18 (5.6)              | 4 (1.2)               | 56 (18.1)             | 7 (2.3)               | 49 (16.1)             | 9 (3.0)               |
| Stomatitis                              | 14 (4.3)              | 0                     | 98 (31.6)             | 20 (6.5)              | 71 (23.4)             | 5 (1.6)               |
| Anaemia                                 | 12 (3.7)              | 2 (0.6)               | 93 (30.0)             | 30 (9.7)              | 67 (22.0)             | 17 (5.6)              |
| Malaise                                 | 12 (3.7)              | 0                     | 50 (16.1)             | 1 (0.3)               | 45 (14.8)             | 0                     |
| Constipation                            | 7 (2.2)               | 1 (0.3)               | 59 (19.0)             | 2 (0.6)               | 66 (21.7)             | 1 (0.3)               |
| Neutrophil count decreased              | 2 (0.6)               | 0                     | 65 (21.0)             | 25 (8.1)              | 52 (17.1)             | 24 (7.9)              |
| Hiccups                                 | 2 (0.6)               | 0                     | 42 (13.5)             | 0                     | 53 (17.4)             | 0                     |
|                                         | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             |
| All-causality Select AEs by Category    |                       |                       |                       |                       |                       |                       |
| Endocrine                               | 92 (28.6)             | 19                    | 40 (12.9)             | 5 (1.6)               | 5 (1.6)               | 0                     |
| Gastrointestinal                        | 78 (24.2)             | 10 (3.1)              | 94 (30.3)             | 12 (3.9)              | 62 (20.4)             | 7 (2.3)               |
| Hepatic                                 | 67 (20.8)             | 24 (7.5)              | 55 (17.7)             | 11 (3.5)              | 22 (7.2)              | 6 (2.0)               |
| Pulmonary                               | 32 (9.9)              | 11 (3.4)              | 22 (7.1)              | 3 (1.0)               | 6 (2.0)               | 1 (0.3)               |
| Renal                                   | 17 (5.3)              | 3 (0.9)               | 81 (26.1)             | 12 (3.9)              | 63 (20.7)             | 5 (1.6)               |
| Skin                                    | 137 (42.5)            | 13 (4.0)              | 82 (26.5)             | 2 (0.6)               | 37 (12.2)             | 0                     |
| Hypersensitivity/Infusion Reactions     | 14 (4.3)              | 0                     | 8 (2.6)               | 1 (0.3)               | 1 (0.3)               | 0                     |
| Drug-Related Select AEs by Category     |                       |                       |                       |                       |                       |                       |
| Endocrine                               | 88 (27.3)             | 19 (5.9)              | 36 (11.6)             | 4 (1.3)               | 1 (0.3)               | 0                     |
| Gastrointestinal                        | 38 (11.8)             | 5 (1.6)               | 64 (20.6)             | 7 (2.3)               | 47 (15.5)             | 7 (2.3)               |

<div style=\"page-break-after: always\"></div>

|                                                                            | No. of Subjects (%)                                                        | No. of Subjects (%)                                                        | No. of Subjects (%)                                                        | No. of Subjects (%)                                                        | No. of Subjects (%)                                                        | No. of Subjects (%)                                                        |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Safety Parameter                                                           | Nivo+Ipi (N=322)                                                           | Nivo+Ipi (N=322)                                                           | Nivo+Chemo (N=310)                                                         | Nivo+Chemo (N=310)                                                         | Chemo (N=304)                                                              | Chemo (N=304)                                                              |
| Hepatic                                                                    | 42 (13.0)                                                                  | 14 (4.3)                                                                   | 32 (10.3)                                                                  | 7 (2.3)                                                                    | 12 (3.9)                                                                   | 2 (0.7)                                                                    |
| Pulmonary                                                                  | 26 (8.1)                                                                   | 9 (2.8)                                                                    | 18 (5.8)                                                                   | 2 (0.6)                                                                    | 2 (0.7)                                                                    | 0                                                                          |
| Renal                                                                      | 8 (2.5)                                                                    | 2 (0.6)                                                                    | 74 (23.9)                                                                  | 7 (2.3)                                                                    | 57 (18.8)                                                                  | 5 (1.6)                                                                    |
| Skin                                                                       | 110 (34.2)                                                                 | 13 (4.0)                                                                   | 54 (17.4)                                                                  | 1 (0.3)                                                                    | 11 (3.6)                                                                   | 0                                                                          |
| Hypersensitivity/Infusion Reactions                                        | 9 (2.8)                                                                    | 0                                                                          | 6 (1.9)                                                                    | 0                                                                          | 1 (0.3)                                                                    | 0                                                                          |
| All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category |
| Diarrhea/Colitis                                                           | 11 (3.4)                                                                   | 4 (1.2)                                                                    | 6 (1.9)                                                                    | 4 (1.3)                                                                    | 0                                                                          | 0                                                                          |
| Hepatitis                                                                  | 13 (4.0)                                                                   | 9 (2.8)                                                                    | 2 (0.6)                                                                    | 1 (0.3)                                                                    | 0                                                                          | 0                                                                          |
| Pneumonitis                                                                | 12 (3.7)                                                                   | 7 (2.2)                                                                    | 10 (3.2)                                                                   | 2 (0.6)                                                                    | 0                                                                          | 0                                                                          |
| Nephritis/Renal Dysfunction                                                | 4 (1.2)                                                                    | 2 (0.6)                                                                    | 3 (1.0)                                                                    | 3 (1.0)                                                                    | 0                                                                          | 0                                                                          |
| Rash                                                                       | 44 (13.7)                                                                  | 8 (2.5)                                                                    | 16 (5.2)                                                                   | 1 (0.3)                                                                    | 2 (0.7)                                                                    | 1 (0.3)                                                                    |
| Hypersensitivity/Infusion Reactions                                        | 1 (0.3)                                                                    | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |
| All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        |
| Adrenal Insufficiency                                                      | 18 (5.6)                                                                   | 7 (2.2)                                                                    | 5 (1.6)                                                                    | 1 (0.3)                                                                    | 0                                                                          | 0                                                                          |
| Hypophysitis                                                               | 21 (6.5)                                                                   | 10 (3.1)                                                                   | 2 (0.6)                                                                    | 1 (0.3)                                                                    | 0                                                                          | 0                                                                          |
| Hypothyroidism/Thyroiditis                                                 | 50 (15.5)                                                                  | 1 (0.3)                                                                    | 19 (6.1)                                                                   | 0                                                                          | 0                                                                          | 0                                                                          |
| Diabetes Mellitus                                                          | 5 (1.6)                                                                    | 2 (0.6)                                                                    | 3 (1.0)                                                                    | 3 (1.0)                                                                    | 0                                                                          | 0                                                                          |
| Hyperthyroidism                                                            | 19 (5.9)                                                                   | 2 (0.6)                                                                    | 7 (2.3)                                                                    | 0                                                                          | 1 (0.3)                                                                    | 0                                                                          |
|                                                                            | Any Grade                                                                  | Grade 3-4                                                                  | Any Grade                                                                  | Grade 3-4                                                                  | Any Grade                                                                  | Grade 3-4                                                                  |
| All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category |
| Pancreatitis                                                               | 5 (1.6)                                                                    | 4 (1.2)                                                                    | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |
| Encephalitis                                                               | 3 (0.9)                                                                    | 3 (0.9)                                                                    | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |
| Myositis/Rhabdomyolysis                                                    | 2 (0.6)                                                                    | 0                                                                          | 2 (0.6)                                                                    | 1 (0.3)                                                                    | 0                                                                          | 0                                                                          |
| Myasthenic Syndrome                                                        | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |
| Demyelination                                                              | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |
| Guillain-Barre Syndrome                                                    | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |
| Uveitis                                                                    | 2 (0.6)                                                                    | 1 (0.3)                                                                    | 2 (0.6)                                                                    | 0                                                                          | 0                                                                          | 0                                                                          |
| Myocarditis                                                                | 2 (0.6)                                                                    | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |
| Graft Versus Host Disease                                                  | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          | 0                                                                          |

MedDRA version 23.1 CTCAE version 4.0.

All events are within 30 days of the last dose of study drug, unless otherwise indicated (eg, any time for deaths, 100 days for IMAEs and OESIs).

Source: Table S.6.15.2 (deaths), Table S.6.3.1.2.3 (All-causality SAEs) , Table S.6.3.1.2.4 (Drug-related SAEs), Table S.6.4.2.2.2 (All-causality AEs leading to DC), Table S.6.4.2.2 (Drug-Related AEs leading to DC), Table S.6.1.31.2.2 (All-causality AEs), Table S.6.1.32.1 (Drug-related AEs), Table S.6.5.1.3.1 (non-endocrine all-causality select AEs), Table S.6.5.1.3.2 (non-endocrine drug-related select AEs), Table S.6.5.1.3.1.3 (Endocrine all-causality select AEs) Table S.6.5.1.3.1.4 (endocrine drug-related select AEs), Table S.6.2.02.4 (non-endocrine IMAEs), Table S.6.2.02.1 (endocrine IMAEs), Table S.6.5.3.3.1 (OESIs)

<div style=\"page-break-after: always\"></div>

## Updated Safety Results of Nivo + Ipi vs Chemo in CA209648 (04 Oct 2021 DBL)

## Updated Safety Results of Nivo + Ipi vs Chemo - All Treated Subjects

Table 36: in CA209648 (04-Oct-2021 Database Lock)

|                                             | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|---------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Safety Parameter                            | Nivo+Ipi N = 322      | Nivo+Ipi N = 322      | Chemo N = 304         | Chemo N = 304         |
| Deaths                                      | 234                   | (72.7)                | 242                   | (79.6)                |
| Primary Reason for Death                    |                       |                       |                       |                       |
| Disease                                     | 190 (59.0)            | 190 (59.0)            | 222 (73.0)            | 222 (73.0)            |
| Study Drug Toxicity                         | 6 (1.9) a             | 6 (1.9) a             | 5 (1.6) b             | 5 (1.6) b             |
| Unknown                                     | 13 (4.0)              | 13 (4.0)              | 6 (2.0)               | 6 (2.0)               |
| Other                                       | 25 (7.8) c            | 25 (7.8) c            | 9 (3.0) d             | 9 (3.0) d             |
|                                             | Adverse Event Grades  | Adverse Event Grades  | Adverse Event Grades  | Adverse Event Grades  |
|                                             | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             |
| All-causality SAEs                          | 219 (68.0)            | 160 (49.7)            | 130 (42.8)            | 100 (32.9)            |
| Drug-related SAEs                           | 105 (32.6)            | 75 (23.3)             | 49 (16.1)             | 40 (13.2)             |
| All-causality AEs leading to DC             | 85 (26.4)             | 57 (17.7)             | 81 (26.6)             | 33 (10.9)             |
| Drug-Related AEs leading to DC              | 59 (18.3)             | 43 (13.4)             | 63 (20.7)             | 18 (5.9)              |
| All-causality AE                            | 317 (98.4)            | 204 (63.4)            | 301 (99.0)            | 170 (55.9)            |
| Drug-related AEs                            | 256 (79.5)            | 105 (32.6)            | 275 (90.5)            | 110 (36.2)            |
| ≥ 15% Drug-related AEs in Any Treatment Arm |                       |                       |                       |                       |
| Rash                                        | 56 (17.4)             | 7 (2.2)               | 5 (1.6)               | 0                     |
| Diarrhoea                                   | 32 (9.9)              | 2 (0.6)               | 46 (15.1)             | 6 (2.0)               |
| Fatigue                                     | 29 (9.0)              | 4 (1.2)               | 50 (16.4)             | 11 (3.6)              |
| Nausea                                      | 26 (8.1)              | 1 (0.3)               | 158 (52.0)            | 8 (2.6)               |
| Decreased appetite                          | 19 (5.9)              | 5 (1.6)               | 130 (42.8)            | 9 (3.0)               |
| Vomiting                                    | 18 (5.6)              | 4 (1.2)               | 49 (16.1)             | 9 (3.0)               |
| Stomatitis                                  | 14 (4.3)              | 0                     | 71 (23.4)             | 5 (1.6)               |
| Anaemia                                     | 13 (4.0)              | 2 (0.6)               | 67 (22.0)             | 17 (5.6)              |
| Constipation                                | 7 (2.2)               | 1 (0.3)               | 66 (21.7)             | 1 (0.3)               |
| Neutrophil count decreased                  | 2 (0.6)               | 0                     | 52 (17.1)             | 24 (7.9)              |
| Hiccups                                     | 2 (0.6)               | 0                     | 53 (17.4)             | 0                     |
| All-causality Select AEs by Category        |                       |                       |                       |                       |
| Endocrine                                   | 92 (28.6)             | 19 (5.9)              | 5 (1.6)               | 0                     |
| Gastrointestinal                            | 78 (24.2)             | 10 (3.1)              | 62 (20.4)             | 7 (2.3)               |
| Hepatic                                     | 67 (20.8)             | 24 (7.5)              | 22 (7.2)              | 5 (1.6)               |
| Pulmonary                                   | 34 (10.6)             | 13 (4.0)              | 6 (2.0)               | 2 (0.7)               |
| Renal                                       | 18 (5.6)              | 3 (0.9)               | 63 (20.7)             | 5 (1.6)               |
| Skin                                        | 137 (42.5)            | 13 (4.0)              | 38 (12.5)             | 0                     |
| Hypersensitivity/Infusion Reactions         | 14 (4.3)              | 0                     | 1 (0.3)               | 0                     |
| Drug-Related Select AEs by Category         |                       |                       |                       |                       |
| Endocrine                                   | 88 (27.3)             | 19 (5.9)              | 1 (0.3)               | 0                     |
| Gastrointestinal                            | 38 (11.8)             | 5 (1.6)               | 47 (15.5)             | 7 (2.3)               |
| Hepatic                                     | 42 (13.0)             | 14 (4.3)              | 12 (3.9)              | 2 (0.7)               |
| Pulmonary                                   | 28 (8.7)              | 10 (3.1)              | 1 (0.3)               | 0                     |
| Renal                                       | 8 (2.5)               | 2 (0.6)               | 57 (18.8)             | 5 (1.6)               |
| Skin                                        | 111 (34.5)            | 13 (4.0)              | 12 (3.9)              | 0                     |
| Hypersensitivity/Infusion Reactions         | 9 (2.8)               | 0                     | 1 (0.3)               | 0                     |

<div style=\"page-break-after: always\"></div>

Table 36: Updated Safety Results of Nivo + Ipi vs Chemo - All Treated Subjects in CA209648 (04-Oct-2021 Database Lock)

|                                                                            | No. of Subjects (%)                                                        | No. of Subjects (%)                                                        | No. of Subjects (%)   | No. of Subjects (%)   |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------|-----------------------|
| Safety Parameter                                                           | Nivo+Ipi N = 322                                                           | Nivo+Ipi N = 322                                                           | Chemo N = 304         | Chemo N = 304         |
|                                                                            | Any Grade                                                                  | Grade 3-4                                                                  | Any Grade             | Grade 3-4             |
| All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category | All-causality IMAEs within 100 d of last dose treated with IMM by Category |                       |                       |
| Diarrhea/Colitis                                                           | 13 (4.0)                                                                   | 5 (1.6)                                                                    | 0                     | 0                     |
| Hepatitis                                                                  | 15 (4.7)                                                                   | 11 (3.4)                                                                   | 0                     | 0                     |
| Pneumonitis                                                                | 16 (5.0)                                                                   | 10 (3.1)                                                                   | 0                     | 0                     |
| Nephritis/Renal Dysfunction                                                | 4 (1.2)                                                                    | 2 (0.6)                                                                    | 0                     | 0                     |
| Rash                                                                       | 48 (14.9)                                                                  | 9 (2.8)                                                                    | 3 (1.0)               | 1 (0.3)               |
| Hypersensitivity/Infusion Reactions                                        | 3 (0.9)                                                                    | 0                                                                          | 0                     | 0                     |
| All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        | All-causality Endocrine IMAEs within 100 d of last dose by Category        |                       |                       |
| Adrenal Insufficiency                                                      | 17 (5.3)                                                                   | 7 (2.2)                                                                    | 0                     | 0                     |
| Hypophysitis                                                               | 22 (6.8)                                                                   | 10 (3.1)                                                                   | 0                     | 0                     |
| Hypothyroidism/Thyroiditis                                                 | 50 (15.5)                                                                  | 1 (0.3)                                                                    | 0                     | 0                     |
| Diabetes Mellitus                                                          | 5 (1.6)                                                                    | 2 (0.6)                                                                    | 0                     | 0                     |
| Hyperthyroidism                                                            | 19 (5.9)                                                                   | 2 (0.6)                                                                    | 1 (0.3)               | 0                     |
| All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category | All-causality OESIs within 100 d of last dose with/without IMM by Category |                       |                       |
| Pancreatitis                                                               | 5 (1.6)                                                                    | 4 (1.2)                                                                    | 0                     | 0                     |
| Encephalitis                                                               | 3 (0.9)                                                                    | 3 (0.9)                                                                    | 0                     | 0                     |
| Myositis/Rhabdomyolysis                                                    | 2 (0.6)                                                                    | 0                                                                          | 0                     | 0                     |
| Myasthenic Syndrome                                                        | 0                                                                          | 0                                                                          | 0                     | 0                     |
| Demyelination                                                              | 0                                                                          | 0                                                                          | 0                     | 0                     |
| Guillain-Barre Syndrome                                                    | 0                                                                          | 0                                                                          | 0                     | 0                     |
| Uveitis                                                                    | 2 (0.6)                                                                    | 1 (0.3)                                                                    | 0                     | 0                     |
| Myocarditis                                                                | 2 (0.6)                                                                    | 0                                                                          | 0                     | 0                     |
| Graft Versus Host Disease                                                  | 0                                                                          | 0                                                                          | 0                     | 0                     |

a  In the nivo + ipi arm, there were 2 additional 'Study Drug Toxicity' deaths as of the 04-Oct-2021 DBL, one subject had the cause of death updated from 'Other' at the 01-Mar-2021 DBL to 'Study Drug Toxicity' as of the 04-Oct-2021 DBL, and there was one new 'Study Drug Toxicity' case reported after the 01-Mar-2021 DBL. See Appendix 1.2.1 for details of changes in cause of death between the two DBLs.

b  In the chemo arm, the cause of death for one subject was updated from 'Unknown' at the 01-Mar-2021 DBL to 'Study Drug Toxicity' as of the 04-Oct-2021 DBL. See Appendix 1.2.1 for further details.

c  In the nivo + ipi arm, there were 3 additional 'Other' deaths as of the 04-Oct-2021 DBL, 2 subjects had the cause of death updated from 'Disease' at the 01-Mar-2021 DBL to 'Other' as of the 04-Oct-2021 DBL, 1 subject had the cause of death updated from 'Study Drug Toxicity' at the 01-Mar-2021 DBL to 'Other' as of the 04-Oct-2021 DBL, and there was one new 'Other' death reported after the 01-Mar-2021 DBL. See Appendix 1.2.1 for further details.

d  In the chemo arm, there was one additional 'Other' death after the 01-Mar-2021 DBL.

MedDRA version 24.0, CTCAE version 4.0.

All events are within 30 days of the last dose of study drug, unless otherwise indicated (eg, any time for deaths, 100 days for IMAEs and OESIs).

Sources: Table S.6.15.2 (deaths), Appendix S.1.E.1 (death listing), Appendix 1.2.1 (changes in cause of death), Table S.6.3.1.2.3 (all-causality SAEs), Table S.6.3.1.2.4 (drug-related SAEs), Table S.6.4.2.3 (all-causality AEs leading to DC),  Table  S.6.4.2.4  (drug-related  AEs  leading  to  DC),  Table  S.6.1.31.1.2  (all-causality  AEs),  Table  S.6.1.32.2 (drug-related  AEs),  Table  S.6.5.1.3.3  (non-endocrine  all-causality  select  AEs),  Table  S.6.5.1.3.4  (non-endocrine drug-related  select  AEs),  Table  S.6.5.1.3.2.3  (endocrine  all-causality  select  AEs)  Table  S.6.5.1.3.2.4  (endocrine drug-related select AEs), Table S.6.2.02.4 (non-endocrine IMAEs), Table S.6.2.02.1 (endocrine IMAEs), and Table S.6.5.3.3.2 (OESIs) in Appendix 1.2

<div style=\"page-break-after: always\"></div>

## Adverse Events (regardless of causality)

Any-grade AEs were reported in 308 (99.4%), 316 (98.1%), and 301 (99.0%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively (Table 35). The most frequently reported (&gt;20%) all-causality AEs of any grade per arm were:

- Nivo + chemo arm: nausea (65.2%), decreased appetite (51.3%), anaemia (45.8%), constipation (44.2%), stomatitis (32.6%), diarrhoea (29.4%), nausea (29.4%), fatigue (25.8%), vomiting (22.6%), and neutrophil count decreased (22.3%)
- Nivo + ipi arm: nausea and pyrexia (22.4% each); diarrhoea and anaemia (22.0% each); rash (21.7%); constipation (20.5%); and neoplasms (20.2%)
- Chemo arm: nausea (55.9%), decreased appetite (49.7%), constipation (43.1%), anaemia (31.9%), stomatitis (24.0%), and hiccups (20.7%)

Grade 3-4 AEs were reported in 216 (69.7%), 192 (59.6%), and 165 (54.3%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively. All-causality Grade 3-4 AEs reported in &gt; 5% of subjects in each treatment arm included the following:

- Nivo + chemo arm: anaemia (16.1%), neutrophil count decreased (9.0%), dysphagia (7.4%), decreased appetite (6.8%), stomatitis (6.5%), malignant neoplasm progression (5.5%), and pneumonia (5.2%)
- Nivo + ipi arm: pneumonia (6.8%), malignant neoplasm progression (6.5%), anaemia (6.2%), and dysphagia (5.3%)
- Chemo arm: anaemia (9.9%), neutrophil count decreased (8.6%), and decreased appetite (5.9%)

## Drug-related Adverse Events

Any grade drug-related AEs in the 3 treatment arms consisted mainly of events in the SOCs as follows:

- Nivo + chemo arm: gastrointestinal disorders (79.4%), metabolism and nutritional disorders (54.8%), and Investigations (49.0%)
- Nivo + ipi arm: skin and subcutaneous tissue disorders (36.6%), gastrointestinal disorders (28.6%), and endocrine disorders (25.8%)
- Chemo arm: gastrointestinal disorders (74.0%), metabolism and nutritional disorders (51.6%), and general disorders and administration site conditions (46.1%)

Drug-related any-grade AEs were reported in 297 (95.8%), 256 (79.5%), and 275 (90.5%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively. The most frequently reported drug-related AEs of any grade were:

- Nivo + chemo arm: nausea (58.7%), decreased appetite (42.6%), and stomatitis (31.6%)
- Nivo + ipi arm: rash (17.1%), and pruritus and hypothyroidism (13.4% each)
- Chemo arm: nausea (52.0%), decreased appetite (42.8%), and stomatitis (23.4%)

Grade 3-4 drug-related AEs were reported in 147 (47.4%), 102 (31.7%), and 108 (35.5%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively. The most commonly reported drug-related Grade 3-4 AEs included:

<div style=\"page-break-after: always\"></div>

- Nivo + chemo arm: anaemia (9.7%), neutrophil count decreased (8.1%), and stomatitis (6.5%)
- Nivo + ipi arm: hyponatraemia (2.5%); and rash, adrenal insufficiency, pneumonitis, alanine aminotransferase increased, and hepatic function abnormal (2.2% each)
- Chemo arm: neutrophil count decreased (7.9%), anaemia (5.6%), and fatigue (3.6%)

## Table 37 . Adverse Events by Worst CTC Grade in ≥10% of All Treated Subjects from CA209648

|                                                                              | Nivo + Ipi N=322              | Nivo + Ipi N=322             | Nivo + Ipi N=322   | Nivo + Chemo N = 310                      | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Chemotherapy N=304             | Chemotherapy N=304   | Chemotherapy N=304   |
|------------------------------------------------------------------------------|-------------------------------|------------------------------|--------------------|-------------------------------------------|------------------------|------------------------|--------------------------------|----------------------|----------------------|
| System Organ Class (t) Preferred Tem (t)                                     | Any Grade                     | Grade 3-4                    | Grade 5            | Hny Grade                                 | Grade 3-4              | Grade 5                | Any Grade                      | Grade 3-4            | Grade 5              |
| TOTAL SUBJECIS WITH AN EVENT                                                 | 316 ( 98.1)                   | 192 ( 59.6)                  | 31 ( 9.6)          | 308 99.4)1                                | 216 ( 69.7)            | 23 (7.4)               | 301 ( 99.0)                    | 165 ( 54.3)          | 14 (4.6)             |
| Gastrointestinal                                                             | 219 68.0)                     | 52 (16.1)                    | 2 0.6)             | 283 91.3)                                 | 91 ( 29.4)             | 0                      | 266 [1 87.51                   | 64 (21.1)            | 1 0.3)               |
| disorders Diarrhoea Nausea.                                                  | 222 966661                    | 663                          | 000000             | 202 65. 2976                              |                        |                        | 170                            |                      | 000000               |
|                                                                              |                               |                              |                    |                                           |                        |                        |                                | 666                  |                      |
| Constipation                                                                 |                               |                              |                    |                                           |                        | 000000                 |                                |                      |                      |
| Vomiting                                                                     | 14.                           | 6)                           |                    | 70 22.                                    |                        |                        | 19.                            | 0)                   |                      |
| Dysphagia                                                                    | 11                            | 3)                           |                    | 14. 21                                    |                        |                        | 11 39                          | 9)                   |                      |
| Stcmatitis                                                                   | 8.1)                          |                              |                    | 101 32.6)                                 |                        |                        | 24.0 0)                        | 6)                   |                      |
| General disorders and                                                        |                               | 13                           | 4 1.2)             | 219 (70.6)                                | 25                     | 4 1.3)                 | 193                            | 23                   | 3 (1.0)              |
| administration site conditions                                               | 160 (49.7)                    | 4.0)                         |                    |                                           | 8.1) 9.3)              |                        | 63.5)                          | 7.6)                 |                      |
| Byrexia Fatigue Malaise Oedema peripheral                                    | 158 49.1) 289                 | m9ooo 0.91 1.2)              |                    | 886435                                    | 2.9) 88 28.4)          | 00000                  | 82386                          | 0.3) 3.9)            | 00000                |
|                                                                              | 96866                         |                              | 00000              |                                           |                        |                        |                                | 1.3)                 |                      |
| Miicosalinflammation                                                         |                               |                              |                    |                                           |                        |                        |                                |                      |                      |
| Metabolism and nutrition                                                     |                               |                              | 口                  | 233 75.2)                                 |                        | 口                      | 67.1)                          | 47 15.5)             | 口                    |
| disorders                                                                    |                               | 62 19.3)                     |                    |                                           |                        |                        | 204                            |                      |                      |
| Decreased appetite Hyponatraemia                                             |                               | 18 3.11                      | 000                | 51 17.                                    |                        | 000                    | 5327                           | 821 8                | 000                  |
| Hypokalaemia                                                                 |                               | 14 4.3)                      |                    |                                           | 3 ( 1.0)               | 0                      | 81 26.6)                       | 口                    | 口                    |
| Skin and subcutaneous tissue disorders                                       | 154 47.81                     |                              | 口                  | 123 39.7)                                 |                        |                        |                                |                      |                      |
| Rash                                                                         |                               | 3.3)                         |                    | 11.6)                                     | ( 0.3)                 |                        |                                | 000                  | 000                  |
| Pruritus Alopecia                                                            |                               | rmo                          | 000                | 642 11.0) 10.3)                           | 100                    | 000                    | 1612                           |                      |                      |
| Investigations Aspartate aminotransferase increased                          | 137 42. 51 40 12.4)           | 49 12.4) 2.2)                | 00                 | 129 61.3) 8.7)                            | 19.01 1.3)             | 00                     | 146  51.3) 3.3)                | N6 ( 16.11 0.7)      | 00                   |
| Weight decreased Alanine                                                     | 39 12.1) 37 11.5)             | 2.83                         | 00                 | 38 (12.3) 25 (8.1)                        | 88 0.6) 1.3)           | 00                     | 33 ( 10.9) 11 (3.6)            | 31 1.0) [ 0.3)       | 00 0                 |
| Platelet count decreased Neutrophil decreased                                | 9 2.81                        | 2 [ 0.6)                     |                    | 42 ( 13.5)                                | 5 （ 1.6)               |                        | 34 ( 11.2) 54 ( 17.8)          | 5 1.6) (             |                      |
| Blood creatinine increased                                                   | 12 3.7)                       | 口                            | 口                  | 45 ( 14.5)                                | 2 (0.6)                | 0                      | 37 ( 12.2)                     | 1( 0.3)              |                      |
| 1count                                                                       |                               |                              | 口 0                |                                           | 28 （ 9.0)              | 0                      |                                | 26 8.6)              | 口 0                  |
| Respiratory, thoracic and mediastinal disorders Cough                        | 3( 0.9) 125 (38.8) 36 1 11.2] | 1 0.3) 28 [ 8.7) 11 [ 0.3) ( | 1.2)               | 69 (22.3) 154 49.7) 40 [ 12.91 53 ( 17.1) | 32 (10.3)              | 0 0                    | 130 ( 42.8) 29 9.5) 63 ( 20.7) | 16 5.3) 1 ( 0.3) 0   | 0.3) 00              |
| Hiccups Infections and infestations                                          | 8(2.5)                        | 0.3) 47 [ 14.6)              | 00 2 0.6)          | 117 ( 37.7)                               | 00 32                  | 0 4 1.3)               | 80 [ 26.3)                     | 18 ( 5.9)            | 3 1.0)               |
| Pneuwmonia.                                                                  | 43 ( 13.4)                    | 22 6.8)                      | 2 0.6)             | 40 ( 12.9) 169 ( 54.5)                    | 16 ( 5.2) （ 21.6)      | 2 0.6) 0               | 29 [ 9.5)                      | 1 2.3)               | 1 [ 0.3)             |
|                                                                              | 118 ( 36.6)                   | 27 8.4)                      | 口                  |                                           | (10.3)                 |                        | 115 [ 37.8)                    | 42 （ 13.81           | 口                    |
| Blood and lymphatic                                                          | 86 (26.7)                     | 21 [ 0.3)                    | 00                 | 142 ( 45.81 32 ( 10.3)                    | 67 50 16.1)            |                        | 1 [                            | 39 2.3               | 00                   |
| system disorders Anaemia Neutropenia                                         | 22 22.0) 0.6)                 | 6.2)                         |                    |                                           | 13 4.2)                | 60                     | 31.9) 6.9)                     |                      |                      |
| Endocrine disorders Hypothyroidism Neoplasms benigm, maligmant and specified | 61 20.2)                      | 8.4)                         |                    | 6.51 16.1)                                | 7.4)                   | 2.3)                   | 319 8 15.8)                    | 4.6)                 |                      |
|                                                                              | 656 26.4!                     | 997 5.9)                     | 5.6)               | 226 10.31                                 | 1.0)                   | 60r                    |                                | ( 0.3)               | 006 2.0)             |
| （incl cysts and polyps)                                                      |                               | 21 6.5)                      | 18 1 5.6)          | 25 8.1)                                   | 17                     | 7 ( 2.3)               | 16                             | 6 3.0)               | 5[ 1.6)              |
|                                                                              | 41 ( 12.71                    |                              |                    |                                           | 5.5)                   |                        | 5.3)                           |                      |                      |
| Malignant neoplasm progression                                               | 26 13.71 8.11                 | 10 0.3)                      | 0 0                | 88 20.31 16.1)                            | 0.3)                   | 10 ( 0.3)              | 29 13. 13.3                    | 31 01                | 00                   |
| Psychiatrie disorders Inscmmia                                               |                               |                              |                    |                                           |                        |                        |                                | 0.3)                 |                      |

<div style=\"page-break-after: always\"></div>

| System Organ Class (4)                               | Nivo + Ipi N= 322   | Nivo + Ipi N= 322   | Nivo + Ipi N= 322   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Chemotherapy N=304   | Chemotherapy N=304     | Chemotherapy N=304   |
|------------------------------------------------------|---------------------|---------------------|---------------------|------------------------|------------------------|------------------------|----------------------|------------------------|----------------------|
| Preferred Term (t)                                   | Any Grade           | Grade 3-4           | Grade 5             | Au Grade               | Grade 3-4              | Grade 5                | Any Grade            | Grade 3-4              | Grade 5              |
| TOTAL SUBJECIS WITH AN EVENT                         | 256 (79.5)          | 102 ( 31.7)         | 2 0.6)              | 297 (95.8)             | 147 (47.4)             | 1 0.3)                 | 275 (90.5)           | 108 (35.5)             | 3 (1.0)              |
| Skin and subcutaneous                                | 118 ( 36.6)         | 14 4.3)             | 0                   | 85 ( 27.4)             | 1 ( 0.3)               | 0                      | 51 16.8)             | 0                      | 0                    |
| tissue disorders Rash                                | ( 17.11             | 6.31                | 000                 | 7.7)                   | 100 ( 0.3)             | 0                      | 1.                   |                        | 0                    |
| Pruritus                                             | 13.4)               |                     |                     | 7.41                   |                        |                        | 522                  |                        |                      |
| Alopecia                                             | 0.6)                | 7mo                 |                     | 10.0)                  |                        | 00                     | 10.5)                | 000                    | 0                    |
| Gastrointestinal                                     | 92 (28.6)           | 15 4.7)             | 口                   | 246 79.4)              | 49 （ 15.81             | 口                      | 225 (74.0)           | 30 9.91                | 口                    |
| disorders Diarrhoea                                  |                     | 0.6)                |                     | 60 19.4) 58.71         | 1.01                   |                        | ( 15.1) 52.0)        | 2.0)                   |                      |
| Nausea. Vemiting                                     | 83 (25.8) 43 (13.4) | 19 5.9) 0           | 0000o               | 19.0)                  | 31702 一 0. 61          | 00000                  | 91665 ( 21.7)        | o  05  9 01 1. 61 0.3) | 00000                |
|                                                      |                     | 21401 6.1           |                     | 18.1) 31.6)            | imd6. 60 51            |                        | 16.1) 23.4)          |                        |                      |
| Stomatitis                                           |                     |                     |                     |                        |                        |                        |                      |                        |                      |
| Constipation                                         |                     | 0.3)                |                     |                        |                        |                        |                      |                        |                      |
| Endocrine disorders Hypothyroidism                   |                     |                     | 口                   | 30 9.71 18 ( 5.8)      | 3 1.0) 0               | 00                     | 10 0.3)              | 10 0.3)                |                      |
|                                                      | 71 ( 22.0)          | 7 2.2)              | 0 0                 | 151 [48.7]             | 17 ( 5.5)              | 0                      | 140 46.1)            | 16 5.31                | 1 [ 0.3)             |
| General disorders and administration site conditions |                     | 4 ( 1.2)            |                     | (19.7)                 | 7                      |                        | 16.4)                | 11 ( 3.61              |                      |
| Fatigue Malaise Mucosal i inflamation                |                     | 00                  | 000                 | 658 16.1) (10.6)       | = 00 66                | 000                    | 14.8 81 8.6)         |                        | 000                  |
| Investigations                                       | 1.9)                |                     | 口 0                 | 152 (49.0)             |                        |                        | 130 42.8)            | ( 1.3)                 |                      |
| Platelet count                                       | 67 20.8)            | 19 5.9) 0           | 0                   | 36 (11.6) 68           | 44 ( 14.2) 3 1.0)      | 00                     | 32 ( 10.5)           | 38 12.51 ( 1.6)        | 0 0                  |
| decreased                                            |                     | 0                   |                     | (12.6)                 | 1 ( 0.3)               |                        |                      |                        |                      |
| Blood creatinine inereased                           | 5 1.6)              |                     |                     |                        |                        | 0                      | 32 (10.5)            | 1 ( 0.3)               | 0                    |
| White blood cell count decreased                     | 3 0.9)              | 0                   | 0                   | 43 ( 13.9)             | 11 3.5)                | 0                      | 28 [ 9.2)            | 6 ( 2.0)               | 0                    |
| Neutrophil count                                     | 2 0.6)              | 0                   | 0                   | 65 ( 21.0)             | 25 8.1)                | 0                      |                      | 24 ( 7.9)              | 0                    |
| decreased                                            |                     | 20                  |                     |                        |                        |                        | 52 ( 17.1)           |                        | 0                    |
| Metabolism and nutrition disorders                   | 47 14.6)            | 6.2)                | 0                   | 170 54.8)              | 45 （ 14.5)             | 0                      | 157 ( 51.6)          | 23 [ 7.6)              |                      |
| Decreased appetite                                   | 19 5.91             | 5 1.6)              | 口                   | 132 42.6)              | 13 4.21                | 0                      | 130 42.8)            | 9 3.0)                 | 0                    |
| Respiratory. thoracic and mediastinal disorders      | 39 (12.1)           | 11 3.4)             | 1 0.3)              | 71 ( 22.9)             | 3 1.0)                 | 0                      | 69 9( 22.7)          | 4 1.3)                 | 1 0.3)               |
| Hiccups                                              | 2 (0.6)             | 0                   | 0                   | 42 ( 13.5)             | 0                      | 0                      | 53 ( 17.4)           | 0                      | 0                    |
| Blood and lymphatic system disorders                 | 23 [ 7.1)           | 3 [ 0.9)            | 0                   | 124 (40.0)             | 44 (14.2)              | 0                      | 84 (27.6)            | 28 9.2)                | 0                    |
| Anaemia.                                             | 12 3.7)             | 2 [ 0.6)            | 0                   | 93( 30.0)              | 30 （ 9.71              | 0                      | 67 (22.0)            | 17 5.61                | 0                    |

MedDRA Version: 23.1

Includes events reported between first dose and 30 days after last dose of study therapy.

CIC Version 4.0

Souce: Table S.6.1.32.1

## Exposure-adjusted Adverse Events Rates

The exposure-adjusted AE incidence rates (per 100 person-year [P-Y]) were 2516.4 with the nivo + chemo arm, 1809.5 with the nivo + ipi arm and 3019.5 with the chemo arm. Per SOC, the higher exposure-adjusted AE incidence rates were gastrointestinal disorders (648.8 with the nivo + chemo arm, 341.7 with the nivo + ipi arm and 878.7 with the chemo arm), investigations (366.9 with the nivo + chemo arm, 219.9 with the nivo + ipi arm and 377.9 with the chemo arm), metabolism and nutrition disorders (307.1 with the nivo + chemo arm, 197.6 with the nivo + ipi arm and 411.6 with the chemo arm), and general disorders and administration site conditions (290.8 with the nivo + chemo arm, 182.9 with the nivo + ipi arm and 357.6 with the chemo arm. Pyrexia was the most frequently reported PT for nivo + ipi (67.0/100 P-Y) and nausea was the most frequently reported PT for nivo + chemo (204.9/100 P-Y) and chemo treatment (286.4/100 P-Y).

When the drug-related AE occurrences were exposure-adjusted, drug-related AE incidence rates (per 100 P-Y) were 636.3 with nivo + ipi vs 1893.5 with chemo treatment. In the nivo + ipi arm, the most frequently reported SOC was investigations (125.8/100 P-Y), and the most frequently reported PT was rash (41.8/100 P-Y). In the chemo arm, the most frequently reported SOC was gastrointestinal disorders (625.2/100 P-Y) with nausea as the most frequently reported PT (266.0/100 P-Y).

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious Adverse Events

Between the nivo + ipi and chemo arms, the overall proportion of subjects with all-causality and drugrelated SAEs were numerically higher in the nivo + ipi arm vs the chemo arm. The proportions of subjects with drug-related SAEs were higher with nivo + ipi vs chemo in the SOCs of Endocrine Disorders (6.8% vs 0.3%) and Respiratory, Thoracic and Mediastinal Disorders (6.2% vs 1.6%), largely due to immune-related AEs coincident with immunotherapy treatment.

All-causality any-grade SAEs were reported in 180 (58.1%), 214 (66.5%), and 128 (42.1%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively (Table 38). The most frequently reported all-causality SAEs of any grade were:

- Nivo + chemo: malignant neoplasm progression (7.7%), pneumonia (7.1%), dysphagia (5.8%)
- Nivo + ipi: malignant neoplasm progression (12.4%), pneumonia (7.5%), and pneumonitis and pyrexia (3.7% each)
- Chemo: malignant neoplasm progression (4.9%), dysphagia and pneumonia (3.6% each), oesophageal stenosis (3.3%)

Drug-related any-grade SAEs were reported in 74 (23.9%), 103 (32.0%), and 49 (16.1%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively (Table 39). The most frequently reported drug-related SAEs of any grade were:

- Nivo + chemo: acute kidney injury (1.9%); colitis, pneumonia, and stomatitis (1.6% each); febrile neutropenia, pneumonitis, vomiting, hyponatraemia, and deceased appetite (1.3% each)
- Nivo + ipi: pneumonitis (3.7%), hepatic function abnormal (2.5%), adrenal insufficiency (2.2%)
- Chemo: vomiting (3.0%), and pulmonary embolism, diarrhoea, nausea, hyponatraemia, dehydration, atrial fibrillation, and acute kidney injury (1.0% each)

SAEs due to COVID-19 occurred in 1 subject in the nivo + chemo arm with Grade 5 COVID-19 pneumonia.

Table 38 . Serious Adverse Events reported in ≥3% of All Treated Subjects

<div style=\"page-break-after: always\"></div>

System Organ Class (t)

Preferred Term (t)

TOTALSUBJECISWITHAN

EVENT

Gastrointestinal

Dysphagia disorders

Neoplasms benigm, wgpecified

(inel cysts maligmant and

and polyps)

progression

Maligmant neoplasm

Infections and

Pneumonia.

infestations

Respiratory, thoracic disorders

and mediastinal

Pneumonitis

Pneumonia aspiration

Generaldlisorders andl conditions

Grade 5

31

9.6)

2

18

18

2

2

4

4

0

Nivo + Chemo

N = 310

Any Grade

180

58.1)

59

19

19.0)

5.8)

2.3)

32

(10.3)

24

7.7)

39

22

31

12.6)

7.1)

10.0)

1.8

21

6(

6.8)

1.9)

Grade 3-4

132

（

42.6)

51

17

7

21

17

27

15

26

10

0

Grade 5

23

7.4)

0

7

7

(

(

4

2

0

4

0

Any Grade

128

(42.1)

48

(15.8)

18

3.3)

3.6)

21

15

24

11

18

13

4

6.9)

4.9)

7.9)

3.6)

5.9)

0.3)

1.6)

4.3)

1.3)

Chemotherapy

N = 304

Grade 3-4

96

(31.6)

41

13

17

7

14

14

4

1

（

13.5)

(

(

(

3.9

6)

2.

4.3)

3.0)

5.6)

2.3)

4.6)

0.3)

1.3)

1.3)

0.3)

Grade 5

14

4.6)

1

0.3)

6(

2.0)

1.6)

3

1

[

(

1

3

[

0

administration site

Pyrexia

Any Grade

214 ( 66.5)

51

(15.8)

11

3.4)

0.9)

3

46 ( 14.3)

40 ( 12.4)

43( 13.4)

24

7.5)

41

(12.7)

12

10

3.7)

3.1)

28

12(

8.7)

3.7)

Nivo + Ipi

N =322

Grade 3-4

146

(45.3)

38

( 11.8)

11

3

24

21

32

17

25

[

7

2[

0.9)

3.4)

7.5)

6.5)

9.9)

5.3)

7.8)

22

:23

2.2)

0.6)

|                                          | Nivo + Ipi N=322   | Nivo + Ipi N=322   | Nivo + Ipi N=322   | +IN N=310    | +IN N=310         | +IN N=310   | Chemotherapy N = 304   | Chemotherapy N = 304   | Chemotherapy N = 304   |
|------------------------------------------|--------------------|--------------------|--------------------|--------------|-------------------|-------------|------------------------|------------------------|------------------------|
| System Organ_Class () Preferred Term (t) | Any Grade          | Grade 3-4          | Grade 5            | Any Grade    | Grade 3-4         | Grade 5     | Any Grade              | Grade 3-4              | Grade 5                |
| TOTALSUBJECISWITHAN EVENT                | 103 ( 32.0)        | 73 [ 22.7)         | 2 0.6)             | 74 23.9)     | 57 (18.4)         | 1 0.3)      | 6 (16.1)               | 38 (12.5)              | 3 (1.0)                |
| Endocrine disorders                      | 22 6.              | [ 5.3)             |                    | 1.9)         | 1.0)              |             | 0.3)                   | 1 0.3)                 |                        |
| Adrenal insufficiency                    |                    |                    |                    | 19.9         | 0.3)              | 0000        | 000r                   | 1000                   |                        |
| Hypophysitis                             |                    |                    |                    |              |                   |             |                        |                        |                        |
|                                          |                    |                    |                    | 6201 0.3)    | 3101 0.3)         |             |                        |                        |                        |
| Hypopituitarism                          | 765 61             | 562                | o000               |              |                   |             |                        |                        | 0000                   |
| Respiratory, thoracic and mediastinal    | 20 6.2)            | 11 3.4)            | 1 0.3)             | 6 1.9)       | 3 1.0)            |             | 5( 1.6)                | 4( 1.3)                | 1( 0.3)                |
| disordlers Pneumonitis                   | 12 3.71 5 1. 6)    | PN 3:3             | 00                 | 1.3 0.3)     | 11 0.3) 0.3) 6.1) |             | 3 17                   | 00 3 (                 | 0 0                    |
| Interstitial lung disease                | 1 0.3)             |                    | 1                  | 口            |                   |             | 00                     |                        |                        |
| Pulmonary embolism                       |                    |                    | 0.3)               |              |                   |             | 1.0)                   | 1.0)                   | 0                      |
| disorders                                | 17 5.3)            | 13 4.0)            | 口                  | 24 [ 7.7)    | 19                | 0           | 5.6)                   | 15 ( 4.9)              | 0                      |
| Vemiting Colitis                         | 43110              | 23110 933 6        | 00000              | 54335 63666  | 中mNm寸 6661 3)     | 00000       | ommmo 18               | 0NNO 3.0)              | 00000                  |
| Diarrhoea                                | 0.3)               |                    |                    |              |                   |             | 133                    | 7)                     |                        |
| Nausea Stomatitis                        |                    |                    |                    |              |                   |             |                        | 0. 7]                  |                        |
|                                          |                    |                    |                    |              | 3)                |             |                        |                        |                        |
| Metabolism and nutrition                 | 14 4.3)            | 13 4.0)            | 口                  | 14 4.5)      | 13 4.2)           |             | 11 3.6)                | 7 2.3)                 | 0                      |
| disorders Hyponatraemia                  | 1. 660             |                    |                    | 442 31       | 中NN 1.3)          | 000         | mNm 1. 01              | 3 ( 1.0)               | 0                      |
| Decreased appetite Dehydration           | 0.                 | 66                 |                    |              | 0. 6              |             |                        | ON                     | 00                     |
|                                          | 0.6)               | 522 8              | 000                |              | 0.6)              |             |                        | 0.7)                   |                        |
| Hepatobiliary disorders Hepatic function | 13 8 ( 4.0) 2.5)   | 13 2.2) 3. 71      |                    | 11 0.3) 0.3) | 11 0.3) 0.3)      |             | 00                     | 00                     |                        |
| sonormel General disorders and           | 7( 2.2)            |                    |                    |              |                   | 0           | 3                      | 0                      | 1(                     |
| administration site conditions           | 6                  | 3( 0.9) 0.31       | 0 0                | 8( 2.6) 61   | 5 （ 1.6)          |             | 1.0) 0.3)              |                        | 0.3)                   |
| Byrexia Fatigue                          | 18.9               | 0.3)               | 0                  | 1:8          | om 1.0)           |             | 0                      | 00                     |                        |
| Infections and infestations Pneumonia.   | 6 ( 1.9) 0         | 1.2) 0             | 0                  | 10  ( 3.2)   | 7( 2.3)           | 1 [ 0.3)    | 4 [ 1.3)               | 3 1.0)                 | 1 0.3)                 |
| system disorders                         | 1 0.3)             |                    | 0                  | 5 1.6)       | 4 1.3)            | 1 0.3)      | 1 0.3)                 | 1 0.3)                 | 0                      |
| Anaemia Febrile neutropenia              |                    |                    | 0 0                | 3 1.0) 1.3)  | 3 4 ( ( 1.3)      | 0 0         | 0.7)                   | 一 0.7)                 | 0                      |
| Blood and lymphatic                      |                    | 0                  | 0                  | 6 [ 2.9)     | 6 ( 2.9)          | 0           | 5 ( 1.6)               | 5 1.6)                 | 0                      |
|                                          | 0                  | 0 0                |                    |              | 1.0)              |             | 9.71                   | 22 0.71                | 0                      |
| Cardiac disorders Atrial fibrillation    | 1 ( 0.3) 0         | 0 0                | D 0                | 60           |                   | 口 0         | 1.0                    | 1. 6) 0.7)             | 0                      |
| Renal and urinary                        | 1                  | 1 0.3)             |                    |              | 5                 |             | 5                      | 3 1.0)                 |                        |
| disorders                                | 0.3)               |                    |                    | 2.6)         | 1.6)              | 0           | 1.6)                   |                        | 0                      |
|                                          | 1( 0.3)            | 1( 0.3)            |                    | 6( 1.9)      | 4( 1.3)           | 0           | 1.0)                   | 2 0.7)                 |                        |
| Acute kicney injury                      |                    |                    | 0                  |              |                   |             | 3(                     |                        | 0                      |

MedDRA Version: 23.1

CIC Version 4.0

Includes events reported between first dose and 30 days after last dose of study therapy.

Source: Table S.6.3.1.2.4

1.0)

0.3)

0.3)

1.0)

[

(

（

16.5)

51

28

(

(

(

6.8)

5.5)

8.7)

4.8)

8.4)

0.3)

6)

1.

3.2)

(

(

(

(

0.6)

5.6)

5.6)

0.6)

0.6)

1.2)

0.3)

1.2)

[

2.3)

2.3)

1.3)

0.6)

1.3)

<div style=\"page-break-after: always\"></div>

Table 39. Drugrelated Serious Adverse Events Reported in ≥1% of All Treated Subjects

|                                                      | Nivo + Ipi N=322   | Nivo + Ipi N=322   | Nivo + Ipi N=322   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Chemotherapy N=304   | Chemotherapy N=304   | Chemotherapy N=304   |
|------------------------------------------------------|--------------------|--------------------|--------------------|------------------------|------------------------|------------------------|----------------------|----------------------|----------------------|
| System Organ Class (t) Preferred Term (t)            | Any Grade          | Grade 3-4          | Grade 5            | Hny Grade              | Grade 3-4              | Grade 5                | Any Grade            | Grade 3-4            | Grade 5              |
| TOTALSUBJECISWITH AN EVENT                           | 103 (32.0)         | 73 (22.7)          | 2 0.6)             | 74 (23.9)              | 57 (18.4)              | 1( 0.3)                | 6 (16.1)             | 38 (12.5)            | 3 (1.0)              |
| Endocrine disorders                                  | 8399               | 17                 | 0000               | 1.9                    | 1.0)                   |                        | 00OH 0.3)            | 1000 0.3)            |                      |
| Adrenal insufficiency                                |                    |                    |                    | 0.6)                   | 0.3)                   |                        |                      |                      |                      |
| Hypophysitis                                         | 06                 |                    |                    |                        |                        | 0000                   |                      |                      |                      |
| Hypopituitarism                                      | 6)                 | 654                |                    | 0.3)                   | m=0= ( 0.3)            |                        |                      |                      | o000                 |
| Respiratory, thoracic and mediastinal                | 20 6.2)            | 11 3.4)            | 1 0.3)             | 6 1.9)                 | 3 ( 1.0)               | 0                      | 5[ 1.6)              | 4( 1.3)              | 1 (0.3)              |
| disorders                                            |                    |                    |                    |                        |                        |                        |                      |                      |                      |
| Pneumonitis                                          | 13 3.71            |                    |                    | 41                     | 9.31                   | 00                     | 00                   |                      | 0                    |
| Interstitial lung disease                            | 1.6)               | PN 3.3             | 60                 |                        | 11 0.3)                |                        |                      | 00                   | 0                    |
| Pulmonary embolism                                   | 1 0.3)             | 0                  | 1 1 0.3)           | 口                      | 口                      | 0                      | 3 1.0)               | 3 1.0)               | 0                    |
| Gastrointestinal                                     | 17 5.3)            | 13 ( 4.0)          | 口                  | 24 [ 7.7)              | 19 ( 6.1)              | 0                      | 17 5.6)              | 15 ( 4.9)            | 0                    |
| disorders                                            |                    |                    |                    |                        |                        |                        |                      |                      |                      |
| Colitis                                              |                    | 0.6 61             |                    |                        |                        |                        |                      |                      |                      |
| Vemiting                                             | 93110 16           | 8.91               |                    |                        |                        |                        | 3.01                 | 3.0)                 |                      |
| Diarrhoea                                            |                    | 0.3)               | 00000              |                        | 6)                     |                        | 1.0)                 | 0.71                 |                      |
| Nausea.                                              | 0.3)               | 23110 0.3)         |                    |                        | 1. 0)                  | 00000                  | 1.0)                 | O0NNO 0.7)           |                      |
| Stomatitis                                           |                    |                    |                    | 63686 133              | 1.31                   |                        | ommmo                |                      |                      |
| Metabolism and nutrition                             | 14 4.3)            | 13 4.0)            | 口                  | 14 4.5)                | 13 4.2)                | 口                      | 11 3.6)              | 7 2.3)               | 0                    |
| disorders                                            |                    |                    |                    |                        |                        |                        |                      |                      |                      |
| Hyponatraemia                                        |                    |                    |                    |                        | 366                    |                        | 1.                   | 3 ( 1.0)             | 口                    |
| Decreased appetite                                   |                    |                    |                    |                        |                        |                        | m4m 18.9 66          |                      |                      |
| Dehydration                                          | 8                  | 666                | 000                | 442 866 366            | 128                    | 000                    |                      | 02 ( 0.7)            | 00                   |
| Hepatobiliary disorders                              | 13 4. 0)           |                    | 00                 |                        | 9.31                   | 00                     |                      | 00                   |                      |
| Hepatic function abnormal                            | 2.5)               | 13 3               |                    | TT 8.31                | 0.3)                   |                        | 00                   |                      |                      |
| General disorders and acministration site conditions | 7 2.2)             | 3 0.9)             | 0                  | 8( 2.6)                | 5 1.6)                 | 0                      | 3 1.0)               | 0                    | 1( 0.3)              |
| Pyrexia.                                             | 1.6)               | 0.3)               | 0                  | ( 0.6)                 | 口                      | 0                      | 1 ( 0.3)             | 0                    | 口                    |
| Fatigue                                              | 0.3)               | 11 0.3)            | 0                  | 内m 1.0)                | 3 （ 1.0)               | 0                      | 0                    | 0                    | 0                    |

|                                           | Nivo + Ipi N = 322   | Nivo + Ipi N = 322   | Nivo + Ipi N = 322   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Chemotherapy N = 304   | Chemotherapy N = 304   | Chemotherapy N = 304   |
|-------------------------------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| System Organ Class (t) Preferred Term (t) | Any Grade            | Grade 3-4            | Grade 5              | Any Grade              | Grade 3-4              | Grade 5                | Any Grade              | Grade 3-4              | Grade 5                |
| Infections and infestations               | 6( 1.9)              | 4 1.2)               | 0                    | 10 ( 3.2)              | 7 2.3)                 | 1 0.3)                 | 4 1.3)                 | 3( 1.0)                | 1 0.3)                 |
| Pneumonia                                 | 0                    | 0                    | 0                    | 5( 1.6)                | 4 1.3)                 | 1 0.31                 | 1 0.3)                 | 1 0.3)                 | 0                      |
| Blood and lynphatic system disorders      | 1 0.3)               | 0                    | 0                    | 9 [ 2.9)               | 9 2.9)                 | 0                      | 5 1.6)                 | 5 1.6)                 | 口                      |
| Anaemia.                                  | 口                    | 0                    | 0                    | 34 [ 1.01              | m4 1.0)                |                        | NN 9.71                | 9.71                   |                        |
| Febrile neutropenia                       | 0                    | 0                    | 0                    | 1.3)                   | 1.3)                   | 00                     | 8.71                   | 0.7)                   | 00                     |
| Cardiac disorders                         | 1 0.3)               | 00                   | 00                   | 00                     | 00                     | 00                     | um 一 1.6) 一 1.0)       | 1.6) 一 0.7)            | 00                     |
| Atrial fibrillation                       | 0                    |                      |                      |                        |                        |                        |                        | 3 1.0)                 |                        |
| Renal and urinary disorders               | 1 0.3)               | 1 0.3)               | 0                    | 8( 2.6)                | 1.6)                   | 口                      | 5( 1.6)                |                        | 口                      |
| Acute kichey injury                       | 1 0.3)               | 1 [ 0.3)             | 0                    | 6( 1.9)                | 4 (1.3)                | 0                      | 3( 1.0)                | 2 0.7)                 | 0                      |

MedDRA Version: 23.1

*Kdereun Apnns go esop 4set tange shep 08 pue asop 1sity ueawneq pe4xodar s4uane sapnlau1

CIC Version 4.0

Source: Table S.6.3.1.2.4

## Deaths

As of the 01-Mar-2021 DBL, the proportions of treated subjects in the nivo + chemo and nivo + ipi arms who died were numerically lower than the chemo arm. Disease progression was the most common cause of death in all 3 arms (Table 40).

Note that only events that led to death within 24 hours were to be documented as Grade 5. Events leading to death &gt;24 hours after onset were to be reported with the worst grade before death. All deaths were required to be reported as an SAE.

<div style=\"page-break-after: always\"></div>

Table 40. Death Summary - All Treated Subjects

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

|                                                                    | Nivo + Ipi N = 322   | Nivo + Chemo N = 310                                                                                                            | Chemotherapy N = 304   | Total N = 936   |
|--------------------------------------------------------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------|
| ­­­                                                                |                      | ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ |                        |                 |
| NUMBER OF SUBJECTS WHO DIED (%) 68.3)                              | 215 ( 66.8)          | 200 ( 64.5)                                                                                                                     | 224 ( 73.7)            | 639 (           |
| PRIMARY REASON FOR DEATH (%)                                       |                      |                                                                                                                                 |                        |                 |
| DISEASE                                                            | 176 ( 54.7)          | 168 ( 54.2)                                                                                                                     | 204 ( 67.1)            | 548 (           |
| 58.5) STUDY DRUG TOXICITY                                          | 5 ( 1.6)             | 5 ( 1.6)                                                                                                                        | 4 ( 1.3)               | 14 (            |
| 1.5) UNKNOWN                                                       | 12 ( 3.7)            | 10 ( 3.2)                                                                                                                       | 8 ( 2.6)               | 30 (            |
| 3.2) OTHER 5.0)                                                    | 22 ( 6.8)            | 17 ( 5.5)                                                                                                                       | 8 ( 2.6)               | 47 (            |
| NUMBER OF SUBJECTS WHO DIED WITHIN 30 DAYS OF LAST DOSE (%) 10.0)  | 45 ( 14.0)           | 29 ( 9.4)                                                                                                                       | 20 ( 6.6)              | 94 (            |
| PRIMARY REASON FOR DEATH (%)                                       |                      |                                                                                                                                 |                        |                 |
| DISEASE                                                            | 28 ( 8.7)            | 15 ( 4.8)                                                                                                                       | 11 ( 3.6)              | 54 (            |
| 5.8) STUDY DRUG TOXICITY                                           | 4 ( 1.2)             | 2 ( 0.6)                                                                                                                        | 3 ( 1.0)               | 9 (             |
| 1.0) UNKNOWN                                                       | 3 ( 0.9)             | 4 ( 1.3)                                                                                                                        | 3 ( 1.0)               | 10 (            |
| 1.1) OTHER 2.2)                                                    | 10 ( 3.1)            | 8 ( 2.6)                                                                                                                        | 3 ( 1.0)               | 21 (            |
| NUMBER OF SUBJECTS WHO DIED WITHIN 100 DAYS OF LAST DOSE (%) 25.1) | 87 ( 27.0)           | 78 ( 25.2)                                                                                                                      | 70 ( 23.0)             | 235 (           |
| PRIMARY REASON FOR DEATH (%)                                       |                      |                                                                                                                                 |                        |                 |
| DISEASE                                                            | 60 ( 18.6)           | 55 ( 17.7)                                                                                                                      | 57 ( 18.8)             | 172 (           |
| 18.4) STUDY DRUG TOXICITY                                          | 5 ( 1.6)             | 4 ( 1.3)                                                                                                                        | 4 ( 1.3)               | 13 (            |
| 1.4) UNKNOWN                                                       | 5 ( 1.6)             | 4 ( 1.3)                                                                                                                        | 4 ( 1.3)               | 13 (            |
| 1.4) OTHER 4.0)                                                    | 17 ( 5.3)            | 15 ( 4.8)                                                                                                                       | 5 ( 1.6)               | 37 (            |

­­­

Source: Table S.6.15.2

## Deaths Attributed to Study Drug Toxicity

Death attributed to study drug toxicity by the investigator was reported as follows:

- Nivo + chemo arm: 5 subjects (1.6%) due to SAEs with reported relationships to study drug:
- o pneumonitis (2 subjects, both reported as related to nivo only)
- o pneumatosis intestinalis (1 subject, reported as related to nivo and chemo)
- o pneumonia (1 subject, reported as related to chemo only)
- o acute kidney injury (1 subject, reported as related to chemo only)
- Nivo + ipi arm: 5 subjects (1.6%), due to the following SAEs reported related to nivo and ipi:
- o pneumonitis (2 subjects)
- o interstitial lung disease (1 subject)
- o pulmonary embolism (1 subject)
- o acute respiratory distress syndrome (1 subject). Note that, while this death was attributed to study drug toxicity and linked to the term of acute respiratory distress

<div style=\"page-break-after: always\"></div>

syndrome, the causality of this fatal SAE was reported on the AE CRF as not related to study therapy by the investigator.

- Chemo arm: 4 subjects (1.3%), due to SAEs reported related to chemo of septic shock, sepsis, acute kidney injury, and pneumonia in 1 subject each.

## Deaths Attributed to Other Reasons

The death module of eCRF lists 4 options as primary cause of death:

1. Disease
2. Study drug toxicity
3. Unknown
4. Other

Typically, investigators select option 'Other' to indicate a primary cause of death that is commonly an outcome of the adverse event due to complications of advanced malignant disease or unrelated conditions.

Deaths attributed to reason reported as 'other' occurred in 17 (5.5%), 22 (6.8%), and 8 (2.6%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively. A review of these deaths was performed by the MAH which showed some consistency between the three treatment arms. Some of them were compatible with complications of advanced esophageal cancer or they were considered as fatal outcomes of unrelated adverse events. However, there were 3 subjects in the nivo + ipi arm and 2 subjects in the chemo arm with a reported drug-related AE with a fatal outcome listed in this group. The most commonly reported cause of death in this list was pneumonia.

There were some changes in the causes of death between the 1-Mar-2021 DBL and the 4-Oct-2021 DBL. In the nivo + ipi arm, two deaths were re-assessed as 'due to drug toxicity' in the latest DBL, one due to internal bleeding and the other one due to pneumonitis. On the contrary, one death caused by acute respiratory syndrome was reassessed and considered not related to treatment within the data update.

## Select Adverse Events

To characterize AEs of special clinical interest that are potentially associated with the use of nivolumab and nivolumab in combination with ipilimumab, the MAH identified select AEs based on the following 4 guiding principles:

- AEs that may differ in type, frequency, or severity from AEs caused by non-immunotherapies
- AEs that may require immunosuppression (eg, corticosteroids) as part of their management
- AEs whose early recognition and management may mitigate severe toxicity
- AEs for which multiple event terms may be used to describe a single type of AE, thereby necessitating the pooling of terms for full characterization

Based on these guiding principles and taking into account the types of AEs already observed across studies of nivolumab monotherapy, select AEs include endocrinopathies, diarrhea/colitis, hepatitis, pneumonitis, interstitial nephritis, and rash. Multiple event terms that may describe each of these were grouped into endocrine, gastrointestinal (GI), hepatic, pulmonary, renal, and skin select AE categories, respectively.

<div style=\"page-break-after: always\"></div>

Hypersensitivity/infusion reactions were analyzed along with the select AE categories because multiple event terms may be used to describe such events and pooling of terms was therefore necessary for full characterization. Hypersensitivity/infusion reactions do not otherwise meet criteria to be considered select AEs.

The majority of select AEs were Grade 1-2 in all treatment arms, and most select AEs were considered drug-related by the investigator. The most frequently reported drug-related select AE categories (any grade) were as follows in each treatment arm:

- Nivo + ipi arm: skin (34.2%), endocrine (27.3%), and hepatic (13.0%)
- Chemo arm: renal (18.8%), gastrointestinal (15.5%), and hepatic (3.9%)

The most frequently reported drug-related select AEs by PT (any grade) were as follows in each treatment arm:

- Nivo + ipi arm: rash (17.1%), hypothyroidism and pruritis (13.4% each), and diarrhoea (9.9%)
- Chemo arm: diarrhoea (15.1%), blood creatinine increased (10.5%), and acute kidney injury (3.3%)

The most frequently reported drug-related serious select AEs by PT (any grade) were as follows in each treatment arm:

- Nivo + ipi arm: pneumonitis (3.7%), adrenal insufficiency (2.2%), and hypophysitis (1.9%)
- Chemo arm: acute kidney injury and diarrhoea (1.0% each), and renal failure (0.7%)

At the time of DBL, with the exception of the endocrine category, the majority of subjects' drug-related select AEs had resolved in the nivo + ipi arm (ranging from 62.5% to 100% across categories). The median time to resolution of drug-related select AEs ranged from 0.14 to 12.14 weeks in the nivo + ipi arm. Some endocrine select AEs were not considered resolved due to the continuing need for hormone replacement therapy (Table 41).

Table 41: Onset, Management, and Resolution of Drug-Related Select AEs - All Subjects Treated with Nivolumab + Ipilimumab (N=322) from CA209648

| Category         | %Treated Subj. with Any Grade/ Grade 3-4 Drug- related Select AEs   | Median Time to Onset of Drug- related Select AEs (range), wks   |   % Treated Subj. with Drug- related Select AEs Leading to DC | %Subj. with Drug-related Select AE Treated with IMM / High- dose Corticosteroi ds a   | Median Time b to Resolution of Drug- related Select AE c,d (range e ), wks   |   %Subj. with Drug- related Select AEs that Resolve d c,d |
|------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------|
| Endocrine        | 27.3 / 5.9                                                          | 8.21 (1.9-72.9)                                                 |                                                           3.4 | 38.6 / 9.1                                                                            | N.E. (0.4+- 154.0+)                                                          |                                                      28.4 |
| Gastrointestinal | 11.8 / 1.6                                                          | 9.14 (0.6-50.3)                                                 |                                                           1.2 | 26.3 / 10.5                                                                           | 2.93 (0.3-79.1+)                                                             |                                                      94.7 |
| Hepatic          | 13.0 / 4.3                                                          | 5.00 (1.0-50.1)                                                 |                                                           2.8 | 31.0 / 21.4                                                                           | 5.14 (1.1-30.9+)                                                             |                                                      88.1 |

<div style=\"page-break-after: always\"></div>

Table 41: Onset, Management, and Resolution of Drug-Related Select AEs - All Subjects Treated with Nivolumab + Ipilimumab (N=322) from CA209648

| Category                    | %Treated Subj. with Any Grade/ Grade 3-4 Drug- related Select AEs   | Median Time to Onset of Drug- related Select AEs (range), wks   |   % Treated Subj. with Drug- related Select AEs Leading to DC | %Subj. with Drug-related Select AE Treated with IMM / High- dose Corticosteroi ds a   | Median Time b to Resolution of Drug- related Select AE c,d (range e ), wks   |   %Subj. with Drug- related Select AEs that Resolve d c,d |
|-----------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------|
| Pulmonary                   | 8.1 / 2.8                                                           | 11.86 (1.9-72.3)                                                |                                                           3.4 | 34.6 / 15.4                                                                           | 12.14 (0.1+- 119.3+)                                                         |                                                      65.4 |
| Renal                       | 2.5 / 0.6                                                           | 7.14 (1.1-47.1)                                                 |                                                           0.6 | 50.0 / 37.5                                                                           | 9.57 (0.7- 142.3+)                                                           |                                                      62.5 |
| Skin                        | 34.2 / 4.0                                                          | 3.93 (0.1-54.3)                                                 |                                                           0.9 | 50.9 / 7.3                                                                            | 11.43 (0.3- 146.6+)                                                          |                                                      70   |
| Hypersensitivity / Infusion | 2.8 / 0                                                             | 0.14 (0.1-10.0)                                                 |                                                           0   | 11.1 / 0                                                                              | 0.14 (0.1-2.1)                                                               |                                                     100   |

MedDRA Version: 23.1. CTC Version 4.0. Includes events reported between first dose and 30 days after last dose of study therapy.

- a Denominator is based on the number of subjects who experienced the event. High dose: dose ≥ 40 mg prednisone or equivalent.

b From Kaplan-Meier estimation.

- c Subjects who experienced select adverse event without worsening from baseline grade were excluded from time to resolution analysis.

d Events without a stop date or with a stop date equal to the death as well as Grade 5 events are considered unresolved.

e Symbol + indicates a censored value.

Source: refer to Table 8.5.1-2 of CA209648 Primary CSR

## Immune-mediated Adverse Events

IMAE analyses included diarrhoea/colitis, hepatitis, pneumonitis, nephritis, renal dysfunction, rash, hypersensitivity/infusion reactions and endocrine events, regardless of causality, occurring within 100 days of the last dose (ie, with extended follow-up). These analyses were limited to subjects who received IMM for treatment of the event, with the exception of endocrine events, which were included in the analysis regardless of treatment since these events are often managed without immunosuppression. In addition, these events were identified by the investigator as IMAEs with no clear alternate etiology, or with an immune-mediated component.

The total number of subjects with all-causality any grade IMAEs in the nivo + ipi and chemo arms were 131 (40.7%) and 3 (1.0%), respectively. Overall, the majority of IMAEs were Grade 1-2. The most frequently reported IMAEs by category were as follows in each treatment arm:

- Nivo + ipi arm (any Grade): hypothyroidism/thyroiditis (15.5%), rash (13.7%), hypophysitis (6.5%), hyperthyroidism (5.9%), adrenal insufficiency (5.6%), hepatitis (4.0%), pneumonitis (3.7%), and diarrhea/colitis (3.4%)

<div style=\"page-break-after: always\"></div>

- o Proportion of subjects with Grade 3-4 IMAEs, by category: hypophysitis (3.1%); rash (2.5%); hepatitis (2.8%); pneumonitis and adrenal insufficiency (2.2% each); diarrhea/colitis (1.2%); nephritis/renal dysfunction, diabetes mellitus, and hyperthyroidism (0.6% each)
- Chemo arm (any Grade): rash (0.7%)
- o Proportion of subjects with Grade 3-4 IMAEs, by category: rash (0.3%)

Across IMAE categories, the majority of events were manageable using established management algorithms, with resolution occurring when IMMs (mostly systemic corticosteroids) were administered (Table 42). Some subjects' endocrine IMAEs were not considered resolved due to the continuing need for hormone replacement therapy.

Re-challenge information was also summarized for subjects who continued to receive nivo + ipi treatment after the onset of an IMAE. Subjects who were rechallenged were subjects with study therapy re-initiated on or after symptom improvement/resolution. A positive re-challenge/recurrence was defined as any occurrence of new event(s) or worsening of any severity grade IMAE on or after study therapy re-initiation.

Table 42: Onset, Management, and Resolution of All-Causality IMAEs within 100 days of Last Dose - All Subjects Treated with Nivolumab + Ipilimumab (N=322) from CA209648

| IMAE Category                | % Subj. with Any Grad e/ Grad e 3-4 IMAE s   | Media n Time to IMAE Onset (rang e), wks   | % Subj. with IMAE leadi ng to DC / Dose Dela y   | %Subj. with IMAEs Receiving IMM / High-dose Corticoster oids a   | Media n Durati on IMM (rang e), wks   |   % Subj. with Resolut ion of IMAE b,c, d | Median e Time to Resolut ion (range f ), wks   | %Subj. with Recurren ce after Reinitiati on g (n/N)   |
|------------------------------|----------------------------------------------|--------------------------------------------|--------------------------------------------------|------------------------------------------------------------------|---------------------------------------|-------------------------------------------|------------------------------------------------|-------------------------------------------------------|
| Pneumonitis                  | 3.7 / 2.2                                    | 11.00 (3.6- 36.6)                          | 2.8 / 0.3                                        | 100 / 50.0                                                       | 3.64 (0.1- 115.3)                     |                                      50   | 13.71 (0.3+- 117.1+)                           | 0 (0/0)                                               |
| Diarrhea/Co litis            | 3.4 / 1.2                                    | 9.43 (1.7- 37.1)                           | 1.2 / 1.6                                        | 100 / 36.4                                                       | 8.14 (0.6- 112.9)                     |                                     100   | 13.57 (0.7- 25.3)                              | 66.7 (2/3)                                            |
| Hepatitis                    | 4.0 / 2.8                                    | 4.29 (2.1- 64.3)                           | 1.9 / 2.2                                        | 100 / 69.2                                                       | 6.71 (0.1- 69.1)                      |                                      84.6 | 8.14 (1.3- 30.1)                               | 33.3 (1/3)                                            |
| Nephritis/R enal Dysfunction | 1.2 / 0.6                                    | 7.21 (4.1- 13.0)                           | 0 / 0.6                                          | 100 / 75.0                                                       | 4.43 (2.6- 10.9)                      |                                      75   | 9.57 (0.9- 14.1)                               | 100 (2/2)                                             |
| Rash                         | 13.7 / 2.5                                   | 5.07 (0.3- 80.0)                           | 0.6 / 2.8                                        | 100 / 20.5                                                       | 5.57 (0.1- 129.6)                     |                                      68.2 | 11.86 (0.3- 122.1+)                            | 37.5 (3/8)                                            |
| Hypersensiti vity            | 0.3 / 0                                      | 2.14 (2.1- 2.1)                            | 0 / 0                                            | 100 / 0                                                          | 0.14 (0.1- 0.1)                       |                                     100   | 0.14 (0.1- 0.1)                                | 0 (0/0)                                               |
| Adrenal Insufficienc y       | 5.6 / 2.2                                    | 14.71 (6.1- 72.9)                          | 1.6 / 2.8                                        | 77.8 / 5.6                                                       | 65.36 (0.6- 143.9)                    |                                      16.7 | N.A. (0.7- 144.7+)                             | 0 (0/4)                                               |

<div style=\"page-break-after: always\"></div>

Table 42: Onset, Management, and Resolution of All-Causality IMAEs within 100 days of Last Dose - All Subjects Treated with Nivolumab + Ipilimumab (N=322) from CA209648

| IMAE Category                | % Subj. with Any Grad e/ Grad e 3-4 IMAE s   | Media n Time to IMAE Onset (rang e), wks   | % Subj. with IMAE leadi ng to DC / Dose Dela y   | %Subj. with IMAEs Receiving IMM / High-dose Corticoster oids a   | Media n Durati on IMM (rang e), wks   |   % Subj. with Resolut ion of IMAE b,c, d | Median e Time to Resolut ion (range f ), wks   | %Subj. with Recurren ce after Reinitiati on g (n/N)   |
|------------------------------|----------------------------------------------|--------------------------------------------|--------------------------------------------------|------------------------------------------------------------------|---------------------------------------|-------------------------------------------|------------------------------------------------|-------------------------------------------------------|
| Hypophysiti s                | 6.5 / 3.1                                    | 12.00 (2.7- 63.3)                          | 0.9 / 4.3                                        | 81.0 / 23.8                                                      | 65.14 (3.1- 142.0)                    |                                      23.8 | N.A. (1.9- 142.0+)                             | 0 (0/5)                                               |
| Hypothyroid ism/ Thyroiditis | 15.5 / 0.3                                   | 7.86 (2.1- 36.4)                           | 0.6 / 3.1                                        | 10.0 / 2.0                                                       | 30.71 (2.3- 92.0)                     |                                      26   | N.A. (0.6- 148.7+)                             | 33.3 (1/3)                                            |
| Hyperthyroi dism             | 5.9 / 0.6                                    | 6.14 (1.9- 16.3)                           | 0.3 / 1.2                                        | 10.5 / 5.3                                                       | 5.21 (3.3- 7.1)                       |                                      78.9 | 7.36 (0.4+- 48.4+)                             | 0 (0/3)                                               |
| Diabetes Mellitus            | 1.6 / 0.6                                    | 39.29 (4.3- 59.4)                          | 0.6 / 0.9                                        | 0 / 0                                                            | N.A. (N.A.- N.A.)                     |                                       0   | N.A. (11.0+- 138.6+)                           | 0 (0/1)                                               |

MedDRA Version: 23.1. CTC Version 4.0. Includes events reported between first dose and 100 days after last dose of study therapy.

a Denominator is based on the number of subjects who experienced the event. High dose: dose ≥ 40 mg prednisone or equivalent.

b Subjects who experienced IMAE without worsening from baseline grade were excluded from time to resolution analysis.

c Events without a stop date or with a stop date equal to the death as well as Grade 5 events are considered unresolved.

d For each subject, the longest duration of immune-mediated AEs where immune modulation is considered.

e From Kaplan-Meier estimation.

f Symbol + indicates a censored value.

g Percentages  of  subjects  with  recurrence  are  based  on  subjects  who  were  re-challenged.  A  positive  rechallenge/recurrence is defined as any occurrence of new event(s) or worsening of any severity grade IMAE on or after study therapy re-initiation. Subjects who were rechallenged are subjects with study therapy re-initiated on or after symptom improvement/resolution.

Source: refer to Table 8.5.2-2 of CA209648 Primary CSR

## Other Events of Special Interest

OESIs do not fulfill all criteria to qualify as IMAEs but may require immunosuppression as part of their management.

Among all treated subjects, OESIs (regardless of causality or IMM treatment, with extended follow-up) were infrequent, and most events resolved by the time of DBL (Table 43):

- Nivo + chemo arm: OESIs were reported in 4 subjects (6 events), of which 4 events resolved. 2 of these events were resolved with IMMs.
- Nivo + ipi arm: OESIs were reported in 14 subjects (23 events), of which 19 events resolved. 11 of these events were resolved with IMMs.
- Chemo arm: no OESIs were reported.

<div style=\"page-break-after: always\"></div>

Table 43. Treatment, Onset, and Resolution Information for Other Events of Special Interest - All Treated Subjects

| OESI Category Grade,Relationship to Study Therapy, PT   | Immune-modulating Medication     | Onset Date (Study Day)   | Duration of Event (Days)   | Resolution (Yes/No)   |
|---------------------------------------------------------|----------------------------------|--------------------------|----------------------------|-----------------------|
| Nivolumab+Chemotherapy                                  |                                  |                          |                            |                       |
| Uveitis                                                 |                                  |                          |                            |                       |
| Grade 2 drug-related AE uveitis                         | betamethasone sodium phosphate   | 21-Feb-2020 (172)        | 32                         | 人                     |
| Grade 2 drug-related AE uveitis                         | betamethasone sodium phosphate   | 06-Aug-2019 (672)        | ongoing                    | N                     |
| Rhabdomyolysis                                          |                                  |                          |                            |                       |
| Grade 3 SAE rhabdomyolysis                              | none                             | 08-Dec-2019 (115)        | 16                         |                       |
| Grade 1 AE rhabdomyolysis                               | none                             | 23-Dec-2019 (130)        | 110                        | 人                     |
| Myositis                                                |                                  |                          |                            |                       |
| Grade 2 SAE myositis                                    | thalidomide, methylprednisolone  | 06-Sep-2019 (28)         | 55                         |                       |
| Grade 1 AE myositis                                     | thalidomide, methylprednisolone  | 30-0ct-2019 (82)         | ongoing                    | N                     |
| Nivolumab+Ipilimumab                                    |                                  |                          |                            |                       |
| Pancreatitis                                            |                                  |                          |                            |                       |
| Grade 3 drug-related SAE pancreatitis                   | prednisolone                     | 08-Feb-2016 (16)         | 45                         |                       |
| Grade 3 SAE pancreatitis                                | none                             | 29-Sep-2020 (649)        | 14                         | 人                     |
| Grade 4 drug-related AE acute pancreatitis              | methylprednisolone               | 11-Aug-2020 (330)        | 2                          | 人                     |
| Grade 3 drug-related AE acute pancreatitis              | prednisone                       | 13-Aug-2020 (332)        | 70                         |                       |
| Grade 2 drug-related SAE pancreatitis                   | methylprednisolone, prednisone   | 03-Feb-2020 (56)         | 3                          | 人                     |
| Grade 3 drug-related SAE pancreatitis                   | prednisolone                     | 04-Mar-2020 (169)        | 13                         | 人                     |
| Myoearditis                                             |                                  |                          |                            |                       |
| Grade 1 drug-related AE myocarditis                     | prednisone                       | 15-Jan-2019 (161)        | ongoing                    | N                     |
| Grade l drug-related AE myocarditis                     | none                             | 24-May-2018 (28)         | 39                         | 1                     |
| OESI Category Grade, Relationship to Study Therapy, PT  | Immune-modulating Medication     | Onset Date (Study Day)   | Duration of Event (Days)   | Resolution (Yes/No)   |
| Nivolumab+Ipilimumab                                    |                                  |                          |                            |                       |
| Uveitis                                                 |                                  |                          |                            |                       |
| Grade 4 drug-related AE uveitis                         | methylprednisolone, prednisone   | 03-Aug-2020 (244)        | 5                          | 人                     |
| Grade 3 drug-related AE uveitis                         | prednisone                       | 08-Aug-2020 (249)        | 13                         | 人                     |
| Grade 2 drug-related AE uveitis                         | prednisone                       | 21-Aug-2020 (262)        | ongoing                    | N                     |
| Grade 2 drug-related SAE Vogt-Koyanagi-Harada disease   | prednisolone                     | 15-Mar-2019 (18)         | 11                         | 人                     |
| Grade 1 drug-related AE Vogt-Koyanagi-Harada disease    | prednisolone                     | 26-Mar-2019 (29)         | ongoing                    | N                     |
| Encephalitis                                            |                                  |                          |                            |                       |
| Grade 4 drug-related SAE encephalitis                   | methylprednisolone               | 01-Sep-2018 (73)         | 44                         | 人                     |
| Grade 2 drug-related SAE encephalitis                   | none                             | 17-Jan-2018 (114)        | 9                          | 人                     |
| Grade 3 drug-related SAE encephalitis                   | none                             | 26-Jan-2018 (123)        | 3                          | 人                     |
| Grade 4 drug-related SAE encephalitis                   | prednisolone                     | 29-Jan-2018 (126)        | 99                         | 人                     |
| Grade 4 drug-related SAE immune-mediated encephalopathy | none                             | 07-Dec-2018 (203)        | 245                        | 人                     |
| Myositis                                                |                                  |                          |                            |                       |
| Grade 1 drug-related AE myositis                        | none                             | 21-May-2018 (33)         | 10                         | 人                     |
| Grade 2 drug-related SAE myositis                       | prednisolone, methylprednisolone | 31-May-2018 (43)         | 19                         | 人                     |
| Grade l drug-related AE myositis                        | prednisolone                     | 18-Jum-2018 (61)         | ongoing                    | N                     |
| Grade 2 drug-related AE myositis                        | none                             | 24-May-2018 (28)         | 2                          | 人                     |
| Grade 1 drug-related AE myositis                        | none                             | 26-May-2018 (30)         | 37                         | 人                     |

All events are within 100 days of the last dose of study drug.

* Event assessed as not related

# No safety narrative available for Subject CA209648 -xxx-xxx as the events of myocarditis and myositis were reported as non-serious AEs.

Source: refer to Table 8.5.3 - 1 of CA209648 Primary CSR

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Laboratory abnormalities (hematology, liver tests, kidney function tests, and electrolytes) were primarily Grade 1-2 in severity and reflected the known laboratory abnormalities associated with the different treatment regimens.

Laboratory test results for all treated subjects are summarized by worst CTC Grade (Grade 1-4 and Grade 3-4) for laboratory parameters that worsened relative to baseline in Table 44 (30-day follow-up, SI units):

Table 44. Summary of On-Treatment Worst CTC Grade (Grade 1-4 and Grade 3-4) Laboratory Parameters that Worsened Relative to Baseline - 30 Days Follow Up - SI Units All Treated Subjects

|                           | Number of Subjects (8)   | Number of Subjects (8)   | Number of Subjects (8)   | Number of Subjects (8)   | Number of Subjects (8)   | Number of Subjects (8)   | Number of Subjects (8)   | Number of Subjects (8)   | Number of Subjects (8)   |
|---------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                           | Nivo + Ipi               | Nivo + Ipi               | Nivo + Ipi               | Nivo + Chemo             | Nivo + Chemo             | Nivo + Chemo             | Chemotherapy             | Chemotherapy             | Chemotherapy             |
| Leb Test Description      | N(A)                     | Grade 1-4                | Grade 3-4                | N(A)                     | Grade 1-4                | Grade 3-4                | N(A)                     | Grade 1-4                | Grade 3-4                |
| HEMOGLOBIN (B)            | 307                      | 160 ( 52.1)              | 20( 6.5)                 | 304                      | 246 ( 80.9)              | 65 (21.4)                | 283                      | 186 ( 65.7)              | 39 (13.8)                |
| PLATELET COUNT            | 307                      | 36 ( 11.7)               | 31 1.0)                  | 304                      | 132 ( 43.4)              | 10 ( 3.3)                | 283                      | 83 ( 29.3)               | 8 (2.8)                  |
| LEUKOCYTES                | 308                      | 27 (8.8)                 | 4 1.3)                   | 305                      | 163 ( 53.4)              | 33 (10.8)                | 282                      | 110 ( 39.0)              | 15 ( 5.3)                |
| LYMPHOCYTES (ABSOLUTE)    | 308                      | 155 ( 50.3)              | 39 ( 12.7)               | 305                      | 205 ( 67.2)              | 71 (23.3)                | 282                      | 124 ( 44.0)              | 23[ 8.2)                 |
| ABSOLUTENEUTROPHILCOUNT   | 308                      | 41 ( 13.3)               | 4 [ 1.3)                 | 305                      | 187 (61.3)               | 54 17.7)                 | 282                      | 135 ( 47.9)              | 38 ( 13.5)               |
| AIKALINE PHOSPHATASE      | 305                      | 96 ( 31.5)               | 10 3.3)                  | 305                      | 78 ( 25.6)               | 4 1.3)                   | 278                      | 43  ( 15.5)              | 0                        |
| ASPARTATEAMINOTRANSEERASE | 306                      | 120 (39.2)               | 17 5.6)                  | 305                      | 70 (23.0)                | 10 3.3)                  | 280                      | 31 ( 11.1)               | 4[ 1.4)                  |
| ALANINEAMTNOTRANSEERASE   | 306                      | 102 (33.3)               | 18 5.9)                  | 305                      | 70 ( 23.0)               | 2.3)                     | 281                      | 23 (8.2)                 | 2 ( 0.7)                 |
| BILIRUBIN, TOTAL          | 305                      | 32 ( 10.5)               | 0.7)                     | 305                      | 19 (6.2)                 | 1( 0.3)                  | 280                      | 10 ( 3.6)                | 0                        |
| CREATININE                | 305                      | 47 ( 15.4)               | 2( 0.7)                  | 304                      | 125  ( 41.1)             | 7( 2.3)                  | 283                      | 86 ( 30.4)               | 2[ 0.7)                  |
| HYPERNATREMIA             | 305                      | 13 (4.3)                 | 2( 0.7)                  | 304                      | 27 (8.9)                 | 2 0.7)                   | 281                      | 15 (5.3)                 | 1[ 0.4)                  |
| HYPONATREMIA              | 305                      | 141 (46.2)               | 36 (11.8)                | 304                      | 157 ( 51.6)              | 45 14.8)                 | 281                      | 114 ( 40.6)              | 25 ( 8.9)                |
| HYPERKALEMIA              | 305                      | 68 (22.3)                | 5 1.6)                   | 305                      | 103  ( 33.8)             | 2.3)                     | 281                      | 66 ( 23.5)               | 2( 0.7)                  |
| HYPOKAIEMTA               | 305                      | 62 2( 20.3)              | 16 5.2)                  | 305                      | 88 (28.9)                | 29 9.5)                  | 281                      | 48 ( 17.1)               | 17 ( 6.0)                |
| HYPERCALCEMIA             | 298                      | 45 ( 15.1)               | 61 2.0)                  | 304                      | 36 ( 11.8)               | 9 3.0)                   | 274                      | 23 (8.4)                 | 1( 0.4)                  |
| HYPOCALCEMIA              | 298                      | 97( 32.6)                | 0                        | 304                      | 138 ( 45.4)              | 3.0)                     | 274                      | 63 ( 23.0)               | 2[ 0.7)                  |
| HYPERMAGNESEMIA           | 59                       | 5 (8.5)                  | 1( 1.71                  | 60                       | 5 (8.3)                  | 0                        | 56                       | 1 (1.8)                  | 0                        |
| HYFOMAGNESEMIA            | 59                       | 11 (18.6)                | 0                        | 60                       | 22 ( 36.7)               | 1( 1.7)                  | 56                       | 15 ( 26.8)               | 1( 1.8)                  |
| HYPERGLYCEMIA             | 138                      | 59 ( 42.8)               | 4.3)                     | 143                      | 49 ( 34.3)               | 0                        | 118                      | 42 ( 35.6)               | 1 ( 0.8)                 |
| HYFOGLYCEMIA              | 243                      | 38 (15.6)                | 3( 1.2)                  | 246                      | 44 ( 17.9)               | 1( 0.4)                  | 213                      | 15 ( 7.0)                | 0                        |

Toxicity Scale: CIC version 4.0.

Includes laboratory results regorted between first dose and last dose of therapy + 30 days

Percentages are based on N as denominator.

'queuneara-uo pue autleseg 4noq wpng xeaeweted uantb eua 1og 4tnsed Aioqetoqel pepeno 2io e 4eTm saoeloms 1N (h

(B) Per Anemia criteria. in CiC version 4.0 there is no grade 4 for hemogldbin.

Source: Appendix GI.Sa-USPI.2.2

## Hematology

Abnormalities in hematology test reported during treatment or within 30 days of last dose of study drug were primarily Grade 1 or 2 in severity. Grade 3-4 hematologic abnormalities that worsened from baseline reported in ≥ 5% of subjects were as follows:

- Nivo + chemo arm: decreased lymphocytes (23.3%), decreased hemoglobin (21.4%), decreased absolute neutrophil count (17.7%), and decreased leukocytes (10.8%)
- Nivo + ipi arm: decreased lymphocytes (12.7%), and decreased hemoglobin (6.5%)
- Chemo arm: decreased hemoglobin (13.8%), decreased absolute neutrophil count (13.5%), decreased lymphocytes (8.2%), and decreased leukocytes (5.3%)

<div style=\"page-break-after: always\"></div>

## Serum Chemistry

## Liver Tests

During the treatment period, abnormalities (increases) in hepatic parameters (alkaline phosphatase [ALP], aspartate aminotransferase [AST], alanine aminotransferase [ALT], and total bilirubin) were primarily Grade 1-2 in each treatment arm. Grade 3-4 hepatic abnormalities that worsened from baseline occurred at higher frequencies in the nivo + ipi arm, though the overall frequencies were &lt;6% of subjects across the treatment arms:

- Nivo + chemo arm: ALP (1.3%), AST (3.3%), ALT (2.3%), total bilirubin (0.3%)
- Nivo + ipi arm: ALP (3.3%), AST (5.6%), ALT (5.9%), total bilirubin (0.7%)
- Chemo arm: AST (1.4%), ALT (0.7%)

Concurrent ALT or AST &gt;3×ULN with total bilirubin &gt;2×ULN within 1 day and within 30 days, based on laboratory results reported after the first dose and within 30 days of last dose of study therapy, was reported in 2/305 (0.7%), 3/306 (1.0%), and 0 subjects with test results in the nivo + chemo, nivo + ipi, and chemo arms, respectively (Table 45).

Table 45. On-Treatment Laboratory Abnormalities in Specific Liver Tests (SI Units) - All Treated Subjects

| Ahnomality (t)                                                                                            | Nivo + Ipi N = 322   | Nivo + Chemo N = 310   | Chemotherapy N = 304   | Total N = 936   |
|-----------------------------------------------------------------------------------------------------------|----------------------|------------------------|------------------------|-----------------|
|                                                                                                           | N = 306              | N = 305                | N = 282                | 868 = N         |
| ALT OR AST >3XUIN                                                                                         | 0 ( 13.1)            | 22 7.2)                | 2.5)                   | 69 7.7)         |
| ALT OR AST > SXUIN                                                                                        | 22 (7.2)             | 12 3.9)                | 1.8)                   | 39 4.4)         |
| ALT OR AST > 10XUIN                                                                                       | 5 (1.6)              | 3 1.0)                 | 00                     | （ 0.9)          |
| ALT OR AST > 20XULN                                                                                       | 2 ( 0.7)             | 1 (0.3)                |                        | 3(0.3)          |
|                                                                                                           | N = 306              | N = 305                | N = 281                | N = 892         |
| TOTALBILIRUBIN>2XULN                                                                                      | 7(2.3)               | 3 (1.0)                | 1 (0.4)                | 11 (1.2)        |
|                                                                                                           | N = 305              | N = 305                | N = 280                | N = 890         |
| ALP >1.SXULN                                                                                              | 69(22.6)             | 48 (15.7)              | 29 ( 10.4)             | 146 ( 16.4)     |
|                                                                                                           | N = 306              | N = 305                | N = 280                | N = 891         |
| CONCURRENTALTORASTELEVATION>3XULNWITHTOTAL BILIRUBIN >1.SXULNWITHIN ONE DAY                               | 3 (1.0)              | 4 (1.3)                | 0                      | 7 (0.8)         |
| CONCURRENTALTORASTELEVATION>3XULNWITHTOTAL                                                                | 3 ( 1.0)             | 41 1.3)                | 0                      | 71 0.8)         |
| BILIRUBIN>1.SXUINWITHIN3ODAYS CONCURRENTALT ORASTEIEVATION>3XULN WITH TOTAL BILIRUBIN >2XUINWITHIN ONEDAY | 3( 1.0)              | 2( 0.7)                | 0                      | 5( 0.6)         |
| CONCURRENTALT OR AST EIEVATION>3XULNWITH TOTAL                                                            | 3( 1.0)              | 21 0.7)                | 0                      | 5( 0.6)         |
| BILIRUBIN>2XULNWITHIN3O DAYS                                                                              |                      |                        |                        |                 |

Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy. Dencminator corresponds to subjects with at least cne on-treatment measurement of the corresponding laboratory parameter Souwce: Table S.7.6.2.2

## Kidney Function Tests

Most subjects with at least 1 on-treatment measurement had normal creatinine values during the treatment reporting period. The abnormalities in creatinine (increases from baseline) were primarily reported as Grade 1 or 2, with Grade 3-4 creatinine (increased) (SI units) reported in 7 (2.3%), 2 (0.7%), and 2 (0.7%) subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively.

## Thyroid Function Tests

The majority of all treated subjects in each treatment arm had normal TSH levels at baseline and throughout the treatment period. TSH (SI units) increases (&gt;ULN) from baseline ( ≤ ULN) were reported in 60 (20.5%), 61 (22.8%), and 9 (7.6%) of subjects in the nivo + chemo, nivo + ipi, and chemo treatment arms, respectively (Table 46). Decreases (&lt;LLN) from baseline ( ≤ LLN) were reported in 35

<div style=\"page-break-after: always\"></div>

(12.0%), 61 (22.8%), and 12 (10.2%) of subjects in the nivo + chemo, nivo + ipi, and chemo treatment arms, respectively.

Table 46. Summary of Laboratory Abnormalities in Specific Thyroid Tests (SI Units) - All Treated Subjects with at Least One On-Treatment TSH Measurement

| Ahnomality (t)                                                                        | Nivo + Ipi N = 267   | Nivo + Chemo N = 292   | Chemotherapy N = 118   | Total N = 677      |
|---------------------------------------------------------------------------------------|----------------------|------------------------|------------------------|--------------------|
|                                                                                       | 83 ( 31.1)           | 84( 28.8)              | 21 ( 17.8)             | 188 ( 27.8)        |
| WITH TSH <= UIN AT BASELINE TSH >UIN                                                  | 61(22.8)             | 60 (20.5)              | 7.6)                   | 130 ( 19.2)        |
| WITH AT IEAST ONE FT3/FT4 TEST VALUE <LIN (A) WITHALLOTHER FT3/FT4TEST VALUES>=LIN(A) | 48 18.0) 23 8.6)     | 45 (15.4) 29 9.9)      | 7 5.9) 11 9.3)         | 100 (14.8) 63 9.31 |
|                                                                                       |                      |                        | 15 ( 12.7)             |                    |
| WITH FT3/FT4 TEST MISSING (A) (B)                                                     | 12 4.5)              | 10 3.4)                | 3 2.5)                 | 25 3.7)            |
| NTI > HSI                                                                             | 74( 27.7)            | 40( 13.7)              |                        | 129 (19.1)         |
| NTI > HSL WITHTSH>=LINATBASELINE                                                      | 61 ( 22.8)           | 35 ( 12.0)             | 12 ( 10.2)             | 108 ( 16.0)        |
| TSH < LIN WITH AT IEAST ONE FT3/FT4 TEST VALUE >ULN (A)                               | 36 (13.5) 28 10.51   | 19 6.5) 14 4.8) 7      | 3 2.5) 10 8.5)         | 58 8.6) 52 7.71    |
| WITH ALL OTHER FT3/FT4 TEST VALUES <= UIN (A)                                         |                      |                        |                        |                    |
| WITH FT3/FT4 TEST MISSING (A) (B)                                                     | 10 (3.7]             | 2.4)                   | 2 1.7)                 | 19 2.8)            |

Includes laboratory results reported after the\\_first dose and within 30 days of last dose of stucdy therapy.

(B) Includes subjects with TSH abnormality and with no FT3/FT4 test values in the 2-week window or with non-abnomal value (s) from only one of the two tests and no value from the other test.

[A)Within a 2-week window after the abnormal TSH test date.

Source: Table S.7.6.2.1

## Electrolytes

Most subjects had normal electrolyte levels during the treatment reporting period. Abnormalities in electrolytes during treatment were primarily Grade 1 to 2 in severity. The following Grade 3-4 abnormalities (SI) in electrolytes from baseline were reported in ≥ 5% of treated subjects with ontreatment laboratory results:

- Nivo + chemo arm: hyponatremia (14.8%) and hypokalemia (9.5%)
- Nivo + ipi arm: hyponatremia (11.8%) and hypokalemia (5.2%)
- Chemo arm: hyponatremia (8.9%) and hypokalemia (6.0%)

## Safety in special populations

In the nivo + ipi vs chemo arms, frequencies of subjects with all-causality (Table 47) and drug-related AEs (Table 48) in the subgroups of sex, age category, race, and region were comparable overall to the frequencies of subjects with AE reported for the overall study populations by arm.

## Sex

Frequencies of all-causality AEs and drug-related AEs overall were comparable by sex in each treatment arm, with the exception of a numerically higher frequency of all-causality AEs reported for females (69.1%) vs males (57.7%) in the nivo + ipi arm.

## Race

Frequencies of subjects with all-causality AEs and drug-related AEs were comparable between Asians and non-Asians in each treatment arm.

## Age Category

Frequencies of all-causality and drug-related AEs were comparable by age category (&lt; 65, ≥ 65 - &lt;75, ≥ 75 - &lt;85, ≥ 65, ≥ 75, and ≥ 85 years) within each treatment arm, with the exception of numerically higher proportions of chemo-treated subjects with all-causality and drug-related Grade 3-4 AEs, respectively, in the ≥ 65 (61.1% and 44.3%) vs &lt;65 (47.7% and 27.1%) categories.

<div style=\"page-break-after: always\"></div>

Interpretation of safety data from the ≥ 75 and ≥ 85 age categories is limited by small sample sizes. The frequencies of AEs for subgroups of age &lt;65 (N=164), 65 to 74 (N=117), and 75 to 84 years (N=26) were similar to the frequencies reported for the overall population (N=310), with these exceptions:

- The 75-84 years subgroup had higher frequency of SAEs (65.4%), fatal events (26.9%), hospitalization/prolongation (61.5%), accident and injuries (19.2%), and cardiac disorders (11.5%) compared to the overall population (58.1%, 11.9%, 54.8%, 9.0%, and 5.2%, respectively), and lower frequency of psychiatric disorders (11.5%) compared to overall population (20.3%).

## Region

Frequencies of all-causality and drug-related Grade 3-4 AEs were numerically lower among subjects from Rest of Asia compared to East Asia and Rest of World within treatment arms:

- Frequencies of all-causality and drug-related Grade 3-4 AEs, respectively, in nivo +chemo arm: Rest of Asia (N = 42; 54.8% and 33.3%), East Asia (N = 178; 74.2% and 49.4%), and Rest of World (N = 90; 67.8% and 50.0%)
- Frequencies of all-causality and drug-related Grade 3-4 AEs, respectively, in nivo +ipi arm: Rest of Asia (N = 44; 50.0% and 27.3%), East Asia (N = 184; 60.9% and 30.4%), and Rest of World (N = 94; 61.7% and 36.2%)

Table 47. Summary of All-causality Adverse Events by Worst CTC Grade and by Demographic Subgroup - All Treated Subjects

|              | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|--------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|              | Nivo + Ipi            | Nivo + Ipi            | Nivo + Ipi            | Nivo + Ipi            | Nivo + Chemo          | Nivo + Chemo          | Nivo + Chemo          | Nivo + Chemo          | Chemo                 | Chemo                 | Chemo                 | Chemo                 |
|              | N                     | Any Grade             | Grade 3-4             | Grade 5               | N                     | Any Grade             | Grade 3-4             | Grade 5               | N                     | Any Grade             | Grade 3-4             | Grade 5               |
| Total        | 322                   | 316 (98.1)            | 192 (59.6)            | 31 (9.6)              | 310                   | 308 (99.4)            | 216 (69.7)            | 23 (7.4)              | 304                   | 301 (99.0)            | 165 (54.3)            | 14 (4.6)              |
| Sex          |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |
| Female       | 55                    | 55 (100.0)            | 38 (69.1)             | 4 (7.3)               | 66                    | 65 (98.5)             | 47 (71.2)             | 3 (4.5)               | 44                    | 44 (100.0)            | 26 (59.1)             | 2 (4.5)               |
| Male         | 267                   | 261 (97.8)            | 154 (57.7)            | 27 (10.1)             | 244                   | 243 (99.6)            | 169 (69.3)            | 20 (8.2)              | 260                   | 257 (98.8)            | 139 (53.5)            | 12 (4.6)              |
| Age Category |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |
| 65           | 182                   | 180 (98.9)            | 113 (62.1)            | 12 (6.6)              | 164                   | 163 (99.4)            | 113 (68.9)            | 9 (5.5)               | 155                   | 153 (98.7)            | 74 (47.7)             | 9 (5.8)               |
| 265-≤75      | 116                   | 112 (96.6)            | 64 (55.2)             | 18 (15.5)             | 117                   | 116 (99.1)            | 83 (70.9)             | 9 (7.7)               | 125                   | 125 (100.0)           | 74 (59.2)             | 3 (2.4)               |
| ≥75-≤85      | 24                    | 24 (100.0)            | 15 (62.5)             | 1 (4.2)               | 26                    | 26 (100.0)            | 18 (69.2)             | 5 (19.2)              | 24                    | 23 (95.8)             | 17 (70.8)             | 2 (8.3)               |
| ≥65          | 140                   | 136 (97.1)            | 79 (56.4)             | 19 (13.6)             | 146                   | 145 (99.3)            | 103 (70.5)            | 14 (9.6)              | 149                   | 148 (99.3)            | 91 (61.1)             | 5 (3.4)               |
| ≥75          | 24                    | 24 (100.0)            | 15 (62.5)             | 1 (4.2)               | 29                    | 29 (100.0)            | 20 (69.0)             | 5 (17.2)              | 忆                     | 23 (95.8)             | 17 (70.8)             | 2 (8.3)               |
| ≥85          | 0                     | N.A.                  | N.A.                  | N.A.                  | 3                     | 3 (100.0)             | 2 (66.7)              | 0                     | 0                     | N.A.                  | N.A.                  | N.A.                  |
| Race         |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |
| Asian        | 230                   | 226 (98.3)            | 136 (59.1)            | 16 (7.0)              |                       | 222 (100.0)           | 157 (70.7)            | 12 (5.4)              | 214                   | 212 (99.1)            | 115 (53.7)            | 7 (3.3)               |
| Non-Asian    | 92                    | 90 (97.8)             | 56 (60.9)             | 15 (16.3)             | 88                    | 86 (97.7)             | 59 (67.0)             | 11 (12.5)             | 90                    | 89 (98.9)             | 50 (55.6)             | 7 (7.8)               |
| Region       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |                       |
| East Asia    | 184                   | 180 (97.8)            | 112 (60.9)            | 12 (6.5)              | 178                   | 178 (100.0)           | 132 (74.2)            | 11 (6.2)              | 176                   | 175 (99.4)            | 94 (53.4)             | 2 (1.1)               |
| Rest of Asia | 44                    | 44 (100.0)            | 22 (50.0)             | 4 (9.1)               | 42                    | 42 (100.0)            | 23 (54.8)             | 1 (2.4)               | 37                    | 36 (97.3)             | 19 (51.4)             | 5 (13.5)              |
| RoW          | 94                    | 92 (97.9)             | 58 (61.7)             | 15 (16.0)             | 06                    | 88 (97.8)             | 61 (67.8)             | 11 (12.2)             | 16                    | 90 (98.9)             | 52 (57.1)             | 7 (7.7)               |

Note: East Asia consists of Japan, Korea, and Taiwan. Rest of Asia consists of China and Hong Kong.

<div style=\"page-break-after: always\"></div>

Table 48. Summary of Drug-related Adverse Events by Worst CTC Grade and by Demographic Subgroup - All Treated Subjects

|              | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   | No.of Subjects(%)   |
|--------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|              | !d1 + 0AIN          | !d1 + 0AIN          | !d1 + 0AIN          | !d1 + 0AIN          | Nivo + Chemo        | Nivo + Chemo        | Nivo + Chemo        | Nivo + Chemo        | Chemo               | Chemo               | Chemo               | Chemo               |
|              | N                   | Any Grade           | Grade 3-4           | Grade 5             | N                   | Any Grade           | Grade 3-4           | Grade 5             | N                   | Any Grade           | Grade 3-4           | Grade 5             |
| Total        | 322                 | 256 (79.5)          | 102 (31.7)          | 2 (0.6)             | 310                 | 297 (95.8)          | 147 (47.4)          | 1 (0.3)             | 304                 | 275 (90.5)          | 108 (35.5)          | 3 (1.0)             |
| Sex          |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Female       | 55                  | 49 (89.1)           | 20 (36.4)           | 0                   | 66                  | 64 (97.0)           | 35 (53.0)           | 0                   | 44                  | 39 (88.6)           | 16 (36.4)           |                     |
| Male         | 267                 | 207 (77.5)          | 82 (30.7)           | 2 (0.7)             | 244                 | 233 (95.5)          | 112 (45.9)          | 1 (0.4)             | 260                 | 236 (90.8)          | 92 (35.4)           | 3 (1.2)             |
| Age Category |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| ≤ 65         | 182                 | 145 (79.7)          | 52 (28.6)           | 1 (0.5)             | 164                 | 156 (95.1)          | 73 (44.5)           | 1 (0.6)             | 155                 | 141 (91.0)          | 42 (27.1)           | 3 (1.9)             |
| ≥65-<75      | 116                 | 91 (78.4)           | 40 (34.5)           | 1 (0.9))            | 117                 | 112 (95.7)          | 59 (50.4)           | 0                   | 125                 | 114 (91.2)          | 56 (44.8)           | 0                   |
| ≥75.≤85      | 24                  | 20 (83.3)           | 10 (41.7)           | 0                   | 26                  | 26 (100.0)          | 13 (50.0)           | 0                   | 24                  | 20 (83.3)           | 10 (41.7)           | 0                   |
| 265          | 140                 | 111 (79.3)          | 50 (35.7)           | 1 (0.7)             | 146                 | 141 (96.6)          | 74 (50.7)           | 0                   | 149                 | 134 (89.9)          | 66 (44.3)           | 0                   |
| ≥75          | 24                  | 20 (83.3)           | 10 (41.7)           | 0                   | 29                  | 29 (100.0)          | 15 (51.7)           | 0                   | 24                  | 20 (83.3)           | 10 (41.7)           | 0                   |
| 85           | 0                   | 0                   | 0                   | 0                   | 3                   | 3 (100.0)           | 2 (66.7)            | 0                   | 0                   | 0                   | 0                   | 0                   |
| Race         |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Asian        | 230                 | 185 (80.4)          | 69 (30.0)           | 1 (0.4)             | 222                 | 215 (96.8)          | 104 (46.8)          | 0                   | 214                 | 198 (92.5)          | 72 (33.6)           | 2 (0.9)             |
| Non-Asian    | 92                  | 71 (77.2)           | 33 (35.9)           | 1 (1.1)             | 88                  | 82 (93.2)           | 43 (48.9)           | 1 (1.1)             | 06                  | 77 (85.6)           | 36 (40.0)           | 1 (1.1)             |
| Region       |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| East Asia    | 184                 | 144 (78.3)          | 56 (30.4)           | 1 (0.5)             | 178                 | 175 (98.3)          | 88 (49.4)           | 0                   | 176                 | 163 (92.6)          | 58 (33.0)           | 1 (0.6)             |
| Rest of Asia | 44                  | 39 (88.6)           | 12 (27.3)           | 0                   | 42                  | 38 (90.5)           | 14 (33.3)           | 0                   | 37                  | 34 (91.9)           | 12 (32.4)           | 1 (2.7)             |
| RoW          | 94                  | 73 (77.7)           | 34 (36.2)           | 1 (1.1)             | 90                  | 84 (93.3)           | 45 (50.0)           | 1 (1.1)             | 91                  | 78 (85.7)           | 38 (41.8)           | 1 (1.1)             |

Note: East Asia consists of Japan, Korea, and Taiwan. Rest of Asia consists of China and Hong Kong.

related AEs by race), Table S.6.1.5.1.4 (drug-related AEs by region)

## Immunogenicity

## Nivolumab + Ipilimumab

Of the 281 nivolumab ADA-evaluable subjects in the nivo + ipi arm, 19 (6.8%) subjects were nivolumab ADA positive at baseline, and 68 (24.2%) subjects were nivolumab ADA positive after start of treatment (Table 49).

- 1 (0.4%) subject was considered persistent positive, and 6 (2.1%) subjects were neutralizing ADA positive.
- Two subjects were positive for nivolumab ADA at baseline, but the titers of post-baseline ADA and neutralizing ADA samples did not exceed ≥ 4-fold titer increase from baseline. Thus, both subjects were not qualified for the definition of ADA-positive or NAb-positive.
- The highest nivolumab ADA titer values observed were 256 and 512, which occurred in 1 subject each. All other titers were low, ranging from 1 to 64.

Of the 282 ipilimumab ADA-evaluable subjects in the nivo + ipi arm, 6 (2.1%) subjects were ipilimumab ADA-positive at baseline and 17 (6.0%) subjects were ipilimumab ADA-positive after the start of treatment (Table 49).

- 1 (0.4%) subject was considered persistent positive for ipilimumab ADA only, and 1 (0.4%) subject was neutralizing ADA positive for ipilimumab ADA only.
- Ipilimumab ADA titers were low, ranging from 1 to 64.

<div style=\"page-break-after: always\"></div>

Table 49. Anti-Drug Antibody Assessments Summary - All Nivolumab + Ipilimumab or Nivolumab + Chemotherapy Treated Subjects with Baseline and at Least One Post-Baseline Assessment

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

|                                                                       | Nivolumab + Ipilimumab                                                                                                                                  | Nivolumab + Ipilimumab      | Nivolumab + Chemotherapy ­­­­­­­­­­­­­­­­­­­­­­­­­­   |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------|
| Subject ADA Status (%)                                                | ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ Nivolumab ADA N = 281 ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ | Ipilimumab ADA N = 282      | Nivolumab ADA N = 276                                 |
| BASELINE ADA POSITIVE                                                 | 19 ( 6.8)                                                                                                                                               | 6 ( 2.1)                    | 15 ( 5.4)                                             |
| ADA POSITIVE                                                          | 68 ( 24.2)                                                                                                                                              | 17 ( 6.0)                   | 12 ( 4.3)                                             |
| PERSISTENT POSITIVE (PP) NOT PP ­ LAST SAMPLE POSITIVE OTHER POSITIVE | 1 ( 0.4) 27 ( 9.6) 40 ( 14.2)                                                                                                                           | 1 ( 0.4) 6 ( 2.1) 10 ( 3.5) | 0 4 ( 1.4) 8 ( 2.9)                                   |
| NEUTRALIZING POSITIVE                                                 | 6 ( 2.1)                                                                                                                                                | 1 ( 0.4)                    | 3 ( 1.1)                                              |
| ADA NEGATIVE                                                          | 213 ( 75.8)                                                                                                                                             | 265 ( 94.0)                 | 264 ( 95.7)                                           |

Baseline ADA Positive : A subject with baseline ADA -positive sample;

ADA Positive : A subject with at least one ADA -positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4 -fold or greater (≥) than baseline positive titer) at any time after initiation of treatment;

Persistent Positive (PP) : ADA -positive sample at 2 or more consecutive time points, where the first and last ADA -positive samples are at least 16 weeks apart;

Not PP-Last Sample Positive : Not persistent but with ADA -positive sample at the last sampling time point;

Other Positive : Not persistent but some ADA -positive samples with the last sample being negative;

Neutralizing Positive : At lea st one ADA -positive sample with neutralizing antibodies detected post-baseline;

ADA Negative : A subject with no ADA -positive sample after initiation of treatment.

Source: Table S.7.10.1

## Effect of Immunogenicity on Efficacy

Based on assessment of the presence of ADAs and NAbs vs BOR per BICR, some subjects positive for nivolumab and/or ipilimumab ADAs and NAbs continued treatment with clinical benefit, and there was no apparent trend showing an effect of positive ADA or NAbs on the efficacy of nivo + ipi.

A BOR of CR or PR per BICR was reported in 24 out of 68 nivolumab ADA-positive subjects and in 7 out of 17 ipilimumab ADA-positive subjects. The ADA titers among all ADA-positive subjects ranged from 1 to 512 for nivolumab and 1 to 64 for ipilimumab. Though these results are based on small sample sizes and should be interpreted with caution, these results are consistent with the ORR observed for all randomized subjects in the nivo + ipi arm (27.7%), which included subjects negative for ADA.

Overall, the incidences of nivolumab and ipilimumab NAbs were low.

- Of the 6 subjects with nivolumab NAbs (Table 49):
- o BORs per BICR were SD for 4 subjects (66.7%) and PD for 2 subjects (33.3%). There were no subjects with CR or PR per BICR.
- o The nivolumab ADA titers in these subjects ranged from 1 to 256.
- For the 1 subject in the nivo + ipi arm with ipilimumab NAbs, BOR per BICR was SD.
- o The ipilimumab ADA titers in this subject ranged from 4 to 64.

## Effect of Immunogenicity on Safety

Overall, an effect of ADA on the safety of nivo + ipi treatment was not observed (Table 50).

Among the nivo + ipi-treated subjects evaluable for nivolumab ADA, the proportions of subjects with hypersensitivity/infusion-related reaction select AEs was 4/68 (5.9%) subjects in the nivolumab ADA-

<div style=\"page-break-after: always\"></div>

positive subgroup vs 8/213 (3.8%) subjects in the nivolumab ADA-negative subgroup. However, though the sample size of the ADA-positive group limits interpretation, all of these hypersensitivity/infusion reactions were Grade 1 or 2, and all events resolved.

Among the nivo + ipi-treated subjects evaluable for ipilimumab ADA, the proportion of subjects with hypersensitivity/infusion-related reaction select AEs was higher in the ipilimumab ADA positive subgroup (2/17 subjects, 11.8%) vs ipilimumab ADA-negative subgroup (10/265 subjects, 3.8%) (Table 50). However, though the sample size of the ADA-positive group limits interpretation, all of these hypersensitivity/infusion reactions were Grade 1 or 2, and all events resolved.

Table 50. Select AEs of Hypersensitivity/Infusion Reaction by ADA Status - All Treated Subjects with ADA Positive or ADA Negative - Nivolumab + Ipilimumab and Nivolumab + Chemotherapy Arms

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

­­­

|                              | Nivolumab + Ipilimumab        | Nivolumab + Ipilimumab                                                                                                         | Nivolumab + Ipilimumab                                                                                                          | Nivolumab + Ipilimumab          |
|------------------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| ­­­ Preferred Term (%)       | Nivolumab ADA Positive N = 68 | ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ Nivolumab ADA Negative N = 213 | Ipilimumab ADA Positive N = 17                                                                                                  | Ipilimumab ADA Negative N = 265 |
| ­­­                          |                               |                                                                                                                                | ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ |                                 |
| TOTAL SUBJECTS WITH AN EVENT | 4 ( 5.9)                      | 8 ( 3.8)                                                                                                                       | 2 ( 11.8)                                                                                                                       | 10 ( 3.8)                       |
| Anaphylactic shock           | 0                             | 0                                                                                                                              | 0                                                                                                                               | 0                               |
| Bronchospasm                 | 0                             | 1 ( 0.5)                                                                                                                       | 0                                                                                                                               | 1 ( 0.4)                        |
| Hypersensitivity             | 2 ( 2.9)                      | 2 ( 0.9)                                                                                                                       | 1 ( 5.9)                                                                                                                        | 3 ( 1.1)                        |
| Infusion related reaction    | 2 ( 2.9)                      | 5 ( 2.3)                                                                                                                       | 1 ( 5.9)                                                                                                                        | 6 ( 2.3)                        |

­­­

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

Nivolumab + Chemotherapy

­­­

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­ ­­­­­­­ ­­­­­­

Nivolumab                Nivolumab

Preferred Term (%)                       N = 12                  N = 264

ADA Positive             ADA Negative

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

­­­

TOTAL SUBJECTS WITH AN EVENT               0                     8 (  3.0)

Anaphylactic shock                         0                     1 (  0.4)

Hypersensitivit y                               0                                       3   (     1 . 1 )

Bronchospasm                               0                     0

Infusion related reaction                  0                     4 (  1.5)

­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­

­­­

MedDRA Version: 23.1

CTC Version 4.0

Includes events between first dose and within the last dose of therapy + 100 days

Source: Table S.7.11.1

## Discontinuation due to adverse events

AEs leading to discontinuation of study therapy were defined as events when 1 or more study drugs of a multidrug regimen were discontinued, even if the subject remained on treatment or in follow-up.

Between the nivo + ipi and chemo arms, the overall proportions of subjects were comparable for allcausality AEs leading to discontinuation (25.2% vs 25.3%) and for drug-related AEs leading to discontinuation (17.7% vs 19.4%).

All-causality any-grade AEs leading to discontinuation of any component of study therapy were reported in 126 (40.6%), 81 (25.2%), and 77 (25.3%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively (Table 51). The most frequently reported all-causality AEs leading to discontinuation of study therapy of any grade were:

<div style=\"page-break-after: always\"></div>

- Nivo + chemo arm: blood creatinine increased (3.5%); pneumonitis, peripheral sensory neuropathy, and chronic kidney disease (2.6% each); and malignant neoplasm progression and creatinine renal clearance decreased (2.3% each)
- Nivo + ipi arm: pneumonitis (2.8%); malignant neoplasm progression (2.2%); and hepatic function abnormal, adrenal insufficiency, and aspartate aminotransferase increased (1.6% each)
- Chemo arm: blood creatinine increased (3.6%); malignant neoplasm progression and renal impairment (2.3% each); peripheral sensory neuropathy (2.0%); and creatinine renal clearance decreased (1.3%)

All-causality Grade 3-4 AEs leading to discontinuation of study therapy were reported in 51 (16.5%), 54 (16.8%), and 28 (9.2%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively.

Drug-related any-grade AEs leading to discontinuation of any component of study therapy were reported in 106 (34.2%), 57 (17.7%), and 59 (19.4%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively (Table 52). The most frequently reported drug-related AEs leading to discontinuation of study therapy of any grade were:

- Nivo + chemo arm:  blood creatinine increased (3.5%); peripheral sensory neuropathy, pneumonitis and chronic kidney disease (2.6% each); creatinine renal clearance decreased (2.3%); and fatigue (1.9%)
- Nivo + ipi arm: pneumonitis (2.5%); and adrenal insufficiency and hepatic function abnormal (1.6% each)
- Chemo arm: blood creatinine increased (3.6%), renal impairment (2.3%), peripheral sensory neuropathy (2.0%), and creatinine renal clearance decreased (1.3%)

Drug-related Grade 3-4 AEs leading to discontinuation were reported in 29 (9.4%), 41 (12.7%), and 14 (4.6%) treated subjects in the nivo + chemo, nivo + ipi, and chemo arms, respectively.

<div style=\"page-break-after: always\"></div>

Table 51 . Adverse Events Leading to Discontinuation in ≥1% of All Treated Subjects

|                                                                   | Nivo + Ipi N=322   | Nivo + Ipi N=322   | Nivo + Ipi N=322   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Chemotherapy N=304   | Chemotherapy N=304   | Chemotherapy N=304   |
|-------------------------------------------------------------------|--------------------|--------------------|--------------------|------------------------|------------------------|------------------------|----------------------|----------------------|----------------------|
| System Organ Class(e) Preferred Term (t)                          | Any Grade          | Grade 3-4          | Grade 5            | Hny Grade              | Grade 3-4              | Grade 5                | Any Grade            | Grade 3-4            | Grade 5              |
| TOTALSUBJECISWITHAN EVENT                                         | 81( 25.2)          | 54 (16.8)          | 2 0.6)             | 126 40.6)              | 51 （ 16.5)             | 1 0.3)                 | 77 (25.3)            | 28 9.2)              | 2 0.71               |
| Respiratory, thoracic and mediastinal disorders                   | 17 5.3)            | 6 [ 1.9)           | 1 ( 0.3)           | 12 ( 3.9)              | 5 1.6)                 | 0                      | 5[ 1.6)              | 4 ( 1.3)             | 1 0.3)               |
| Pneumonitis                                                       | 9 2.8)             | 3 0.9)             | 0                  | 8 2.6)                 | 1 0.3)                 | 0                      | 0                    | 0                    | 0                    |
| Hepatcbiliary disorders Hepatic function sbnormal                 | 11 3.41 1.6)       | 10 3.11 4 ( 1.2)   | 00                 | 21 9.91 0.31           | 0.6) 0.3)              | 00                     | 0 0                  | 0 0                  | 0 0                  |
| Endocrine disorders Adrenal insufficiency                         | 10 5 1.8 1.        | 8                  | 00                 | 8.31                   | 00                     | 00                     | 00                   |                      | 00                   |
| Gastrointestinal                                                  | 10 3.1)            | 8 2.5)             | 0                  | 17 5.5)                | 7 2.3)                 | 口                      | 6 (2.0)              | 5 (1.6)              | 0                    |
| disorders Colitis                                                 | mooo 0.9)          | N000 [ 0.6)        | 口 000              | 4313 9929 3) 01        | 1.3)                   | 0000                   | 0030                 | 60                   | 口 口 口                |
| Nausea. Oesophageal stenosis Stomatitis                           |                    |                    |                    |                        | 4010 0.3)              |                        | 1.0)                 | 20 ( 0.7)            | 口                    |
| Neoplasms benigm, maligmant and specified (incl cysts and polyps) | 9 (2.8)            | 2.2)               | 0                  | 7 2.3)                 | 7 2.3)                 | 0                      | 16 3.0)              | 6 2.0)               | 1 0.3)               |
| Malignant neoplasm progression                                    | 7 2.2)             | 1.9)               | 0                  | 7 2.3)                 | 7 2.3)                 | 0                      | 7 2.3)               | 4 ( 1.3)             | 1 0.3)               |
|                                                                   |                    | 6 [ 1.9)           |                    | 27 8.71                | 6 1.91                 |                        | 18 5.91              | 1 ( 0.3)             |                      |
| Investigations Aspartate aminotransferase increased               | 8 2.51 5 1.6)      | 3 0.9)             | 00                 | 2 0.6)                 | 1 0.3)                 | 60                     | 0                    | 0                    | 0 0                  |
| Alanine aminotransferase increased                                | 4( 1.2)            | 3[ 0.9)            | 0                  | 1( 0.3)                | 1 0.3)                 | 0                      | 0                    | 0                    | 0                    |
| Blood creatinine                                                  | 0                  | 0                  | 0                  | 11 ( 3.5)              | 0                      | 口                      | 11 ( 3.6)            | 0                    | 0                    |
| increased                                                         | 0                  | 0                  | 0                  |                        |                        |                        |                      |                      |                      |
| Creatinine renal clearance decreased                              |                    |                    |                    | 7(2.3)                 | 0                      | 0                      | 4(1.3)               | 0                    | 0                    |

|                                                                              | Nivo + Ipi N=322   | Nivo + Ipi N=322   | Nivo + Ipi N=322   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Chemotherapy N=304   | Chemotherapy N=304   | Chemotherapy N=304   |
|------------------------------------------------------------------------------|--------------------|--------------------|--------------------|------------------------|------------------------|------------------------|----------------------|----------------------|----------------------|
| System Organ Class (%) Preferred Term (4)                                    | Any Grade          | Grade 3-4          | Grade 5            | Any Grade              | Grade 3-4              | Grade 5                | Any Grade            | Grade 3-4            | Grade 5              |
| Infections and infestations                                                  | 4 1.2)             | 2 0.6)             | 1 0.3)             | 9 2.9)                 | 6 2.9)                 | 0                      | 2[ 0.7)              | 1 0.3)               | 0                    |
| Pneumonia                                                                    | 2 0.6)             | 1 0.3)             | 1 0.3)             | 6 1.9)                 | 6 1.9)                 | 0                      | 0                    | 0                    | 0                    |
| Metabolism and nutrition disorders                                           | 6 1.9)             | 6 1.9)             | 0                  | 11 3.5)                | 6 ( 1.9)               | 0                      | 3 1.0)               | 2 0.7)               | 0                    |
| Decreased appetite                                                           | 0.3)               | 1 [ 0.3)           | 0                  | 5 1.6)                 | 0                      | 0                      | 1 0.3)               | 0                    | 0                    |
| Blood and lymphatic system disorders                                         | 2 0.6)             | 0                  | 0                  | 5 1.6)                 | 2 ( 0.6)               | 0                      | 1 [ 0.3)             | 1 ( 0.3)             | 0                    |
| Anaemia.                                                                     | 0.3)               | 0                  | 0                  | 3 1.0)                 | 1 0.3)                 | 0                      | 0                    | 0                    | 0                    |
| Renal and urinary disorders                                                  | 2 0.6)             | 0                  | 0                  | 24 [ 7.7)              | 4 1.3)                 | 0                      | 16 5.3)              | 2 0.7)               | 0                    |
| Acute kicney injury Chronic kicmey disease Renal failure Renal inpairment    | 1 0.3) 0 0 0       | 0000               | 0 1000             | 鲜                      | 3 ( 1.0) 0H0 0.3)      | 口 000                  | NmmP 6999            | 0 0 10 0.3)          | 0 0 口                |
| General disorders and administration site conditions                         | 1 0.3)             | 1 [ 0.3)           | 0                  | 19 6.1)                | 4 1.3)                 | 0                      | 4 [ 1.3)             | 1 0.3)               | 0                    |
| Pyrexia                                                                      | 0                  |                    | 0                  | 3 [ 1.0)               | 口                      | 口                      | 口                    | 口                    | 口                    |
| Nervous system disorders Neuropathy peripheral Feripheral Axosues neuwopathy | 1 00 0.3)          | 000                | 00                 | 258 1. 6.8) 66         | 411 88 1.31            | 000                    | 13 [ 83 4.3)         | 01 1.3) 0.3)         | 000                  |

MedDRA Version: 23.1

CIC Version 4.0

Adeteun Apnns go esop 1set xeage slep oe pue asop 1sity ueameq peatodet sauene sapnlou1

Sowce: Table S.6.4.2.2.2

<div style=\"page-break-after: always\"></div>

Table 52. Drug-Related Adverse Events Leading to Discontinuatio n in ≥1% of All Treated Subjects

|                                                 | Nivo + Ipi N =322   | Nivo + Ipi N =322   | Nivo + Ipi N =322   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Nivo + Chemo N = 310   | Chemotherapy N = 304   | Chemotherapy N = 304   | Chemotherapy N = 304   |
|-------------------------------------------------|---------------------|---------------------|---------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| System Organ Class (t) Preferred Term (t)       | Any Grade           | Grade 3-4           | Grade 5             | Any Grade              | Grade 3-4              | Grade 5                | Any Grade              | Grade 3-4              | Grade 5                |
| TOTAL SUBJECIS WITH AN EVENT                    | 57( 17.7)           | 41 (12.7]           | 0                   | 106 ( 34.2)            | 29 9.41                | 0                      | 59( 19.4)              | 14 1 4.6)              | 0                      |
| Respiratory, thoracic and mediastinal disorders | 11 3.4)             | 4 1.2)              | 0                   | 10 ( 3.2)              | 3 1.0)                 | 0                      | 0                      | 0                      | 0                      |
| Pneumonitis                                     | 8 2.5)              | 3 0.9)              | 0                   | 8 2.6)                 | 1 0.3)                 | 0                      | 0                      | 0                      | 0                      |
| Endocrine disorders Adrenal insufficiency       | 10 3.1) 5 1.6)      | 85 [ 2.5 51 [ 1. 6) | 0 0                 | 11 0.3) 0.3)           | 0 0                    | 0 口                    | 0 0                    | 0 0                    | 0 0                    |
| Hepatobiliary disorders                         | 10 3.11             |                     | 00                  | 11 8.31                | 0.3)                   | 00                     |                        |                        |                        |
| Hepatic function sbnomal                        | 5 1.6)              | 94 1.8              |                     |                        | 11 8.31                |                        | 00                     | 00                     |                        |
| Gastrointestinal disorders                      | 2.5)                | 7 [ 2.2)            | 0                   | 15 4.8)                | 5 1.6)                 | 0                      | 3[ 1.0)                | 3 1.0)                 | 0                      |
| Colitis Nausea. Stomatitis                      | 3 0.91 06           | 0.6)                | 0 100               |                        | 4 ( 1.3) 00            | 000                    | 0 00                   | 0 00                   | 0 00                   |
| Metabolism and nutrition disorders              | 6 1.9)              | 6 1.9)              | 0                   | 11 3.5)                | 6 1.9)                 | 口                      | 3 1.0)                 | 2( 0.7)                | 口                      |
| Hyponatraemia Decreased eppetite                | 21 0.6) 0.3)        | 21 [ 0.6) [ 0.3)    | 0 0                 | 1.3                    | 10 ( 0.31              | 0                      | 01 0.3)                | 0                      | 0 0                    |
| Investigations                                  |                     |                     |                     | 15 6)                  |                        | 口                      |                        | 0                      |                        |
| Blood creatinine increased Creatinine renal     | 5 1.6) 口            | 1.6)                |                     | 31 8.71 3.5)           | 6 1.9) 0               | 0                      | 18 5.9) 11 3.6)        | 1 0.3) 口               | 0 0                    |
| clearance decreased                             | 0                   | 0                   | 口                   | 7 2.3)                 | 0                      | 0                      | 4 [ 1.3)               | 0                      | 0                      |
| Renal and urinary                               | 2 0.6)              | 0                   | 0                   | 7.7)                   | 4                      | 0                      | 5.3)                   | 2 [ 0.7)               |                        |
| disorders                                       |                     |                     |                     | 24                     | 1.3)                   |                        | 16                     |                        | 0                      |
| Acute kidmey injury Chronic kicmey disease      | 00 1 0.3)           |                     | 00000               | 2.8 66                 | 3 1.0)                 |                        | NmHmr                  |                        |                        |
| Nephropathy toxic                               |                     | 00000               |                     |                        | 00HO 0.3)              | 00000                  |                        | 0.3)                   | o0000                  |
| Renal failire                                   | 口                   |                     |                     |                        |                        |                        | 0)                     | 0.3)                   |                        |
| Renal inpairment                                | 0                   |                     |                     | 6)                     |                        |                        |                        |                        |                        |

|                                                                   | Nivo + Ipi N = 322   | Nivo + Ipi N = 322   | Nivo + Ipi N = 322   | cWeUp + ONIN N = 310   | cWeUp + ONIN N = 310   | cWeUp + ONIN N = 310   | Chemotherapy N = 304   | Chemotherapy N = 304   | Chemotherapy N = 304   |
|-------------------------------------------------------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| System Organ Class (t) Preferred Term ($)                         | Any Grade            | Grade 3-4            | Grade 5              | Any Grade              | Grade 3-4              | Grade 5                | Any Grade              | Grade 3-4              | Grade 5                |
| Blood and lymphatic system disorders                              | 1 0.3)               | 0                    | 0                    | 5 ( 1.6)               | 2 0.6)                 | 0                      | 1 0.3)                 | 1 0.3)                 | 0                      |
| Anaemia                                                           | 0                    | 0                    | 0                    | 3 1.0)                 | 1 0.3)                 | 0                      | 口                      | 口                      | 0                      |
| Nervous system disorders Neuropathy peripheral Peripheral sensory | 1 0 0.3)             | 0 口                  | 0 0                  | 19 6.1) 61             | 11 8 0.3) 1.0)         | 0                      | 236 183 3.9)           | 01 3 ( 1.0)            | 0 0                    |
| General disorders and                                             | 0                    | 口                    | 0                    | 00 6                   | 0.3)                   |                        | 3                      | 0.3)                   | 口                      |
| administration site conditions                                    | 0                    | 0                    | 0                    | 16 ( 5.2)              | 2 0.6)                 | 0                      | 1.0)                   | 0                      | 0                      |
| Fatigue                                                           | 0                    | 0                    | 0                    | 6 (1.9)                | 1( 0.3)                | 0                      | 0                      | 0                      | 0                      |

MedDRA Version: 23.1

Includes events reported between first dose and 30 days after last dose of study therapy.

CIC Version 4.0

Source: Table S.6.4.2.2

## Safety in All Treated Subjects with Tumour Cell PDL1 ≥1%

The safety profiles of nivo + chemo, nivo + ipi and chemo among all treated subjects with tumour cell PDL1 expression ≥1% were comparable to those for all treated subjects (Table 53).

Table 53: Summary of Safety - All Treated Subjects with Tumor Cell PD-L 1 ≥ 1%

|                                  | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|----------------------------------|-----------------------|-----------------------|-----------------------|
| Safety Parameter                 | Nivo + Ipi (N=158)    | Nivo + Chemo (N=155)  | Chemo (N=145)         |
| Deaths                           | 106 (67.1)            | 96 (61.9)             | 116 (80.0)            |
| Primary Reason for Death Disease | 87 (55.1)             | 79 (51.0)             | 104 (71.7)            |

<div style=\"page-break-after: always\"></div>

Table 53: Summary of Safety - All Treated Subjects with Tumor Cell PD-L 1 ≥ 1%

|                                       | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|---------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Safety Parameter                      | Nivo + Ipi (N=158)    | Nivo + Ipi (N=158)    | Nivo + Chemo (N=155)  | Nivo + Chemo (N=155)  | Chemo (N=145)         | Chemo (N=145)         |
| Study Drug Toxicity                   | 1 (0.6)               | 1 (0.6)               | 5 (3.2)               | 5 (3.2)               | 1 (0.7)               | 1 (0.7)               |
| Unknown                               | 7 (4.4)               | 7 (4.4)               | 5 (3.2)               | 5 (3.2)               | 7 (4.8)               | 7 (4.8)               |
| Other                                 | 11 (7.0)              | 11 (7.0)              | 7 (4.5)               | 7 (4.5)               | 4 (2.8)               | 4 (2.8)               |
|                                       | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             |
| All-causality SAEs                    | 104 (65.8)            | 74 (46.8)             | 87 (56.1)             | 65 (41.9)             | 67 (46.2)             | 47 (32.4)             |
| Drug-related SAEs                     | 49 (31.0)             | 36 (22.8)             | 40 (25.8)             | 32 (20.6)             | 24 (16.6)             | 18 (12.4)             |
| All-causality AEs leading to DC       | 45 (28.5)             | 30 (19.0)             | 69 (44.5)             | 28 (18.1)             | 35 (24.1)             | 14 (9.7)              |
| Drug-Related AEs leading to DC        | 35 (22.2)             | 25 (15.8)             | 60 (38.7)             | 18 (11.6)             | 27 (18.6)             | 6 (4.1)               |
| All-causality AE                      | 155 (98.1)            | 96 (60.8)             | 155 (100.0)           | 109 (70.3)            | 144 (99.3)            | 85 (58.6)             |
| Drug-related AEs                      | 128 (81.0)            | 49 (31.0)             | 149 (96.1)            | 77 (49.7)             | 133 (91.7)            | 60 (41.4)             |
| ≥15% of Subjects in any Treatment Arm |                       |                       |                       |                       |                       |                       |
| Rash                                  | 31 (19.6)             | 2 (1.3)               | 13 (8.4)              | 0                     | 2 (1.4)               | 0                     |
| Pruritus                              | 25 (15.8)             | 1 (0.6)               | 13 (8.4)              | 0                     | 0                     | 0                     |
| Diarrhoea                             | 17 (10.8)             | 1 (0.6)               | 36 (23.2)             | 3 (1.9)               | 18 (12.4)             | 2 (1.4)               |
| Nausea                                | 11 (7.0)              | 1 (0.6)               | 91 (58.7)             | 4 (2.6)               | 78 (53.8)             | 5 (3.4)               |
| Stomatitis                            | 9 (5.7)               | 0                     | 52 (33.5)             | 10 (6.5)              | 32 (22.1)             | 4 (2.8)               |
| Vomiting                              | 9 (5.7)               | 3 (1.9)               | 25 (16.1)             | 2 (1.3)               | 23 (15.9)             | 7 (4.8)               |
| Constipation                          | 3 (1.9)               | 1 (0.6)               | 20 (12.9)             | 1 (0.6)               | 35 (24.1)             | 1 (0.7)               |
| Neutrophil count decreased            | 1 (0.6)               | 0                     | 28 (18.1)             | 13 (8.4)              | 19 (13.1)             | 9 (6.2)               |
| Fatigue                               | 14 (8.9)              | 3 (1.9)               | 27 (17.4)             | 3 (1.9)               | 21 (14.5)             | 4 (2.8)               |
| Malaise                               | 9 (5.7)               | 0                     | 23 (14.8)             | 0                     | 23 (15.9)             | 0                     |
| Decreased appetite                    | 9 (5.7)               | 2 (1.3)               | 70 (45.2)             | 7 (4.5)               | 66 (45.5)             | 4 (2.8)               |
| Hiccups                               | 2 (1.3)               | 0                     | 19 (12.3)             | 0                     | 27 (18.6)             | 0                     |
| Anaemia                               | 3 (1.9)               | 1 (0.6)               | 45 (29.0)             | 10 (6.5)              | 33 (22.8)             | 12 (8.3)              |
|                                       | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             |
| All-causality Select AEs by Category  |                       |                       |                       |                       |                       |                       |
| Gastrointestinal                      | 39 (24.7)             | 6 (3.8)               | 52 (33.5)             | 8 (5.2)               | 23 (15.9)             | 2 (1.4)               |
| Hepatic                               | 39 (24.7)             | 12 (7.6)              | 29 (18.7)             | 6 (3.9)               | 10 (6.9)              | 2 (1.4)               |

<div style=\"page-break-after: always\"></div>

Table 53: Summary of Safety - All Treated Subjects with Tumor Cell PD-L 1 ≥ 1%

|                                                                       | No. of Subjects (%)                                                   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   | No. of Subjects (%)   |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Safety Parameter                                                      | Nivo + Ipi (N=158)                                                    | Nivo + Ipi (N=158)    | Nivo + Chemo (N=155)  | Nivo + Chemo (N=155)  | Chemo (N=145)         | Chemo (N=145)         |
| Pulmonary                                                             | 13 (8.2)                                                              | 5 (3.2)               | 11 (7.1)              | 1 (0.6)               | 3 (2.1)               | 1 (0.7)               |
| Renal                                                                 | 9 (5.7)                                                               | 2 (1.3)               | 39 (25.2)             | 5 (3.2)               | 34 (23.4)             | 2 (1.4)               |
| Skin                                                                  | 71 (44.9)                                                             | 5 (3.2)               | 45 (29.0)             | 1 (0.6)               | 14 (9.7)              | 0                     |
| Hypersensitivity/Infusion Reactions                                   | 10 (6.3)                                                              | 0                     | 3 (1.9)               | 0                     | 1 (0.7)               | 0                     |
| Drug-Related Select AEs by Category                                   |                                                                       |                       |                       |                       |                       |                       |
| Gastrointestinal                                                      | 18 (11.4)                                                             | 3 (1.9)               | 39 (25.2)             | 7 (4.5)               | 18 (12.4)             | 2 (1.4)               |
| Hepatic                                                               | 25 (15.8)                                                             | 8 (5.1)               | 19 (12.3)             | 4 (2.6)               | 7 (4.8)               | 1 (0.7)               |
| Pulmonary                                                             | 11 (7.0)                                                              | 4 (2.5)               | 11 (7.1)              | 1 (0.6)               | 1 (0.7)               | 0                     |
| Renal                                                                 | 7 (4.4)                                                               | 2 (1.3)               | 36 (23.2)             | 5 (3.2)               | 32 (22.1)             | 2 (1.4)               |
| Skin                                                                  | 57 (36.1)                                                             | 5 (3.2)               | 29 (18.7)             | 0                     | 4 (2.8)               | 0                     |
| Hypersensitivity/Infusion Reactions                                   | 8 (5.1)                                                               | 0                     | 2 (1.3)               | 0                     | 1 (0.7)               | 0                     |
| All-causality IMAEs within 100 d of last treated with IMM by Category |                                                                       | dose                  |                       |                       |                       |                       |
| Diarrhea/Colitis                                                      | 6 (3.8)                                                               | 3 (1.9)               | 6 (3.9)               | 4 (2.6)               | 0                     | 0                     |
| Hepatitis                                                             | 7 (4.4)                                                               | 4 (2.5)               | 2 (1.3)               | 1 (0.6)               | 0                     | 0                     |
| Pneumonitis                                                           | 7 (4.4)                                                               | 5 (3.2)               | 7 (4.5)               | 2 (1.3)               | 0                     | 0                     |
| Nephritis/Renal                                                       | 4 (2.5)                                                               | 2 (1.3)               | 2 (1.3)               | 2 (1.3)               | 0                     | 0                     |
| Dysfunction Rash                                                      | 25 (15.8)                                                             | 5 (3.2)               | 10 (6.5)              | 0                     | 2 (1.4)               | 1 (0.7)               |
| Hypersensitivity/Infusion Reactions                                   | 0                                                                     | 0                     | 0                     | 0                     | 0                     | 0                     |
| All-causality Endocrine IMAEs within last dose by Category            | All-causality Endocrine IMAEs within last dose by Category            | 100 d of              |                       |                       |                       |                       |
| Adrenal Insufficiency                                                 | 12 (7.6)                                                              | 5 (3.2)               | 1 (0.6)               | 0                     | 0                     | 0                     |
| Hypophysitis                                                          | 13 (8.2)                                                              | 5 (3.2)               | 1 (0.6)               | 1 (0.6)               | 0                     | 0                     |
| Hypothyroidism/Thyroiditis                                            | 27 (17.1)                                                             | 0                     | 11 (7.1)              | 0                     | 0                     | 0                     |
| Diabetes Mellitus                                                     | 3 (1.9)                                                               | 2 (1.3)               | 1 (0.6)               | 1 (0.6)               | 0                     | 0                     |
| Hyperthyroidism                                                       | 12 (7.6)                                                              | 2 (1.3)               | 2 (1.3)               | 0                     | 1 (0.7)               | 0                     |
|                                                                       | Any Grade                                                             | Grade 3-4             | Any Grade             | Grade 3-4             | Any Grade             | Grade 3-4             |
| All-causality OESIs within 100 d of last with/without IMM by Category | All-causality OESIs within 100 d of last with/without IMM by Category | dose                  |                       |                       |                       |                       |
| Pancreatitis                                                          | 3 (1.9)                                                               | 3 (1.9)               | 0                     | 0                     | 0                     | 0                     |
| Encephalitis                                                          | 0                                                                     | 0                     | 0                     | 0                     | 0                     | 0                     |
| Myositis/Rhabdomyolysis                                               | 0                                                                     | 0                     | 1 (0.6)               | 0                     | 0                     | 0                     |
| Myasthenic Syndrome                                                   | 0                                                                     | 0                     | 0                     | 0                     | 0                     | 0                     |
| Demyelination                                                         | 0                                                                     | 0                     | 0                     | 0                     | 0                     | 0                     |
| Guillain-Barre Syndrome                                               | 0                                                                     | 0                     | 0                     | 0                     | 0                     | 0                     |
| Uveitis                                                               | 2 (1.3)                                                               | 1 (0.6)               | 1 (0.6)               | 0                     | 0                     | 0                     |
| Myocarditis                                                           | 1 (0.6)                                                               | 0                     | 0                     | 0                     | 0                     | 0                     |
| Graft Versus Host Disease                                             | 0                                                                     | 0                     | 0                     | 0                     | 0                     | 0                     |

<div style=\"page-break-after: always\"></div>

MedDRA version 23.1 CTCAE version 4.0.

All events are within 30 days of the last dose of study drug, unless otherwise indicated (eg, any time for deaths, 100 days for IMAEs and OESIs).

Source: Table S.6.15.1 (deaths), Table S.6.3.1.2.1 (All-causality SAEs), Table S.6.3.1.2.2 (Drug-related SAEs), Table S.6.4.2.2.1 (All-causality AEs leading to DC). Table S.6.4.2.1 (Drug-Related AEs leading to DC), Table S.6.1.31.2.1 (All-causality  AEs),  Table  S.6.1.32.1.1  (Drug-related  AEs),  Table  S.6.5.1.3.2.1  (select  AEs),  Table  S.6.5.1.3.2.2 (related  select  AEs),  Table  S.6.2.02.1.1  (endocrine  IMAEs),  Table  S.6.2.02.1.2  (non-endocrine  IMAEs),  Table S.6.5.3.3.1.1 (OESIs)

## Safety to Support the Product Information (PI)

Based on The EU guidance document 'A guideline on summary of product characteristics (SmPC) September 2009' and EMA guideline on the evaluation of anticancer medicinal products in man (EMA/CHMP/205/95 Rev.5), the following methodology was used to generate the adverse reactions with nivolumab 3 mg/kg Q2W + ipilimumab 1 mg/kg Q6W for Section 4.8 of the OPDIVO SmPC and Section 4.8 of the YERVOY SmPC.

- Integrate all-causality AEs data from CA209648 and CA209743 (1L unresectable malignant pleural mesothelioma) for the intended dose and regimen of nivolumab 3 mg/kg Q2W + ipilimumab 1 mg/kg Q6W.
- Programmatically remap MedDRA PTs representing the same or similar clinical conditions for the integrated AE data and generate summary tables.
- Identify clinically relevant events based on BMS medical review of the all-causality re-mapped AE summary table.
- Present resulting clinically relevant re-mapped events by SOC and all-causality frequency in the final adverse drug reaction (ADR) table.
- To calculate the frequencies of laboratory ADR, BMS used the laboratory abnormality change from baseline tables.

As explained above, for labeling purposes, some MedDRA PTs were remapped for the purposes of generating summary tables to support Section 4.8 of the SmPC pooling PTs representing the same or similar clinical conditions. For the proposed nivolumab and ipilimumab SmPC, selection of specific ADRs (Section 4.8 of the nivolumab and ipilimumab SmPC) is based on clinical relevance as determined by the BMS medical reviewer.

A review of all-causality AEs was conducted for CA209648 and the integrated safety data from CA209648 and CA209743 to ensure that the appropriate MedDRA PTs are represented in the proposed Table of ADRs. The list of PTs included in the proposed Table of ADRs in Section 4.8 of the SmPC for both nivolumab and ipilimumab reflects the ADRs that were observed with nivo + ipi in CA209648 and its aim is to provide concise, relevant information, enabling HCPs to make appropriate decisions regarding patient treatment and management based on information regarding the frequency and nature of the ADRs that may occur in patients in clinical practice. In line with the above mentioned guidelines, frequency of ADR is presented based on all-causality AEs. To calculate the frequencies of laboratory ADR, BMS used the laboratory abnormality change from baseline tables for the pooled subjects from CA209648 + CA209743 (with 30 days of follow-up). The denominator used to compute frequency is the number of subjects for whom laboratory data were available, as opposed to all treated subjects. Hence, there is variability in the denominator for each individual laboratory abnormality and the respective reported frequency. Also note: CA209648 scheduled safety assessment did not include the collection of amylase and lipase data; hence, the total amylase and total lipase in Section 4.8 of the SmPC under nivolumab 3 mg/kg in combination with ipilimumab 1 mg/kg in the 3rd column of Table 7 remain unchanged and are based only on data from CA209743 (MPM).

<div style=\"page-break-after: always\"></div>

## OPDIVO SmPC

The presentation of ADRs in Section 4.8 of the current approved OPDIVO SmPC displays 3 columns in Table 7, one for nivolumab 1 mg/kg in combination with ipilimumab 3 mg/kg in melanoma, one for nivolumab 3 mg/kg in combination with ipilimumab 1 mg/kg in renal cell carcinoma (RCC) and dMMR or MSI-H colorectal cancer (CRC), and one for nivolumab 3 mg/kg in combination with ipilimumab 1 mg/kg in malignant pleural mesothelioma (MPM).

With the current application, the 3rd column in the ADR table is updated with pooled data from 1L treatment of OSCC (n=322 of treated patients from CA209648) and 1L treatment of MPM (n=300 of treated patients from CA209743) for nivolumab 3 mg/kg Q2W in combination with ipilimumab 1 mg/kg Q6W. The intended dose regimen and/or schedule of administration for OSCC was the same as the approved regimen for MPM. The patient population with tumour cell PD L1 ≥ 1% from CA209648 presented with a similar safety profile, and a qualitative statement was added in Section 4.8 of the OPDIVO SmPC.

## YERVOY SmPC

The presentation of ADRs in Section 4.8 of the current approved YERVOY SmPC displays 3 columns in Table 5, one for ipilimumab 3 mg/kg in combination with nivolumab 1 mg/kg in melanoma, one for ipilimumab 1 mg/kg in combination with nivolumab 3 mg/kg in RCC and dMMR or MSI-H CRC, and one for ipilimumab 1 mg/kg in combination with nivolumab 3 mg/kg in MPM.

With the current application, the 3rd column in the ADR table is updated with pooled data from 1L treatment of OSCC (n=322 of treated patients from CA209648) and 1L treatment of MPM (n=300 of treated patients from CA209743) for ipilimumab 1 mg/kg Q6W in combination with nivolumab 3 mg/kg Q2W. The intended dose regimen and/or schedule of administration for OSCC was the same as the approved regimen for MPM. The patient population with tumor cell PD L1 ≥ 1% from CA209648 presented with a similar safety profile, and a qualitative statement was added in the Section 4.8 of the YERVOY SmPC.

## OPDIVO and YERVOY Package Leaflets (PL)

In line with the approach for the SmPC, PL Sections 4 is updated. With this application, the list of side effects reported in 'clinical trials with nivolumab in combination with ipilimumab' is updated with highest frequency, as needed.

## Presentation of Clinically Relevant Adverse Reactions

Text on the proposed dosage and administration of nivolumab (OPDIVO) in combination with ipilimumab (YERVOY) is provided in Section 4.2 of the nivolumab and ipilimumab SmPCs. Detailed guidelines for the management of immune-related adverse reactions are described in Sections 4.4 of the nivolumab and ipilimumab SmPCs.

In this application, no amendments or changes in the management of adverse reactions are proposed based on the data from CA209648 and the integrated safety data.

## Safety Results of Nivolumab in Combination with Ipilimumab in First-Line OSCC (CA209648) and Pooled Studies across Tumour Types

Safety data for 1L treatment of OSCC with nivo + ipi from CA209648 were pooled with safety data for 1L treatment of MPM with Nivo + ipi from CA209743. The intended dose regimen and/or schedule of administration for OSCC was the same as the approved regimen for MPM: nivolumab 3 mg/kg Q2W in combination with ipilimumab 1 mg/kg Q6W.

<div style=\"page-break-after: always\"></div>

A summary of re-mapped all-causality, and drug-related AEs (within 30 days of the last dose) for nivo + ipi arm in CA209648 (n=322) is shown side-by-side with the integrated safety data from CA209743 (n=300), and pooled analysis of the nivo + ipi arm from CA209648 and CA209743 (n=622) in Table 54 and Table 55, respectively. Overall, the types of AEs reported in CA209648 were consistent with CA209743 and the pooled analysis of CA209648 and CA209743 for nivolumab in combination with ipilimumab.

The frequencies of any grade, all-causality, and drug-related AEs were comparable or lower in nivo + ipi treated subjects in CA209648 when compared with the pooled analysis except the following differences:

- The frequencies of any grade all-causality AEs were higher in nivo + ipi treated subjects in CA209648 vs the pooled for dysphagia (11.8% vs 7.2%), anaemia (23.0% vs 19.1%), pneumonia (14.3% vs 10.5%), transaminase increased (15.2% vs 12.2%), and weight decreased (12.1% vs 8.8%) (Table 54).
- The frequencies of drug-related AEs were higher in nivo + ipi treated subjects in CA209648 vs the pooled for, transaminases increased (10.9% vs 8.8%) and stomatitis (5.9% vs 4.0%) (Table 55).

Table 54. Summary of Any Adverse Events using Re-mapped Terms Occurring in At Least 10% of Subjects - All Nivolumab + Ipilimumab Treated Subjects from CA209748, CA209743 and Pooled Analysis (CA209648 + CA209743)

|                                                      | CA209648                                                                                                                       | CA209648                                                                                                                       | CA209648                                                                                                                       | CA209743                                                                                                                       | CA209743                                                                                                                       | CA209743                                                                                                                       | Niwo + Ipi Pooled                                                                                                              | Niwo + Ipi Pooled                                                                                                              | Niwo + Ipi Pooled                                                                                                              |
|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| System Organ Class (t)                               | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 N = 622 |
| Preferred Term (b)                                   | Any Grade                                                                                                                      | Grade 3-4                                                                                                                      | Grade 5                                                                                                                        | Any Grade                                                                                                                      | Grade 3-4                                                                                                                      | Grade 5                                                                                                                        | Any Grade                                                                                                                      | Grade 3-4                                                                                                                      | Grade 5                                                                                                                        |
| TOTAL SUBJECIS WITH AN EVENT                         | 316 (98.1)                                                                                                                     | 192 (59.6)                                                                                                                     | 31 [ 9.6)                                                                                                                      | 299 (99.7)                                                                                                                     | 159 （53.0)                                                                                                                     | 25 8.3)                                                                                                                        | 615 (98.9)                                                                                                                     | 351 (56.4)                                                                                                                     | 56 （ 9.0)                                                                                                                      |
| Gastrointestinal disorders                           | 219 68.0)                                                                                                                      | 52 16.1)                                                                                                                       | 2 0.6)                                                                                                                         | 186 62.0)                                                                                                                      | 28 9.31                                                                                                                        | 0                                                                                                                              | 405 65.1)                                                                                                                      | 80 12.9)                                                                                                                       | 2 [ 0.3)                                                                                                                       |
| Diarrhoea                                            | 2222                                                                                                                           | 6660                                                                                                                           |                                                                                                                                |                                                                                                                                | 4.3                                                                                                                            | 0000000                                                                                                                        |                                                                                                                                |                                                                                                                                | 0000000                                                                                                                        |
| Nausea.                                              |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |
| Constipation                                         |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                | 0.3)                                                                                                                           |                                                                                                                                |                                                                                                                                | 6666                                                                                                                           |                                                                                                                                |
| Vemiting                                             |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                | 81                                                                                                                             |                                                                                                                                |
| Abdcminal pain                                       |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                | 1.01                                                                                                                           |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |
| Stomatitis                                           |                                                                                                                                | 666                                                                                                                            |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                | 668                                                                                                                            |                                                                                                                                |
| Dysphagia                                            | 726483538 8956766 11                                                                                                           |                                                                                                                                | 0000000                                                                                                                        |                                                                                                                                | 0.3)                                                                                                                           |                                                                                                                                | 2)                                                                                                                             | 91                                                                                                                             |                                                                                                                                |
| General disorders and administration site conditions | 159 49.4)                                                                                                                      | 13 4.01                                                                                                                        | 4 1.2)                                                                                                                         | 206 68.7)                                                                                                                      | 28 9.3)                                                                                                                        | 0                                                                                                                              | 365 58.71                                                                                                                      | 41 6.6)                                                                                                                        | 4 0.6)                                                                                                                         |
| Fatigue                                              | Ⅱ记乳6                                                                                                                           |                                                                                                                                |                                                                                                                                | 9386                                                                                                                           | 4.31                                                                                                                           |                                                                                                                                |                                                                                                                                |                                                                                                                                | 0600                                                                                                                           |
| Pyrexia                                              |                                                                                                                                | 6. 66                                                                                                                          |                                                                                                                                | 0                                                                                                                              | 1.31                                                                                                                           |                                                                                                                                |                                                                                                                                | 1.13                                                                                                                           |                                                                                                                                |
| Oedema                                               | 9759                                                                                                                           |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |                                                                                                                                |
| Chest pain                                           | 2273                                                                                                                           | 0.31                                                                                                                           | 0000                                                                                                                           |                                                                                                                                | 3.0)                                                                                                                           | 0000                                                                                                                           | 6676                                                                                                                           | 1.6)                                                                                                                           |                                                                                                                                |
| Skin and subcutaneous tissue disorders               | 154 47.81                                                                                                                      | 14 4.31                                                                                                                        |                                                                                                                                | 154 51.3)                                                                                                                      | 12 4.0)                                                                                                                        | 口                                                                                                                              | 308 49.5)                                                                                                                      | 26 4.2)                                                                                                                        | 口                                                                                                                              |
| Rash                                                 | 30.71                                                                                                                          | 19 3.11                                                                                                                        |                                                                                                                                | 38.31                                                                                                                          |                                                                                                                                | 00                                                                                                                             | 118  30.51                                                                                                                     | 17 3.7.                                                                                                                        |                                                                                                                                |
| Pruwitus                                             | 2 17.4)                                                                                                                        | 0.9)                                                                                                                           | 00                                                                                                                             | 6.6 20.71                                                                                                                      | Fm 1.831                                                                                                                       |                                                                                                                                | 19.0)                                                                                                                          | 6 1.0)                                                                                                                         | 00                                                                                                                             |
| Respiratory, thoracic and mediastinal                | 124 ( 38.5)                                                                                                                    | 28 8.7)                                                                                                                        | 4 1.2)                                                                                                                         | 169 56.3)                                                                                                                      | 27 9.0)                                                                                                                        | 2 ( 0.7)                                                                                                                       | 293 47.1)                                                                                                                      | 55 8.8)                                                                                                                        | 6 1.0)                                                                                                                         |
| disorders Cough Dyspncea                             | 13.0 8.4                                                                                                                       | 12 1 8.81                                                                                                                      | 00                                                                                                                             | 1 2务:81                                                                                                                        | NT 2.33                                                                                                                        | 00                                                                                                                             | 10 1 17.3                                                                                                                      | mm 1.8                                                                                                                         | 00                                                                                                                             |
| Metabolism and nutritionl60 ( 49.7)                  |                                                                                                                                | 63 ( 19.6)                                                                                                                     | 口                                                                                                                              | 122 ( 40.7)                                                                                                                    | 22 ( 7.3)                                                                                                                      | 1 0.3)                                                                                                                         | 282 (45.3)                                                                                                                     | 85 (13.7)                                                                                                                      | 1 0.2)                                                                                                                         |
| disorders Decreased appetite                         | 56 ( 17.4)                                                                                                                     | 13 4.0)                                                                                                                        | 0                                                                                                                              | 71 ( 23.7)                                                                                                                     | 3 1.0)                                                                                                                         | 0                                                                                                                              | 127 ( 20.4)                                                                                                                    | 16 2.6)                                                                                                                        | 0                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                                      | CA209648                                                                                                                         | CA209648                   | CA209648   | CA209743                       | CA209743        | CA209743           | Nivo + Ipi Pooled   | Nivo + Ipi Pooled   | Nivo + Ipi Pooled   |
|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------|------------|--------------------------------|-----------------|--------------------|---------------------|---------------------|---------------------|
| System Organ_Class_(6) Preferred Term (t)            | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg QeWNivo 3 mg/kg Q2W +.Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 N = 300 Any Grade | Grade 3-4                  | Grade 5    | Any Grade                      | Grade 3-4       | Grade 5            | Any Grade           | N = 622 Grade 3-4   | Grade 5             |
| Infections and infestations                          | 119 37.0)                                                                                                                        | 47 ( 14.6)                 | 2 [ 0.6)   | 130 43.3)                      | 25 8.3)         | 2 0.7)             | 249 40.01           | 72 (11.6)           | 4 0.6)              |
| Pneumonia Upper respiratory                          | 46 14.3) 23 7.1)                                                                                                                 | 25 7.81 1.2)               | [ 0.6)     | 19 6.3) 36 12.0)               | 01 2.7) 0.3)    | 00                 | 65 ( 10.5) 59 9.5)  | 33 5.31 5 0.8)      | 20 0.3)             |
| Imvestigations Transaminases increased               | 129 40. .1) 49 15.2)                                                                                                             | 10.6) 3.7)                 | 口          | 100 33.3) 27 9.0)              | 31 10.31 8 2.7) | 0                  | 229 36.81 76 12.2)  | 65 10.51 20 3.2)    | 0 0                 |
| Weight decreased                                     | 39 ( 12.1)                                                                                                                       | 6 1.9)                     | 0          | 16 5.3)                        | 口               | 0                  | 55 [ 8.81           | 6 1.0)              | 0                   |
| Musculoskeletal and comnective tissue disorders      | 78(24.2)                                                                                                                         | 6 1.9)                     | 0          | 117 ( 39.0)                    | 13 4.3)         | 0                  | 195 (31.4)          | 19 3.1)             | 0                   |
| Misculoskeletal Arthralgia pain                      | 20 46 14.3) 6.2) 45                                                                                                              | 20 ( 0.6)                  | 00         | 2 17.3) 24.91                  |                 | 1.3 00             | 118 72 11.6) 19.01  | [ 0.81 1.21         | 00                  |
| Blood and lymphatic system disorders                 | 66 ( 30.7)                                                                                                                       | 32 [ 9.9)                  | 0          | 69 ( 23.0)                     | 19 6.3)         | 0                  | 168 ( 27.0)         | 51 8.2)             | 口                   |
| Anaemia                                              | 74 ( 23.0)                                                                                                                       | 20 ( 6.2)                  | 0          | 45 ( 15.0)                     | 8 2.7)          | 0                  | 119 19.1)           | 28 4.5)             | 0                   |
| Endocrine disorders Hypothyroidism Neoplasms benign, | 85 5 [ 45 14.0) 65 ( 20.2)                                                                                                       | (26.4) 19 [ 5.9) 0 27 8.4) | 00         | 57 （ 19.0) 39 13.0) 42 ( 14.0) | 1.7) 0 12 4.0)  | 1 [ 0.3) 0 19 6.3) | 142 22.8) 84 13.5)  | 24 3.9) 0 6.3)      | 1 （ 0.2) 0          |
| maligmant and specified (incl cysts and polyps)      |                                                                                                                                  |                            | 18 [ 5.6)  |                                |                 |                    | 107 ( 17.2)         | 39                  | 37 5.9)             |
| Maligmant neoplasm                                   | 43(13.4)                                                                                                                         | 22（ 6.8)                   | 18( 5.6)   | 32(10.7)                       | 6 [ 3.0)        | 19 6.3)            | 75 (12.1)           | 31( 5.0)            | 37（ 5.9)            |

'sep oo + Adeteu go esop 1set pue asop 1sity uearaeo peatoder sauana sapnioui

MedDRA Version: 23.1; C1C Version 4.0

Scme preferred terms are re-mepped based on\\_EMs medical review.

Source: Appendix Gf.145A-EUsMPC.1.1 in Appendix 1

Nivo  Ipi pooled group. consists of Nivo + Ipi treatment group from studies CA209743 and CA209648.

Table 55. Summary of Drug-related Adverse Events using Re-mapped Terms Occurring in At Least 5% of Subjects - All Nivolumab + Ipilimumab Treated Subjects from CA209648, CA209743 and Pooled Analysis (CA209743 + CA209648)

|                                                      | CA209648               | CA209648       | CA209648                                  | CA209743           | CA209743                                     | Nivo + Ipi Pooled      | Nivo + Ipi Pooled   | Nivo + Ipi Pooled             |
|------------------------------------------------------|------------------------|----------------|-------------------------------------------|--------------------|----------------------------------------------|------------------------|---------------------|-------------------------------|
| System Organ_Class (t) Preferred Term (t)            | Nivo 3 mg/kg Any Grade | =322 Grade 3-4 | Q2W + Ipi 1 mg/kg QeWNivo 3 mg/kg 9 Grade | Any  Grade         | Q2W + Ipi 1 mg/kg Q6W N =300 Grade 3-4 Grade | Nivo 3 mg/kg Any Grade | N = 622 Grade 3-4   | Q2W + Ipi 1 mg/kg QEW Grade 5 |
| TOTAL SUBJECIS WITH AN EVENT                         | 256 ( 79.5)            | 102 2 ( 31.7)  | 2 0.6)                                    | 240 80.0)          | 91 ( 30.3) 1                                 | 496 (79.7)             | 193 ( 31.0)         | 0.5)                          |
| Skin and subcutaneous tissue disorders               | 118 (36.6]             | 14 4.3)        | 0                                         | 116 (38.7)         | 10 3.3) 口                                    | 234 (37.6)             | 24 [ 3.9)           |                               |
| Rash Pruritus                                        | 68 25.21 13.4)         | 3.11 16.0      | 00                                        | 79 ( ( 24.71 16.3) | 63 3.81 00                                   | 155 92 ( 24.9) 14.8)   | 16 1.8) 2.6)        | 00                            |
| Gastrointestinal disorders                           | 95 29.51               | 15 [ 4.7)      | 口                                         | 102 ( 34.0) 17     | 5.7)                                         | 197 31.7)              | 32 5.1)             | 口                             |
| Nausea. Diarrhoea Vemiting Stomatitis                | 6166                   | 2140           | 0000                                      | 23.86              | 8.3 0000                                     | 15. .11                | 660                 | 0000                          |
| General disorders and administration site conditions | 68 21.1)               | 7 2.2)         | 口                                         | 88 29.3)           | 3 1.0) 口                                     | 156 ( 25.1)            | 10 1.6)             |                               |
| Fatigue Pyrexia                                      |                        |                | 00                                        | 615 21.71 5.3)     | 30 1.0) 00                                   | 102 16.2) 18.9         | 0  0.2) 1.3)        | 00                            |
| Endocrine disorders Hypothyroidi sm Hyperthyroidism  | 868 637                | 5.9) 0.6)      | 000                                       | 5:31 66F           | 1.7) 000                                     |                        | 3.9)                | 000                           |
| Investigations Transeminases increased               | 83 18.3                | 17             | 00                                        | 528 18.71          | 2.83 00                                      | 8                      | 0.3) 14 23          | 00                            |
| Amylase increased Lipase increased                   | 5 1.8                  | 1.3            |                                           | 23                 | 00                                           | 2强 4:81                | 1 283               |                               |
| Metabolism and nutrition                             | 47 14.6)               | 20 6.2)        | 00                                        | 37 (12.3)          | 13 3.3 7 2.31                                | 84 13.5)               | 27 4.3)             | 00 口                          |
| disorders                                            | [ 5.9)                 | 5 1.6)         | 口                                         | 29 9.7)            | 0 2 0.7)                                     | 7.7)                   | 7 1.1)              | 口                             |
| Decreased appetite                                   | 19                     |                |                                           |                    | 口                                            | 48                     |                     |                               |
| Respiratory, thoracic and mediastinal                |                        |                |                                           |                    |                                              |                        |                     |                               |
|                                                      | 39 ( 12.1)             | 11 3.4)        | 1 0.3)                                    | 32 (10.7)          | 2 0.7) 0                                     | 71 11.4)               | 13 2.1)             | 1                             |
| disorders                                            |                        |                |                                           |                    |                                              |                        |                     | 0.2)                          |

<div style=\"page-break-after: always\"></div>

|                                                | CA209648                                                                                                       | CA209648   | CA209648   | CA209743   | CA209743   | CA209743   | Nivo + Ipi Pooled   | Nivo + Ipi Pooled   | Nivo + Ipi Pooled   |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------|------------|------------|------------|------------|------------|---------------------|---------------------|---------------------|
|                                                | Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6WNiwo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W N = 322 |            |            |            | N = 300    |            |                     | N = 622             |                     |
| System Organ Class (e) Preferred Term (b)      | Any Grade                                                                                                      | Grade 3-4  | Grade 5    | Any Grade  | Grade 3-4  | Grade 5    | Any Grade           | Grade 3-4           | Grade 5             |
| Pneumonitis                                    | [181.97                                                                                                        | 2.8)       | 0          | (8°9].61   | 0.71       | 0          | 45 (7.2)            | 111 (8T             |                     |
| Musculoskeletal and disorders                  | 21 (6.5)                                                                                                       | 0          | 0          | 44 (14.7)  | 6( 2.0)    | 0          | 65 ( 10.5)          | 6 1.0)              | 0                   |
| Miusculoskeletal pain                          | 1.8                                                                                                            |            | 00         | 8.31       | 0.3)       | 00         | 324 5.5)            | 0.2)                | 0                   |
| Arthralgia                                     |                                                                                                                | 00         |            | 7.7)       | 0.71       |            | 18.1                | H2 0.3)             | 0                   |
| Hepatobiliary disorders                        | 23 7.1)                                                                                                        | 13 4.01    | 0          | 23 7.7)    | 14 4.71    | 00         | 7.4) (              | 27 4.3)             | 0                   |
| Hepatie function abonormal                     | 16 5.0)                                                                                                        | 7 2.2)     | 0          | 6 3.0)     | 山 1.71     |            | 4.0)                | 12 1.9)             | 0                   |
| Injury, poisoning and procedural cumplications | 9 2.81                                                                                                         | 0          | 0          | 26 8.7)    | 1.0)       | 0          | 35 ( 5.6)           | 3 0.5)              | 0                   |
| Infusion related reaction                      | 8 2.5)                                                                                                         | 0          | 0          | 24 8.0)    | 3 （ 1.01   | 0          | 32 ( 5.1)           | 3 0.5)              | 0                   |

'sAep oo + Adexeup go esop 1set pue esop 1sttg ueamneq peaxodex sauene sepntoui

'8b960zto pue 8hl60zto setpn4s wotg dnoub queuneara rd1 + oniN 3o s1sTsuoo d1onb pelood td1 + onTN

Some preferred terms are re-mapped based on\\_EMs medical review.

Source: Appendix GI.143-EUSMPC.1.1 in Appendix 1

Additional safety data for nivo+ipi treated subjects in CA209648 vs pooled analysis of all nivo + ipi treated subjects in CA209648 and CA209743 (N=622) have been generated to support the SmPC.

## 2.5.1. Discussion on clinical safety

In the phase 3 CA209648 study supporting this application, 936 subjects were treated with nivo + chemo (N=310), nivo + ipi (N=322) or chemo (N=304). Patients in the nivo + ipi arm were to receive nivolumab 240 mg as a 30-min IV infusion Q2W and ipilimumab 1 mg/kg as a 30-minute IV infusion Q6W. Patients in the chemo arm received fluorouracil 800 mg/m2/day, as a continuous IV infusion on Days 1-5 Q4W, and cisplatin 80 mg/m2 as a 30-120-minute IV infusion on Day 1 Q4W. At the time of the DBL (1-Mar-2021), with a minimum follow-up of 12.9 months, a total of 886 subjects (94.7%) had discontinued treatment, 301 (93.5%) from the nivo + ipi arm and 300 (98.7%) from the chemotherapy treatment arm. The main reason for not continuing in the treatment period was disease progression in all cases but, for 59 (18.3%) subjects from the nivo + ipi arm and 40 (13.2%) from the chemotherapy arm, the reason for not continuing in the treatment period was reported as study drug toxicity. The median duration of study therapy was 2.79 (0 -24.0) months in the nivo + ipi arm and 3.35 (0-19.0) months in the chemo arm. The median number of treatment doses received by subjects in the nivo + ipi arm was 6 (1-52) for nivolumab and 3 (1-18) for ipilimumab while, in the chemotherapy arm, the median number of doses was 4 for each component (1-17 cisplatin, 1-21 fluorouracil), partly due to higher rate of disease progression (54% vs. 63.5%) reported by subjects from the chemo arm. The proportion of patients who received ≥ 90% of the planned relative dose intensity was comparable between both treatment groups but these figures are difficult to be interpreted, as in the nivo + ipi arm relative dose intensity accounts for dose delays (no dose reductions are allowed) and in the chemo arm, variations from the planned relative dose intensity account for dose reductions and cycle delays. Updated safety data was later provided based on a 04Oct-2021 DBL and a summary of these results has been included after the initial assessment. The overall safety profile remained consistent with that previously reported in the primary analysis.

The most frequently reported AEs (&gt;20%) in the nivo + ipi arm were nausea and pyrexia (22.4% each), diarrhoea and anaemia (22.0% each), rash (21.7%), constipation (20.5%) and neoplasms (20.2%) while; in the chemo arm, they were nausea (55.9%), decreased appetite (49.7%), constipation (43.1%), anaemia (31.9%), stomatitis (24.0%), and hiccups (20.7%). Grade 3-4 AEs were reported by 59.6% of subjects in the nivo + ipi arm and 54.3% in the chemo arm. The most common (&gt;5%) Grade 3-4 AEs were pneumonia (6.8%), malignant neoplasm progression (6.5%), anaemia (6.2%), and dysphagia (5.3%) in the nivo + ipi arm and anaemia (9.9%), neutrophil count decreased (8.6%), and decreased appetite (5.9%) in the chemo arm. Regarding treatment-related AEs, any-grade treatment-related AEs were reported by the 79.5% of subjects in the nivo + ipi arm

<div style=\"page-break-after: always\"></div>

and 90.5% subjects in the chemo arm, being the most commonly reported: rash (17.1%), and pruritus and hypothyroidism (13.4% each) in the nivo + ipi arm and nausea (52.0%), decreased appetite (42.8%), and stomatitis (23.4%) in the chemo arm. When considering only Grade 3-4 AEs, these were reported in the 31.7% of subjects in the nivo + ipi arm and the 35.5% subjects from the chemo arm, being the most common: hyponatraemia (2.5%); and rash, adrenal insufficiency, pneumonitis, alanine aminotransferase increased, and hepatic function abnormal (2.2% each) in the nivo + ipi arm, and neutrophil count decreased (7.9%), anaemia (5.6%), and fatigue (3.6%) in the chemo arm.

The frequencies of SAEs were higher in the nivo + ipi arm compared with the chemo arm (66.5% vs. 42.1%). The most frequently reported were malignant neoplasm progression (12.4%), pneumonia (7.5%), and pneumonitis and pyrexia (3.7% each) in the nivo + ipi arm; and malignant neoplasm progression (4.9%), dysphagia and pneumonia (3.6% each), oesophageal stenosis (3.3%) in the chemo treatment arm. Focusing on drug-related SAEs, they were reported by 32% subjects in the nivo + ipi arm and 16.1% in the chemo arm, being the most common SAEs pneumonitis (3.7%), hepatic function abnormal (2.5%), adrenal insufficiency (2.2%) in the nivo + ipi arm and vomiting (3.0%), and pulmonary embolism, diarrhoea, nausea, hyponatraemia, dehydration, atrial fibrillation, and acute kidney injury (1.0% each) in the chemo treatment arm.

Up to the data cut-off (DCO), the number of patients who died was numerically lower in the nivo + ipi arm compared with the chemo arm (66.8% vs. 73.7%). The primary reason for death was mainly disease progression. Deaths attributable to study drug toxicity were 5 (1.6%) in the nivo + ipi arm and 4 (1.3%) in the chemo treatment arm. The SAEs reported as primary reason for death in the nivo + ipi arm were: pneumonitis (2 subjects), interstitial lung disease, pulmonary embolism and acute respiratory syndrome. Up to the latest DBL (4 Oct 2021), 72.7% subjects in the nivo + ipi arm and 79.6% subjects in the chemo arm had died. The main reasons of death were generally consistent with the previous ones although there were two deaths reassessed as drug toxicity in the nivo + ipi arm.

Adverse events of special interest (AESI) for nivolumab and ipilimumab are classified into Select Adverse Events, immune-mediated AEs (IMAEs) and other events of special interest (OESIs). The most frequently reported drug-related select AE categories were skin (34.2%), endocrine (27.3%) and hepatic (13.0%) in the nivo + ipi arm, and renal (18.8%), gastrointestinal (15.5%), and hepatic (3.9%) in the chemo arm. By PT, the most common select AEs were rash (17.1%), hypothyroidism and pruritus (13.4% each), and diarrhoea (9.9%), and diarrhoea (15.1%), blood creatinine increased (10.5%), and acute kidney injury (3.3%) in the chemotherapy treatment arm. As seen with other nivolumab therapeutic indications, endocrine AEs tend to have the lowest rate resolved events (28.6% of subjects), followed by renal (62.5%) and pulmonary (65.4%) in the nivo + ipi treatment arm. Regarding IMAEs, analyses included endocrine events in addition to all events which required immunosuppressive therapy for their management. As expected, incidence of IMAEs was higher in the nivo + ipi arm compared with the chemo arm where rash (0.7%) was the only reported event of this type. In the nivo + ipi arm, 40.7% of subjects reported any IMAE being the most common: hypothyroidism/thyroiditis (15.5%), rash (13.7%), hypophysitis (6.5%), hyperthyroidism (5.9%), adrenal insufficiency (5.6%), hepatitis (4.0%), pneumonitis (3.7%), and diarrhoea/colitis (3.4%). The proportion of subjects who reported Grade 3-4 IMAEs (by category) was hypophysitis (3.1%), rash (2.5%), hepatitis (2.8%), pneumonitis and adrenal insufficiency (2.2% each), diarrhoea/colitis (1.2%), nephritis/renal dysfunction, diabetes mellitus, and hyperthyroidism (0.6% each). OESIs, events that do not fulfil all criteria to be considered IMAEs but which may require immunosuppression for their management, were reported by 14 subjects from the nivo + ipi group. These events were Grade 2-4 pancreatitis, Grade 1 myocarditis, Grade 1-4 uveitis, Grade 2-4 encephalitis and Grade 1-2 myositis. All of them were considered resolved except for a Grade 1 event of myocarditis, one Grade 2 event of uveitis and Grade 1 myositis.

<div style=\"page-break-after: always\"></div>

Focusing on laboratory abnormalities (up to 30 days after last treatment dose), reported increases in hepatic parameters were higher in the nivo + ipi arm compared with the chemo arm, while this trend was not observed regarding hematology values whose alterations are generally attributed to chemotherapy. Concurrent ALT or AST &gt;3×ULN with total bilirubin &gt;2×ULN after the first dose and within 30 days of last dose of study therapy was reported in 3/306 (1%) in the nivo + ipi arm and 0 subjects, with test results, in the chemo arm. The most common thyroid function test abnormality was TSH increase (&gt;ULN) which was reported by the 22.8% and the 7.6% of subjects from the nivo + ipi arm and the chemo arm, respectively. Electrolytes alterations were also slightly higher in the nivo + ipi arm compared with the chemo arm, although differences were not as remarkable as those observed for the third treatment arm (nivo + chemo). Discussion about the relation between these abnormalities and the high rate of diarrhoea and colitis reported with nivolumab has been included in previous submissions and, although very limited number of these results have clinical relevance, their relation cannot be excluded. Vital signs observations were submitted by individual patient listings in the initial application. Upon request, the MAH performed a manual review of PTs that could be linked to vital sign-related AEs. Overall, reported incidences of these events were comparable between both treatment arms with no relevant differences.

Considering safety in special populations, reported AEs were, in general, comparable between treatment arms. Overall, all-causality AEs and drug-related AEs (by SOC and PT) presented higher incidences in females but a thorough comparison between male and female subjects for both treatment arms did not show any particular trend. Frequencies of all-causality and drug-related AEs were also comparable between different age groups. Data for ≥ 75 is limited due to the small sample size (24 subjects in each arm) and no data is available for ≥ 85.

The proportion of subjects with drug-related AEs leading to discontinuation was similar in the nivo + ipi arm vs. the chemo arm (17.7% vs. 19.4%). The most frequently reported drug-related AEs leading to discontinuation of study therapy were pneumonitis (2.5%), and adrenal insufficiency and hepatic function abnormal (1.6% each) in the nivo + ipi arm; and blood creatinine increased (3.6%), malignant neoplasm progression and renal impairment (2.3% each), peripheral sensory neuropathy (2.0%), and creatinine renal clearance decreased (1.3%) in the chemo arm. Drug-related Grade 3-4 AEs leading to discontinuation were reported in 41 (12.7%) subjects from the nivo + ipi arm and 14 (4.6%) subjects in the chemo treatment arm.

Safety data analyses have also been submitted for the All Treated Subjects with Tumour Cell PD-L1 ≥ 1% population. Overall, no major differences were reported between these subjects and the All Treated population.

Regarding data to support safety information included in section 4.8 of the PI, pooling of safety results from studies CA209648 (current application) and CA209743 (Malignant Pleural Mesothelioma therapeutic indication) has been proposed. This approach seems reasonable due to the fact that both studies were performed using the same posology (nivolumab 3 mg/kg Q2W and ipilimumab 1 mg/kg Q6W). Detailed justification for the proposed information to be included in the PI has been submitted, comparing frequencies of AEs between both studies and the pooled analysis using the already explained re-mapping methodology. When comparing safety results from study CA209648 vs. the pooled dataset, some differences were identified: the incidences of any grade all-causality AEs were higher in nivo + ipi treated subjects in CA209648 for dysphagia (11.8% vs 7.2%), anaemia (23.0% vs 19.1%), pneumonia (14.3% vs 10.5%), transaminase increased (15.2% vs 12.2%), and weight decreased (12.1% vs 8.8%). Also, drug-related AEs were higher in nivo + ipi treated subjects in CA209648 vs the pooled for, transaminases increased (10.9% vs 8.8%) and stomatitis (5.9% vs 4.0%). These differences are not considered clinically relevant and the pooling strategy is endorsed.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on clinical safety

The safety profile of nivolumab in combination with ipilimumab for the 1L treatment of adult patients with unresectable advanced, recurrent or metastatic OSCC has been characterised based on the results from study CA209648, by comparison with subjects who received standard chemotherapy.

Subjects treated with nivolumab + ipilimumab reported less all-causality and drug-related AEs but considerably higher rates of SAEs, including drug-related SAEs. There was also high incidence of discontinuations due to drug-related Grade 3-4 AEs. Deaths attributable to treatment were comparable between arms. As expected, select AEs, IMAEs and OESIs were frequently reported with this combination, especially regarding endocrine, hepatic, pulmonary and skin categories. Early detention and management of these toxicities continue to be crucial for patients receiving this combination treatment.

For the purpose of including identified ADRs in the PI, safety results from study CA209648 have been pooled with those from study CA209743 (MPM), as both studies used the same posology.

Overall, the combination of nivolumab and ipilimumab in this OSCC setting presents considerable toxicity that, compared with standard chemotherapy, seems to be manageable but especial attention must be drawn to IMAEs and their established clinical management and follow-up.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The WSA submitted updated RMP versions with this application.

## OPDIVO

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 26.2 is acceptable.

The CHMP endorsed the Risk Management Plan version 26.2 with the following content:

## Safety concerns

## Table 56:

## Summary of Safety Concerns

| Important identified risks   | Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction Immune-related endocrinopathies Immune-related skin ARs Other immune-related ARs Severe infusion reactions   |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Embryofetal toxicity Immunogenicity                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

## Table 56:

## Summary of Safety Concerns

|                     | Complications of allogeneic HSCT following nivolumab therapy in cHL Risk of GVHD with Nivolumab after allogeneic HSCT                                                  |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing information | Patients with severe hepatic and/or renal impairment Patients with autoimmune disease Patients already receiving systemic immunosuppressants before starting nivolumab |

The safety concerns remain unchanged.

## Pharmacovigilance plan

Table 57:

## Ongoing and Planned Additional Pharmacovigilance Activities

| Study / Status   | Summary of objectives   | Safety concerns addressed   | Milestone(s)   | Due Date(s)   |
|------------------|-------------------------|-----------------------------|----------------|---------------|

## Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization

None

## Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances

None

## Category 3 - Required additional pharmacovigilance activities

| CA209234: Pattern of use and safety/effective ness of nivolumab in routine oncology practice Ongoing   | To assess use pattern, effectiveness, and safety of nivolumab, and management of important identified risks of nivolumab in patients with lung cancer or melanoma in routine oncology practice   | Post-marketing use safety profile, management and outcome of immune- related pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, rash, other immune-related adverse reactions (uveitis, pancreatitis, demyelination, Guillain- Barre syndrome, myasthenic syndrome, encephalitis, myositis, myocarditis, rhabdomyolysis, solid organ transplant rejection, and VKH), and infusion reactions   | 1. Interim report 2. Final CSR submission   | Interim results provided annually 4Q2024       |
|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|
| CA209835: A registry study in patients with Hodgkin lymphoma who underwent post-nivolumab              | To assess transplant-related complications following prior nivolumab use                                                                                                                         | Postmarketing safety assessment of the outcome of post- nivolumab allogeneic HSCT                                                                                                                                                                                                                                                                                                                                             | 1. Annual update 2. Interim CSR submission  | With PSUR starting at DLP 03- Jul-2017 06-2019 |
|                                                                                                        |                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                               | 3. Final CSR submission                     |                                                |
| allogeneic HSCTOngoing                                                                                 |                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                               |                                             | 4Q2022                                         |

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 58: Summary of Risk Minimization Measures

| Safety Concern                                                                                                                                            | Risk Minimization Measures                                                                                | Pharmacovigilance Activities                                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related pneumonitis Immune-related colitis Immune-related hepatitis Immune-related nephritis and renal dysfunction Immune-related endocrinopathies | Routine risk minimization measures: SmPC Sections 4.2, 4.4 and 4.8                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                              |
| Immune-related skin ARs Other immune-related ARs                                                                                                          | Additional risk minimization measures: Patient Alert Card                                                 | Additional pharmacovigilance activities: Postmarketing pharmacoepidemiology study (CA209234)                                                                                                    |
| Severe Infusion Reactions                                                                                                                                 | Routine risk minimization measures: SmPC Sections 4.4 and 4.8 Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Postmarketing pharmacoepidemiology study (CA209234) |
| Embryofetal toxicity                                                                                                                                      | Routine risk minimization measures: SmPC Sections 4.6 and 5.3                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                              |
| Immunogenicity                                                                                                                                            | Routine risk minimization measures: SmPC Section 4.8 Additional risk minimization measures: None          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                |
| Complications of allogeneic HSCT following nivolumab therapy in cHL                                                                                       | Routine risk minimization measures: SmPC Sections 4.4 and 4.8 Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Registry study (CA209835)                           |
| Risk of GVHD with nivolumab after allogeneic HSCT                                                                                                         | Routine risk minimization measures: SmPC Section 4.4 and 4.8 Additional risk minimization measures: None  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                |
| Patients with severe hepatic and/or renal impairment                                                                                                      | Routine risk minimization measures: SmPC Sections 4.2 and 5.2                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                                              |

<div style=\"page-break-after: always\"></div>

Table 58:

## Summary of Risk Minimization Measures

| Safety Concern                                                                   | Risk Minimization Measures                                    | Pharmacovigilance Activities                                                                       |
|----------------------------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                                                                  | Additional risk minimization measures: None                   | Additional pharmacovigilance activities: None                                                      |
| Patients with autoimmune disease                                                 | Routine risk minimization measures: SmPC Section 4.4          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None |
| Patients with autoimmune disease                                                 | Additional risk minimization measures: None                   | Additional pharmacovigilance activities: None                                                      |
| Patients already receiving systemic immunosuppressants before starting nivolumab | Routine risk minimization measures: SmPC Sections 4.4 and 4.5 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None |
| Patients already receiving systemic immunosuppressants before starting nivolumab | Additional risk minimization measures: None                   | Additional pharmacovigilance activities: None                                                      |

The risk minimization measures and pharmacovigilance activities remain unchanged

## Yervoy

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 35.0 is acceptable.

The CHMP endorsed the Risk Management Plan version 35.0 with the following content:

## Safety concerns

## Table 59:

## Summary of Safety Concerns

| Important identified risks   | • GI irARs (eg, diarrhoea, colitis, GI perforation) • Hepatic irARs (eg, hepatitis) • Skin irARs (eg, rash, pruritus, TEN, and DRESS) • Neurologic irARs (eg, neuropathy) • Endocrine irARs (eg, hypopituitarism, hypothyroidism, adrenal insufficiency) • Other irARs (eg, pneumonitis, nephritis, non-infective myocarditis, and pancreatitis) • Severe infusion reactions   |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | • Immunogenicity                                                                                                                                                                                                                                                                                                                                                               |
| Missing information          | • Long-term safety in adolescent patients > 12 years of age • Potential PD interaction with systemic immunosuppressants • Patients with severe hepatic impairment • Patients with severe renal impairment • Patients with autoimmune disease                                                                                                                                   |

The safety concerns remain unchanged.

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

Table 60:

## On-going and Planned Additional Pharmacovigilance Activities

| Study / Status                                                                                                                                                                                                             | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestone(s)                                                                                                                                                                                                               | Due Date(s)                                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| MAH to sponsor extension of the Dutch Melanoma Treatment Registry (DMTR) to include paediatric subjects and to collect their safety data (CA184557) i                                                                      | To obtain additional safety information in paediatric patients                                                                                                                                                             | Long-term safety in adolescent patients > 12 years of age                                                                                                                                                                  | 1. Synopsis of the DMTR 2. Submission of protocol 3. Start of data collection 4. Recruitment period a 5. Progress Report 6. Interim Study Report 7. End of data collection 6. Final report of study results                | 16-Apr-2018 02-Nov-2019 End of 2Q 2019 2Q 2019 until 1Q 2029 End of 2Q 2022 End of 2Q 2024 End of Q1 2029 End of 2Q 2029                                                                                                   |

a The recruitment period began in 2Q 2019, when the Princess Maxima Center officially confirmed its collaboration to the paediatric extension of the DMTR, but the data will include all paediatric patients entered in the DMTR who received ipilimumab prior to the start of data collection.

The pharmacovigilance activities remain unchanged

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 61:

## Summary of Risk Minimization Measures

| Safety Concern                                                                                                                                | Risk Minimization Measures                                                                                                                                                                                                                                                                                | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Identified Risks Immune-related Adverse Reactions (GI irARs, hepatic irARs, skin irARs, neurological irARs, endocrine irARs, and other irARs) | Routine risk minimisation measures: SmPC Section 4.4 specific warning/precautions; Sections 4.2 and 4.4 guidelines on monitoring, diagnosis, dose modification, and corticosteroids intervention; and Section 4.8 ADR list Additional risk minimisation measures:Patient Information Guide and Alert Card | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Severe Infusion Reactions                                                                                                                     | Routine risk minimisation measures: SmPC Section 4.3 Contraindication, Section 4.4 Special warnings, Section 4.8 Undesirable effects Additional risk minimisation                                                                                                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Immunogenicity                                                                                                                                | and Alert Card Routine risk minimisation measures: SmPC Section 4.8 Immunogenicity Additional risk minimisation                                                                                                                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Long-term safety in adolescent patients > 12 years of age                                                                                     | measures: None Routine risk minimisation measures: SmPC Section 4.2, 4.4, 4.8, and 5.2                                                                                                                                                                                                                    | activities: None Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • A PIP for ipilimumab in malignant neoplasms (except melanoma, nervous system, haematopoietic, and lymphoid tissue) and a second PIP in melanoma have been completed in the EU. • Reporting of long-term safety data in paediatric patients in studies of nivolumab and ipilimumab combination therapy (CA209070 and CA209908 a ). • Monitoring of initial AEs and continued follow-up while on therapy and/or 100 days after the last dose by the treating physician. Follow-up information obtained by BMS using specified procedures (telephone interviews or |

<div style=\"page-break-after: always\"></div>

Table 61:

Safety Concern

## Summary of Risk Minimization Measures

## Risk Minimization Measures Pharmacovigilance Activities

mailing a questionnaire to the treating physician).

|                                                           | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: MAH to sponsor extension of the DMTR to include paediatric subjects and to collect their safety data (CA184557).   |
|-----------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Potential PD interaction with systemic immunosuppressants | Routine risk minimisation measures: SmPC Section 4.5          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                          |
| Potential PD interaction with systemic immunosuppressants | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: None                                                                                                               |
| Patients with severe renal impairment                     | Routine risk minimisation measures: SmPC Sections 4.2 and 5.2 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                          |
| Patients with severe renal impairment                     | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: None                                                                                                               |
| Patients with severe hepatic impairment                   | Routine risk minimisation measures: SmPC Sections 4.2 and 5.2 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                          |
| Patients with severe hepatic impairment                   | Additional risk minimisation measures: None                   | Additional pharmacovigilance activities: None                                                                                                               |
| Patients with autoimmune disease                          | Routine risk minimisation measures: SmPC Section 4.4          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance                             |
| Patients with autoimmune disease                          | Additional risk minimisation measures: None                   | activities: None                                                                                                                                            |

a   The primary CSR for CA209908 was completed and reported to fulfil the obligation set out by Article 46 of Regulation (EC) No 1901/2006 (the 'Paediatric Regulation') for both OPDIVO and YERVOY. In the YERVOY PSUR #14, this study was listed as completed.

The risk minimization measures remain unchanged

## 2.7. Changes to the Product Information

As a result of this variation, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are being updated. The Package Leaflet (PL) is updated accordingly.

<div style=\"page-break-after: always\"></div>

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the WSA and has been found &lt;acceptable&gt; &lt;unacceptable&gt; for the following reasons:

The inclusion of the new proposed indication for Opdivo (i.e. in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, does not have a relevant impact on the PIL and therefore it is agreed with the MAH that there is no need to conduct additional consultation with target patients groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The MAH is seeking an extension of the indication for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PDL1 expression ≥1%.

## 3.1.1. Disease or condition

Oesophageal cancer (OC) is the eighth-most common cancer and the sixth-most common cause of death worldwide, with an estimated 604,100 new cases (3.1% of all cancers) and 544,076 cancer deaths (5.5% of all cancer deaths) 4 . In the UE, oesophageal cancer is the 19th most common cancer, although variability between countries is high. There are two distinct histologic types of OC: squamous cell carcinoma (SCC) and adenocarcinoma (AC). Globally, OSCC is the most common histological subtype, however while the incidence of OSCC has decreased in many regions, a marked increase in the incidence of OAC has been observed in Europe, North America, and Australia during the past four decades 5 .

The main risk factors for SCC are smoking and alcohol consumption.

## 3.1.2. Available therapies and unmet medical need

For patients with advanced and recurrent OC and a good performance status (PS) palliative chemotherapy is commonly used, particularly for patients with AC. In SCC, the value of palliative chemotherapy is less proved and best supportive care (BSC) or palliative monotherapy can also be considered 6 . Among the regimens used in the first-line setting, a combination of fluoropyrimidine (either 5-FU or capecitabine) and cisplatin or oxaliplatin are the preferred recommended regimens 7 . Use of oxaliplatin is also preferred over cisplatin due to lower toxicity.

Recent findings from the KEYNOTE 590 study showed that immune checkpoint inhibitor pembrolizumab in combination with chemotherapy in the first line (1L) setting was superior to chemotherapy for overall survival (OS) and progression free survival (PFS) in patients with locally advanced/unresectable or metastatic OAC, OSCC (73% of the study population), or GEJ adenocarcinoma. Based on these

4  GLOBOCAN 2020 (accessed October 2021)

5  Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017 Nov 25;390(10110):2383-2396.

6  Lordick F, Mariette C, Haustermans K et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and

follow-up. Annals of Oncology 27 (Supplement 5): v50-v57, 2016

7  NCCN Clinical Practice Guidelines in Oncology. Esophageal and Esophagogastric junction cancers. Version 4.2021.

<div style=\"page-break-after: always\"></div>

study findings, pembrolizumab (in combination with platinum- and fluoropyrimidine-based chemotherapy) has been approved in the EU for the 1L treatment of patients with locally advanced unresectable or metastatic oesophageal carcinoma (including OSCC) whose tumours express PD -L1 with a CPS ≥10 (Keytruda II/97).

## 3.1.3. Main clinical studies

The evidence in support of the claimed indication is based on results from the study CA209648 . The study CA209648 is a Phase 3, randomised, multicentre, open-label study of nivolumab plus ipilimumab or  nivolumab  in  combination  with  chemotherapy  (fluorouracil  plus  cisplatin)  versus  chemotherapy (fluorouracil plus cisplatin) in subjects with unresectable advanced, recurrent or metastatic previously untreated OSCC.

The primary endpoints were OS and PFS, as assessed by BICR per RECIST 1.1 criteria, in patients with PDL1≥ 1%. Secondary endpoints included OS and PFS in all randomised subjects and ORR (both in PDL1≥1% a nd the overall population, by BICR). A hierarchical testing strategy was used for the primary and secondary endpoints.

A total of 970 patients were randomised (325 in the nivo+ipi arm, 321 in the nivo+chemo arm and 324 in the chemo arm). Results presented below are based on the comparison of nivo+ipi vs. chemo at the time of the primary analysis (DBL: 1 March 2021).

## 3.2. Favourable effects

## Primary endpoints ( PDL1≥1 % ) (n=315)

OS results (event rate 67.1% nivo+ipi vs. 77.1% chemo) showed a statistically significant improvement in favour of the nivo+ipi arm over chemo arm (HR 0.64; 98.6% CI: 0.46, 0.90). Median OS was of 13.70 (95% CI: 11.24, 17.02) months in the nivo+ipi group and 9.07 (95% CI: 7.69, 9.95) months in the chemo group.

Regarding PFS (event rate 77.8% nivo+ipi vs. 63.7% chemo) no statistically significant differences were observed between treatment arms (HR 1.02; 98.5% CI: 0.73, 1.43). Median PFS was 4.04 (95% CI: 2.40, 4.93) months and 4.44 (95% CI: 2.89, 5.82) months, in the nivo+ipi and chemo groups, respectively.

## Secondary endpoints

OS in the all-randomised patients (event rate of 66.5% in the nivo+ipi arm and 71.6% in the chemo arm), showed a statistically significant benefit of nivo+ipi over chemo (HR 0.78; 98.2% CI: 0.62, 0.98). Median OS was of 12.75 (95% CI: 11.27, 15.47) months and 10.71 (95% CI: 9.40, 11.93) months in the experimental and control arm, respectively.

Results in terms of PFS (by BICR) in the all-randomised patients did not reach statistical significance (HR 1.26; 98.5% CI: NA, NA). Median PFS was 2.92 (95%CI: 2.66, 4.17) months in the nivo+ipi arm versus 5.59 (95% CI: 4.27, 5.88) months in the chemo arm.

The ORR (by BICR) was higher in the nivo+ipi arm compared with the chemo arm in patients with PDL1≥1 % (35.4% vs. 19.7%) while no differences were observed in the all-randomised patients (27.7% vs. 26.9%).

Updated efficacy data were provided during the procedure with a DBL of 04 Oct 2021 and a minimum follow-up of 20 months. Results were consistent with the primary analysis.

<div style=\"page-break-after: always\"></div>

## 3.3. Uncertainties and limitations about favourable effects

The combination of nivo+ipi demonstrated a statistically significant improvement in OS in the allrandomised patient population. However, this effect appears to be driven mostly by patients with tumour cell PD-L1 expression ≥ 1%. In patients with PD-L1&lt;1%, the benefit of the combination of nivo+ipi over chemotherapy is not justified. As a result the indication was restricted to patients with tumour cell PD-L1 expression ≥ 1%.

Further, there was a higher rate of early deaths in the nivo+ipi arm compared with the chemo arm, being disease progression the main cause of these deaths. The delay in the onset of action of immunotherapy along with some prognostic factors appear the most plausible explanation. This issue has been observed in previous clinical trials with immunotherapy.

## 3.4. Unfavourable effects

In study CA209648, 98.1% of subjects in the nivo + ipi arm and 99% in the chemo arm reported any AEs. The most common AEs in the nivo + ipi arm were nausea and pyrexia (22.4% each), diarrhoea and anaemia (22.0% each), rash (21.7%), constipation (20.5%) and neoplasms (20.2%). Grade 3-4 AEs were reported by 59.6% subjects in the nivo + ipi arm compared with a 54.3% of subjects from the chemo arm.

Drug-related AEs were reported more frequently in the chemo arm (79.5% vs. 90.5%), being the most common events in the nivo + ipi arm: rash (17.1%), and pruritus and hypothyroidism (13.4% each).

SAEs were observed in 66.5% subjects in the nivo + ipi arm compared with the 42.1% in the chemo arm and same differences were observed for drug-related SAEs (32% vs. 16.1%). The most common drug-related SAEs reported in the nivo + ipi arm were pneumonitis (3.7%), hepatic function abnormal (2.5%) and adrenal insufficiency (2.2%). There were 5 (1.6%) subjects for which primary reason for death was recorded as study drug toxicity in the nivo + ipi arm and 4 (1.3%) subjects in the chemo arm.

IMAEs  observed  were  in  line  with  other  already  approved  nivolumab  and  ipilimumab  therapeutic indications.

The proportion of subjects with AEs leading to discontinuation was similar in both treatment arms (25.2% vs. 25.3%). Also, for drug-related AEs leading to discontinuation, the same trend was observed (17.7% vs. 19.4%).

## 3.5. Uncertainties and limitations about unfavourable effects

Liver tests abnormalities were more commonly reported in the nivo + ipi arm compared with the chemo arm but not all these abnormalities were translated into hepatic adverse events although liver enzymes and  bilirubin  monitoring  are  useful  for  early  identification  of  these  events.  Recommendations  for management of immuno-related hepatitis are already included in section 4.8 of the SmPC.

Vital signs observations were submitted by individual patient listings in the initial application so a proper assessment of the possible changes has not been performed. Instead, a manual review of PTs that could be linked to vital sign-related AEs was presented.

Some differences were identified in the incidences of all-causality any-grade AEs by sex but no particular trend could be identified.

## 3.6. Effects Table

Effects Table for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-

<div style=\"page-break-after: always\"></div>

line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (data cut-off: 18 Jan 2021) - Study CA209648

| Effect                                                | Short description                                                                                                                        | Unit                                                  | Treatm ent                                            | Control                                               | Uncertainties / Strength of evidence                  | References                                            |
|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Favourable Effects                                    | Favourable Effects                                                                                                                       | Favourable Effects                                    | Favourable Effects                                    | Favourable Effects                                    | Favourable Effects                                    | Favourable Effects                                    |
| Primary endpoints (PD- L1≥ 1 % ; N=315)               | Primary endpoints (PD- L1≥ 1 % ; N=315)                                                                                                  | Primary endpoints (PD- L1≥ 1 % ; N=315)               | Primary endpoints (PD- L1≥ 1 % ; N=315)               | Primary endpoints (PD- L1≥ 1 % ; N=315)               | Primary endpoints (PD- L1≥ 1 % ; N=315)               | Primary endpoints (PD- L1≥ 1 % ; N=315)               |
| OS                                                    | Overall survival; Time from randomisation until death from any cause                                                                     | Median, months (95%CI)                                | 13.70 (11.24, 17.02)                                  | 9.07 (7.69, 9.95)                                     | HR 0.64 (98.6% CI: 0.46, 0.90); p a < 0.0010          | CSR                                                   |
| PFS                                                   | Progression free survival; Time until progressive disease (BICR-assessed per RECIST 1.1) or death from any cause, whichever occurs first | Median, months (95%CI)                                | 4.04 (2.40, 4.93)                                     | 4.44 (2.89, 5.82)                                     | HR 1.02 (98.5% CI: 0.73, 1.43); p a =0.8958           | CSR                                                   |
| Secondary endpoints (All randomised patients; N= 649) | Secondary endpoints (All randomised patients; N= 649)                                                                                    | Secondary endpoints (All randomised patients; N= 649) | Secondary endpoints (All randomised patients; N= 649) | Secondary endpoints (All randomised patients; N= 649) | Secondary endpoints (All randomised patients; N= 649) | Secondary endpoints (All randomised patients; N= 649) |
| OS                                                    | Overall survival                                                                                                                         | Median, months (95%CI)                                | 12.75 (11.27, 15.47)                                  | 10.71 (9.40, 11.93)                                   | HR 0.78 (98.2% CI: 0.62, 0.98); p a = 0.0110          | CSR                                                   |
| PFS                                                   | Progression free survival                                                                                                                | Median, months (95%CI)                                | 2.92 (2.66, 4.17)                                     | 5.59 (4.27, 5.88)                                     | HR 1.26 (98.5% CI: NA, NA) p a = NA                   | CSR                                                   |
| ORR                                                   | Overall response rate per BICR (complete response + partial response)                                                                    | % (95% CI)                                            | 27.7 (22.9, 32.9)                                     | 26.9 (22.1, 32.0)                                     | Difference: 0.9 (95% CI: -5.9, 7.6)                   | CSR                                                   |
| Secondary endpoint (PD- L1≥1% ); N= 315               | Secondary endpoint (PD- L1≥1% ); N= 315                                                                                                  | Secondary endpoint (PD- L1≥1% ); N= 315               | Secondary endpoint (PD- L1≥1% ); N= 315               | Secondary endpoint (PD- L1≥1% ); N= 315               | Secondary endpoint (PD- L1≥1% ); N= 315               | Secondary endpoint (PD- L1≥1% ); N= 315               |
| ORR                                                   | Overall response rate per BICR (complete response + partial response)                                                                    | % (95% CI)                                            | 35.4 (28.0, 43.4)                                     | 19.7 (13.8, 26.8)                                     | Difference: 15.7 (95% CI: 5.9, 25.4)                  | CSR                                                   |
| Unfavourable Effects b                                | Unfavourable Effects b                                                                                                                   | Unfavourable Effects b                                | Unfavourable Effects b                                | Unfavourable Effects b                                | Unfavourable Effects b                                | Unfavourable Effects b                                |
| AEs                                                   | All causality (drug-related)                                                                                                             | %                                                     | 98.4 (79.5)                                           | 99 90.5)                                              |                                                       |                                                       |
| Grade 3-4 AEs                                         | All causality (drug-related)                                                                                                             | %                                                     | 63.4 (32.6)                                           | 55.9 (36.2)                                           |                                                       |                                                       |
| Deaths                                                | Due to study drug toxicity                                                                                                               | %                                                     | 1.9                                                   | 1.6                                                   |                                                       |                                                       |
| AE leadin g to DC                                     | All causality (drug-related)                                                                                                             | %                                                     | 26.4 (18.3)                                           | 26.6 (2.7)                                            |                                                       |                                                       |
| SAEs                                                  | All causality (drug-related)                                                                                                             | %                                                     | 68 (32.6)                                             | 42.8 (16.1)                                           |                                                       |                                                       |

Abbreviations: AE: adverse event; BICR: blinded independent central review; CSR: clinical study report; HR: hazard ratio; RECIST 1.1: Response Evaluation Criteria In Solid Tumours version 1.1; SAE: serious adverse event.

Notes:  a  Stratified 2-sided log-rank test p-value. b Safety data presented in the above table are based on a DBL of 04 Oct 2021.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In study CA209648 treatment with nivolumab in combination with ipilimumab showed a statistically significant improvement in OS compared with chemotherapy (fluorouracil plus cisplatin) in the allrandomised patient population. No statistically significant differences were observed between both treatment arms in PFS, as assessed by BICR. However, results in the overall population are considered

<div style=\"page-break-after: always\"></div>

to be driven by patients with tumour cell PD-L1 ≥ 1% (primary efficacy population). In patients with PDL1&lt;1%, the benefit of the combination of nivo+ipi over chemotherapy is not justified and therefore the indication has been restricted to patients with tumour cell PD-L1 expression ≥ 1%.

From a safety point of view the combination of nivo+ ipi is characterised by substantial toxicity, with a higher rate of SAEs compared with chemotherapy. The most commonly reported drug-related AEs with nivo+ipi were rash, pruritus and hypothyroidism. As expected, select AEs, IMAEs and OESIs were frequently reported with this combination, especially regarding endocrine, hepatic, pulmonary and skin categories. However, overall the safety profile appears in line with the already known safety profile of this combination.

## 3.7.2. Balance of benefits and risks

Nivolumab in combination with ipilimumab has demonstrated superiority over chemotherapy in OS (and ORR) in patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%. Moreover, while this combination entails an important toxicity it may be an alternative treatment option for this patient population with a different safety profile.

Having all considered, the benefit/risk balance of nivolumab in combination with ipilimumab in the claimed indication is considered positive.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable

## 3.8. Conclusions

The overall benefit/risk of Opdivo and Yervoy in the currently applied indication is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell PDL1 expression ≥ 1% for Opdivo in combination with Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 26.2 of the Opdivo RMP and version 35.0 of the Yervoy RMP have also been submitted.

The worksharing procedure leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

<div style=\"page-break-after: always\"></div>

## Amendments to the marketing authorisation

In view of the data submitted with the worksharing procedure, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'OPDIVO/Yervoy-H-C-3985/2213/WS/2113'

i Protocol CA184557: Long-term Follow-up of Ipilimumab-treated Pediatric Patients Enrolled in the Dutch Melanoma Treatment Registry (DMTR). Bristol Myers Squibb Company; 2019. Document Control No. 930139126.